id	sid	tid	token	lemma	pos
dpc-1540	1	1	dermatology	dermatology	NOUN
dpc-1540	1	2	:	:	PUNCT
dpc-1540	1	3	practical	practical	ADJ
dpc-1540	1	4	and	and	CCONJ
dpc-1540	1	5	conceptual	conceptual	ADJ
dpc-1540	1	6	dermatology	dermatology	NOUN
dpc-1540	1	7	practical	practical	ADJ
dpc-1540	1	8	&	&	CCONJ
dpc-1540	1	9	conceptual	conceptual	ADJ
dpc-1540	1	10	research	research	NOUN
dpc-1540	1	11	|	|	ADV
dpc-1540	1	12	dermatol	dermatol	ADJ
dpc-1540	1	13	pract	pract	NOUN
dpc-1540	1	14	concept	concept	NOUN
dpc-1540	1	15	.	.	PUNCT
dpc-1540	2	1	2021;11(3):e2021049	2021;11(3):e2021049	NUM
dpc-1540	2	2	1	1	NUM
dpc-1540	2	3	prevalence	prevalence	NOUN
dpc-1540	2	4	of	of	ADP
dpc-1540	2	5	metabolic	metabolic	NOUN
dpc-1540	2	6	syndrome	syndrome	NOUN
dpc-1540	2	7	and	and	CCONJ
dpc-1540	2	8	its	its	PRON
dpc-1540	2	9	parameters	parameter	NOUN
dpc-1540	2	10	and	and	CCONJ
dpc-1540	2	11	their	their	PRON
dpc-1540	2	12	correlations	correlation	NOUN
dpc-1540	2	13	with	with	ADP
dpc-1540	2	14	psoriasis	psoriasis	NOUN
dpc-1540	2	15	duration	duration	NOUN
dpc-1540	2	16	,	,	PUNCT
dpc-1540	2	17	severity	severity	NOUN
dpc-1540	2	18	,	,	PUNCT
dpc-1540	2	19	and	and	CCONJ
dpc-1540	2	20	sleep	sleep	VERB
dpc-1540	2	21	quality	quality	NOUN
dpc-1540	2	22	in	in	ADP
dpc-1540	2	23	psoriasis	psoriasis	NOUN
dpc-1540	2	24	patients	patient	NOUN
dpc-1540	2	25	:	:	PUNCT
dpc-1540	2	26	a	a	DET
dpc-1540	2	27	cross	cross	ADJ
dpc-1540	2	28	-	-	ADJ
dpc-1540	2	29	sectional	sectional	ADJ
dpc-1540	2	30	study	study	NOUN
dpc-1540	2	31	betul	betul	PROPN
dpc-1540	2	32	tas1	tas1	PROPN
dpc-1540	2	33	,	,	PUNCT
dpc-1540	2	34	vasfiye	vasfiye	NOUN
dpc-1540	2	35	kabeloglu2	kabeloglu2	NOUN
dpc-1540	2	36	1	1	NUM
dpc-1540	2	37	department	department	NOUN
dpc-1540	2	38	of	of	ADP
dpc-1540	2	39	dermatology	dermatology	NOUN
dpc-1540	2	40	and	and	CCONJ
dpc-1540	2	41	venereology	venereology	NOUN
dpc-1540	2	42	,	,	PUNCT
dpc-1540	2	43	university	university	NOUN
dpc-1540	2	44	of	of	ADP
dpc-1540	2	45	health	health	PROPN
dpc-1540	2	46	sciences	sciences	PROPN
dpc-1540	2	47	,	,	PUNCT
dpc-1540	2	48	istanbul	istanbul	PROPN
dpc-1540	2	49	bagcilar	bagcilar	VERB
dpc-1540	2	50	research	research	NOUN
dpc-1540	2	51	and	and	CCONJ
dpc-1540	2	52	training	training	NOUN
dpc-1540	2	53	hospital	hospital	NOUN
dpc-1540	2	54	,	,	PUNCT
dpc-1540	2	55	istanbul	istanbul	PROPN
dpc-1540	2	56	,	,	PUNCT
dpc-1540	2	57	turkey	turkey	PROPN
dpc-1540	2	58	2	2	NUM
dpc-1540	2	59	department	department	NOUN
dpc-1540	2	60	of	of	ADP
dpc-1540	2	61	neurology	neurology	NOUN
dpc-1540	2	62	,	,	PUNCT
dpc-1540	2	63	university	university	NOUN
dpc-1540	2	64	of	of	ADP
dpc-1540	2	65	health	health	PROPN
dpc-1540	2	66	sciences	sciences	PROPN
dpc-1540	2	67	,	,	PUNCT
dpc-1540	2	68	bakirkoy	bakirkoy	PROPN
dpc-1540	2	69	prof	prof	PROPN
dpc-1540	2	70	.	.	PUNCT
dpc-1540	3	1	dr	dr	PROPN
dpc-1540	3	2	.	.	PROPN
dpc-1540	3	3	mazhar	mazhar	PROPN
dpc-1540	3	4	osman	osman	PROPN
dpc-1540	3	5	research	research	PROPN
dpc-1540	3	6	and	and	CCONJ
dpc-1540	3	7	training	training	NOUN
dpc-1540	3	8	hospital	hospital	NOUN
dpc-1540	3	9	,	,	PUNCT
dpc-1540	3	10	istanbul	istanbul	PROPN
dpc-1540	3	11	,	,	PUNCT
dpc-1540	3	12	turkey	turkey	PROPN
dpc-1540	3	13	key	key	ADJ
dpc-1540	3	14	words	word	NOUN
dpc-1540	3	15	:	:	PUNCT
dpc-1540	3	16	psoriasis	psoriasis	NOUN
dpc-1540	3	17	,	,	PUNCT
dpc-1540	3	18	metabolic	metabolic	NOUN
dpc-1540	3	19	syndrome	syndrome	NOUN
dpc-1540	3	20	,	,	PUNCT
dpc-1540	3	21	sleep	sleep	NOUN
dpc-1540	3	22	quality	quality	NOUN
dpc-1540	3	23	,	,	PUNCT
dpc-1540	3	24	comorbidity	comorbidity	NOUN
dpc-1540	3	25	citation	citation	NOUN
dpc-1540	3	26	:	:	PUNCT
dpc-1540	3	27	tas	tas	PROPN
dpc-1540	3	28	b	b	PROPN
dpc-1540	3	29	,	,	PUNCT
dpc-1540	3	30	kabeloglu	kabeloglu	NOUN
dpc-1540	3	31	v.	v.	ADP
dpc-1540	3	32	prevalence	prevalence	NOUN
dpc-1540	3	33	of	of	ADP
dpc-1540	3	34	metabolic	metabolic	NOUN
dpc-1540	3	35	syndrome	syndrome	NOUN
dpc-1540	3	36	and	and	CCONJ
dpc-1540	3	37	its	its	PRON
dpc-1540	3	38	parameters	parameter	NOUN
dpc-1540	3	39	and	and	CCONJ
dpc-1540	3	40	their	their	PRON
dpc-1540	3	41	correlations	correlation	NOUN
dpc-1540	3	42	with	with	ADP
dpc-1540	3	43	psoriasis	psoriasis	NOUN
dpc-1540	3	44	duration	duration	NOUN
dpc-1540	3	45	,	,	PUNCT
dpc-1540	3	46	severity	severity	NOUN
dpc-1540	3	47	,	,	PUNCT
dpc-1540	3	48	and	and	CCONJ
dpc-1540	3	49	sleep	sleep	VERB
dpc-1540	3	50	quality	quality	NOUN
dpc-1540	3	51	in	in	ADP
dpc-1540	3	52	psoriasis	psoriasis	NOUN
dpc-1540	3	53	patients	patient	NOUN
dpc-1540	3	54	:	:	PUNCT
dpc-1540	3	55	a	a	DET
dpc-1540	3	56	cross	cross	ADJ
dpc-1540	3	57	-	-	ADJ
dpc-1540	3	58	sectional	sectional	ADJ
dpc-1540	3	59	study	study	NOUN
dpc-1540	3	60	.	.	PUNCT
dpc-1540	4	1	dermatol	dermatol	NOUN
dpc-1540	4	2	pract	pract	PROPN
dpc-1540	4	3	concept	concept	NOUN
dpc-1540	4	4	.	.	PUNCT
dpc-1540	5	1	2021;11(3):e2021049.doi	2021;11(3):e2021049.doi	NUM
dpc-1540	5	2	:	:	PUNCT
dpc-1540	5	3	https://doi	https://doi	PROPN
dpc-1540	5	4	.	.	PUNCT
dpc-1540	5	5	org/10.5826	org/10.5826	NUM
dpc-1540	5	6	/	/	SYM
dpc-1540	5	7	dpc.1103a49	dpc.1103a49	PROPN
dpc-1540	5	8	accepted	accept	VERB
dpc-1540	5	9	:	:	PUNCT
dpc-1540	5	10	december	december	PROPN
dpc-1540	5	11	14	14	NUM
dpc-1540	5	12	,	,	PUNCT
dpc-1540	5	13	2020	2020	NUM
dpc-1540	5	14	;	;	PUNCT
dpc-1540	5	15	published	publish	VERB
dpc-1540	5	16	:	:	PUNCT
dpc-1540	5	17	may	may	AUX
dpc-1540	5	18	20	20	NUM
dpc-1540	5	19	,	,	PUNCT
dpc-1540	5	20	2021	2021	NUM
dpc-1540	5	21	copyright	copyright	NOUN
dpc-1540	5	22	:	:	PUNCT
dpc-1540	5	23	©	©	PROPN
dpc-1540	5	24	2021	2021	NUM
dpc-1540	5	25	tas	ta	NOUN
dpc-1540	5	26	and	and	CCONJ
dpc-1540	5	27	kabeloglu	kabeloglu	NOUN
dpc-1540	5	28	.	.	PUNCT
dpc-1540	6	1	this	this	PRON
dpc-1540	6	2	is	be	AUX
dpc-1540	6	3	an	an	DET
dpc-1540	6	4	open	open	ADJ
dpc-1540	6	5	-	-	PUNCT
dpc-1540	6	6	access	access	NOUN
dpc-1540	6	7	article	article	NOUN
dpc-1540	6	8	distributed	distribute	VERB
dpc-1540	6	9	under	under	ADP
dpc-1540	6	10	the	the	DET
dpc-1540	6	11	terms	term	NOUN
dpc-1540	6	12	of	of	ADP
dpc-1540	6	13	the	the	DET
dpc-1540	6	14	creative	creative	ADJ
dpc-1540	6	15	commons	common	NOUN
dpc-1540	6	16	attribution	attribution	NOUN
dpc-1540	6	17	license	license	NOUN
dpc-1540	6	18	by	by	ADP
dpc-1540	6	19	-	-	PUNCT
dpc-1540	6	20	nc-4.0	nc-4.0	NOUN
dpc-1540	6	21	,	,	PUNCT
dpc-1540	6	22	which	which	PRON
dpc-1540	6	23	permits	permit	VERB
dpc-1540	6	24	unrestricted	unrestricted	ADJ
dpc-1540	6	25	noncommercial	noncommercial	ADJ
dpc-1540	6	26	use	use	NOUN
dpc-1540	6	27	,	,	PUNCT
dpc-1540	6	28	distribution	distribution	NOUN
dpc-1540	6	29	,	,	PUNCT
dpc-1540	6	30	and	and	CCONJ
dpc-1540	6	31	reproduction	reproduction	NOUN
dpc-1540	6	32	in	in	ADP
dpc-1540	6	33	any	any	DET
dpc-1540	6	34	medium	medium	NOUN
dpc-1540	6	35	,	,	PUNCT
dpc-1540	6	36	provided	provide	VERB
dpc-1540	6	37	the	the	DET
dpc-1540	6	38	original	original	ADJ
dpc-1540	6	39	authors	author	NOUN
dpc-1540	6	40	and	and	CCONJ
dpc-1540	6	41	source	source	NOUN
dpc-1540	6	42	are	be	AUX
dpc-1540	6	43	credited	credit	VERB
dpc-1540	6	44	.	.	PUNCT
dpc-1540	7	1	funding	funding	NOUN
dpc-1540	7	2	:	:	PUNCT
dpc-1540	7	3	none	none	NOUN
dpc-1540	7	4	.	.	PUNCT
dpc-1540	8	1	competing	compete	VERB
dpc-1540	8	2	interests	interest	NOUN
dpc-1540	8	3	:	:	PUNCT
dpc-1540	8	4	the	the	DET
dpc-1540	8	5	authors	author	NOUN
dpc-1540	8	6	have	have	VERB
dpc-1540	8	7	no	no	DET
dpc-1540	8	8	conflicts	conflict	NOUN
dpc-1540	8	9	of	of	ADP
dpc-1540	8	10	interest	interest	NOUN
dpc-1540	8	11	to	to	PART
dpc-1540	8	12	disclose	disclose	VERB
dpc-1540	8	13	.	.	PUNCT
dpc-1540	9	1	authorship	authorship	NOUN
dpc-1540	9	2	:	:	PUNCT
dpc-1540	9	3	both	both	DET
dpc-1540	9	4	authors	author	NOUN
dpc-1540	9	5	have	have	AUX
dpc-1540	9	6	contributed	contribute	VERB
dpc-1540	9	7	significantly	significantly	ADV
dpc-1540	9	8	to	to	ADP
dpc-1540	9	9	this	this	DET
dpc-1540	9	10	publication	publication	NOUN
dpc-1540	9	11	.	.	PUNCT
dpc-1540	10	1	corresponding	correspond	VERB
dpc-1540	10	2	author	author	NOUN
dpc-1540	10	3	:	:	PUNCT
dpc-1540	10	4	betul	betul	PROPN
dpc-1540	10	5	tas	tas	PROPN
dpc-1540	10	6	,	,	PUNCT
dpc-1540	10	7	md	md	PROPN
dpc-1540	10	8	,	,	PUNCT
dpc-1540	10	9	department	department	NOUN
dpc-1540	10	10	of	of	ADP
dpc-1540	10	11	dermatology	dermatology	NOUN
dpc-1540	10	12	and	and	CCONJ
dpc-1540	10	13	venereology	venereology	NOUN
dpc-1540	10	14	,	,	PUNCT
dpc-1540	10	15	university	university	NOUN
dpc-1540	10	16	of	of	ADP
dpc-1540	10	17	health	health	PROPN
dpc-1540	10	18	sciences	sciences	PROPN
dpc-1540	10	19	,	,	PUNCT
dpc-1540	10	20	istanbul	istanbul	PROPN
dpc-1540	10	21	bagcilar	bagcilar	VERB
dpc-1540	10	22	research	research	NOUN
dpc-1540	10	23	and	and	CCONJ
dpc-1540	10	24	training	training	NOUN
dpc-1540	10	25	hospital	hospital	NOUN
dpc-1540	10	26	,	,	PUNCT
dpc-1540	10	27	atakoy	atakoy	NOUN
dpc-1540	10	28	7	7	NUM
dpc-1540	10	29	-	-	SYM
dpc-1540	10	30	8	8	NUM
dpc-1540	10	31	,	,	PUNCT
dpc-1540	10	32	kısım	kısım	NOUN
dpc-1540	10	33	,	,	PUNCT
dpc-1540	10	34	martı	martı	PROPN
dpc-1540	10	35	14/105	14/105	PROPN
dpc-1540	10	36	,	,	PUNCT
dpc-1540	10	37	bakirkoy	bakirkoy	PROPN
dpc-1540	10	38	,	,	PUNCT
dpc-1540	10	39	istanbul	istanbul	PROPN
dpc-1540	10	40	,	,	PUNCT
dpc-1540	10	41	turkey	turkey	PROPN
dpc-1540	10	42	.	.	PUNCT
dpc-1540	11	1	email	email	NOUN
dpc-1540	11	2	:	:	PUNCT
dpc-1540	12	1	betulavc@yahoo.com	betulavc@yahoo.com	X
dpc-1540	12	2	background	background	NOUN
dpc-1540	12	3	:	:	PUNCT
dpc-1540	12	4	psoriasis	psoriasis	NOUN
dpc-1540	12	5	is	be	AUX
dpc-1540	12	6	an	an	DET
dpc-1540	12	7	inflammatory	inflammatory	ADJ
dpc-1540	12	8	skin	skin	NOUN
dpc-1540	12	9	disease	disease	NOUN
dpc-1540	12	10	that	that	PRON
dpc-1540	12	11	may	may	AUX
dpc-1540	12	12	lead	lead	VERB
dpc-1540	12	13	to	to	ADP
dpc-1540	12	14	comorbidities	comorbiditie	NOUN
dpc-1540	12	15	,	,	PUNCT
dpc-1540	12	16	including	include	VERB
dpc-1540	12	17	metabolic	metabolic	NOUN
dpc-1540	12	18	syndrome	syndrome	NOUN
dpc-1540	12	19	(	(	PUNCT
dpc-1540	12	20	ms	ms	NOUN
dpc-1540	12	21	)	)	PUNCT
dpc-1540	12	22	.	.	PUNCT
dpc-1540	13	1	objective	objective	NOUN
dpc-1540	13	2	:	:	PUNCT
dpc-1540	13	3	we	we	PRON
dpc-1540	13	4	determined	determine	VERB
dpc-1540	13	5	the	the	DET
dpc-1540	13	6	prevalence	prevalence	NOUN
dpc-1540	13	7	of	of	ADP
dpc-1540	13	8	ms	ms	NOUN
dpc-1540	13	9	and	and	CCONJ
dpc-1540	13	10	its	its	PRON
dpc-1540	13	11	correlation	correlation	NOUN
dpc-1540	13	12	with	with	ADP
dpc-1540	13	13	psoriasis	psoriasis	NOUN
dpc-1540	13	14	duration	duration	NOUN
dpc-1540	13	15	,	,	PUNCT
dpc-1540	13	16	severity	severity	NOUN
dpc-1540	13	17	,	,	PUNCT
dpc-1540	13	18	and	and	CCONJ
dpc-1540	13	19	sleep	sleep	VERB
dpc-1540	13	20	quality	quality	NOUN
dpc-1540	13	21	in	in	ADP
dpc-1540	13	22	psoriasis	psoriasis	NOUN
dpc-1540	13	23	patients	patient	NOUN
dpc-1540	13	24	.	.	PUNCT
dpc-1540	14	1	methods	method	NOUN
dpc-1540	14	2	:	:	PUNCT
dpc-1540	14	3	a	a	DET
dpc-1540	14	4	total	total	NOUN
dpc-1540	14	5	of	of	ADP
dpc-1540	14	6	112	112	NUM
dpc-1540	14	7	subjects	subject	NOUN
dpc-1540	14	8	with	with	ADP
dpc-1540	14	9	chronic	chronic	ADJ
dpc-1540	14	10	plaque	plaque	NOUN
dpc-1540	14	11	psoriasis	psoriasis	NOUN
dpc-1540	14	12	were	be	AUX
dpc-1540	14	13	studied	study	VERB
dpc-1540	14	14	.	.	PUNCT
dpc-1540	15	1	demographics	demographic	NOUN
dpc-1540	15	2	,	,	PUNCT
dpc-1540	15	3	ms	ms	PROPN
dpc-1540	15	4	parameters	parameter	NOUN
dpc-1540	15	5	,	,	PUNCT
dpc-1540	15	6	disease	disease	NOUN
dpc-1540	15	7	duration	duration	NOUN
dpc-1540	15	8	,	,	PUNCT
dpc-1540	15	9	severity	severity	NOUN
dpc-1540	15	10	,	,	PUNCT
dpc-1540	15	11	and	and	CCONJ
dpc-1540	15	12	sleep	sleep	NOUN
dpc-1540	15	13	quality	quality	NOUN
dpc-1540	15	14	were	be	AUX
dpc-1540	15	15	examined	examine	VERB
dpc-1540	15	16	.	.	PUNCT
dpc-1540	16	1	the	the	DET
dpc-1540	16	2	psoriasis	psoriasis	NOUN
dpc-1540	16	3	area	area	NOUN
dpc-1540	16	4	and	and	CCONJ
dpc-1540	16	5	severity	severity	NOUN
dpc-1540	16	6	index	index	NOUN
dpc-1540	16	7	(	(	PUNCT
dpc-1540	16	8	pasi	pasi	NOUN
dpc-1540	16	9	)	)	PUNCT
dpc-1540	16	10	and	and	CCONJ
dpc-1540	16	11	the	the	DET
dpc-1540	16	12	pittsburgh	pittsburgh	PROPN
dpc-1540	16	13	sleep	sleep	NOUN
dpc-1540	16	14	quality	quality	PROPN
dpc-1540	16	15	index	index	NOUN
dpc-1540	16	16	(	(	PUNCT
dpc-1540	16	17	psqi	psqi	PROPN
dpc-1540	16	18	)	)	PUNCT
dpc-1540	16	19	were	be	AUX
dpc-1540	16	20	used	use	VERB
dpc-1540	16	21	to	to	PART
dpc-1540	16	22	assess	assess	VERB
dpc-1540	16	23	psoriasis	psoriasis	NOUN
dpc-1540	16	24	severity	severity	NOUN
dpc-1540	16	25	and	and	CCONJ
dpc-1540	16	26	sleep	sleep	VERB
dpc-1540	16	27	quality	quality	NOUN
dpc-1540	16	28	,	,	PUNCT
dpc-1540	16	29	respectively	respectively	ADV
dpc-1540	16	30	.	.	PUNCT
dpc-1540	17	1	presence	presence	NOUN
dpc-1540	17	2	of	of	ADP
dpc-1540	17	3	ms	ms	NOUN
dpc-1540	17	4	and	and	CCONJ
dpc-1540	17	5	its	its	PRON
dpc-1540	17	6	correlations	correlation	NOUN
dpc-1540	17	7	with	with	ADP
dpc-1540	17	8	psoriasis	psoriasis	NOUN
dpc-1540	17	9	duration	duration	NOUN
dpc-1540	17	10	,	,	PUNCT
dpc-1540	17	11	severity	severity	NOUN
dpc-1540	17	12	and	and	CCONJ
dpc-1540	17	13	sleep	sleep	NOUN
dpc-1540	17	14	quality	quality	NOUN
dpc-1540	17	15	were	be	AUX
dpc-1540	17	16	investigated	investigate	VERB
dpc-1540	17	17	.	.	PUNCT
dpc-1540	18	1	results	result	NOUN
dpc-1540	18	2	:	:	PUNCT
dpc-1540	18	3	of	of	ADP
dpc-1540	18	4	112	112	NUM
dpc-1540	18	5	patients	patient	NOUN
dpc-1540	18	6	,	,	PUNCT
dpc-1540	18	7	76	76	NUM
dpc-1540	18	8	(	(	PUNCT
dpc-1540	18	9	67.8	67.8	NUM
dpc-1540	18	10	%	%	NOUN
dpc-1540	18	11	)	)	PUNCT
dpc-1540	18	12	were	be	AUX
dpc-1540	18	13	diagnosed	diagnose	VERB
dpc-1540	18	14	with	with	ADP
dpc-1540	18	15	ms	ms	PROPN
dpc-1540	18	16	.	.	PROPN
dpc-1540	18	17	of	of	ADP
dpc-1540	18	18	all	all	DET
dpc-1540	18	19	patients	patient	NOUN
dpc-1540	18	20	,	,	PUNCT
dpc-1540	18	21	74.1	74.1	NUM
dpc-1540	18	22	%	%	NOUN
dpc-1540	18	23	had	have	VERB
dpc-1540	18	24	a	a	DET
dpc-1540	18	25	high	high	ADJ
dpc-1540	18	26	pasi	pasi	NOUN
dpc-1540	18	27	,	,	PUNCT
dpc-1540	18	28	and	and	CCONJ
dpc-1540	18	29	84.8	84.8	NUM
dpc-1540	18	30	%	%	NOUN
dpc-1540	18	31	had	have	VERB
dpc-1540	18	32	a	a	DET
dpc-1540	18	33	high	high	ADJ
dpc-1540	18	34	psqi	psqi	NOUN
dpc-1540	18	35	.	.	PUNCT
dpc-1540	19	1	the	the	DET
dpc-1540	19	2	mean	mean	ADJ
dpc-1540	19	3	values	value	NOUN
dpc-1540	19	4	of	of	ADP
dpc-1540	19	5	psoriasis	psoriasis	NOUN
dpc-1540	19	6	duration	duration	NOUN
dpc-1540	19	7	,	,	PUNCT
dpc-1540	19	8	body	body	NOUN
dpc-1540	19	9	mass	mass	PROPN
dpc-1540	19	10	index	index	NOUN
dpc-1540	19	11	,	,	PUNCT
dpc-1540	19	12	waist	waist	NOUN
dpc-1540	19	13	circumference	circumference	NOUN
dpc-1540	19	14	,	,	PUNCT
dpc-1540	19	15	fasting	fast	VERB
dpc-1540	19	16	glucose	glucose	NOUN
dpc-1540	19	17	,	,	PUNCT
dpc-1540	19	18	homa	homa	NOUN
dpc-1540	19	19	-	-	PUNCT
dpc-1540	19	20	ir	ir	NOUN
dpc-1540	19	21	,	,	PUNCT
dpc-1540	19	22	triglyceride	triglyceride	ADJ
dpc-1540	19	23	levels	level	NOUN
dpc-1540	19	24	,	,	PUNCT
dpc-1540	19	25	blood	blood	NOUN
dpc-1540	19	26	pressure	pressure	NOUN
dpc-1540	19	27	,	,	PUNCT
dpc-1540	19	28	psqi	psqi	NOUN
dpc-1540	19	29	,	,	PUNCT
dpc-1540	19	30	sleep	sleep	NOUN
dpc-1540	19	31	latency	latency	NOUN
dpc-1540	19	32	,	,	PUNCT
dpc-1540	19	33	and	and	CCONJ
dpc-1540	19	34	daytime	daytime	NOUN
dpc-1540	19	35	sleep	sleep	NOUN
dpc-1540	19	36	dysfunction	dysfunction	NOUN
dpc-1540	19	37	were	be	AUX
dpc-1540	19	38	significantly	significantly	ADV
dpc-1540	19	39	higher	high	ADJ
dpc-1540	19	40	in	in	ADP
dpc-1540	19	41	the	the	DET
dpc-1540	19	42	ms	ms	PROPN
dpc-1540	19	43	group	group	NOUN
dpc-1540	19	44	than	than	ADP
dpc-1540	19	45	non	non	ADJ
dpc-1540	19	46	-	-	ADJ
dpc-1540	19	47	ms	ms	ADJ
dpc-1540	19	48	group	group	NOUN
dpc-1540	19	49	,	,	PUNCT
dpc-1540	19	50	whereas	whereas	SCONJ
dpc-1540	19	51	the	the	DET
dpc-1540	19	52	mean	mean	PROPN
dpc-1540	19	53	hdl	hdl	PROPN
dpc-1540	19	54	level	level	NOUN
dpc-1540	19	55	was	be	AUX
dpc-1540	19	56	lower	low	ADJ
dpc-1540	19	57	.	.	PUNCT
dpc-1540	20	1	the	the	DET
dpc-1540	20	2	prevalences	prevalence	NOUN
dpc-1540	20	3	of	of	ADP
dpc-1540	20	4	ms	ms	PROPN
dpc-1540	20	5	,	,	PUNCT
dpc-1540	20	6	high	high	ADJ
dpc-1540	20	7	fasting	fasting	NOUN
dpc-1540	20	8	glucose	glucose	NOUN
dpc-1540	20	9	,	,	PUNCT
dpc-1540	20	10	and	and	CCONJ
dpc-1540	20	11	low	low	ADJ
dpc-1540	20	12	hdl	hdl	PROPN
dpc-1540	20	13	were	be	AUX
dpc-1540	20	14	significantly	significantly	ADV
dpc-1540	20	15	higher	high	ADJ
dpc-1540	20	16	among	among	ADP
dpc-1540	20	17	female	female	NOUN
dpc-1540	20	18	,	,	PUNCT
dpc-1540	20	19	but	but	CCONJ
dpc-1540	20	20	not	not	PART
dpc-1540	20	21	male	male	ADJ
dpc-1540	20	22	,	,	PUNCT
dpc-1540	20	23	patients	patient	NOUN
dpc-1540	20	24	with	with	ADP
dpc-1540	20	25	severe	severe	ADJ
dpc-1540	20	26	psoriasis	psoriasis	NOUN
dpc-1540	20	27	(	(	PUNCT
dpc-1540	20	28	pasi	pasi	NOUN
dpc-1540	20	29	>	>	X
dpc-1540	20	30	10	10	NUM
dpc-1540	20	31	)	)	PUNCT
dpc-1540	20	32	than	than	ADP
dpc-1540	20	33	those	those	PRON
dpc-1540	20	34	without	without	ADP
dpc-1540	20	35	severe	severe	ADJ
dpc-1540	20	36	psoriasis	psoriasis	NOUN
dpc-1540	20	37	.	.	PUNCT
dpc-1540	21	1	disease	disease	NOUN
dpc-1540	21	2	duration	duration	NOUN
dpc-1540	21	3	,	,	PUNCT
dpc-1540	21	4	high	high	ADJ
dpc-1540	21	5	body	body	NOUN
dpc-1540	21	6	mass	mass	PROPN
dpc-1540	21	7	index	index	NOUN
dpc-1540	21	8	,	,	PUNCT
dpc-1540	21	9	waist	waist	NOUN
dpc-1540	21	10	circumference	circumference	NOUN
dpc-1540	21	11	,	,	PUNCT
dpc-1540	21	12	blood	blood	NOUN
dpc-1540	21	13	pressure	pressure	NOUN
dpc-1540	21	14	,	,	PUNCT
dpc-1540	21	15	fasting	fast	VERB
dpc-1540	21	16	abstract	abstract	ADJ
dpc-1540	21	17	2	2	NUM
dpc-1540	21	18	research	research	NOUN
dpc-1540	21	19	|	|	ADV
dpc-1540	21	20	dermatol	dermatol	ADJ
dpc-1540	21	21	pract	pract	NOUN
dpc-1540	21	22	concept	concept	NOUN
dpc-1540	21	23	.	.	PUNCT
dpc-1540	22	1	2021;11(3):e2021049	2021;11(3):e2021049	NUM
dpc-1540	22	2	introduction	introduction	NOUN
dpc-1540	22	3	psoriasis	psoriasis	NOUN
dpc-1540	22	4	is	be	AUX
dpc-1540	22	5	an	an	DET
dpc-1540	22	6	immune	immune	NOUN
dpc-1540	22	7	-	-	PUNCT
dpc-1540	22	8	mediated	mediate	VERB
dpc-1540	22	9	,	,	PUNCT
dpc-1540	22	10	inflammatory	inflammatory	ADJ
dpc-1540	22	11	skin	skin	NOUN
dpc-1540	22	12	disease	disease	NOUN
dpc-1540	22	13	.	.	PUNCT
dpc-1540	23	1	because	because	SCONJ
dpc-1540	23	2	of	of	ADP
dpc-1540	23	3	the	the	DET
dpc-1540	23	4	increasing	increase	VERB
dpc-1540	23	5	rate	rate	NOUN
dpc-1540	23	6	of	of	ADP
dpc-1540	23	7	coexistence	coexistence	NOUN
dpc-1540	23	8	with	with	ADP
dpc-1540	23	9	many	many	ADJ
dpc-1540	23	10	co	co	NOUN
dpc-1540	23	11	morbidities	morbidity	NOUN
dpc-1540	23	12	,	,	PUNCT
dpc-1540	23	13	psoriasis	psoriasis	NOUN
dpc-1540	23	14	is	be	AUX
dpc-1540	23	15	starting	start	VERB
dpc-1540	23	16	to	to	PART
dpc-1540	23	17	be	be	AUX
dpc-1540	23	18	considered	consider	VERB
dpc-1540	23	19	a	a	DET
dpc-1540	23	20	multisystem	multisystem	NOUN
dpc-1540	23	21	disease	disease	NOUN
dpc-1540	23	22	.	.	PUNCT
dpc-1540	24	1	many	many	ADJ
dpc-1540	24	2	comorbidities	comorbiditie	NOUN
dpc-1540	24	3	have	have	AUX
dpc-1540	24	4	been	be	AUX
dpc-1540	24	5	described	describe	VERB
dpc-1540	24	6	,	,	PUNCT
dpc-1540	24	7	such	such	ADJ
dpc-1540	24	8	as	as	ADP
dpc-1540	24	9	arthritis	arthritis	NOUN
dpc-1540	24	10	,	,	PUNCT
dpc-1540	24	11	obesity	obesity	NOUN
dpc-1540	24	12	,	,	PUNCT
dpc-1540	24	13	hypertension	hypertension	NOUN
dpc-1540	24	14	,	,	PUNCT
dpc-1540	24	15	dyslipidemia	dyslipidemia	NOUN
dpc-1540	24	16	,	,	PUNCT
dpc-1540	24	17	diabetes	diabetes	NOUN
dpc-1540	24	18	mellitus	mellitus	NOUN
dpc-1540	24	19	,	,	PUNCT
dpc-1540	24	20	cardiovascular	cardiovascular	ADJ
dpc-1540	24	21	diseases	disease	NOUN
dpc-1540	24	22	(	(	PUNCT
dpc-1540	24	23	cvds	cvds	PROPN
dpc-1540	24	24	)	)	PUNCT
dpc-1540	24	25	,	,	PUNCT
dpc-1540	24	26	and	and	CCONJ
dpc-1540	24	27	sleep	sleep	VERB
dpc-1540	24	28	disorders	disorder	NOUN
dpc-1540	24	29	[	[	X
dpc-1540	24	30	1,2	1,2	NUM
dpc-1540	24	31	]	]	PUNCT
dpc-1540	24	32	.	.	PUNCT
dpc-1540	25	1	various	various	ADJ
dpc-1540	25	2	factors	factor	NOUN
dpc-1540	25	3	play	play	VERB
dpc-1540	25	4	roles	role	NOUN
dpc-1540	25	5	in	in	ADP
dpc-1540	25	6	the	the	DET
dpc-1540	25	7	sharing	sharing	NOUN
dpc-1540	25	8	of	of	ADP
dpc-1540	25	9	pathogenetic	pathogenetic	ADJ
dpc-1540	25	10	mechanisms	mechanism	NOUN
dpc-1540	25	11	between	between	ADP
dpc-1540	25	12	psoriasis	psoriasis	NOUN
dpc-1540	25	13	and	and	CCONJ
dpc-1540	25	14	these	these	DET
dpc-1540	25	15	comorbidities	comorbiditie	NOUN
dpc-1540	25	16	.	.	PUNCT
dpc-1540	26	1	common	common	ADJ
dpc-1540	26	2	pathways	pathway	NOUN
dpc-1540	26	3	and	and	CCONJ
dpc-1540	26	4	cytokine	cytokine	ADJ
dpc-1540	26	5	profiles	profile	NOUN
dpc-1540	26	6	are	be	AUX
dpc-1540	26	7	used	use	VERB
dpc-1540	26	8	to	to	PART
dpc-1540	26	9	explain	explain	VERB
dpc-1540	26	10	this	this	DET
dpc-1540	26	11	interaction	interaction	NOUN
dpc-1540	26	12	.	.	PUNCT
dpc-1540	27	1	thanks	thank	NOUN
dpc-1540	27	2	to	to	ADP
dpc-1540	27	3	these	these	DET
dpc-1540	27	4	relationships	relationship	NOUN
dpc-1540	27	5	,	,	PUNCT
dpc-1540	27	6	psoriasis	psoriasis	NOUN
dpc-1540	27	7	is	be	AUX
dpc-1540	27	8	beginning	begin	VERB
dpc-1540	27	9	to	to	PART
dpc-1540	27	10	be	be	AUX
dpc-1540	27	11	associated	associate	VERB
dpc-1540	27	12	with	with	ADP
dpc-1540	27	13	metabolic	metabolic	NOUN
dpc-1540	27	14	syndrome	syndrome	NOUN
dpc-1540	27	15	(	(	PUNCT
dpc-1540	27	16	ms	ms	PROPN
dpc-1540	27	17	)	)	PUNCT
dpc-1540	28	1	[	[	X
dpc-1540	28	2	3	3	NUM
dpc-1540	28	3	]	]	PUNCT
dpc-1540	28	4	.	.	PUNCT
dpc-1540	29	1	on	on	ADP
dpc-1540	29	2	the	the	DET
dpc-1540	29	3	other	other	ADJ
dpc-1540	29	4	hand	hand	NOUN
dpc-1540	29	5	,	,	PUNCT
dpc-1540	29	6	ms	ms	PROPN
dpc-1540	29	7	itself	itself	PRON
dpc-1540	29	8	is	be	AUX
dpc-1540	29	9	a	a	DET
dpc-1540	29	10	multisystem	multisystem	NOUN
dpc-1540	29	11	disease	disease	NOUN
dpc-1540	29	12	that	that	PRON
dpc-1540	29	13	is	be	AUX
dpc-1540	29	14	associated	associate	VERB
dpc-1540	29	15	with	with	ADP
dpc-1540	29	16	disorders	disorder	NOUN
dpc-1540	29	17	such	such	ADJ
dpc-1540	29	18	as	as	ADP
dpc-1540	29	19	hypertension	hypertension	NOUN
dpc-1540	29	20	,	,	PUNCT
dpc-1540	29	21	dyslipidemia	dyslipidemia	NOUN
dpc-1540	29	22	,	,	PUNCT
dpc-1540	29	23	high	high	ADJ
dpc-1540	29	24	blood	blood	NOUN
dpc-1540	29	25	glucose	glucose	NOUN
dpc-1540	29	26	,	,	PUNCT
dpc-1540	29	27	and	and	CCONJ
dpc-1540	29	28	cvds	cvds	PROPN
dpc-1540	29	29	.	.	PUNCT
dpc-1540	30	1	psoriasis	psoriasis	NOUN
dpc-1540	30	2	and	and	CCONJ
dpc-1540	30	3	obesity	obesity	NOUN
dpc-1540	30	4	are	be	AUX
dpc-1540	30	5	chronic	chronic	ADJ
dpc-1540	30	6	inflammatory	inflammatory	ADJ
dpc-1540	30	7	diseases	disease	NOUN
dpc-1540	30	8	,	,	PUNCT
dpc-1540	30	9	and	and	CCONJ
dpc-1540	30	10	a	a	DET
dpc-1540	30	11	strong	strong	ADJ
dpc-1540	30	12	correlation	correlation	NOUN
dpc-1540	30	13	has	have	AUX
dpc-1540	30	14	been	be	AUX
dpc-1540	30	15	reported	report	VERB
dpc-1540	30	16	between	between	ADP
dpc-1540	30	17	these	these	DET
dpc-1540	30	18	two	two	NUM
dpc-1540	30	19	disorders	disorder	NOUN
dpc-1540	30	20	.	.	PUNCT
dpc-1540	31	1	abdominal	abdominal	ADJ
dpc-1540	31	2	obesity	obesity	NOUN
dpc-1540	31	3	is	be	AUX
dpc-1540	31	4	considered	consider	VERB
dpc-1540	31	5	the	the	DET
dpc-1540	31	6	most	most	ADV
dpc-1540	31	7	important	important	ADJ
dpc-1540	31	8	parameter	parameter	NOUN
dpc-1540	31	9	in	in	ADP
dpc-1540	31	10	the	the	DET
dpc-1540	31	11	development	development	NOUN
dpc-1540	31	12	of	of	ADP
dpc-1540	31	13	ms	ms	PROPN
dpc-1540	31	14	in	in	ADP
dpc-1540	31	15	psoriasis	psoriasis	NOUN
dpc-1540	31	16	patients	patient	NOUN
dpc-1540	31	17	[	[	X
dpc-1540	31	18	4	4	NUM
dpc-1540	31	19	]	]	PUNCT
dpc-1540	31	20	.	.	PUNCT
dpc-1540	32	1	adipose	adipose	ADP
dpc-1540	32	2	tissue	tissue	NOUN
dpc-1540	32	3	secretes	secrete	NOUN
dpc-1540	32	4	cytokines	cytokine	VERB
dpc-1540	32	5	like	like	ADP
dpc-1540	32	6	tumor	tumor	NOUN
dpc-1540	32	7	necrosis	necrosis	NOUN
dpc-1540	32	8	factor	factor	NOUN
dpc-1540	32	9	alpha	alpha	NOUN
dpc-1540	32	10	(	(	PUNCT
dpc-1540	32	11	tnf	tnf	PROPN
dpc-1540	32	12	-	-	PUNCT
dpc-1540	32	13	alpha	alpha	NOUN
dpc-1540	32	14	)	)	PUNCT
dpc-1540	32	15	,	,	PUNCT
dpc-1540	32	16	which	which	PRON
dpc-1540	32	17	induces	induce	VERB
dpc-1540	32	18	the	the	DET
dpc-1540	32	19	production	production	NOUN
dpc-1540	32	20	of	of	ADP
dpc-1540	32	21	free	free	ADJ
dpc-1540	32	22	fatty	fatty	NOUN
dpc-1540	32	23	acids	acid	NOUN
dpc-1540	32	24	,	,	PUNCT
dpc-1540	32	25	decreases	decrease	VERB
dpc-1540	32	26	adiponectin	adiponectin	NOUN
dpc-1540	32	27	synthesis	synthesis	NOUN
dpc-1540	32	28	,	,	PUNCT
dpc-1540	32	29	disrupts	disrupt	VERB
dpc-1540	32	30	insulin	insulin	NOUN
dpc-1540	32	31	signaling	signal	VERB
dpc-1540	32	32	,	,	PUNCT
dpc-1540	32	33	and	and	CCONJ
dpc-1540	32	34	ultimately	ultimately	ADV
dpc-1540	32	35	leads	lead	VERB
dpc-1540	32	36	to	to	ADP
dpc-1540	32	37	insulin	insulin	NOUN
dpc-1540	32	38	resistance	resistance	NOUN
dpc-1540	33	1	[	[	X
dpc-1540	33	2	5].levels	5].levels	NUM
dpc-1540	33	3	of	of	ADP
dpc-1540	33	4	tnf	tnf	PROPN
dpc-1540	33	5	-	-	PUNCT
dpc-1540	33	6	alpha	alpha	NOUN
dpc-1540	33	7	has	have	AUX
dpc-1540	33	8	been	be	AUX
dpc-1540	33	9	found	find	VERB
dpc-1540	33	10	to	to	PART
dpc-1540	33	11	be	be	AUX
dpc-1540	33	12	significantly	significantly	ADV
dpc-1540	33	13	higher	high	ADJ
dpc-1540	33	14	in	in	ADP
dpc-1540	33	15	the	the	DET
dpc-1540	33	16	skin	skin	NOUN
dpc-1540	33	17	of	of	ADP
dpc-1540	33	18	psoriasis	psoriasis	NOUN
dpc-1540	33	19	patients	patient	NOUN
dpc-1540	33	20	than	than	ADP
dpc-1540	33	21	unaffected	unaffected	ADJ
dpc-1540	33	22	people	people	NOUN
dpc-1540	34	1	[	[	X
dpc-1540	34	2	6,7	6,7	NUM
dpc-1540	34	3	]	]	PUNCT
dpc-1540	34	4	.	.	PUNCT
dpc-1540	35	1	thus	thus	ADV
dpc-1540	35	2	,	,	PUNCT
dpc-1540	35	3	it	it	PRON
dpc-1540	35	4	is	be	AUX
dpc-1540	35	5	suggested	suggest	VERB
dpc-1540	35	6	that	that	SCONJ
dpc-1540	35	7	obesity	obesity	NOUN
dpc-1540	35	8	plays	play	VERB
dpc-1540	35	9	an	an	DET
dpc-1540	35	10	important	important	ADJ
dpc-1540	35	11	role	role	NOUN
dpc-1540	35	12	in	in	ADP
dpc-1540	35	13	increasing	increase	VERB
dpc-1540	35	14	the	the	DET
dpc-1540	35	15	risk	risk	NOUN
dpc-1540	35	16	of	of	ADP
dpc-1540	35	17	development	development	NOUN
dpc-1540	35	18	of	of	ADP
dpc-1540	35	19	ms	ms	NOUN
dpc-1540	35	20	,	,	PUNCT
dpc-1540	35	21	diabetes	diabetes	NOUN
dpc-1540	35	22	mellitus	mellitus	NOUN
dpc-1540	35	23	and	and	CCONJ
dpc-1540	35	24	cvds	cvds	PROPN
dpc-1540	35	25	in	in	ADP
dpc-1540	35	26	psoriasis	psoriasis	NOUN
dpc-1540	35	27	patients	patient	NOUN
dpc-1540	35	28	[	[	X
dpc-1540	35	29	8,9].psoriasis	8,9].psoriasis	NOUN
dpc-1540	35	30	may	may	AUX
dpc-1540	35	31	also	also	ADV
dpc-1540	35	32	lead	lead	VERB
dpc-1540	35	33	to	to	ADP
dpc-1540	35	34	poor	poor	ADJ
dpc-1540	35	35	sleep	sleep	NOUN
dpc-1540	35	36	quality	quality	NOUN
dpc-1540	35	37	,	,	PUNCT
dpc-1540	35	38	because	because	SCONJ
dpc-1540	35	39	it	it	PRON
dpc-1540	35	40	causes	cause	VERB
dpc-1540	35	41	itchiness	itchiness	NOUN
dpc-1540	35	42	and	and	CCONJ
dpc-1540	35	43	sleep	sleep	NOUN
dpc-1540	35	44	disturbances	disturbance	NOUN
dpc-1540	35	45	[	[	X
dpc-1540	35	46	10,11].thus	10,11].thus	NUM
dpc-1540	35	47	,	,	PUNCT
dpc-1540	35	48	we	we	PRON
dpc-1540	35	49	investigated	investigate	VERB
dpc-1540	35	50	the	the	DET
dpc-1540	35	51	presence	presence	NOUN
dpc-1540	35	52	of	of	ADP
dpc-1540	35	53	ms	ms	PROPN
dpc-1540	35	54	and	and	CCONJ
dpc-1540	35	55	ms	ms	PROPN
dpc-1540	35	56	parameters	parameter	NOUN
dpc-1540	35	57	and	and	CCONJ
dpc-1540	35	58	their	their	PRON
dpc-1540	35	59	correlations	correlation	NOUN
dpc-1540	35	60	with	with	ADP
dpc-1540	35	61	psoriasis	psoriasis	NOUN
dpc-1540	35	62	duration	duration	NOUN
dpc-1540	35	63	,	,	PUNCT
dpc-1540	35	64	severity	severity	NOUN
dpc-1540	35	65	,	,	PUNCT
dpc-1540	35	66	and	and	CCONJ
dpc-1540	35	67	sleep	sleep	VERB
dpc-1540	35	68	quality	quality	NOUN
dpc-1540	35	69	,	,	PUNCT
dpc-1540	35	70	and	and	CCONJ
dpc-1540	35	71	also	also	ADV
dpc-1540	35	72	detected	detect	VERB
dpc-1540	35	73	predictive	predictive	ADJ
dpc-1540	35	74	factors	factor	NOUN
dpc-1540	35	75	in	in	ADP
dpc-1540	35	76	the	the	DET
dpc-1540	35	77	development	development	NOUN
dpc-1540	35	78	of	of	ADP
dpc-1540	35	79	ms	ms	NOUN
dpc-1540	35	80	in	in	ADP
dpc-1540	35	81	psoriasis	psoriasis	NOUN
dpc-1540	35	82	patients	patient	NOUN
dpc-1540	35	83	.	.	PUNCT
dpc-1540	36	1	patients	patient	NOUN
dpc-1540	36	2	and	and	CCONJ
dpc-1540	36	3	methods	method	NOUN
dpc-1540	36	4	this	this	PRON
dpc-1540	36	5	was	be	AUX
dpc-1540	36	6	a	a	DET
dpc-1540	36	7	cross	cross	ADJ
dpc-1540	36	8	-	-	ADJ
dpc-1540	36	9	sectional	sectional	ADJ
dpc-1540	36	10	,	,	PUNCT
dpc-1540	36	11	observational	observational	ADJ
dpc-1540	36	12	study	study	NOUN
dpc-1540	36	13	.	.	PUNCT
dpc-1540	37	1	the	the	DET
dpc-1540	37	2	study	study	NOUN
dpc-1540	37	3	protocol	protocol	NOUN
dpc-1540	37	4	was	be	AUX
dpc-1540	37	5	approved	approve	VERB
dpc-1540	37	6	by	by	ADP
dpc-1540	37	7	the	the	DET
dpc-1540	37	8	ethics	ethic	NOUN
dpc-1540	37	9	committee	committee	PROPN
dpc-1540	37	10	of	of	ADP
dpc-1540	37	11	university	university	PROPN
dpc-1540	37	12	of	of	ADP
dpc-1540	37	13	health	health	PROPN
dpc-1540	37	14	sciences	sciences	PROPN
dpc-1540	37	15	,	,	PUNCT
dpc-1540	37	16	istanbul	istanbul	PROPN
dpc-1540	37	17	bagcilar	bagcilar	VERB
dpc-1540	37	18	research	research	NOUN
dpc-1540	37	19	and	and	CCONJ
dpc-1540	37	20	training	training	NOUN
dpc-1540	37	21	hospital	hospital	NOUN
dpc-1540	37	22	(	(	PUNCT
dpc-1540	37	23	approval	approval	NOUN
dpc-1540	37	24	code	code	NOUN
dpc-1540	37	25	,	,	PUNCT
dpc-1540	37	26	2018.11.1.08.108	2018.11.1.08.108	NUM
dpc-1540	37	27	)	)	PUNCT
dpc-1540	37	28	,	,	PUNCT
dpc-1540	37	29	and	and	CCONJ
dpc-1540	37	30	written	write	VERB
dpc-1540	37	31	informed	informed	ADJ
dpc-1540	37	32	consent	consent	NOUN
dpc-1540	37	33	was	be	AUX
dpc-1540	37	34	obtained	obtain	VERB
dpc-1540	37	35	from	from	ADP
dpc-1540	37	36	all	all	DET
dpc-1540	37	37	study	study	NOUN
dpc-1540	37	38	subjects	subject	NOUN
dpc-1540	37	39	.	.	PUNCT
dpc-1540	38	1	study	study	NOUN
dpc-1540	38	2	participants	participant	NOUN
dpc-1540	38	3	were	be	AUX
dpc-1540	38	4	recruited	recruit	VERB
dpc-1540	38	5	from	from	ADP
dpc-1540	38	6	patients	patient	NOUN
dpc-1540	38	7	who	who	PRON
dpc-1540	38	8	attended	attend	VERB
dpc-1540	38	9	our	our	PRON
dpc-1540	38	10	dermatology	dermatology	NOUN
dpc-1540	38	11	clinics	clinic	NOUN
dpc-1540	38	12	between	between	ADP
dpc-1540	38	13	january	january	PROPN
dpc-1540	38	14	and	and	CCONJ
dpc-1540	38	15	july	july	PROPN
dpc-1540	38	16	2019.the	2019.the	DET
dpc-1540	38	17	study	study	NOUN
dpc-1540	38	18	was	be	AUX
dpc-1540	38	19	conducted	conduct	VERB
dpc-1540	38	20	in	in	ADP
dpc-1540	38	21	accordance	accordance	NOUN
dpc-1540	38	22	with	with	ADP
dpc-1540	38	23	the	the	DET
dpc-1540	38	24	world	world	PROPN
dpc-1540	38	25	medical	medical	PROPN
dpc-1540	38	26	association	association	PROPN
dpc-1540	38	27	’s	’s	PART
dpc-1540	38	28	declaration	declaration	NOUN
dpc-1540	38	29	of	of	ADP
dpc-1540	38	30	helsinki	helsinki	PROPN
dpc-1540	38	31	,	,	PUNCT
dpc-1540	38	32	2013	2013	NUM
dpc-1540	38	33	.	.	PUNCT
dpc-1540	39	1	inclusion	inclusion	NOUN
dpc-1540	39	2	criteria	criterion	NOUN
dpc-1540	39	3	were	be	AUX
dpc-1540	39	4	:	:	PUNCT
dpc-1540	39	5	≥18	≥18	NUM
dpc-1540	39	6	years	year	NOUN
dpc-1540	39	7	of	of	ADP
dpc-1540	39	8	age	age	NOUN
dpc-1540	39	9	,	,	PUNCT
dpc-1540	39	10	clinical	clinical	ADJ
dpc-1540	39	11	and	and	CCONJ
dpc-1540	39	12	histopathological	histopathological	ADJ
dpc-1540	39	13	diagnosis	diagnosis	NOUN
dpc-1540	39	14	of	of	ADP
dpc-1540	39	15	psoriasis	psoriasis	NOUN
dpc-1540	39	16	,	,	PUNCT
dpc-1540	39	17	proficiency	proficiency	NOUN
dpc-1540	39	18	in	in	ADP
dpc-1540	39	19	communication	communication	NOUN
dpc-1540	39	20	,	,	PUNCT
dpc-1540	39	21	enough	enough	ADJ
dpc-1540	39	22	understanding	understanding	NOUN
dpc-1540	39	23	of	of	ADP
dpc-1540	39	24	questionnaires	questionnaire	NOUN
dpc-1540	39	25	,	,	PUNCT
dpc-1540	39	26	having	have	VERB
dpc-1540	39	27	no	no	DET
dpc-1540	39	28	other	other	ADJ
dpc-1540	39	29	dermatological	dermatological	ADJ
dpc-1540	39	30	disorders	disorder	NOUN
dpc-1540	39	31	,	,	PUNCT
dpc-1540	39	32	and	and	CCONJ
dpc-1540	39	33	absence	absence	NOUN
dpc-1540	39	34	of	of	ADP
dpc-1540	39	35	a	a	DET
dpc-1540	39	36	previous	previous	ADJ
dpc-1540	39	37	ms	ms	NOUN
dpc-1540	39	38	-	-	PUNCT
dpc-1540	39	39	diagnosis	diagnosis	NOUN
dpc-1540	39	40	.	.	PUNCT
dpc-1540	40	1	exclusion	exclusion	NOUN
dpc-1540	40	2	criteria	criterion	NOUN
dpc-1540	40	3	were	be	AUX
dpc-1540	40	4	:	:	PUNCT
dpc-1540	40	5	cognitive	cognitive	ADJ
dpc-1540	40	6	impairment	impairment	NOUN
dpc-1540	40	7	,	,	PUNCT
dpc-1540	40	8	having	have	VERB
dpc-1540	40	9	other	other	ADJ
dpc-1540	40	10	dermatological	dermatological	ADJ
dpc-1540	40	11	,	,	PUNCT
dpc-1540	40	12	neurological	neurological	ADJ
dpc-1540	40	13	,	,	PUNCT
dpc-1540	40	14	ear	ear	NOUN
dpc-1540	40	15	-	-	PUNCT
dpc-1540	40	16	nose	nose	NOUN
dpc-1540	40	17	-	-	PUNCT
dpc-1540	40	18	throat	throat	NOUN
dpc-1540	40	19	disorders	disorder	NOUN
dpc-1540	40	20	,	,	PUNCT
dpc-1540	40	21	or	or	CCONJ
dpc-1540	40	22	having	have	VERB
dpc-1540	40	23	an	an	DET
dpc-1540	40	24	acute	acute	ADJ
dpc-1540	40	25	upper	upper	ADJ
dpc-1540	40	26	-	-	PUNCT
dpc-1540	40	27	respiratory	respiratory	ADJ
dpc-1540	40	28	-	-	PUNCT
dpc-1540	40	29	tract	tract	NOUN
dpc-1540	40	30	infection	infection	NOUN
dpc-1540	40	31	that	that	PRON
dpc-1540	40	32	could	could	AUX
dpc-1540	40	33	cause	cause	VERB
dpc-1540	40	34	poor	poor	ADJ
dpc-1540	40	35	sleep	sleep	NOUN
dpc-1540	40	36	quality	quality	NOUN
dpc-1540	40	37	.	.	PUNCT
dpc-1540	41	1	patients	patient	NOUN
dpc-1540	41	2	were	be	AUX
dpc-1540	41	3	recruited	recruit	VERB
dpc-1540	41	4	until	until	SCONJ
dpc-1540	41	5	the	the	DET
dpc-1540	41	6	number	number	NOUN
dpc-1540	41	7	enrolled	enrol	VERB
dpc-1540	41	8	reached	reach	VERB
dpc-1540	41	9	a	a	DET
dpc-1540	41	10	previously	previously	ADV
dpc-1540	41	11	determined	determine	VERB
dpc-1540	41	12	sample	sample	NOUN
dpc-1540	41	13	size	size	NOUN
dpc-1540	41	14	(	(	PUNCT
dpc-1540	41	15	it	it	PRON
dpc-1540	41	16	was	be	AUX
dpc-1540	41	17	detected	detect	VERB
dpc-1540	41	18	using	use	VERB
dpc-1540	41	19	a	a	DET
dpc-1540	41	20	sample	sample	NOUN
dpc-1540	41	21	calculation	calculation	NOUN
dpc-1540	41	22	with	with	ADP
dpc-1540	41	23	a	a	DET
dpc-1540	41	24	single	single	ADJ
dpc-1540	41	25	group	group	NOUN
dpc-1540	41	26	proportional	proportional	ADJ
dpc-1540	41	27	data	datum	NOUN
dpc-1540	41	28	size	size	NOUN
dpc-1540	41	29	)	)	PUNCT
dpc-1540	41	30	.	.	PUNCT
dpc-1540	42	1	referencing	reference	VERB
dpc-1540	42	2	the	the	DET
dpc-1540	42	3	average	average	ADJ
dpc-1540	42	4	number	number	NOUN
dpc-1540	42	5	of	of	ADP
dpc-1540	42	6	patients	patient	NOUN
dpc-1540	42	7	who	who	PRON
dpc-1540	42	8	were	be	AUX
dpc-1540	42	9	admitted	admit	VERB
dpc-1540	42	10	to	to	ADP
dpc-1540	42	11	our	our	PRON
dpc-1540	42	12	clinics	clinic	NOUN
dpc-1540	42	13	in	in	ADP
dpc-1540	42	14	the	the	DET
dpc-1540	42	15	determined	determined	ADJ
dpc-1540	42	16	period	period	NOUN
dpc-1540	42	17	,	,	PUNCT
dpc-1540	42	18	the	the	DET
dpc-1540	42	19	sample	sample	NOUN
dpc-1540	42	20	size	size	NOUN
dpc-1540	42	21	was	be	AUX
dpc-1540	42	22	determined	determine	VERB
dpc-1540	42	23	to	to	PART
dpc-1540	42	24	be	be	AUX
dpc-1540	42	25	99with	99with	NUM
dpc-1540	42	26	a	a	DET
dpc-1540	42	27	95	95	NUM
dpc-1540	42	28	%	%	NOUN
dpc-1540	42	29	level	level	NOUN
dpc-1540	42	30	of	of	ADP
dpc-1540	42	31	confidence	confidence	NOUN
dpc-1540	42	32	and	and	CCONJ
dpc-1540	42	33	a	a	DET
dpc-1540	42	34	5	5	NUM
dpc-1540	42	35	%	%	NOUN
dpc-1540	42	36	of	of	ADP
dpc-1540	42	37	margin	margin	NOUN
dpc-1540	42	38	of	of	ADP
dpc-1540	42	39	error	error	NOUN
dpc-1540	42	40	.	.	PUNCT
dpc-1540	43	1	however	however	ADV
dpc-1540	43	2	,	,	PUNCT
dpc-1540	43	3	approximately	approximately	ADV
dpc-1540	43	4	10	10	NUM
dpc-1540	43	5	%	%	NOUN
dpc-1540	43	6	more	more	ADJ
dpc-1540	43	7	subjects	subject	NOUN
dpc-1540	43	8	were	be	AUX
dpc-1540	43	9	enrolled	enrol	VERB
dpc-1540	43	10	,	,	PUNCT
dpc-1540	43	11	in	in	ADP
dpc-1540	43	12	case	case	NOUN
dpc-1540	43	13	any	any	PRON
dpc-1540	43	14	of	of	ADP
dpc-1540	43	15	the	the	DET
dpc-1540	43	16	enrolled	enrol	VERB
dpc-1540	43	17	subjects	subject	NOUN
dpc-1540	43	18	dropped	drop	VERB
dpc-1540	43	19	out	out	ADP
dpc-1540	43	20	of	of	ADP
dpc-1540	43	21	the	the	DET
dpc-1540	43	22	study	study	NOUN
dpc-1540	43	23	.	.	PUNCT
dpc-1540	44	1	data	datum	NOUN
dpc-1540	44	2	collection	collection	NOUN
dpc-1540	44	3	and	and	CCONJ
dpc-1540	44	4	analyses	analyse	VERB
dpc-1540	44	5	the	the	DET
dpc-1540	44	6	study	study	NOUN
dpc-1540	44	7	subjects	subject	NOUN
dpc-1540	44	8	’	'	PUNCT
dpc-1540	44	9	age	age	NOUN
dpc-1540	44	10	,	,	PUNCT
dpc-1540	44	11	gender	gender	NOUN
dpc-1540	44	12	,	,	PUNCT
dpc-1540	44	13	disease	disease	NOUN
dpc-1540	44	14	duration	duration	NOUN
dpc-1540	44	15	,	,	PUNCT
dpc-1540	44	16	smoking	smoking	NOUN
dpc-1540	44	17	habit	habit	NOUN
dpc-1540	44	18	,	,	PUNCT
dpc-1540	44	19	alcohol	alcohol	NOUN
dpc-1540	44	20	consumption	consumption	NOUN
dpc-1540	44	21	habit	habit	NOUN
dpc-1540	44	22	were	be	AUX
dpc-1540	44	23	recorded	record	VERB
dpc-1540	44	24	,	,	PUNCT
dpc-1540	44	25	as	as	SCONJ
dpc-1540	44	26	were	be	AUX
dpc-1540	44	27	previously	previously	ADV
dpc-1540	44	28	diagnosed	diagnose	VERB
dpc-1540	44	29	coexistent	coexistent	ADJ
dpc-1540	44	30	chronic	chronic	ADJ
dpc-1540	44	31	diseases	disease	NOUN
dpc-1540	44	32	,	,	PUNCT
dpc-1540	44	33	namely	namely	ADV
dpc-1540	44	34	diabetes	diabete	VERB
dpc-1540	44	35	mellitus	mellitus	NOUN
dpc-1540	44	36	,	,	PUNCT
dpc-1540	44	37	hypertension	hypertension	NOUN
dpc-1540	44	38	,	,	PUNCT
dpc-1540	44	39	lung	lung	NOUN
dpc-1540	44	40	disease	disease	NOUN
dpc-1540	44	41	,	,	PUNCT
dpc-1540	44	42	chronic	chronic	ADJ
dpc-1540	44	43	kidney	kidney	NOUN
dpc-1540	44	44	disease	disease	NOUN
dpc-1540	44	45	,	,	PUNCT
dpc-1540	44	46	cerebrovascular	cerebrovascular	ADJ
dpc-1540	44	47	disease	disease	NOUN
dpc-1540	44	48	,	,	PUNCT
dpc-1540	44	49	and	and	CCONJ
dpc-1540	44	50	thyroid	thyroid	NOUN
dpc-1540	44	51	disease	disease	NOUN
dpc-1540	44	52	.	.	PUNCT
dpc-1540	45	1	psoriasis	psoriasis	NOUN
dpc-1540	45	2	severity	severity	NOUN
dpc-1540	45	3	was	be	AUX
dpc-1540	45	4	evaluated	evaluate	VERB
dpc-1540	45	5	using	use	VERB
dpc-1540	45	6	the	the	DET
dpc-1540	45	7	psoriasis	psoriasis	NOUN
dpc-1540	45	8	area	area	NOUN
dpc-1540	45	9	and	and	CCONJ
dpc-1540	45	10	severity	severity	NOUN
dpc-1540	45	11	index	index	NOUN
dpc-1540	45	12	(	(	PUNCT
dpc-1540	45	13	pasi	pasi	NOUN
dpc-1540	45	14	)	)	PUNCT
dpc-1540	46	1	[	[	X
dpc-1540	46	2	12	12	NUM
dpc-1540	46	3	]	]	PUNCT
dpc-1540	46	4	.	.	PUNCT
dpc-1540	47	1	this	this	DET
dpc-1540	47	2	index	index	NOUN
dpc-1540	47	3	combines	combine	VERB
dpc-1540	47	4	a	a	DET
dpc-1540	47	5	score	score	NOUN
dpc-1540	47	6	for	for	ADP
dpc-1540	47	7	severity	severity	NOUN
dpc-1540	47	8	(	(	PUNCT
dpc-1540	47	9	erythema	erythema	ADV
dpc-1540	47	10	,	,	PUNCT
dpc-1540	47	11	induration	induration	NOUN
dpc-1540	47	12	and	and	CCONJ
dpc-1540	47	13	desquamation	desquamation	NOUN
dpc-1540	47	14	,	,	PUNCT
dpc-1540	47	15	grades	grade	NOUN
dpc-1540	47	16	of	of	ADP
dpc-1540	47	17	0	0	NUM
dpc-1540	47	18	-	-	SYM
dpc-1540	47	19	4	4	NUM
dpc-1540	47	20	)	)	PUNCT
dpc-1540	47	21	and	and	CCONJ
dpc-1540	47	22	the	the	DET
dpc-1540	47	23	percentage	percentage	NOUN
dpc-1540	47	24	of	of	ADP
dpc-1540	47	25	affected	affect	VERB
dpc-1540	47	26	areas	area	NOUN
dpc-1540	47	27	(	(	PUNCT
dpc-1540	47	28	head	head	NOUN
dpc-1540	47	29	,	,	PUNCT
dpc-1540	47	30	arms	arm	NOUN
dpc-1540	47	31	,	,	PUNCT
dpc-1540	47	32	trunk	trunk	NOUN
dpc-1540	47	33	and	and	CCONJ
dpc-1540	47	34	legs	leg	NOUN
dpc-1540	47	35	,	,	PUNCT
dpc-1540	47	36	from	from	ADP
dpc-1540	47	37	0	0	NUM
dpc-1540	47	38	%	%	NOUN
dpc-1540	47	39	to	to	PART
dpc-1540	47	40	100	100	NUM
dpc-1540	47	41	%	%	NOUN
dpc-1540	47	42	)	)	PUNCT
dpc-1540	47	43	.	.	PUNCT
dpc-1540	48	1	minimum	minimum	NOUN
dpc-1540	48	2	and	and	CCONJ
dpc-1540	48	3	maximum	maximum	ADJ
dpc-1540	48	4	scores	score	NOUN
dpc-1540	48	5	are	be	AUX
dpc-1540	48	6	0	0	NUM
dpc-1540	48	7	and	and	CCONJ
dpc-1540	48	8	72	72	NUM
dpc-1540	48	9	,	,	PUNCT
dpc-1540	48	10	respectively	respectively	ADV
dpc-1540	48	11	.	.	PUNCT
dpc-1540	49	1	values	value	NOUN
dpc-1540	49	2	higher	high	ADJ
dpc-1540	49	3	than	than	ADP
dpc-1540	49	4	10	10	NUM
dpc-1540	49	5	indicate	indicate	VERB
dpc-1540	49	6	moderate	moderate	ADJ
dpc-1540	49	7	-	-	PUNCT
dpc-1540	49	8	severe	severe	ADJ
dpc-1540	49	9	psoriasis	psoriasis	NOUN
dpc-1540	49	10	.	.	PUNCT
dpc-1540	50	1	sleep	sleep	NOUN
dpc-1540	50	2	quality	quality	NOUN
dpc-1540	50	3	was	be	AUX
dpc-1540	50	4	evaluated	evaluate	VERB
dpc-1540	50	5	with	with	ADP
dpc-1540	50	6	the	the	DET
dpc-1540	50	7	pittsburgh	pittsburgh	PROPN
dpc-1540	50	8	sleep	sleep	NOUN
dpc-1540	50	9	quality	quality	PROPN
dpc-1540	50	10	index	index	NOUN
dpc-1540	50	11	(	(	PUNCT
dpc-1540	50	12	psqi	psqi	PROPN
dpc-1540	50	13	)	)	PUNCT
dpc-1540	50	14	,	,	PUNCT
dpc-1540	50	15	which	which	DET
dpc-1540	50	16	measures	measure	NOUN
dpc-1540	50	17	sleep	sleep	VERB
dpc-1540	50	18	quality	quality	NOUN
dpc-1540	50	19	over	over	ADP
dpc-1540	50	20	the	the	DET
dpc-1540	50	21	previous	previous	ADJ
dpc-1540	50	22	month	month	NOUN
dpc-1540	50	23	,	,	PUNCT
dpc-1540	50	24	and	and	CCONJ
dpc-1540	50	25	includes	include	VERB
dpc-1540	50	26	19	19	NUM
dpc-1540	50	27	questions	question	NOUN
dpc-1540	50	28	to	to	PART
dpc-1540	50	29	be	be	AUX
dpc-1540	50	30	answered	answer	VERB
dpc-1540	50	31	by	by	ADP
dpc-1540	50	32	patients	patient	NOUN
dpc-1540	50	33	and	and	CCONJ
dpc-1540	50	34	5questions	5question	NOUN
dpc-1540	50	35	rated	rate	VERB
dpc-1540	50	36	by	by	ADP
dpc-1540	50	37	their	their	PRON
dpc-1540	50	38	bed	bed	NOUN
dpc-1540	50	39	or	or	CCONJ
dpc-1540	50	40	room	room	NOUN
dpc-1540	50	41	partner	partner	NOUN
dpc-1540	50	42	(	(	PUNCT
dpc-1540	50	43	if	if	SCONJ
dpc-1540	50	44	one	one	PRON
dpc-1540	50	45	exists	exist	VERB
dpc-1540	50	46	)	)	PUNCT
dpc-1540	50	47	.	.	PUNCT
dpc-1540	51	1	the	the	DET
dpc-1540	51	2	questions	question	NOUN
dpc-1540	51	3	form	form	VERB
dpc-1540	51	4	the	the	DET
dpc-1540	51	5	component	component	NOUN
dpc-1540	51	6	scores	score	NOUN
dpc-1540	51	7	,	,	PUNCT
dpc-1540	51	8	each	each	PRON
dpc-1540	51	9	of	of	ADP
dpc-1540	51	10	which	which	PRON
dpc-1540	51	11	has	have	VERB
dpc-1540	51	12	a	a	DET
dpc-1540	51	13	range	range	NOUN
dpc-1540	51	14	of	of	ADP
dpc-1540	51	15	0	0	NUM
dpc-1540	51	16	-	-	SYM
dpc-1540	51	17	3	3	NUM
dpc-1540	51	18	points	point	NOUN
dpc-1540	51	19	.	.	PUNCT
dpc-1540	52	1	a	a	DET
dpc-1540	52	2	score	score	NOUN
dpc-1540	52	3	of	of	ADP
dpc-1540	52	4	0	0	NUM
dpc-1540	52	5	indicates	indicate	VERB
dpc-1540	52	6	no	no	DET
dpc-1540	52	7	glucose	glucose	NOUN
dpc-1540	52	8	,	,	PUNCT
dpc-1540	52	9	homa	homa	NOUN
dpc-1540	52	10	-	-	PUNCT
dpc-1540	52	11	ir	ir	NOUN
dpc-1540	52	12	,	,	PUNCT
dpc-1540	52	13	triglyceride	triglyceride	ADJ
dpc-1540	52	14	levels	level	NOUN
dpc-1540	52	15	,	,	PUNCT
dpc-1540	52	16	low	low	ADJ
dpc-1540	52	17	hdl	hdl	PROPN
dpc-1540	52	18	,	,	PUNCT
dpc-1540	52	19	and	and	CCONJ
dpc-1540	52	20	poor	poor	ADJ
dpc-1540	52	21	sleep	sleep	NOUN
dpc-1540	52	22	quality	quality	NOUN
dpc-1540	52	23	were	be	AUX
dpc-1540	52	24	significantly	significantly	ADV
dpc-1540	52	25	correlated	correlate	VERB
dpc-1540	52	26	with	with	ADP
dpc-1540	52	27	the	the	DET
dpc-1540	52	28	presence	presence	NOUN
dpc-1540	52	29	of	of	ADP
dpc-1540	52	30	ms	ms	PROPN
dpc-1540	52	31	.	.	PROPN
dpc-1540	53	1	however	however	ADV
dpc-1540	53	2	,	,	PUNCT
dpc-1540	53	3	only	only	ADV
dpc-1540	53	4	waist	waist	NOUN
dpc-1540	53	5	circumference	circumference	NOUN
dpc-1540	53	6	,	,	PUNCT
dpc-1540	53	7	fasting	fast	VERB
dpc-1540	53	8	glucose	glucose	NOUN
dpc-1540	53	9	,	,	PUNCT
dpc-1540	53	10	blood	blood	NOUN
dpc-1540	53	11	pressure	pressure	NOUN
dpc-1540	53	12	,	,	PUNCT
dpc-1540	53	13	and	and	CCONJ
dpc-1540	53	14	low	low	ADJ
dpc-1540	53	15	hdl	hdl	PROPN
dpc-1540	53	16	were	be	AUX
dpc-1540	53	17	predictive	predictive	ADJ
dpc-1540	53	18	of	of	ADP
dpc-1540	53	19	the	the	DET
dpc-1540	53	20	development	development	NOUN
dpc-1540	53	21	of	of	ADP
dpc-1540	53	22	ms	ms	PROPN
dpc-1540	53	23	.	.	PROPN
dpc-1540	53	24	conclusions	conclusion	NOUN
dpc-1540	53	25	:	:	PUNCT
dpc-1540	53	26	ms	ms	PROPN
dpc-1540	53	27	is	be	AUX
dpc-1540	53	28	common	common	ADJ
dpc-1540	53	29	among	among	ADP
dpc-1540	53	30	psoriasis	psoriasis	NOUN
dpc-1540	53	31	patients	patient	NOUN
dpc-1540	53	32	,	,	PUNCT
dpc-1540	53	33	and	and	CCONJ
dpc-1540	53	34	especially	especially	ADV
dpc-1540	53	35	in	in	ADP
dpc-1540	53	36	females	female	NOUN
dpc-1540	53	37	with	with	ADP
dpc-1540	53	38	advanced	advanced	ADJ
dpc-1540	53	39	psoriasis	psoriasis	NOUN
dpc-1540	53	40	,	,	PUNCT
dpc-1540	53	41	high	high	ADJ
dpc-1540	53	42	fasting	fasting	NOUN
dpc-1540	53	43	glucose	glucose	NOUN
dpc-1540	53	44	,	,	PUNCT
dpc-1540	53	45	and	and	CCONJ
dpc-1540	53	46	low	low	ADJ
dpc-1540	53	47	hdl	hdl	PROPN
dpc-1540	53	48	levels	level	NOUN
dpc-1540	53	49	.	.	PUNCT
dpc-1540	54	1	besides	besides	SCONJ
dpc-1540	54	2	diagnostic	diagnostic	ADJ
dpc-1540	54	3	criteria	criterion	NOUN
dpc-1540	54	4	of	of	ADP
dpc-1540	54	5	ms	ms	NOUN
dpc-1540	54	6	,	,	PUNCT
dpc-1540	54	7	a	a	DET
dpc-1540	54	8	long	long	ADJ
dpc-1540	54	9	duration	duration	NOUN
dpc-1540	54	10	of	of	ADP
dpc-1540	54	11	psoriasis	psoriasis	NOUN
dpc-1540	54	12	,	,	PUNCT
dpc-1540	54	13	poor	poor	ADJ
dpc-1540	54	14	sleep	sleep	NOUN
dpc-1540	54	15	quality	quality	NOUN
dpc-1540	54	16	and	and	CCONJ
dpc-1540	54	17	high	high	ADJ
dpc-1540	54	18	-	-	PUNCT
dpc-1540	54	19	homa	homa	NOUN
dpc-1540	54	20	-	-	PUNCT
dpc-1540	54	21	ir	ir	NOUN
dpc-1540	54	22	correlate	correlate	VERB
dpc-1540	54	23	with	with	ADP
dpc-1540	54	24	the	the	DET
dpc-1540	54	25	development	development	NOUN
dpc-1540	54	26	of	of	ADP
dpc-1540	54	27	ms	ms	PROPN
dpc-1540	54	28	.	.	PROPN
dpc-1540	54	29	high	high	ADJ
dpc-1540	54	30	fasting	fasting	NOUN
dpc-1540	54	31	glucose	glucose	NOUN
dpc-1540	54	32	and	and	CCONJ
dpc-1540	54	33	low	low	ADJ
dpc-1540	54	34	hdl	hdl	PROPN
dpc-1540	54	35	levels	level	NOUN
dpc-1540	54	36	may	may	AUX
dpc-1540	54	37	facilitate	facilitate	VERB
dpc-1540	54	38	ms	ms	ADJ
dpc-1540	54	39	development	development	NOUN
dpc-1540	54	40	in	in	ADP
dpc-1540	54	41	association	association	NOUN
dpc-1540	54	42	with	with	ADP
dpc-1540	54	43	psoriasis	psoriasis	NOUN
dpc-1540	54	44	severity	severity	NOUN
dpc-1540	54	45	in	in	ADP
dpc-1540	54	46	females	female	NOUN
dpc-1540	54	47	.	.	PUNCT
dpc-1540	55	1	research	research	NOUN
dpc-1540	55	2	|	|	ADV
dpc-1540	55	3	dermatol	dermatol	ADJ
dpc-1540	55	4	pract	pract	NOUN
dpc-1540	55	5	concept	concept	NOUN
dpc-1540	55	6	.	.	PUNCT
dpc-1540	56	1	2021;11(3):e2021049	2021;11(3):e2021049	NUM
dpc-1540	56	2	3	3	NUM
dpc-1540	56	3	difficulty	difficulty	NOUN
dpc-1540	56	4	in	in	ADP
dpc-1540	56	5	sleep	sleep	NOUN
dpc-1540	56	6	,	,	PUNCT
dpc-1540	56	7	while	while	SCONJ
dpc-1540	56	8	a	a	DET
dpc-1540	56	9	score	score	NOUN
dpc-1540	56	10	of	of	ADP
dpc-1540	56	11	3	3	NUM
dpc-1540	56	12	indicates	indicate	VERB
dpc-1540	56	13	severe	severe	ADJ
dpc-1540	56	14	difficulty	difficulty	NOUN
dpc-1540	56	15	.	.	PUNCT
dpc-1540	57	1	the	the	DET
dpc-1540	57	2	7sub	7sub	PROPN
dpc-1540	57	3	-	-	PUNCT
dpc-1540	57	4	component	component	NOUN
dpc-1540	57	5	scores	score	NOUN
dpc-1540	57	6	,	,	PUNCT
dpc-1540	57	7	which	which	PRON
dpc-1540	57	8	indicate	indicate	VERB
dpc-1540	57	9	subjective	subjective	ADJ
dpc-1540	57	10	sleep	sleep	NOUN
dpc-1540	57	11	quality	quality	NOUN
dpc-1540	57	12	(	(	PUNCT
dpc-1540	57	13	pssq	pssq	NOUN
dpc-1540	57	14	)	)	PUNCT
dpc-1540	57	15	,	,	PUNCT
dpc-1540	57	16	sleep	sleep	NOUN
dpc-1540	57	17	latency	latency	NOUN
dpc-1540	57	18	(	(	PUNCT
dpc-1540	57	19	psl	psl	PROPN
dpc-1540	57	20	)	)	PUNCT
dpc-1540	57	21	,	,	PUNCT
dpc-1540	57	22	sleep	sleep	VERB
dpc-1540	57	23	duration	duration	NOUN
dpc-1540	57	24	(	(	PUNCT
dpc-1540	57	25	psdu	psdu	NOUN
dpc-1540	57	26	)	)	PUNCT
dpc-1540	57	27	,	,	PUNCT
dpc-1540	57	28	habitual	habitual	ADJ
dpc-1540	57	29	sleep	sleep	NOUN
dpc-1540	57	30	efficiency	efficiency	NOUN
dpc-1540	57	31	(	(	PUNCT
dpc-1540	57	32	phse	phse	NOUN
dpc-1540	57	33	)	)	PUNCT
dpc-1540	57	34	,	,	PUNCT
dpc-1540	57	35	sleep	sleep	NOUN
dpc-1540	57	36	disturbances	disturbance	NOUN
dpc-1540	57	37	(	(	PUNCT
dpc-1540	57	38	psdi	psdi	NOUN
dpc-1540	57	39	)	)	PUNCT
dpc-1540	57	40	,	,	PUNCT
dpc-1540	57	41	use	use	NOUN
dpc-1540	57	42	of	of	ADP
dpc-1540	57	43	sleeping	sleep	VERB
dpc-1540	57	44	medication	medication	NOUN
dpc-1540	57	45	(	(	PUNCT
dpc-1540	57	46	pusm	pusm	NOUN
dpc-1540	57	47	)	)	PUNCT
dpc-1540	57	48	,	,	PUNCT
dpc-1540	57	49	and	and	CCONJ
dpc-1540	57	50	daytime	daytime	NOUN
dpc-1540	57	51	sleep	sleep	NOUN
dpc-1540	57	52	dysfunction	dysfunction	NOUN
dpc-1540	57	53	(	(	PUNCT
dpc-1540	57	54	pdsd	pdsd	NOUN
dpc-1540	57	55	)	)	PUNCT
dpc-1540	57	56	,	,	PUNCT
dpc-1540	57	57	add	add	VERB
dpc-1540	57	58	up	up	ADP
dpc-1540	57	59	to	to	ADP
dpc-1540	57	60	a	a	DET
dpc-1540	57	61	total	total	ADJ
dpc-1540	57	62	score	score	NOUN
dpc-1540	57	63	(	(	PUNCT
dpc-1540	57	64	0	0	NUM
dpc-1540	57	65	-	-	SYM
dpc-1540	57	66	21	21	NUM
dpc-1540	57	67	points	point	NOUN
dpc-1540	57	68	)	)	PUNCT
dpc-1540	57	69	.	.	PUNCT
dpc-1540	58	1	a	a	DET
dpc-1540	58	2	total	total	ADJ
dpc-1540	58	3	score	score	NOUN
dpc-1540	58	4	≥5	≥5	NUM
dpc-1540	58	5	indicates	indicate	VERB
dpc-1540	58	6	poor	poor	ADJ
dpc-1540	58	7	sleep	sleep	NOUN
dpc-1540	58	8	quality	quality	NOUN
dpc-1540	58	9	[	[	X
dpc-1540	58	10	13	13	NUM
dpc-1540	58	11	]	]	PUNCT
dpc-1540	58	12	.	.	PUNCT
dpc-1540	59	1	the	the	DET
dpc-1540	59	2	psqi	psqi	NOUN
dpc-1540	59	3	was	be	AUX
dpc-1540	59	4	adapted	adapt	VERB
dpc-1540	59	5	to	to	ADP
dpc-1540	59	6	the	the	DET
dpc-1540	59	7	turkish	turkish	ADJ
dpc-1540	59	8	population	population	NOUN
dpc-1540	59	9	by	by	ADP
dpc-1540	59	10	agargun	agargun	NOUN
dpc-1540	59	11	et	et	PROPN
dpc-1540	59	12	al	al	PROPN
dpc-1540	60	1	[	[	X
dpc-1540	60	2	14	14	NUM
dpc-1540	60	3	]	]	PUNCT
dpc-1540	60	4	.	.	PUNCT
dpc-1540	61	1	the	the	DET
dpc-1540	61	2	national	national	ADJ
dpc-1540	61	3	cholesterol	cholesterol	PROPN
dpc-1540	61	4	education	education	NOUN
dpc-1540	61	5	program	program	NOUN
dpc-1540	61	6	adult	adult	NOUN
dpc-1540	61	7	treatment	treatment	NOUN
dpc-1540	61	8	panel	panel	NOUN
dpc-1540	61	9	iii	iii	X
dpc-1540	61	10	(	(	PUNCT
dpc-1540	61	11	atp	atp	PROPN
dpc-1540	61	12	iii	iii	PROPN
dpc-1540	61	13	)	)	PUNCT
dpc-1540	61	14	criteria	criterion	NOUN
dpc-1540	61	15	were	be	AUX
dpc-1540	61	16	used	use	VERB
dpc-1540	61	17	to	to	PART
dpc-1540	61	18	investigate	investigate	VERB
dpc-1540	61	19	ms	ms	NOUN
dpc-1540	61	20	parameters	parameter	NOUN
dpc-1540	61	21	[	[	X
dpc-1540	61	22	15	15	NUM
dpc-1540	61	23	]	]	PUNCT
dpc-1540	61	24	.	.	PUNCT
dpc-1540	62	1	first	first	ADV
dpc-1540	62	2	,	,	PUNCT
dpc-1540	62	3	the	the	DET
dpc-1540	62	4	anthropometric	anthropometric	ADJ
dpc-1540	62	5	parameters	parameter	NOUN
dpc-1540	62	6	of	of	ADP
dpc-1540	62	7	weight	weight	NOUN
dpc-1540	62	8	,	,	PUNCT
dpc-1540	62	9	body	body	NOUN
dpc-1540	62	10	mass	mass	NOUN
dpc-1540	62	11	index	index	NOUN
dpc-1540	62	12	(	(	PUNCT
dpc-1540	62	13	bmi	bmi	PROPN
dpc-1540	62	14	)	)	PUNCT
dpc-1540	62	15	,	,	PUNCT
dpc-1540	62	16	and	and	CCONJ
dpc-1540	62	17	waist	waist	NOUN
dpc-1540	62	18	circumference	circumference	NOUN
dpc-1540	62	19	,	,	PUNCT
dpc-1540	62	20	and	and	CCONJ
dpc-1540	62	21	systolic	systolic	ADJ
dpc-1540	62	22	and	and	CCONJ
dpc-1540	62	23	diastolic	diastolic	ADJ
dpc-1540	62	24	blood	blood	NOUN
dpc-1540	62	25	pressures	pressure	NOUN
dpc-1540	62	26	(	(	PUNCT
dpc-1540	62	27	sbp	sbp	PROPN
dpc-1540	62	28	,	,	PUNCT
dpc-1540	62	29	dbp	dbp	PROPN
dpc-1540	62	30	)	)	PUNCT
dpc-1540	62	31	were	be	AUX
dpc-1540	62	32	measured	measure	VERB
dpc-1540	62	33	[	[	X
dpc-1540	62	34	14	14	NUM
dpc-1540	62	35	]	]	PUNCT
dpc-1540	62	36	.	.	PUNCT
dpc-1540	63	1	subjects	subject	NOUN
dpc-1540	63	2	who	who	PRON
dpc-1540	63	3	had	have	VERB
dpc-1540	63	4	≥3	≥3	PROPN
dpc-1540	63	5	of	of	ADP
dpc-1540	63	6	the	the	DET
dpc-1540	63	7	following	follow	VERB
dpc-1540	63	8	parameters	parameter	NOUN
dpc-1540	63	9	were	be	AUX
dpc-1540	63	10	diagnosed	diagnose	VERB
dpc-1540	63	11	with	with	ADP
dpc-1540	63	12	ms	ms	NOUN
dpc-1540	63	13	:	:	PUNCT
dpc-1540	63	14	fasting	fast	VERB
dpc-1540	63	15	glucose	glucose	NOUN
dpc-1540	63	16	≥110	≥110	ADJ
dpc-1540	63	17	mg	mg	PROPN
dpc-1540	63	18	/	/	SYM
dpc-1540	63	19	dl	dl	PROPN
dpc-1540	63	20	;	;	PUNCT
dpc-1540	63	21	fasting	fast	VERB
dpc-1540	63	22	triglyceride	triglyceride	ADP
dpc-1540	63	23	≥150	≥150	NOUN
dpc-1540	63	24	mg	mg	PROPN
dpc-1540	63	25	/	/	SYM
dpc-1540	63	26	dl	dl	PROPN
dpc-1540	63	27	;	;	PUNCT
dpc-1540	63	28	hdl<50	hdl<50	PROPN
dpc-1540	63	29	mg	mg	PROPN
dpc-1540	63	30	/	/	SYM
dpc-1540	63	31	dl	dl	PROPN
dpc-1540	63	32	for	for	ADP
dpc-1540	63	33	women	woman	NOUN
dpc-1540	63	34	and<40	and<40	ADP
dpc-1540	63	35	mg	mg	PROPN
dpc-1540	63	36	/	/	SYM
dpc-1540	63	37	dl	dl	PROPN
dpc-1540	63	38	for	for	ADP
dpc-1540	63	39	men	man	NOUN
dpc-1540	63	40	;	;	PUNCT
dpc-1540	63	41	waist	waist	NOUN
dpc-1540	63	42	circumference>88	circumference>88	PROPN
dpc-1540	63	43	cm	cm	NOUN
dpc-1540	63	44	for	for	ADP
dpc-1540	63	45	women	woman	NOUN
dpc-1540	63	46	and	and	CCONJ
dpc-1540	63	47	>	>	X
dpc-1540	63	48	102	102	NUM
dpc-1540	63	49	cm	cm	NOUN
dpc-1540	63	50	for	for	ADP
dpc-1540	63	51	men	man	NOUN
dpc-1540	63	52	;	;	PUNCT
dpc-1540	63	53	and	and	CCONJ
dpc-1540	63	54	sbp	sbp	PROPN
dpc-1540	63	55	≥130	≥130	NOUN
dpc-1540	63	56	mmhg	mmhg	PROPN
dpc-1540	63	57	or	or	CCONJ
dpc-1540	63	58	dbp	dbp	PROPN
dpc-1540	63	59	≥85	≥85	PROPN
dpc-1540	63	60	mmhg	mmhg	PROPN
dpc-1540	64	1	[	[	X
dpc-1540	64	2	15	15	NUM
dpc-1540	64	3	]	]	PUNCT
dpc-1540	64	4	.	.	PUNCT
dpc-1540	65	1	bmi	bmi	PROPN
dpc-1540	65	2	was	be	AUX
dpc-1540	65	3	calculated	calculate	VERB
dpc-1540	65	4	as	as	ADP
dpc-1540	65	5	weight	weight	NOUN
dpc-1540	65	6	(	(	PUNCT
dpc-1540	65	7	kilograms	kilogram	NOUN
dpc-1540	65	8	)	)	PUNCT
dpc-1540	65	9	divided	divide	VERB
dpc-1540	65	10	by	by	ADP
dpc-1540	65	11	height	height	NOUN
dpc-1540	65	12	(	(	PUNCT
dpc-1540	65	13	square	square	ADJ
dpc-1540	65	14	meters	meter	NOUN
dpc-1540	65	15	)	)	PUNCT
dpc-1540	65	16	,	,	PUNCT
dpc-1540	65	17	and	and	CCONJ
dpc-1540	65	18	was	be	AUX
dpc-1540	65	19	evaluated	evaluate	VERB
dpc-1540	65	20	as	as	ADP
dpc-1540	65	21	non	non	ADJ
dpc-1540	65	22	-	-	ADJ
dpc-1540	65	23	obese	obese	ADJ
dpc-1540	65	24	(	(	PUNCT
dpc-1540	65	25	<	<	X
dpc-1540	65	26	30	30	NUM
dpc-1540	65	27	)	)	PUNCT
dpc-1540	65	28	and	and	CCONJ
dpc-1540	65	29	obese	obese	NOUN
dpc-1540	65	30	(	(	PUNCT
dpc-1540	65	31	≥30	≥30	PROPN
dpc-1540	65	32	)	)	PUNCT
dpc-1540	66	1	[	[	X
dpc-1540	66	2	16	16	NUM
dpc-1540	66	3	]	]	PUNCT
dpc-1540	66	4	.	.	PUNCT
dpc-1540	67	1	waist	waist	NOUN
dpc-1540	67	2	circumference	circumference	NOUN
dpc-1540	67	3	was	be	AUX
dpc-1540	67	4	measured	measure	VERB
dpc-1540	67	5	at	at	ADP
dpc-1540	67	6	the	the	DET
dpc-1540	67	7	midpoint	midpoint	NOUN
dpc-1540	67	8	between	between	ADP
dpc-1540	67	9	the	the	DET
dpc-1540	67	10	twelfth	twelfth	ADJ
dpc-1540	67	11	rib	rib	NOUN
dpc-1540	67	12	and	and	CCONJ
dpc-1540	67	13	the	the	DET
dpc-1540	67	14	iliac	iliac	NOUN
dpc-1540	67	15	crest	crest	NOUN
dpc-1540	67	16	[	[	X
dpc-1540	67	17	17	17	NUM
dpc-1540	67	18	]	]	PUNCT
dpc-1540	67	19	.	.	PUNCT
dpc-1540	68	1	sbp	sbp	PROPN
dpc-1540	68	2	and	and	CCONJ
dpc-1540	68	3	dbp	dbp	PROPN
dpc-1540	68	4	were	be	AUX
dpc-1540	68	5	measured	measure	VERB
dpc-1540	68	6	following	follow	VERB
dpc-1540	68	7	the	the	DET
dpc-1540	68	8	jnc-7	jnc-7	ADJ
dpc-1540	68	9	guidelines	guideline	NOUN
dpc-1540	68	10	[	[	X
dpc-1540	68	11	18	18	NUM
dpc-1540	68	12	]	]	PUNCT
dpc-1540	68	13	.	.	PUNCT
dpc-1540	69	1	plasma	plasma	NOUN
dpc-1540	69	2	fasting	fast	VERB
dpc-1540	69	3	glucose	glucose	NOUN
dpc-1540	69	4	,	,	PUNCT
dpc-1540	69	5	hdl	hdl	PROPN
dpc-1540	69	6	and	and	CCONJ
dpc-1540	69	7	triglyceride	triglyceride	ADJ
dpc-1540	69	8	levels	level	NOUN
dpc-1540	69	9	were	be	AUX
dpc-1540	69	10	analyzed	analyze	VERB
dpc-1540	69	11	by	by	ADP
dpc-1540	69	12	automated	automate	VERB
dpc-1540	69	13	enzyme	enzyme	NOUN
dpc-1540	69	14	immunoassay	immunoassay	NOUN
dpc-1540	69	15	and	and	CCONJ
dpc-1540	69	16	serum	serum	NOUN
dpc-1540	69	17	insulin	insulin	NOUN
dpc-1540	69	18	levels	level	NOUN
dpc-1540	69	19	were	be	AUX
dpc-1540	69	20	measured	measure	VERB
dpc-1540	69	21	using	use	VERB
dpc-1540	69	22	an	an	DET
dpc-1540	69	23	electrochemiluminescence	electrochemiluminescence	NOUN
dpc-1540	69	24	immunoassay	immunoassay	NOUN
dpc-1540	69	25	(	(	PUNCT
dpc-1540	69	26	cobras	cobras	PROPN
dpc-1540	69	27	6000	6000	NUM
dpc-1540	69	28	-	-	SYM
dpc-1540	69	29	601	601	NUM
dpc-1540	69	30	automated	automate	VERB
dpc-1540	69	31	analyzer	analyzer	NOUN
dpc-1540	69	32	,	,	PUNCT
dpc-1540	69	33	roche	roche	NOUN
dpc-1540	69	34	diagnostics	diagnostic	NOUN
dpc-1540	69	35	)	)	PUNCT
dpc-1540	69	36	.	.	PUNCT
dpc-1540	70	1	insulin	insulin	NOUN
dpc-1540	70	2	resistance	resistance	NOUN
dpc-1540	70	3	was	be	AUX
dpc-1540	70	4	detected	detect	VERB
dpc-1540	70	5	by	by	ADP
dpc-1540	70	6	calculating	calculate	VERB
dpc-1540	70	7	the	the	DET
dpc-1540	70	8	homeostatic	homeostatic	ADJ
dpc-1540	70	9	model	model	NOUN
dpc-1540	70	10	assessment	assessment	NOUN
dpc-1540	70	11	-	-	PUNCT
dpc-1540	70	12	insulin	insulin	NOUN
dpc-1540	70	13	resistance	resistance	NOUN
dpc-1540	70	14	(	(	PUNCT
dpc-1540	70	15	homa	homa	NOUN
dpc-1540	70	16	-	-	PUNCT
dpc-1540	70	17	ir	ir	NOUN
dpc-1540	70	18	)	)	PUNCT
dpc-1540	70	19	index	index	NOUN
dpc-1540	70	20	as	as	SCONJ
dpc-1540	70	21	follows	follow	VERB
dpc-1540	70	22	:	:	PUNCT
dpc-1540	70	23	homa	homa	NOUN
dpc-1540	70	24	-	-	PUNCT
dpc-1540	70	25	ir	ir	NOUN
dpc-1540	70	26	=	=	NOUN
dpc-1540	70	27	fasting	fast	VERB
dpc-1540	70	28	insulin	insulin	NOUN
dpc-1540	70	29	(	(	PUNCT
dpc-1540	70	30	miu	miu	PROPN
dpc-1540	70	31	/	/	SYM
dpc-1540	70	32	l)×fasting	l)×faste	VERB
dpc-1540	70	33	glucose	glucose	NOUN
dpc-1540	70	34	(	(	PUNCT
dpc-1540	70	35	mg	mg	PROPN
dpc-1540	70	36	/	/	SYM
dpc-1540	70	37	dl)/405	dl)/405	PROPN
dpc-1540	71	1	[	[	X
dpc-1540	71	2	19	19	NUM
dpc-1540	71	3	]	]	PUNCT
dpc-1540	71	4	.	.	PUNCT
dpc-1540	72	1	values	value	NOUN
dpc-1540	72	2	of	of	ADP
dpc-1540	72	3	homa	homa	NOUN
dpc-1540	72	4	-	-	PUNCT
dpc-1540	72	5	ir	ir	PROPN
dpc-1540	72	6	were	be	AUX
dpc-1540	72	7	considered	consider	VERB
dpc-1540	72	8	normal	normal	ADJ
dpc-1540	72	9	if	if	SCONJ
dpc-1540	72	10	<	<	X
dpc-1540	72	11	2.5	2.5	NUM
dpc-1540	72	12	and	and	CCONJ
dpc-1540	72	13	high	high	ADJ
dpc-1540	72	14	if	if	SCONJ
dpc-1540	72	15	≥2.5	≥2.5	NOUN
dpc-1540	72	16	[	[	X
dpc-1540	72	17	20	20	NUM
dpc-1540	72	18	]	]	PUNCT
dpc-1540	72	19	.	.	PUNCT
dpc-1540	73	1	statistical	statistical	ADJ
dpc-1540	73	2	analyses	analysis	NOUN
dpc-1540	73	3	ncss	ncss	PROPN
dpc-1540	73	4	(	(	PUNCT
dpc-1540	73	5	number	number	NOUN
dpc-1540	73	6	cruncher	cruncher	NOUN
dpc-1540	73	7	statistical	statistical	ADJ
dpc-1540	73	8	system	system	NOUN
dpc-1540	73	9	,	,	PUNCT
dpc-1540	73	10	2007	2007	NUM
dpc-1540	73	11	)	)	PUNCT
dpc-1540	73	12	software	software	NOUN
dpc-1540	73	13	was	be	AUX
dpc-1540	73	14	used	use	VERB
dpc-1540	73	15	.	.	PUNCT
dpc-1540	74	1	standard	standard	ADJ
dpc-1540	74	2	descriptive	descriptive	ADJ
dpc-1540	74	3	statistics	statistic	NOUN
dpc-1540	74	4	were	be	AUX
dpc-1540	74	5	expressed	express	VERB
dpc-1540	74	6	as	as	ADP
dpc-1540	74	7	mean	mean	ADJ
dpc-1540	74	8	and	and	CCONJ
dpc-1540	74	9	standard	standard	ADJ
dpc-1540	74	10	deviation	deviation	NOUN
dpc-1540	74	11	(	(	PUNCT
dpc-1540	74	12	sd	sd	NOUN
dpc-1540	74	13	)	)	PUNCT
dpc-1540	74	14	or	or	CCONJ
dpc-1540	74	15	number	number	NOUN
dpc-1540	74	16	and	and	CCONJ
dpc-1540	74	17	percentage	percentage	NOUN
dpc-1540	74	18	.	.	PUNCT
dpc-1540	75	1	the	the	DET
dpc-1540	75	2	normality	normality	NOUN
dpc-1540	75	3	assumptions	assumption	NOUN
dpc-1540	75	4	were	be	AUX
dpc-1540	75	5	checked	check	VERB
dpc-1540	75	6	using	use	VERB
dpc-1540	75	7	the	the	DET
dpc-1540	75	8	kolmogorov	kolmogorov	ADJ
dpc-1540	75	9	-	-	PUNCT
dpc-1540	75	10	smirnov	smirnov	ADJ
dpc-1540	75	11	test	test	NOUN
dpc-1540	75	12	.	.	PUNCT
dpc-1540	76	1	independent	independent	ADJ
dpc-1540	76	2	-	-	PUNCT
dpc-1540	76	3	samples	sample	NOUN
dpc-1540	76	4	t	t	NOUN
dpc-1540	76	5	-	-	PUNCT
dpc-1540	76	6	test	test	NOUN
dpc-1540	76	7	was	be	AUX
dpc-1540	76	8	used	use	VERB
dpc-1540	76	9	to	to	PART
dpc-1540	76	10	compare	compare	VERB
dpc-1540	76	11	quantitative	quantitative	ADJ
dpc-1540	76	12	data	datum	NOUN
dpc-1540	76	13	when	when	SCONJ
dpc-1540	76	14	their	their	PRON
dpc-1540	76	15	distribution	distribution	NOUN
dpc-1540	76	16	was	be	AUX
dpc-1540	76	17	normal	normal	ADJ
dpc-1540	76	18	,	,	PUNCT
dpc-1540	76	19	whereas	whereas	SCONJ
dpc-1540	76	20	the	the	DET
dpc-1540	76	21	mann‐whitney	mann‐whitney	NOUN
dpc-1540	76	22	u	u	PROPN
dpc-1540	76	23	test	test	NOUN
dpc-1540	76	24	was	be	AUX
dpc-1540	76	25	used	use	VERB
dpc-1540	76	26	to	to	PART
dpc-1540	76	27	compare	compare	VERB
dpc-1540	76	28	means	mean	NOUN
dpc-1540	76	29	when	when	SCONJ
dpc-1540	76	30	the	the	DET
dpc-1540	76	31	distribution	distribution	NOUN
dpc-1540	76	32	was	be	AUX
dpc-1540	76	33	not	not	PART
dpc-1540	76	34	normal	normal	ADJ
dpc-1540	76	35	.	.	PUNCT
dpc-1540	77	1	qualitative	qualitative	ADJ
dpc-1540	77	2	data	datum	NOUN
dpc-1540	77	3	was	be	AUX
dpc-1540	77	4	compared	compare	VERB
dpc-1540	77	5	with	with	ADP
dpc-1540	77	6	pearson	pearson	PROPN
dpc-1540	77	7	’s	’s	PART
dpc-1540	77	8	chi	chi	ADJ
dpc-1540	77	9	-	-	PUNCT
dpc-1540	77	10	square	square	ADJ
dpc-1540	77	11	test	test	NOUN
dpc-1540	77	12	.	.	PUNCT
dpc-1540	78	1	spearman	spearman	NOUN
dpc-1540	78	2	’s	’s	PART
dpc-1540	78	3	rho	rho	ADJ
dpc-1540	78	4	test	test	NOUN
dpc-1540	78	5	was	be	AUX
dpc-1540	78	6	used	use	VERB
dpc-1540	78	7	for	for	ADP
dpc-1540	78	8	the	the	DET
dpc-1540	78	9	correlation	correlation	NOUN
dpc-1540	78	10	of	of	ADP
dpc-1540	78	11	dependent	dependent	ADJ
dpc-1540	78	12	and	and	CCONJ
dpc-1540	78	13	independent	independent	ADJ
dpc-1540	78	14	variables	variable	NOUN
dpc-1540	78	15	which	which	PRON
dpc-1540	78	16	were	be	AUX
dpc-1540	78	17	distributed	distribute	VERB
dpc-1540	78	18	asymmetrically	asymmetrically	ADV
dpc-1540	78	19	,	,	PUNCT
dpc-1540	78	20	a	a	DET
dpc-1540	78	21	p	p	NOUN
dpc-1540	78	22	value	value	NOUN
dpc-1540	78	23	<	<	X
dpc-1540	78	24	.05	.05	NUM
dpc-1540	78	25	was	be	AUX
dpc-1540	78	26	considered	consider	VERB
dpc-1540	78	27	significant	significant	ADJ
dpc-1540	78	28	.	.	PUNCT
dpc-1540	79	1	strength	strength	NOUN
dpc-1540	79	2	of	of	ADP
dpc-1540	79	3	correlations	correlation	NOUN
dpc-1540	79	4	was	be	AUX
dpc-1540	79	5	determined	determine	VERB
dpc-1540	79	6	according	accord	VERB
dpc-1540	79	7	to	to	ADP
dpc-1540	79	8	rho	rho	ADJ
dpc-1540	79	9	(	(	PUNCT
dpc-1540	79	10	r	r	NOUN
dpc-1540	79	11	)	)	PUNCT
dpc-1540	79	12	values	value	NOUN
dpc-1540	79	13	,	,	PUNCT
dpc-1540	79	14	as	as	SCONJ
dpc-1540	79	15	follows	follow	VERB
dpc-1540	79	16	:	:	PUNCT
dpc-1540	79	17	r	r	X
dpc-1540	79	18	<	<	X
dpc-1540	79	19	0.2	0.2	NUM
dpc-1540	79	20	(	(	PUNCT
dpc-1540	79	21	very	very	ADV
dpc-1540	79	22	weak	weak	ADJ
dpc-1540	79	23	,	,	PUNCT
dpc-1540	79	24	no	no	DET
dpc-1540	79	25	correlation	correlation	NOUN
dpc-1540	79	26	)	)	PUNCT
dpc-1540	79	27	,	,	PUNCT
dpc-1540	79	28	r=0.2	r=0.2	NOUN
dpc-1540	79	29	-	-	PUNCT
dpc-1540	79	30	0.4	0.4	NUM
dpc-1540	79	31	(	(	PUNCT
dpc-1540	79	32	weak	weak	ADJ
dpc-1540	79	33	)	)	PUNCT
dpc-1540	79	34	,	,	PUNCT
dpc-1540	79	35	r=0.4	r=0.4	NOUN
dpc-1540	79	36	-	-	PUNCT
dpc-1540	79	37	0.6	0.6	NUM
dpc-1540	79	38	(	(	PUNCT
dpc-1540	79	39	moderate	moderate	ADJ
dpc-1540	79	40	)	)	PUNCT
dpc-1540	79	41	,	,	PUNCT
dpc-1540	79	42	r=0.6	r=0.6	NOUN
dpc-1540	79	43	-	-	SYM
dpc-1540	79	44	0.8	0.8	NUM
dpc-1540	79	45	(	(	PUNCT
dpc-1540	79	46	strong	strong	ADJ
dpc-1540	79	47	)	)	PUNCT
dpc-1540	79	48	,	,	PUNCT
dpc-1540	79	49	and	and	CCONJ
dpc-1540	79	50	r	r	X
dpc-1540	79	51	>	>	X
dpc-1540	79	52	0.8	0.8	NUM
dpc-1540	79	53	(	(	PUNCT
dpc-1540	79	54	very	very	ADV
dpc-1540	79	55	strong	strong	ADJ
dpc-1540	79	56	)	)	PUNCT
dpc-1540	79	57	.	.	PUNCT
dpc-1540	80	1	predictivity	predictivity	NOUN
dpc-1540	80	2	of	of	ADP
dpc-1540	80	3	determinant	determinant	ADJ
dpc-1540	80	4	factors	factor	NOUN
dpc-1540	80	5	was	be	AUX
dpc-1540	80	6	detected	detect	VERB
dpc-1540	80	7	with	with	ADP
dpc-1540	80	8	logistic	logistic	ADJ
dpc-1540	80	9	regression	regression	NOUN
dpc-1540	80	10	analysis	analysis	NOUN
dpc-1540	80	11	.	.	PUNCT
dpc-1540	81	1	results	result	NOUN
dpc-1540	81	2	were	be	AUX
dpc-1540	81	3	determined	determine	VERB
dpc-1540	81	4	with	with	ADP
dpc-1540	81	5	95	95	NUM
dpc-1540	81	6	%	%	NOUN
dpc-1540	81	7	confidence	confidence	NOUN
dpc-1540	81	8	.	.	PUNCT
dpc-1540	82	1	results	result	VERB
dpc-1540	82	2	a	a	DET
dpc-1540	82	3	total	total	NOUN
dpc-1540	82	4	of	of	ADP
dpc-1540	82	5	112	112	NUM
dpc-1540	82	6	patients	patient	NOUN
dpc-1540	82	7	with	with	ADP
dpc-1540	82	8	psoriasis	psoriasis	NOUN
dpc-1540	82	9	(	(	PUNCT
dpc-1540	82	10	53	53	NUM
dpc-1540	82	11	men	man	NOUN
dpc-1540	82	12	and	and	CCONJ
dpc-1540	82	13	59	59	NUM
dpc-1540	82	14	women	woman	NOUN
dpc-1540	82	15	)	)	PUNCT
dpc-1540	82	16	were	be	AUX
dpc-1540	82	17	included	include	VERB
dpc-1540	82	18	in	in	ADP
dpc-1540	82	19	the	the	DET
dpc-1540	82	20	study	study	NOUN
dpc-1540	82	21	(	(	PUNCT
dpc-1540	82	22	table	table	NOUN
dpc-1540	82	23	1	1	NUM
dpc-1540	82	24	)	)	PUNCT
dpc-1540	82	25	.	.	PUNCT
dpc-1540	83	1	their	their	PRON
dpc-1540	83	2	mean	mean	ADJ
dpc-1540	83	3	age	age	NOUN
dpc-1540	83	4	was	be	AUX
dpc-1540	83	5	46.5	46.5	NUM
dpc-1540	83	6	years	year	NOUN
dpc-1540	83	7	(	(	PUNCT
dpc-1540	83	8	sd	sd	NOUN
dpc-1540	83	9	=	=	SYM
dpc-1540	83	10	13.2years	13.2year	NOUN
dpc-1540	83	11	;	;	PUNCT
dpc-1540	83	12	range	range	NOUN
dpc-1540	83	13	,	,	PUNCT
dpc-1540	83	14	21	21	NUM
dpc-1540	83	15	-	-	SYM
dpc-1540	83	16	73	73	NUM
dpc-1540	83	17	years	year	NOUN
dpc-1540	83	18	)	)	PUNCT
dpc-1540	83	19	.	.	PUNCT
dpc-1540	84	1	overall	overall	ADV
dpc-1540	84	2	,	,	PUNCT
dpc-1540	84	3	50	50	NUM
dpc-1540	84	4	%	%	NOUN
dpc-1540	84	5	of	of	ADP
dpc-1540	84	6	them	they	PRON
dpc-1540	84	7	was	be	AUX
dpc-1540	84	8	obese	obese	ADJ
dpc-1540	84	9	and	and	CCONJ
dpc-1540	84	10	78.6	78.6	NUM
dpc-1540	84	11	%	%	NOUN
dpc-1540	84	12	had	have	VERB
dpc-1540	84	13	high	high	ADJ
dpc-1540	84	14	waist	waist	NOUN
dpc-1540	84	15	circumference;42.0	circumference;42.0	NOUN
dpc-1540	84	16	%	%	NOUN
dpc-1540	84	17	had	have	VERB
dpc-1540	84	18	high	high	ADJ
dpc-1540	84	19	fasting	fasting	NOUN
dpc-1540	84	20	glucose	glucose	NOUN
dpc-1540	84	21	,	,	PUNCT
dpc-1540	84	22	83.0	83.0	NUM
dpc-1540	84	23	%	%	NOUN
dpc-1540	84	24	had	have	VERB
dpc-1540	84	25	high	high	ADJ
dpc-1540	84	26	triglyceride	triglyceride	ADV
dpc-1540	84	27	,	,	PUNCT
dpc-1540	84	28	and	and	CCONJ
dpc-1540	84	29	61.6	61.6	NUM
dpc-1540	84	30	%	%	NOUN
dpc-1540	84	31	had	have	VERB
dpc-1540	84	32	low	low	ADJ
dpc-1540	84	33	hdl	hdl	PROPN
dpc-1540	84	34	levels	level	NOUN
dpc-1540	84	35	.	.	PUNCT
dpc-1540	85	1	hypertension	hypertension	NOUN
dpc-1540	85	2	and	and	CCONJ
dpc-1540	85	3	high	high	ADJ
dpc-1540	85	4	homa	homa	NOUN
dpc-1540	85	5	-	-	PUNCT
dpc-1540	85	6	ir	ir	PROPN
dpc-1540	85	7	were	be	AUX
dpc-1540	85	8	detected	detect	VERB
dpc-1540	85	9	in	in	ADP
dpc-1540	85	10	23.2	23.2	NUM
dpc-1540	85	11	%	%	NOUN
dpc-1540	85	12	and	and	CCONJ
dpc-1540	85	13	63.4	63.4	NUM
dpc-1540	85	14	%	%	NOUN
dpc-1540	85	15	of	of	ADP
dpc-1540	85	16	cases	case	NOUN
dpc-1540	85	17	,	,	PUNCT
dpc-1540	85	18	respectively	respectively	ADV
dpc-1540	85	19	.	.	PUNCT
dpc-1540	86	1	pasi	pasi	NOUN
dpc-1540	86	2	values	value	NOUN
dpc-1540	86	3	were	be	AUX
dpc-1540	86	4	high	high	ADJ
dpc-1540	86	5	in	in	ADP
dpc-1540	86	6	74.1	74.1	NUM
dpc-1540	86	7	%	%	NOUN
dpc-1540	86	8	of	of	ADP
dpc-1540	86	9	subjects	subject	NOUN
dpc-1540	86	10	,	,	PUNCT
dpc-1540	86	11	whereas	whereas	SCONJ
dpc-1540	86	12	84.8	84.8	NUM
dpc-1540	86	13	%	%	NOUN
dpc-1540	86	14	had	have	VERB
dpc-1540	86	15	high	high	ADJ
dpc-1540	86	16	psqi	psqi	NOUN
dpc-1540	86	17	values	value	NOUN
dpc-1540	86	18	.	.	PUNCT
dpc-1540	87	1	the	the	DET
dpc-1540	87	2	most	most	ADV
dpc-1540	87	3	detected	detect	VERB
dpc-1540	87	4	comorbidity	comorbidity	NOUN
dpc-1540	87	5	was	be	AUX
dpc-1540	87	6	hypertension	hypertension	NOUN
dpc-1540	87	7	(	(	PUNCT
dpc-1540	87	8	23.2	23.2	NUM
dpc-1540	87	9	%	%	NOUN
dpc-1540	87	10	)	)	PUNCT
dpc-1540	87	11	.	.	PUNCT
dpc-1540	88	1	alcohol	alcohol	NOUN
dpc-1540	88	2	consumption	consumption	NOUN
dpc-1540	88	3	was	be	AUX
dpc-1540	88	4	reported	report	VERB
dpc-1540	88	5	by	by	ADP
dpc-1540	88	6	15.2	15.2	NUM
dpc-1540	88	7	%	%	NOUN
dpc-1540	88	8	,	,	PUNCT
dpc-1540	88	9	whereas	whereas	SCONJ
dpc-1540	88	10	38.4	38.4	NUM
dpc-1540	88	11	%	%	NOUN
dpc-1540	88	12	were	be	AUX
dpc-1540	88	13	smokers	smoker	NOUN
dpc-1540	88	14	.	.	PUNCT
dpc-1540	89	1	ms	ms	PROPN
dpc-1540	89	2	was	be	AUX
dpc-1540	89	3	diagnosed	diagnose	VERB
dpc-1540	89	4	in	in	ADP
dpc-1540	89	5	76	76	NUM
dpc-1540	89	6	(	(	PUNCT
dpc-1540	89	7	67.8	67.8	NUM
dpc-1540	89	8	%	%	NOUN
dpc-1540	89	9	)	)	PUNCT
dpc-1540	89	10	of	of	ADP
dpc-1540	89	11	the	the	DET
dpc-1540	89	12	112	112	NUM
dpc-1540	89	13	patients	patient	NOUN
dpc-1540	89	14	.	.	PUNCT
dpc-1540	90	1	proportionately	proportionately	ADV
dpc-1540	90	2	more	more	ADJ
dpc-1540	90	3	women	woman	NOUN
dpc-1540	90	4	had	have	VERB
dpc-1540	90	5	ms	ms	NOUN
dpc-1540	90	6	,	,	PUNCT
dpc-1540	90	7	but	but	CCONJ
dpc-1540	90	8	this	this	DET
dpc-1540	90	9	association	association	NOUN
dpc-1540	90	10	was	be	AUX
dpc-1540	90	11	not	not	PART
dpc-1540	90	12	significant	significant	ADJ
dpc-1540	90	13	(	(	PUNCT
dpc-1540	90	14	table	table	NOUN
dpc-1540	90	15	2	2	NUM
dpc-1540	90	16	)	)	PUNCT
dpc-1540	90	17	.	.	PUNCT
dpc-1540	91	1	more	more	ADJ
dpc-1540	91	2	patients	patient	NOUN
dpc-1540	91	3	in	in	ADP
dpc-1540	91	4	the	the	DET
dpc-1540	91	5	ms	ms	PROPN
dpc-1540	91	6	group	group	NOUN
dpc-1540	91	7	than	than	ADP
dpc-1540	91	8	non	non	ADJ
dpc-1540	91	9	-	-	PROPN
dpc-1540	91	10	the	the	DET
dpc-1540	91	11	ms	ms	PROPN
dpc-1540	91	12	group	group	NOUN
dpc-1540	91	13	had	have	VERB
dpc-1540	91	14	high	high	ADJ
dpc-1540	91	15	values	value	NOUN
dpc-1540	91	16	of	of	ADP
dpc-1540	91	17	waist	waist	NOUN
dpc-1540	91	18	circumference	circumference	NOUN
dpc-1540	91	19	,	,	PUNCT
dpc-1540	91	20	bmi	bmi	NOUN
dpc-1540	91	21	,	,	PUNCT
dpc-1540	91	22	triglyceride	triglyceride	ADJ
dpc-1540	91	23	levels	level	NOUN
dpc-1540	91	24	,	,	PUNCT
dpc-1540	91	25	fasting	fast	VERB
dpc-1540	91	26	glucose	glucose	NOUN
dpc-1540	91	27	,	,	PUNCT
dpc-1540	91	28	blood	blood	NOUN
dpc-1540	91	29	pressure	pressure	NOUN
dpc-1540	91	30	(	(	PUNCT
dpc-1540	91	31	each	each	PRON
dpc-1540	91	32	p	p	NOUN
dpc-1540	91	33	=	=	SYM
dpc-1540	91	34	.0001	.0001	NOUN
dpc-1540	91	35	)	)	PUNCT
dpc-1540	91	36	and	and	CCONJ
dpc-1540	91	37	homa	homa	PROPN
dpc-1540	91	38	-	-	PUNCT
dpc-1540	91	39	ir	ir	PROPN
dpc-1540	91	40	(	(	PUNCT
dpc-1540	91	41	p=	p=	PROPN
dpc-1540	91	42	.014	.014	NUM
dpc-1540	91	43	)	)	PUNCT
dpc-1540	91	44	,	,	PUNCT
dpc-1540	91	45	and	and	CCONJ
dpc-1540	91	46	low	low	ADJ
dpc-1540	91	47	values	value	NOUN
dpc-1540	91	48	of	of	ADP
dpc-1540	91	49	hdl	hdl	PROPN
dpc-1540	91	50	(	(	PUNCT
dpc-1540	91	51	p=	p=	NOUN
dpc-1540	91	52	.0001	.0001	PROPN
dpc-1540	91	53	)	)	PUNCT
dpc-1540	91	54	.	.	PUNCT
dpc-1540	92	1	more	more	ADJ
dpc-1540	92	2	patients	patient	NOUN
dpc-1540	92	3	in	in	ADP
dpc-1540	92	4	the	the	DET
dpc-1540	92	5	ms	ms	PROPN
dpc-1540	92	6	group	group	NOUN
dpc-1540	92	7	had	have	VERB
dpc-1540	92	8	psqi	psqi	NOUN
dpc-1540	92	9	scores	score	NOUN
dpc-1540	92	10	≥5(p	≥5(p	X
dpc-1540	92	11	=	=	SYM
dpc-1540	92	12	.046	.046	NUM
dpc-1540	92	13	)	)	PUNCT
dpc-1540	92	14	,	,	PUNCT
dpc-1540	92	15	while	while	SCONJ
dpc-1540	92	16	similar	similar	ADJ
dpc-1540	92	17	percentages	percentage	NOUN
dpc-1540	92	18	of	of	ADP
dpc-1540	92	19	patients	patient	NOUN
dpc-1540	92	20	in	in	ADP
dpc-1540	92	21	both	both	DET
dpc-1540	92	22	groups	group	NOUN
dpc-1540	92	23	had	have	VERB
dpc-1540	92	24	pasi	pasi	NOUN
dpc-1540	92	25	scores	score	NOUN
dpc-1540	92	26	>	>	X
dpc-1540	92	27	10	10	NUM
dpc-1540	92	28	.	.	PUNCT
dpc-1540	93	1	mean	mean	ADJ
dpc-1540	93	2	values	value	NOUN
dpc-1540	93	3	of	of	ADP
dpc-1540	93	4	age	age	NOUN
dpc-1540	93	5	,	,	PUNCT
dpc-1540	93	6	disease	disease	NOUN
dpc-1540	93	7	duration	duration	NOUN
dpc-1540	93	8	,	,	PUNCT
dpc-1540	93	9	ms	ms	PROPN
dpc-1540	93	10	parameters	parameter	NOUN
dpc-1540	93	11	,	,	PUNCT
dpc-1540	93	12	pasi	pasi	NOUN
dpc-1540	93	13	,	,	PUNCT
dpc-1540	93	14	psqi	psqi	NOUN
dpc-1540	93	15	and	and	CCONJ
dpc-1540	93	16	its	its	PRON
dpc-1540	93	17	subgroups	subgroup	NOUN
dpc-1540	93	18	are	be	AUX
dpc-1540	93	19	compared	compare	VERB
dpc-1540	93	20	in	in	ADP
dpc-1540	93	21	table	table	NOUN
dpc-1540	93	22	3	3	NUM
dpc-1540	93	23	.	.	PUNCT
dpc-1540	94	1	the	the	DET
dpc-1540	94	2	means	mean	NOUN
dpc-1540	94	3	of	of	ADP
dpc-1540	94	4	disease	disease	NOUN
dpc-1540	94	5	duration	duration	NOUN
dpc-1540	94	6	,	,	PUNCT
dpc-1540	94	7	bmi	bmi	PROPN
dpc-1540	94	8	,	,	PUNCT
dpc-1540	94	9	waist	waist	NOUN
dpc-1540	94	10	circumference	circumference	NOUN
dpc-1540	94	11	,	,	PUNCT
dpc-1540	94	12	fasting	fast	VERB
dpc-1540	94	13	glucose	glucose	NOUN
dpc-1540	94	14	,	,	PUNCT
dpc-1540	94	15	homa	homa	NOUN
dpc-1540	94	16	-	-	PUNCT
dpc-1540	94	17	ir	ir	NOUN
dpc-1540	94	18	,	,	PUNCT
dpc-1540	94	19	triglyceride	triglyceride	ADJ
dpc-1540	94	20	levels	level	NOUN
dpc-1540	94	21	,	,	PUNCT
dpc-1540	94	22	psqi	psqi	NOUN
dpc-1540	94	23	,	,	PUNCT
dpc-1540	94	24	psl	psl	NOUN
dpc-1540	94	25	,	,	PUNCT
dpc-1540	94	26	and	and	CCONJ
dpc-1540	94	27	pdsd	pdsd	NOUN
dpc-1540	94	28	were	be	AUX
dpc-1540	94	29	significantly	significantly	ADV
dpc-1540	94	30	higher	high	ADJ
dpc-1540	94	31	,	,	PUNCT
dpc-1540	94	32	and	and	CCONJ
dpc-1540	94	33	hdl	hdl	PROPN
dpc-1540	94	34	values	value	NOUN
dpc-1540	94	35	were	be	AUX
dpc-1540	94	36	significantly	significantly	ADV
dpc-1540	94	37	lower	low	ADJ
dpc-1540	94	38	in	in	ADP
dpc-1540	94	39	the	the	DET
dpc-1540	94	40	ms	ms	PROPN
dpc-1540	94	41	group	group	NOUN
dpc-1540	94	42	.	.	PUNCT
dpc-1540	95	1	then	then	ADV
dpc-1540	95	2	,	,	PUNCT
dpc-1540	95	3	for	for	ADP
dpc-1540	95	4	all	all	DET
dpc-1540	95	5	112	112	NUM
dpc-1540	95	6	patients	patient	NOUN
dpc-1540	95	7	,	,	PUNCT
dpc-1540	95	8	ms	ms	PROPN
dpc-1540	95	9	parameters	parameter	NOUN
dpc-1540	95	10	were	be	AUX
dpc-1540	95	11	compared	compare	VERB
dpc-1540	95	12	in	in	ADP
dpc-1540	95	13	subgroups	subgroup	NOUN
dpc-1540	95	14	according	accord	VERB
dpc-1540	95	15	to	to	ADP
dpc-1540	95	16	pasi	pasi	NOUN
dpc-1540	95	17	(	(	PUNCT
dpc-1540	95	18	≤10	≤10	PROPN
dpc-1540	95	19	vs.	vs.	X
dpc-1540	95	20	>	>	X
dpc-1540	95	21	10	10	NUM
dpc-1540	95	22	)	)	PUNCT
dpc-1540	95	23	and	and	CCONJ
dpc-1540	95	24	gender	gender	NOUN
dpc-1540	95	25	(	(	PUNCT
dpc-1540	95	26	table	table	NOUN
dpc-1540	95	27	4	4	NUM
dpc-1540	95	28	)	)	PUNCT
dpc-1540	95	29	.	.	PUNCT
dpc-1540	96	1	high	high	ADJ
dpc-1540	96	2	fasting	fasting	NOUN
dpc-1540	96	3	glucose	glucose	NOUN
dpc-1540	96	4	,	,	PUNCT
dpc-1540	96	5	low	low	ADJ
dpc-1540	96	6	hdl	hdl	PROPN
dpc-1540	96	7	levels	level	NOUN
dpc-1540	96	8	,	,	PUNCT
dpc-1540	96	9	and	and	CCONJ
dpc-1540	96	10	a	a	DET
dpc-1540	96	11	diagnosis	diagnosis	NOUN
dpc-1540	96	12	of	of	ADP
dpc-1540	96	13	ms	ms	NOUN
dpc-1540	96	14	were	be	AUX
dpc-1540	96	15	significantly	significantly	ADV
dpc-1540	96	16	more	more	ADV
dpc-1540	96	17	frequent	frequent	ADJ
dpc-1540	96	18	only	only	ADV
dpc-1540	96	19	in	in	ADP
dpc-1540	96	20	females	female	NOUN
dpc-1540	96	21	with	with	ADP
dpc-1540	96	22	high	high	ADJ
dpc-1540	96	23	pasi	pasi	NOUN
dpc-1540	96	24	(	(	PUNCT
dpc-1540	96	25	p	p	NOUN
dpc-1540	96	26	=	=	NOUN
dpc-1540	96	27	.003	.003	NUM
dpc-1540	96	28	,	,	PUNCT
dpc-1540	96	29	p	p	X
dpc-1540	96	30	=	=	PUNCT
dpc-1540	96	31	.027	.027	NUM
dpc-1540	96	32	,	,	PUNCT
dpc-1540	96	33	p	p	X
dpc-1540	96	34	=	=	X
dpc-1540	96	35	.031	.031	NUM
dpc-1540	96	36	,	,	PUNCT
dpc-1540	96	37	respectively	respectively	ADV
dpc-1540	96	38	)	)	PUNCT
dpc-1540	96	39	.	.	PUNCT
dpc-1540	97	1	correlations	correlation	NOUN
dpc-1540	97	2	between	between	ADP
dpc-1540	97	3	diagnosis	diagnosis	NOUN
dpc-1540	97	4	of	of	ADP
dpc-1540	97	5	ms	ms	NOUN
dpc-1540	97	6	and	and	CCONJ
dpc-1540	97	7	clinical	clinical	ADJ
dpc-1540	97	8	characteristics	characteristic	NOUN
dpc-1540	97	9	such	such	ADJ
dpc-1540	97	10	as	as	ADP
dpc-1540	97	11	psoriasis	psoriasis	NOUN
dpc-1540	97	12	duration	duration	NOUN
dpc-1540	97	13	,	,	PUNCT
dpc-1540	97	14	pasi	pasi	NOUN
dpc-1540	97	15	and	and	CCONJ
dpc-1540	97	16	psqi	psqi	NOUN
dpc-1540	97	17	are	be	AUX
dpc-1540	97	18	shown	show	VERB
dpc-1540	97	19	in	in	ADP
dpc-1540	97	20	table	table	NOUN
dpc-1540	97	21	5	5	NUM
dpc-1540	97	22	.	.	PUNCT
dpc-1540	97	23	positive	positive	ADJ
dpc-1540	97	24	correlations	correlation	NOUN
dpc-1540	97	25	were	be	AUX
dpc-1540	97	26	detected	detect	VERB
dpc-1540	97	27	between	between	ADP
dpc-1540	97	28	ms	ms	NOUN
dpc-1540	97	29	and	and	CCONJ
dpc-1540	97	30	disease	disease	NOUN
dpc-1540	97	31	duration	duration	NOUN
dpc-1540	97	32	,	,	PUNCT
dpc-1540	97	33	bmi	bmi	PROPN
dpc-1540	97	34	,	,	PUNCT
dpc-1540	97	35	waist	waist	NOUN
dpc-1540	97	36	circumference	circumference	NOUN
dpc-1540	97	37	,	,	PUNCT
dpc-1540	97	38	high	high	ADJ
dpc-1540	97	39	blood	blood	NOUN
dpc-1540	97	40	pressure	pressure	NOUN
dpc-1540	97	41	,	,	PUNCT
dpc-1540	97	42	fasting	fast	VERB
dpc-1540	97	43	glucose	glucose	NOUN
dpc-1540	97	44	,	,	PUNCT
dpc-1540	97	45	homa	homa	NOUN
dpc-1540	97	46	-	-	PUNCT
dpc-1540	97	47	ir	ir	PROPN
dpc-1540	97	48	,	,	PUNCT
dpc-1540	97	49	triglyceride	triglyceride	ADP
dpc-1540	97	50	levels	level	NOUN
dpc-1540	97	51	and	and	CCONJ
dpc-1540	97	52	psqi	psqi	NOUN
dpc-1540	97	53	,	,	PUNCT
dpc-1540	97	54	whereas	whereas	SCONJ
dpc-1540	97	55	hdl	hdl	PROPN
dpc-1540	97	56	values	value	NOUN
dpc-1540	97	57	were	be	AUX
dpc-1540	97	58	negatively	negatively	ADV
dpc-1540	97	59	correlated	correlate	VERB
dpc-1540	97	60	with	with	ADP
dpc-1540	97	61	it	it	PRON
dpc-1540	97	62	.	.	PUNCT
dpc-1540	98	1	the	the	DET
dpc-1540	98	2	impacts	impact	NOUN
dpc-1540	98	3	of	of	ADP
dpc-1540	98	4	the	the	DET
dpc-1540	98	5	correlative	correlative	ADJ
dpc-1540	98	6	parameters	parameter	NOUN
dpc-1540	98	7	on	on	ADP
dpc-1540	98	8	ms	ms	PROPN
dpc-1540	98	9	development	development	NOUN
dpc-1540	98	10	are	be	AUX
dpc-1540	98	11	shown	show	VERB
dpc-1540	98	12	in	in	ADP
dpc-1540	98	13	table	table	NOUN
dpc-1540	98	14	6	6	NUM
dpc-1540	98	15	.	.	PUNCT
dpc-1540	99	1	only	only	ADV
dpc-1540	99	2	waist	waist	NOUN
dpc-1540	99	3	circumference	circumference	NOUN
dpc-1540	99	4	,	,	PUNCT
dpc-1540	99	5	fasting	fast	VERB
dpc-1540	99	6	glucose	glucose	NOUN
dpc-1540	99	7	,	,	PUNCT
dpc-1540	99	8	high	high	ADJ
dpc-1540	99	9	blood	blood	NOUN
dpc-1540	99	10	pressure	pressure	NOUN
dpc-1540	99	11	,	,	PUNCT
dpc-1540	99	12	and	and	CCONJ
dpc-1540	99	13	low	low	ADJ
dpc-1540	99	14	hdl	hdl	PROPN
dpc-1540	99	15	had	have	VERB
dpc-1540	99	16	predictive	predictive	ADJ
dpc-1540	99	17	effects	effect	NOUN
dpc-1540	99	18	.	.	PUNCT
dpc-1540	100	1	discussion	discussion	NOUN
dpc-1540	100	2	psoriasis	psoriasis	NOUN
dpc-1540	100	3	is	be	AUX
dpc-1540	100	4	a	a	DET
dpc-1540	100	5	chronic	chronic	ADJ
dpc-1540	100	6	inflammatory	inflammatory	ADJ
dpc-1540	100	7	skin	skin	NOUN
dpc-1540	100	8	disease	disease	NOUN
dpc-1540	100	9	that	that	PRON
dpc-1540	100	10	affects	affect	VERB
dpc-1540	100	11	2%-4	2%-4	NUM
dpc-1540	100	12	%	%	NOUN
dpc-1540	100	13	of	of	ADP
dpc-1540	100	14	the	the	DET
dpc-1540	100	15	general	general	ADJ
dpc-1540	100	16	population	population	NOUN
dpc-1540	101	1	[	[	X
dpc-1540	101	2	21,22	21,22	X
dpc-1540	101	3	]	]	X
dpc-1540	101	4	.	.	PUNCT
dpc-1540	102	1	the	the	DET
dpc-1540	102	2	prevalence	prevalence	NOUN
dpc-1540	102	3	of	of	ADP
dpc-1540	102	4	ms	ms	PROPN
dpc-1540	102	5	has	have	AUX
dpc-1540	102	6	been	be	AUX
dpc-1540	102	7	reported	report	VERB
dpc-1540	102	8	to	to	ADP
dpc-1540	102	9	be35	be35	PROPN
dpc-1540	102	10	%	%	NOUN
dpc-1540	102	11	in	in	ADP
dpc-1540	102	12	the	the	DET
dpc-1540	102	13	united	united	PROPN
dpc-1540	102	14	states	states	PROPN
dpc-1540	102	15	[	[	X
dpc-1540	102	16	21	21	NUM
dpc-1540	102	17	]	]	PUNCT
dpc-1540	102	18	.	.	PUNCT
dpc-1540	103	1	in	in	ADP
dpc-1540	103	2	the	the	DET
dpc-1540	103	3	turkish	turkish	ADJ
dpc-1540	103	4	population	population	NOUN
dpc-1540	103	5	,	,	PUNCT
dpc-1540	103	6	it	it	PRON
dpc-1540	103	7	has	have	AUX
dpc-1540	103	8	been	be	AUX
dpc-1540	103	9	reported	report	VERB
dpc-1540	103	10	to	to	ADP
dpc-1540	103	11	be34.9	be34.9	NUM
dpc-1540	103	12	%	%	NOUN
dpc-1540	103	13	(	(	PUNCT
dpc-1540	103	14	25.2	25.2	NUM
dpc-1540	103	15	%	%	NOUN
dpc-1540	103	16	in	in	ADP
dpc-1540	103	17	men	man	NOUN
dpc-1540	103	18	and	and	CCONJ
dpc-1540	103	19	40.1	40.1	NUM
dpc-1540	103	20	%	%	NOUN
dpc-1540	103	21	in	in	ADP
dpc-1540	103	22	women	woman	NOUN
dpc-1540	103	23	)	)	PUNCT
dpc-1540	103	24	by	by	ADP
dpc-1540	103	25	gündo4	gündo4	PROPN
dpc-1540	103	26	research	research	NOUN
dpc-1540	103	27	|	|	ADV
dpc-1540	103	28	dermatol	dermatol	ADJ
dpc-1540	103	29	pract	pract	NOUN
dpc-1540	103	30	concept	concept	NOUN
dpc-1540	103	31	.	.	PUNCT
dpc-1540	104	1	2021;11(3):e2021049	2021;11(3):e2021049	NUM
dpc-1540	104	2	gan	gin	VERB
dpc-1540	104	3	et	et	NOUN
dpc-1540	104	4	al	al	PROPN
dpc-1540	105	1	[	[	X
dpc-1540	105	2	23	23	NUM
dpc-1540	105	3	]	]	PUNCT
dpc-1540	105	4	and	and	CCONJ
dpc-1540	105	5	33.9	33.9	NUM
dpc-1540	105	6	%	%	NOUN
dpc-1540	105	7	by	by	ADP
dpc-1540	105	8	gemalmaz	gemalmaz	PROPN
dpc-1540	105	9	et	et	PROPN
dpc-1540	105	10	al	al	PROPN
dpc-1540	106	1	[	[	X
dpc-1540	106	2	24	24	NUM
dpc-1540	106	3	]	]	PUNCT
dpc-1540	106	4	.	.	PUNCT
dpc-1540	107	1	although	although	SCONJ
dpc-1540	107	2	there	there	PRON
dpc-1540	107	3	was	be	VERB
dpc-1540	107	4	a	a	DET
dpc-1540	107	5	female	female	ADJ
dpc-1540	107	6	predominance	predominance	NOUN
dpc-1540	107	7	(	(	PUNCT
dpc-1540	107	8	52.7	52.7	NUM
dpc-1540	107	9	%	%	NOUN
dpc-1540	107	10	)	)	PUNCT
dpc-1540	107	11	in	in	ADP
dpc-1540	107	12	our	our	PRON
dpc-1540	107	13	study	study	NOUN
dpc-1540	107	14	,	,	PUNCT
dpc-1540	107	15	the	the	DET
dpc-1540	107	16	prevalence	prevalence	NOUN
dpc-1540	107	17	of	of	ADP
dpc-1540	107	18	ms	ms	NOUN
dpc-1540	107	19	in	in	ADP
dpc-1540	107	20	men	man	NOUN
dpc-1540	107	21	and	and	CCONJ
dpc-1540	107	22	women	woman	NOUN
dpc-1540	107	23	was	be	AUX
dpc-1540	107	24	similar	similar	ADJ
dpc-1540	107	25	(	(	PUNCT
dpc-1540	107	26	p	p	NOUN
dpc-1540	107	27	=	=	NOUN
dpc-1540	107	28	.230	.230	NUM
dpc-1540	107	29	)	)	PUNCT
dpc-1540	107	30	.	.	PUNCT
dpc-1540	108	1	although	although	SCONJ
dpc-1540	108	2	the	the	DET
dpc-1540	108	3	exact	exact	ADJ
dpc-1540	108	4	relationship	relationship	NOUN
dpc-1540	108	5	is	be	AUX
dpc-1540	108	6	not	not	PART
dpc-1540	108	7	fully	fully	ADV
dpc-1540	108	8	understood	understand	VERB
dpc-1540	108	9	,	,	PUNCT
dpc-1540	108	10	it	it	PRON
dpc-1540	108	11	is	be	AUX
dpc-1540	108	12	well	well	ADV
dpc-1540	108	13	known	know	VERB
dpc-1540	108	14	that	that	SCONJ
dpc-1540	108	15	psoriasis	psoriasis	NOUN
dpc-1540	108	16	patients	patient	NOUN
dpc-1540	108	17	have	have	VERB
dpc-1540	108	18	a	a	DET
dpc-1540	108	19	higher	high	ADJ
dpc-1540	108	20	prevalence	prevalence	NOUN
dpc-1540	108	21	of	of	ADP
dpc-1540	108	22	ms	ms	PROPN
dpc-1540	108	23	,	,	PUNCT
dpc-1540	108	24	which	which	PRON
dpc-1540	108	25	changes	change	VERB
dpc-1540	108	26	with	with	ADP
dpc-1540	108	27	a	a	DET
dpc-1540	108	28	person	person	NOUN
dpc-1540	108	29	’s	’s	PART
dpc-1540	108	30	genetic	genetic	ADJ
dpc-1540	108	31	susceptibility	susceptibility	NOUN
dpc-1540	108	32	,	,	PUNCT
dpc-1540	108	33	aging	aging	NOUN
dpc-1540	108	34	,	,	PUNCT
dpc-1540	108	35	dietary	dietary	ADJ
dpc-1540	108	36	habits	habit	NOUN
dpc-1540	108	37	,	,	PUNCT
dpc-1540	108	38	and	and	CCONJ
dpc-1540	108	39	sedentary	sedentary	ADJ
dpc-1540	108	40	behaviors	behavior	NOUN
dpc-1540	108	41	[	[	X
dpc-1540	108	42	25	25	NUM
dpc-1540	108	43	]	]	PUNCT
dpc-1540	108	44	.	.	PUNCT
dpc-1540	109	1	in	in	ADP
dpc-1540	109	2	a	a	DET
dpc-1540	109	3	comprehensive	comprehensive	ADJ
dpc-1540	109	4	meta	meta	ADJ
dpc-1540	109	5	-	-	PUNCT
dpc-1540	109	6	analysis	analysis	NOUN
dpc-1540	109	7	,	,	PUNCT
dpc-1540	109	8	the	the	DET
dpc-1540	109	9	prevalence	prevalence	NOUN
dpc-1540	109	10	of	of	ADP
dpc-1540	109	11	ms	ms	NOUN
dpc-1540	109	12	among	among	ADP
dpc-1540	109	13	people	people	NOUN
dpc-1540	109	14	with	with	ADP
dpc-1540	109	15	psoriasis	psoriasis	NOUN
dpc-1540	109	16	was	be	AUX
dpc-1540	109	17	in	in	ADP
dpc-1540	109	18	the	the	DET
dpc-1540	109	19	range	range	NOUN
dpc-1540	109	20	of	of	ADP
dpc-1540	109	21	20%-50	20%-50	NUM
dpc-1540	109	22	%	%	NOUN
dpc-1540	109	23	,	,	PUNCT
dpc-1540	109	24	in	in	ADP
dpc-1540	109	25	which	which	PRON
dpc-1540	109	26	adjusted	adjust	VERB
dpc-1540	109	27	ors	or	NOUN
dpc-1540	109	28	were	be	AUX
dpc-1540	109	29	reported	report	VERB
dpc-1540	109	30	as	as	ADP
dpc-1540	109	31	1.22	1.22	NUM
dpc-1540	109	32	,	,	PUNCT
dpc-1540	109	33	1.56	1.56	NUM
dpc-1540	109	34	,	,	PUNCT
dpc-1540	109	35	and	and	CCONJ
dpc-1540	109	36	1.98	1.98	NUM
dpc-1540	109	37	for	for	ADP
dpc-1540	109	38	mild	mild	ADJ
dpc-1540	109	39	,	,	PUNCT
dpc-1540	109	40	moderate	moderate	ADJ
dpc-1540	109	41	and	and	CCONJ
dpc-1540	109	42	severe	severe	ADJ
dpc-1540	109	43	psoriasis	psoriasis	NOUN
dpc-1540	109	44	,	,	PUNCT
dpc-1540	109	45	respectively	respectively	ADV
dpc-1540	109	46	[	[	X
dpc-1540	109	47	26	26	NUM
dpc-1540	109	48	]	]	PUNCT
dpc-1540	109	49	.	.	PUNCT
dpc-1540	110	1	another	another	DET
dpc-1540	110	2	meta	meta	ADJ
dpc-1540	110	3	-	-	PUNCT
dpc-1540	110	4	analysis	analysis	NOUN
dpc-1540	110	5	of	of	ADP
dpc-1540	110	6	12studies	12studies	NUM
dpc-1540	110	7	found	find	VERB
dpc-1540	110	8	that	that	SCONJ
dpc-1540	110	9	the	the	DET
dpc-1540	110	10	prevalence	prevalence	NOUN
dpc-1540	110	11	of	of	ADP
dpc-1540	110	12	ms	ms	PROPN
dpc-1540	110	13	was	be	AUX
dpc-1540	110	14	2.2	2.2	NUM
dpc-1540	110	15	-	-	PUNCT
dpc-1540	110	16	times	time	NOUN
dpc-1540	110	17	higher	high	ADJ
dpc-1540	110	18	in	in	ADP
dpc-1540	110	19	psoriasis	psoriasis	NOUN
dpc-1540	110	20	patients	patient	NOUN
dpc-1540	110	21	than	than	ADP
dpc-1540	110	22	in	in	ADP
dpc-1540	110	23	the	the	DET
dpc-1540	110	24	general	general	ADJ
dpc-1540	110	25	population	population	NOUN
dpc-1540	110	26	.	.	PUNCT
dpc-1540	111	1	it	it	PRON
dpc-1540	111	2	was	be	AUX
dpc-1540	111	3	reported	report	VERB
dpc-1540	111	4	as	as	ADP
dpc-1540	111	5	49.4	49.4	NUM
dpc-1540	111	6	%	%	NOUN
dpc-1540	111	7	by	by	ADP
dpc-1540	111	8	ferdinando	ferdinando	NOUN
dpc-1540	111	9	et	et	PROPN
dpc-1540	111	10	al	al	PROPN
dpc-1540	112	1	[	[	X
dpc-1540	112	2	25	25	NUM
dpc-1540	112	3	]	]	PUNCT
dpc-1540	112	4	,	,	PUNCT
dpc-1540	112	5	which	which	PRON
dpc-1540	112	6	was	be	AUX
dpc-1540	112	7	1.8	1.8	NUM
dpc-1540	112	8	-	-	PUNCT
dpc-1540	112	9	times	time	NOUN
dpc-1540	112	10	higher	high	ADJ
dpc-1540	112	11	(	(	PUNCT
dpc-1540	112	12	35.0	35.0	NUM
dpc-1540	112	13	%	%	NOUN
dpc-1540	112	14	)	)	PUNCT
dpc-1540	112	15	than	than	ADP
dpc-1540	112	16	in	in	ADP
dpc-1540	112	17	the	the	DET
dpc-1540	112	18	control	control	NOUN
dpc-1540	112	19	group	group	NOUN
dpc-1540	112	20	.	.	PUNCT
dpc-1540	113	1	in	in	ADP
dpc-1540	113	2	another	another	DET
dpc-1540	113	3	meta	meta	ADJ
dpc-1540	113	4	-	-	PUNCT
dpc-1540	113	5	analysis	analysis	NOUN
dpc-1540	113	6	of	of	ADP
dpc-1540	113	7	35	35	NUM
dpc-1540	113	8	studies	study	NOUN
dpc-1540	113	9	from	from	ADP
dpc-1540	113	10	20	20	NUM
dpc-1540	113	11	countries	country	NOUN
dpc-1540	113	12	,	,	PUNCT
dpc-1540	113	13	the	the	DET
dpc-1540	113	14	pooled	pooled	ADJ
dpc-1540	113	15	or	or	CCONJ
dpc-1540	113	16	for	for	ADP
dpc-1540	113	17	ms	ms	NOUN
dpc-1540	113	18	in	in	ADP
dpc-1540	113	19	psoriasis	psoriasis	NOUN
dpc-1540	113	20	patients	patient	NOUN
dpc-1540	113	21	was	be	AUX
dpc-1540	113	22	2.14	2.14	NUM
dpc-1540	113	23	compared	compare	VERB
dpc-1540	113	24	to	to	ADP
dpc-1540	113	25	the	the	DET
dpc-1540	113	26	general	general	ADJ
dpc-1540	113	27	population	population	NOUN
dpc-1540	114	1	[	[	X
dpc-1540	114	2	21	21	NUM
dpc-1540	114	3	]	]	PUNCT
dpc-1540	114	4	.	.	PUNCT
dpc-1540	115	1	additionally	additionally	ADV
dpc-1540	115	2	,	,	PUNCT
dpc-1540	115	3	ors	or	NOUN
dpc-1540	115	4	have	have	AUX
dpc-1540	115	5	been	be	AUX
dpc-1540	115	6	reported	report	VERB
dpc-1540	115	7	to	to	ADP
dpc-1540	115	8	be2.94	be2.94	PROPN
dpc-1540	115	9	and	and	CCONJ
dpc-1540	115	10	3.65	3.65	NUM
dpc-1540	115	11	in	in	ADP
dpc-1540	115	12	different	different	ADJ
dpc-1540	115	13	provinces	province	NOUN
dpc-1540	115	14	of	of	ADP
dpc-1540	115	15	turkey	turkey	NOUN
dpc-1540	115	16	,	,	PUNCT
dpc-1540	115	17	by	by	ADP
dpc-1540	115	18	zindanci	zindanci	PROPN
dpc-1540	115	19	et	et	PROPN
dpc-1540	115	20	al	al	PROPN
dpc-1540	116	1	[	[	X
dpc-1540	116	2	27	27	NUM
dpc-1540	116	3	]	]	PUNCT
dpc-1540	116	4	and	and	CCONJ
dpc-1540	116	5	tasliyurt	tasliyurt	VERB
dpc-1540	116	6	et	et	NOUN
dpc-1540	116	7	al	al	PROPN
dpc-1540	117	1	[	[	X
dpc-1540	117	2	28	28	NUM
dpc-1540	117	3	]	]	PUNCT
dpc-1540	117	4	.	.	PUNCT
dpc-1540	118	1	adisen	adisen	PROPN
dpc-1540	118	2	et	et	PROPN
dpc-1540	118	3	al	al	PROPN
dpc-1540	118	4	found	find	VERB
dpc-1540	118	5	that	that	SCONJ
dpc-1540	118	6	the	the	DET
dpc-1540	118	7	prevalence	prevalence	NOUN
dpc-1540	118	8	was	be	AUX
dpc-1540	118	9	12.6	12.6	NUM
dpc-1540	118	10	%	%	NOUN
dpc-1540	118	11	in	in	ADP
dpc-1540	118	12	563	563	NUM
dpc-1540	118	13	psoriasis	psoriasis	NOUN
dpc-1540	118	14	patients	patient	NOUN
dpc-1540	118	15	[	[	X
dpc-1540	118	16	29	29	NUM
dpc-1540	118	17	]	]	PUNCT
dpc-1540	118	18	,	,	PUNCT
dpc-1540	118	19	whereas	whereas	SCONJ
dpc-1540	118	20	baeta	baeta	PROPN
dpc-1540	118	21	et	et	PROPN
dpc-1540	118	22	al	al	PROPN
dpc-1540	118	23	showed	show	VERB
dpc-1540	118	24	that	that	SCONJ
dpc-1540	118	25	it	it	PRON
dpc-1540	118	26	was	be	AUX
dpc-1540	118	27	44.9	44.9	NUM
dpc-1540	118	28	%	%	NOUN
dpc-1540	118	29	in	in	ADP
dpc-1540	118	30	190	190	NUM
dpc-1540	118	31	psoriasis	psoriasis	NOUN
dpc-1540	118	32	patients	patient	NOUN
dpc-1540	119	1	[	[	X
dpc-1540	119	2	30	30	NUM
dpc-1540	119	3	]	]	PUNCT
dpc-1540	119	4	.	.	PUNCT
dpc-1540	120	1	in	in	ADP
dpc-1540	120	2	our	our	PRON
dpc-1540	120	3	study	study	NOUN
dpc-1540	120	4	,	,	PUNCT
dpc-1540	120	5	67.8	67.8	NUM
dpc-1540	120	6	%	%	NOUN
dpc-1540	120	7	of	of	ADP
dpc-1540	120	8	patients	patient	NOUN
dpc-1540	120	9	had	have	VERB
dpc-1540	120	10	ms	ms	NOUN
dpc-1540	120	11	(	(	PUNCT
dpc-1540	120	12	72.8	72.8	NUM
dpc-1540	120	13	%	%	NOUN
dpc-1540	120	14	in	in	ADP
dpc-1540	120	15	females	female	NOUN
dpc-1540	120	16	and	and	CCONJ
dpc-1540	120	17	62.2	62.2	NUM
dpc-1540	120	18	%	%	NOUN
dpc-1540	120	19	in	in	ADP
dpc-1540	120	20	males	male	NOUN
dpc-1540	120	21	)	)	PUNCT
dpc-1540	120	22	.	.	PUNCT
dpc-1540	121	1	although	although	SCONJ
dpc-1540	121	2	the	the	DET
dpc-1540	121	3	age	age	NOUN
dpc-1540	121	4	range	range	NOUN
dpc-1540	121	5	,	,	PUNCT
dpc-1540	121	6	mean	mean	NOUN
dpc-1540	121	7	age	age	NOUN
dpc-1540	121	8	,	,	PUNCT
dpc-1540	121	9	and	and	CCONJ
dpc-1540	121	10	gender	gender	NOUN
dpc-1540	121	11	distribution	distribution	NOUN
dpc-1540	121	12	of	of	ADP
dpc-1540	121	13	our	our	PRON
dpc-1540	121	14	study	study	NOUN
dpc-1540	121	15	were	be	AUX
dpc-1540	121	16	similar	similar	ADJ
dpc-1540	121	17	to	to	ADP
dpc-1540	121	18	those	those	PRON
dpc-1540	121	19	in	in	ADP
dpc-1540	121	20	the	the	DET
dpc-1540	121	21	aforementioned	aforementioned	ADJ
dpc-1540	121	22	studies	study	NOUN
dpc-1540	121	23	,	,	PUNCT
dpc-1540	121	24	they	they	PRON
dpc-1540	121	25	were	be	AUX
dpc-1540	121	26	still	still	ADV
dpc-1540	121	27	higher	high	ADJ
dpc-1540	121	28	than	than	ADP
dpc-1540	121	29	in	in	ADP
dpc-1540	121	30	those	those	DET
dpc-1540	121	31	studies	study	NOUN
dpc-1540	121	32	.	.	PUNCT
dpc-1540	122	1	however	however	ADV
dpc-1540	122	2	,	,	PUNCT
dpc-1540	122	3	another	another	DET
dpc-1540	122	4	study	study	NOUN
dpc-1540	122	5	from	from	ADP
dpc-1540	122	6	turkey	turkey	NOUN
dpc-1540	122	7	indicated	indicate	VERB
dpc-1540	122	8	that	that	SCONJ
dpc-1540	122	9	ms	ms	PROPN
dpc-1540	122	10	prevalence	prevalence	NOUN
dpc-1540	122	11	was	be	AUX
dpc-1540	122	12	43.5	43.5	NUM
dpc-1540	122	13	%	%	NOUN
dpc-1540	122	14	in	in	ADP
dpc-1540	122	15	females	female	NOUN
dpc-1540	122	16	and	and	CCONJ
dpc-1540	122	17	41.4	41.4	NUM
dpc-1540	122	18	%	%	NOUN
dpc-1540	122	19	in	in	ADP
dpc-1540	122	20	males	male	NOUN
dpc-1540	122	21	in	in	ADP
dpc-1540	122	22	2010	2010	NUM
dpc-1540	122	23	;	;	PUNCT
dpc-1540	122	24	this	this	DET
dpc-1540	122	25	study	study	NOUN
dpc-1540	122	26	predicted	predict	VERB
dpc-1540	122	27	that	that	SCONJ
dpc-1540	122	28	the	the	DET
dpc-1540	122	29	table	table	NOUN
dpc-1540	122	30	1	1	NUM
dpc-1540	122	31	.	.	PUNCT
dpc-1540	122	32	clinical	clinical	ADJ
dpc-1540	122	33	characteristics	characteristic	NOUN
dpc-1540	122	34	of	of	ADP
dpc-1540	122	35	112	112	NUM
dpc-1540	122	36	psoriasis	psoriasis	NOUN
dpc-1540	122	37	patients	patient	NOUN
dpc-1540	122	38	characteristic	characteristic	ADJ
dpc-1540	122	39	patients	patient	NOUN
dpc-1540	122	40	,	,	PUNCT
dpc-1540	122	41	no	no	INTJ
dpc-1540	122	42	.	.	PUNCT
dpc-1540	123	1	(	(	PUNCT
dpc-1540	123	2	%	%	INTJ
dpc-1540	123	3	)	)	PUNCT
dpc-1540	123	4	gender	gender	NOUN
dpc-1540	123	5	m	m	PROPN
dpc-1540	123	6	53	53	NUM
dpc-1540	123	7	(	(	PUNCT
dpc-1540	123	8	47.3	47.3	NUM
dpc-1540	123	9	)	)	PUNCT
dpc-1540	123	10	f	f	PROPN
dpc-1540	123	11	59	59	NUM
dpc-1540	123	12	(	(	PUNCT
dpc-1540	123	13	52.7	52.7	NUM
dpc-1540	123	14	)	)	PUNCT
dpc-1540	123	15	bmi	bmi	NOUN
dpc-1540	123	16	(	(	PUNCT
dpc-1540	123	17	kg	kg	NOUN
dpc-1540	123	18	/	/	SYM
dpc-1540	123	19	m2	m2	PROPN
dpc-1540	123	20	)	)	PUNCT
dpc-1540	123	21	<	<	X
dpc-1540	123	22	30	30	NUM
dpc-1540	123	23	56	56	NUM
dpc-1540	123	24	(	(	PUNCT
dpc-1540	123	25	50.0	50.0	NUM
dpc-1540	123	26	)	)	PUNCT
dpc-1540	123	27	≥30	≥30	PROPN
dpc-1540	123	28	56	56	NUM
dpc-1540	123	29	(	(	PUNCT
dpc-1540	123	30	50.0	50.0	NUM
dpc-1540	123	31	)	)	PUNCT
dpc-1540	123	32	waist	waist	NOUN
dpc-1540	123	33	circumference	circumference	NOUN
dpc-1540	123	34	(	(	PUNCT
dpc-1540	123	35	cm	cm	NOUN
dpc-1540	123	36	)	)	PUNCT
dpc-1540	123	37	m<102	m<102	NUM
dpc-1540	123	38	,	,	PUNCT
dpc-1540	123	39	f<88	f<88	PROPN
dpc-1540	123	40	24	24	NUM
dpc-1540	123	41	(	(	PUNCT
dpc-1540	123	42	21.4	21.4	NUM
dpc-1540	123	43	)	)	PUNCT
dpc-1540	123	44	m>102	m>102	PROPN
dpc-1540	123	45	,	,	PUNCT
dpc-1540	123	46	f>88	f>88	NUM
dpc-1540	123	47	88	88	NUM
dpc-1540	123	48	(	(	PUNCT
dpc-1540	123	49	78.6	78.6	NUM
dpc-1540	123	50	)	)	PUNCT
dpc-1540	123	51	alcohol	alcohol	NOUN
dpc-1540	123	52	consumption	consumption	NOUN
dpc-1540	123	53	17	17	NUM
dpc-1540	123	54	(	(	PUNCT
dpc-1540	123	55	15.2	15.2	NUM
dpc-1540	123	56	)	)	PUNCT
dpc-1540	123	57	smoking	smoking	NOUN
dpc-1540	123	58	habit	habit	NOUN
dpc-1540	123	59	43	43	NUM
dpc-1540	123	60	(	(	PUNCT
dpc-1540	123	61	38.4	38.4	NUM
dpc-1540	123	62	)	)	PUNCT
dpc-1540	123	63	triglyceride	triglyceride	ADV
dpc-1540	123	64	(	(	PUNCT
dpc-1540	123	65	mg	mg	PROPN
dpc-1540	123	66	/	/	SYM
dpc-1540	123	67	dl	dl	NOUN
dpc-1540	123	68	)	)	PUNCT
dpc-1540	123	69	<	<	X
dpc-1540	123	70	150	150	NUM
dpc-1540	123	71	19	19	NUM
dpc-1540	123	72	(	(	PUNCT
dpc-1540	123	73	17.0	17.0	NUM
dpc-1540	123	74	)	)	PUNCT
dpc-1540	123	75	≥150	≥150	NOUN
dpc-1540	123	76	93	93	NUM
dpc-1540	123	77	(	(	PUNCT
dpc-1540	123	78	83.0	83.0	NUM
dpc-1540	123	79	)	)	PUNCT
dpc-1540	123	80	hdl	hdl	NOUN
dpc-1540	123	81	(	(	PUNCT
dpc-1540	123	82	mg	mg	PROPN
dpc-1540	123	83	/	/	SYM
dpc-1540	123	84	dl	dl	NOUN
dpc-1540	123	85	)	)	PUNCT
dpc-1540	123	86	m<40	m<40	NOUN
dpc-1540	123	87	,	,	PUNCT
dpc-1540	123	88	f<50	f<50	VERB
dpc-1540	123	89	69	69	NUM
dpc-1540	123	90	(	(	PUNCT
dpc-1540	123	91	61.6	61.6	NUM
dpc-1540	123	92	)	)	PUNCT
dpc-1540	123	93	m>40	m>40	NOUN
dpc-1540	123	94	,	,	PUNCT
dpc-1540	123	95	f>50	f>50	ADJ
dpc-1540	123	96	43	43	NUM
dpc-1540	123	97	(	(	PUNCT
dpc-1540	123	98	38.4	38.4	NUM
dpc-1540	123	99	)	)	PUNCT
dpc-1540	123	100	blood	blood	NOUN
dpc-1540	123	101	pressure(mmhg	pressure(mmhg	PROPN
dpc-1540	123	102	)	)	PUNCT
dpc-1540	123	103	sbp<130	sbp<130	PROPN
dpc-1540	123	104	,	,	PUNCT
dpc-1540	123	105	dbp<85	dbp<85	PROPN
dpc-1540	123	106	86	86	NUM
dpc-1540	123	107	(	(	PUNCT
dpc-1540	123	108	76.8	76.8	NUM
dpc-1540	123	109	)	)	PUNCT
dpc-1540	123	110	sbp≥130	sbp≥130	NOUN
dpc-1540	123	111	,	,	PUNCT
dpc-1540	123	112	dbp≥85	dbp≥85	PROPN
dpc-1540	123	113	26	26	NUM
dpc-1540	123	114	(	(	PUNCT
dpc-1540	123	115	23.2	23.2	NUM
dpc-1540	123	116	)	)	PUNCT
dpc-1540	123	117	fasting	fast	VERB
dpc-1540	123	118	glucose(mg	glucose(mg	PROPN
dpc-1540	123	119	/	/	SYM
dpc-1540	123	120	dl	dl	PROPN
dpc-1540	123	121	)	)	PUNCT
dpc-1540	124	1	<	<	X
dpc-1540	124	2	110	110	NUM
dpc-1540	124	3	65	65	NUM
dpc-1540	124	4	(	(	PUNCT
dpc-1540	124	5	58.0	58.0	NUM
dpc-1540	124	6	)	)	PUNCT
dpc-1540	124	7	≥110	≥110	NOUN
dpc-1540	124	8	47	47	NUM
dpc-1540	124	9	(	(	PUNCT
dpc-1540	124	10	42.0	42.0	NUM
dpc-1540	124	11	)	)	PUNCT
dpc-1540	124	12	homa	homa	NOUN
dpc-1540	124	13	-	-	PUNCT
dpc-1540	124	14	ir	ir	PROPN
dpc-1540	124	15	<	<	PROPN
dpc-1540	124	16	2.5	2.5	NUM
dpc-1540	124	17	41	41	NUM
dpc-1540	124	18	(	(	PUNCT
dpc-1540	124	19	36.6	36.6	NUM
dpc-1540	124	20	)	)	PUNCT
dpc-1540	124	21	≥2.5	≥2.5	NOUN
dpc-1540	124	22	71	71	NUM
dpc-1540	124	23	(	(	PUNCT
dpc-1540	124	24	63.4	63.4	NUM
dpc-1540	124	25	)	)	PUNCT
dpc-1540	124	26	pasi	pasi	NOUN
dpc-1540	124	27	≤10	≤10	ADP
dpc-1540	124	28	29	29	NUM
dpc-1540	124	29	(	(	PUNCT
dpc-1540	124	30	25.9	25.9	NUM
dpc-1540	124	31	)	)	PUNCT
dpc-1540	124	32	>	>	PUNCT
dpc-1540	124	33	10	10	NUM
dpc-1540	124	34	83	83	NUM
dpc-1540	124	35	(	(	PUNCT
dpc-1540	124	36	74.1	74.1	NUM
dpc-1540	124	37	)	)	PUNCT
dpc-1540	124	38	psqi	psqi	NOUN
dpc-1540	124	39	<	<	X
dpc-1540	124	40	5	5	NUM
dpc-1540	124	41	17	17	NUM
dpc-1540	124	42	(	(	PUNCT
dpc-1540	124	43	15.2	15.2	NUM
dpc-1540	124	44	)	)	PUNCT
dpc-1540	124	45	≥5	≥5	NUM
dpc-1540	124	46	95	95	NUM
dpc-1540	124	47	(	(	PUNCT
dpc-1540	124	48	84.8	84.8	NUM
dpc-1540	124	49	)	)	PUNCT
dpc-1540	124	50	comorbidities	comorbiditie	NOUN
dpc-1540	124	51	chronic	chronic	ADJ
dpc-1540	124	52	lung	lung	NOUN
dpc-1540	124	53	disease	disease	NOUN
dpc-1540	124	54	1	1	NUM
dpc-1540	124	55	(	(	PUNCT
dpc-1540	124	56	0.9	0.9	NUM
dpc-1540	124	57	)	)	PUNCT
dpc-1540	124	58	chronic	chronic	ADJ
dpc-1540	124	59	kidney	kidney	NOUN
dpc-1540	124	60	disease	disease	NOUN
dpc-1540	124	61	0	0	NUM
dpc-1540	125	1	(	(	PUNCT
dpc-1540	125	2	0	0	NUM
dpc-1540	125	3	)	)	PUNCT
dpc-1540	125	4	cerebrovascular	cerebrovascular	ADJ
dpc-1540	125	5	disease	disease	NOUN
dpc-1540	125	6	0	0	NUM
dpc-1540	126	1	(	(	PUNCT
dpc-1540	126	2	0	0	NUM
dpc-1540	126	3	)	)	PUNCT
dpc-1540	126	4	thyroid	thyroid	NOUN
dpc-1540	126	5	disease	disease	NOUN
dpc-1540	126	6	5	5	NUM
dpc-1540	126	7	(	(	PUNCT
dpc-1540	126	8	4.5	4.5	NUM
dpc-1540	126	9	)	)	PUNCT
dpc-1540	126	10	hypertension	hypertension	NOUN
dpc-1540	126	11	26(23.2	26(23.2	NOUN
dpc-1540	126	12	)	)	PUNCT
dpc-1540	126	13	diabetes	diabetes	NOUN
dpc-1540	126	14	mellitus	mellitus	NOUN
dpc-1540	126	15	23	23	NUM
dpc-1540	126	16	(	(	PUNCT
dpc-1540	126	17	20.5	20.5	NUM
dpc-1540	126	18	)	)	PUNCT
dpc-1540	126	19	bmi	bmi	NOUN
dpc-1540	126	20	=	=	SYM
dpc-1540	126	21	body	body	PROPN
dpc-1540	126	22	mass	mass	PROPN
dpc-1540	126	23	index	index	NOUN
dpc-1540	126	24	;	;	PUNCT
dpc-1540	126	25	dbp	dbp	PROPN
dpc-1540	126	26	=	=	PUNCT
dpc-1540	126	27	diastolic	diastolic	NOUN
dpc-1540	126	28	blood	blood	NOUN
dpc-1540	126	29	pressure	pressure	NOUN
dpc-1540	126	30	;	;	PUNCT
dpc-1540	126	31	f	f	NOUN
dpc-1540	126	32	=	=	SYM
dpc-1540	126	33	female	female	NOUN
dpc-1540	126	34	;	;	PUNCT
dpc-1540	126	35	hdl	hdl	PROPN
dpc-1540	126	36	=	=	PUNCT
dpc-1540	126	37	high	high	ADJ
dpc-1540	126	38	-	-	PUNCT
dpc-1540	126	39	density	density	NOUN
dpc-1540	126	40	lipoprotein	lipoprotein	NOUN
dpc-1540	126	41	;	;	PUNCT
dpc-1540	126	42	homa	homa	NOUN
dpc-1540	126	43	-	-	PUNCT
dpc-1540	126	44	ir	ir	NOUN
dpc-1540	126	45	=	=	NOUN
dpc-1540	126	46	homeostatic	homeostatic	ADJ
dpc-1540	126	47	model	model	NOUN
dpc-1540	126	48	assessment	assessment	NOUN
dpc-1540	126	49	insulin	insulin	NOUN
dpc-1540	126	50	resistance	resistance	NOUN
dpc-1540	126	51	;	;	PUNCT
dpc-1540	126	52	m	m	VERB
dpc-1540	126	53	=	=	ADJ
dpc-1540	126	54	male	male	NOUN
dpc-1540	126	55	;	;	PUNCT
dpc-1540	126	56	pasi	pasi	NOUN
dpc-1540	126	57	=	=	NOUN
dpc-1540	126	58	psoriasis	psoriasis	NOUN
dpc-1540	126	59	area	area	NOUN
dpc-1540	126	60	and	and	CCONJ
dpc-1540	126	61	severity	severity	NOUN
dpc-1540	126	62	index	index	NOUN
dpc-1540	126	63	;	;	PUNCT
dpc-1540	126	64	psqi	psqi	NOUN
dpc-1540	126	65	=	=	SYM
dpc-1540	126	66	pittsburg	pittsburg	PROPN
dpc-1540	126	67	sleep	sleep	NOUN
dpc-1540	126	68	quality	quality	PROPN
dpc-1540	126	69	index	index	NOUN
dpc-1540	126	70	;	;	PUNCT
dpc-1540	126	71	sbp	sbp	NOUN
dpc-1540	126	72	=	=	SYM
dpc-1540	126	73	systolic	systolic	ADJ
dpc-1540	126	74	blood	blood	NOUN
dpc-1540	126	75	pressure	pressure	NOUN
dpc-1540	126	76	.	.	PUNCT
dpc-1540	127	1	research	research	NOUN
dpc-1540	127	2	|	|	ADV
dpc-1540	127	3	dermatol	dermatol	ADJ
dpc-1540	127	4	pract	pract	NOUN
dpc-1540	127	5	concept	concept	NOUN
dpc-1540	127	6	.	.	PUNCT
dpc-1540	128	1	2021;11(3):e2021049	2021;11(3):e2021049	NUM
dpc-1540	128	2	5	5	NUM
dpc-1540	128	3	prevalence	prevalence	NOUN
dpc-1540	128	4	of	of	ADP
dpc-1540	128	5	ms	ms	PROPN
dpc-1540	128	6	will	will	AUX
dpc-1540	128	7	increase	increase	VERB
dpc-1540	128	8	in	in	ADP
dpc-1540	128	9	the	the	DET
dpc-1540	128	10	coming	come	VERB
dpc-1540	128	11	years	year	NOUN
dpc-1540	129	1	[	[	X
dpc-1540	129	2	29	29	NUM
dpc-1540	129	3	]	]	PUNCT
dpc-1540	129	4	.	.	PUNCT
dpc-1540	130	1	considering	consider	VERB
dpc-1540	130	2	this	this	DET
dpc-1540	130	3	information	information	NOUN
dpc-1540	130	4	[	[	X
dpc-1540	130	5	21,23,31	21,23,31	X
dpc-1540	130	6	]	]	PUNCT
dpc-1540	130	7	and	and	CCONJ
dpc-1540	130	8	due	due	ADP
dpc-1540	130	9	to	to	ADP
dpc-1540	130	10	the	the	DET
dpc-1540	130	11	fact	fact	NOUN
dpc-1540	130	12	that	that	SCONJ
dpc-1540	130	13	ms	ms	PROPN
dpc-1540	130	14	is	be	AUX
dpc-1540	130	15	more	more	ADV
dpc-1540	130	16	common	common	ADJ
dpc-1540	130	17	in	in	ADP
dpc-1540	130	18	psoriasis	psoriasis	NOUN
dpc-1540	130	19	patients	patient	NOUN
dpc-1540	130	20	[	[	X
dpc-1540	130	21	25	25	NUM
dpc-1540	130	22	,	,	PUNCT
dpc-1540	130	23	26	26	NUM
dpc-1540	130	24	,	,	PUNCT
dpc-1540	130	25	29	29	NUM
dpc-1540	130	26	,	,	PUNCT
dpc-1540	130	27	30	30	NUM
dpc-1540	130	28	,	,	PUNCT
dpc-1540	130	29	31	31	NUM
dpc-1540	130	30	]	]	PUNCT
dpc-1540	130	31	,	,	PUNCT
dpc-1540	130	32	our	our	PRON
dpc-1540	130	33	results	result	NOUN
dpc-1540	130	34	are	be	AUX
dpc-1540	130	35	in	in	ADP
dpc-1540	130	36	line	line	NOUN
dpc-1540	130	37	with	with	ADP
dpc-1540	130	38	the	the	DET
dpc-1540	130	39	expectations	expectation	NOUN
dpc-1540	130	40	mentioned	mention	VERB
dpc-1540	130	41	.	.	PUNCT
dpc-1540	131	1	the	the	DET
dpc-1540	131	2	role	role	NOUN
dpc-1540	131	3	of	of	ADP
dpc-1540	131	4	age	age	NOUN
dpc-1540	131	5	and	and	CCONJ
dpc-1540	131	6	gender	gender	NOUN
dpc-1540	131	7	on	on	ADP
dpc-1540	131	8	ms	ms	PROPN
dpc-1540	131	9	development	development	NOUN
dpc-1540	131	10	in	in	ADP
dpc-1540	131	11	psoriasis	psoriasis	NOUN
dpc-1540	131	12	patients	patient	NOUN
dpc-1540	131	13	varied	varied	ADJ
dpc-1540	131	14	in	in	ADP
dpc-1540	131	15	different	different	ADJ
dpc-1540	131	16	studies	study	NOUN
dpc-1540	131	17	.	.	PUNCT
dpc-1540	132	1	kim	kim	PROPN
dpc-1540	132	2	et	et	PROPN
dpc-1540	132	3	al	al	PROPN
dpc-1540	133	1	[	[	X
dpc-1540	133	2	32	32	NUM
dpc-1540	133	3	]	]	PUNCT
dpc-1540	133	4	and	and	CCONJ
dpc-1540	133	5	altunay	altunay	PROPN
dpc-1540	133	6	et	et	PROPN
dpc-1540	133	7	al	al	PROPN
dpc-1540	134	1	[	[	X
dpc-1540	134	2	3	3	X
dpc-1540	134	3	]	]	PUNCT
dpc-1540	134	4	showed	show	VERB
dpc-1540	134	5	that	that	SCONJ
dpc-1540	134	6	the	the	DET
dpc-1540	134	7	presence	presence	NOUN
dpc-1540	134	8	of	of	ADP
dpc-1540	134	9	ms	ms	PROPN
dpc-1540	134	10	was	be	AUX
dpc-1540	134	11	significantly	significantly	ADV
dpc-1540	134	12	higher	high	ADJ
dpc-1540	134	13	in	in	ADP
dpc-1540	134	14	older	old	ADJ
dpc-1540	134	15	psoriasis	psoriasis	NOUN
dpc-1540	134	16	patients	patient	NOUN
dpc-1540	134	17	,	,	PUNCT
dpc-1540	134	18	and	and	CCONJ
dpc-1540	134	19	the	the	DET
dpc-1540	134	20	prevalence	prevalence	NOUN
dpc-1540	134	21	was	be	AUX
dpc-1540	134	22	insignificantly	insignificantly	ADV
dpc-1540	134	23	higher	high	ADJ
dpc-1540	134	24	in	in	ADP
dpc-1540	134	25	males	male	NOUN
dpc-1540	134	26	.	.	PUNCT
dpc-1540	135	1	adisen	adisen	NOUN
dpc-1540	135	2	et	et	NOUN
dpc-1540	135	3	al	al	PROPN
dpc-1540	136	1	[	[	X
dpc-1540	136	2	29	29	NUM
dpc-1540	136	3	]	]	PUNCT
dpc-1540	136	4	also	also	ADV
dpc-1540	136	5	stated	state	VERB
dpc-1540	136	6	that	that	SCONJ
dpc-1540	136	7	it	it	PRON
dpc-1540	136	8	did	do	AUX
dpc-1540	136	9	not	not	PART
dpc-1540	136	10	vary	vary	VERB
dpc-1540	136	11	by	by	ADP
dpc-1540	136	12	gender	gender	NOUN
dpc-1540	136	13	but	but	CCONJ
dpc-1540	136	14	was	be	AUX
dpc-1540	136	15	higher	high	ADJ
dpc-1540	136	16	in	in	ADP
dpc-1540	136	17	older	old	ADJ
dpc-1540	136	18	people	people	NOUN
dpc-1540	136	19	[	[	X
dpc-1540	136	20	29	29	NUM
dpc-1540	136	21	]	]	PUNCT
dpc-1540	136	22	.	.	PUNCT
dpc-1540	137	1	we	we	PRON
dpc-1540	137	2	did	do	AUX
dpc-1540	137	3	not	not	PART
dpc-1540	137	4	find	find	VERB
dpc-1540	137	5	a	a	DET
dpc-1540	137	6	significant	significant	ADJ
dpc-1540	137	7	difference	difference	NOUN
dpc-1540	137	8	according	accord	VERB
dpc-1540	137	9	to	to	ADP
dpc-1540	137	10	either	either	DET
dpc-1540	137	11	age	age	NOUN
dpc-1540	137	12	or	or	CCONJ
dpc-1540	137	13	gender	gender	NOUN
dpc-1540	137	14	.	.	PUNCT
dpc-1540	138	1	the	the	DET
dpc-1540	138	2	exact	exact	ADJ
dpc-1540	138	3	mechanism	mechanism	NOUN
dpc-1540	138	4	for	for	ADP
dpc-1540	138	5	the	the	DET
dpc-1540	138	6	link	link	NOUN
dpc-1540	138	7	between	between	ADP
dpc-1540	138	8	psoriasis	psoriasis	NOUN
dpc-1540	138	9	and	and	CCONJ
dpc-1540	138	10	ms	ms	NOUN
dpc-1540	138	11	is	be	AUX
dpc-1540	138	12	uncertain	uncertain	ADJ
dpc-1540	138	13	.	.	PUNCT
dpc-1540	139	1	however	however	ADV
dpc-1540	139	2	,	,	PUNCT
dpc-1540	139	3	common	common	ADJ
dpc-1540	139	4	pathways	pathway	NOUN
dpc-1540	139	5	through	through	ADP
dpc-1540	139	6	th1	th1	PROPN
dpc-1540	139	7	/	/	SYM
dpc-1540	139	8	th17	th17	PROPN
dpc-1540	139	9	cells	cell	NOUN
dpc-1540	139	10	,	,	PUNCT
dpc-1540	139	11	and	and	CCONJ
dpc-1540	139	12	common	common	ADJ
dpc-1540	139	13	effects	effect	NOUN
dpc-1540	139	14	of	of	ADP
dpc-1540	139	15	pro	pro	ADJ
dpc-1540	139	16	-	-	ADJ
dpc-1540	139	17	inflammatory	inflammatory	ADJ
dpc-1540	139	18	cytokines	cytokine	NOUN
dpc-1540	139	19	on	on	ADP
dpc-1540	139	20	adipocytes	adipocyte	NOUN
dpc-1540	139	21	,	,	PUNCT
dpc-1540	139	22	glucose	glucose	NOUN
dpc-1540	139	23	regulation	regulation	NOUN
dpc-1540	139	24	,	,	PUNCT
dpc-1540	139	25	lipid	lipid	NOUN
dpc-1540	139	26	status	status	NOUN
dpc-1540	139	27	,	,	PUNCT
dpc-1540	139	28	and	and	CCONJ
dpc-1540	139	29	endothelial	endothelial	ADJ
dpc-1540	139	30	function	function	NOUN
dpc-1540	139	31	are	be	AUX
dpc-1540	139	32	used	use	VERB
dpc-1540	139	33	to	to	PART
dpc-1540	139	34	try	try	VERB
dpc-1540	139	35	to	to	PART
dpc-1540	139	36	explain	explain	VERB
dpc-1540	139	37	it	it	PRON
dpc-1540	139	38	[	[	X
dpc-1540	139	39	21	21	NUM
dpc-1540	139	40	,	,	PUNCT
dpc-1540	139	41	25	25	NUM
dpc-1540	139	42	]	]	PUNCT
dpc-1540	139	43	.	.	PUNCT
dpc-1540	140	1	psoriasis	psoriasis	NOUN
dpc-1540	140	2	and	and	CCONJ
dpc-1540	140	3	ms	ms	NOUN
dpc-1540	140	4	can	can	AUX
dpc-1540	140	5	develop	develop	VERB
dpc-1540	140	6	in	in	ADP
dpc-1540	140	7	a	a	DET
dpc-1540	140	8	person	person	NOUN
dpc-1540	140	9	independently	independently	ADV
dpc-1540	140	10	of	of	ADP
dpc-1540	140	11	each	each	DET
dpc-1540	140	12	other	other	ADJ
dpc-1540	140	13	.	.	PUNCT
dpc-1540	141	1	however	however	ADV
dpc-1540	141	2	,	,	PUNCT
dpc-1540	141	3	it	it	PRON
dpc-1540	141	4	is	be	AUX
dpc-1540	141	5	suggested	suggest	VERB
dpc-1540	141	6	that	that	SCONJ
dpc-1540	141	7	the	the	DET
dpc-1540	141	8	existence	existence	NOUN
dpc-1540	141	9	of	of	ADP
dpc-1540	141	10	one	one	NUM
dpc-1540	141	11	of	of	ADP
dpc-1540	141	12	them	they	PRON
dpc-1540	141	13	can	can	AUX
dpc-1540	141	14	facilitate	facilitate	VERB
dpc-1540	141	15	the	the	DET
dpc-1540	141	16	development	development	NOUN
dpc-1540	141	17	of	of	ADP
dpc-1540	141	18	the	the	DET
dpc-1540	141	19	other	other	ADJ
dpc-1540	141	20	,	,	PUNCT
dpc-1540	141	21	because	because	SCONJ
dpc-1540	141	22	of	of	ADP
dpc-1540	141	23	a	a	DET
dpc-1540	141	24	shared	share	VERB
dpc-1540	141	25	immunopathogenesis	immunopathogenesis	NOUN
dpc-1540	141	26	involving	involve	VERB
dpc-1540	141	27	chronic	chronic	ADJ
dpc-1540	141	28	inflammation	inflammation	NOUN
dpc-1540	141	29	mediated	mediate	VERB
dpc-1540	141	30	by	by	ADP
dpc-1540	141	31	cytokines	cytokine	NOUN
dpc-1540	141	32	such	such	ADJ
dpc-1540	141	33	as	as	ADP
dpc-1540	141	34	ifn	ifn	NOUN
dpc-1540	141	35	-	-	PUNCT
dpc-1540	141	36	gamma	gamma	NOUN
dpc-1540	141	37	,	,	PUNCT
dpc-1540	141	38	il-17	il-17	ADV
dpc-1540	141	39	,	,	PUNCT
dpc-1540	141	40	il-23	il-23	NOUN
dpc-1540	141	41	,	,	PUNCT
dpc-1540	141	42	and	and	CCONJ
dpc-1540	141	43	tnf	tnf	PROPN
dpc-1540	141	44	-	-	PUNCT
dpc-1540	141	45	alpha	alpha	NOUN
dpc-1540	141	46	.	.	PUNCT
dpc-1540	142	1	similarly	similarly	ADV
dpc-1540	142	2	,	,	PUNCT
dpc-1540	142	3	insulin	insulin	NOUN
dpc-1540	142	4	-	-	PUNCT
dpc-1540	142	5	like	like	ADJ
dpc-1540	142	6	growth	growth	NOUN
dpc-1540	142	7	factor	factor	NOUN
dpc-1540	142	8	is	be	AUX
dpc-1540	142	9	a	a	DET
dpc-1540	142	10	shared	share	VERB
dpc-1540	142	11	mediator	mediator	NOUN
dpc-1540	142	12	for	for	ADP
dpc-1540	142	13	the	the	DET
dpc-1540	142	14	development	development	NOUN
dpc-1540	142	15	of	of	ADP
dpc-1540	142	16	diabetes	diabetes	NOUN
dpc-1540	142	17	mellitus	mellitus	NOUN
dpc-1540	142	18	,	,	PUNCT
dpc-1540	142	19	hyperlipidemia	hyperlipidemia	NOUN
dpc-1540	142	20	and	and	CCONJ
dpc-1540	142	21	keratinocyte	keratinocyte	NOUN
dpc-1540	142	22	proliferation	proliferation	NOUN
dpc-1540	142	23	in	in	ADP
dpc-1540	142	24	psoriatic	psoriatic	ADJ
dpc-1540	142	25	skin	skin	NOUN
dpc-1540	142	26	[	[	X
dpc-1540	142	27	21	21	NUM
dpc-1540	142	28	]	]	PUNCT
dpc-1540	142	29	.	.	PUNCT
dpc-1540	143	1	it	it	PRON
dpc-1540	143	2	is	be	AUX
dpc-1540	143	3	also	also	ADV
dpc-1540	143	4	suggested	suggest	VERB
dpc-1540	143	5	that	that	SCONJ
dpc-1540	143	6	obesity	obesity	NOUN
dpc-1540	143	7	in	in	ADP
dpc-1540	143	8	psoriasis	psoriasis	NOUN
dpc-1540	143	9	patients	patient	NOUN
dpc-1540	143	10	plays	play	VERB
dpc-1540	143	11	a	a	DET
dpc-1540	143	12	key	key	ADJ
dpc-1540	143	13	role	role	NOUN
dpc-1540	143	14	in	in	ADP
dpc-1540	143	15	the	the	DET
dpc-1540	143	16	increased	increase	VERB
dpc-1540	143	17	risk	risk	NOUN
dpc-1540	143	18	for	for	ADP
dpc-1540	143	19	ms	ms	PROPN
dpc-1540	143	20	development	development	PROPN
dpc-1540	143	21	[	[	X
dpc-1540	143	22	8,9	8,9	NUM
dpc-1540	143	23	]	]	PUNCT
dpc-1540	143	24	.	.	PUNCT
dpc-1540	144	1	common	common	ADJ
dpc-1540	144	2	outcomes	outcome	NOUN
dpc-1540	144	3	of	of	ADP
dpc-1540	144	4	both	both	DET
dpc-1540	144	5	psoriasis	psoriasis	NOUN
dpc-1540	144	6	and	and	CCONJ
dpc-1540	144	7	ms	ms	NOUN
dpc-1540	144	8	are	be	AUX
dpc-1540	144	9	abdominal	abdominal	ADJ
dpc-1540	144	10	obesity	obesity	NOUN
dpc-1540	144	11	,	,	PUNCT
dpc-1540	144	12	hypertension	hypertension	NOUN
dpc-1540	144	13	,	,	PUNCT
dpc-1540	144	14	dyslipidemia	dyslipidemia	NOUN
dpc-1540	144	15	,	,	PUNCT
dpc-1540	144	16	and	and	CCONJ
dpc-1540	144	17	insulin	insulin	NOUN
dpc-1540	144	18	resistance	resistance	NOUN
dpc-1540	144	19	[	[	X
dpc-1540	144	20	21	21	NUM
dpc-1540	144	21	]	]	PUNCT
dpc-1540	144	22	.	.	PUNCT
dpc-1540	145	1	although	although	SCONJ
dpc-1540	145	2	the	the	DET
dpc-1540	145	3	relationship	relationship	NOUN
dpc-1540	145	4	between	between	ADP
dpc-1540	145	5	psoriasis	psoriasis	NOUN
dpc-1540	145	6	severity	severity	NOUN
dpc-1540	145	7	and	and	CCONJ
dpc-1540	145	8	ms	ms	NOUN
dpc-1540	145	9	has	have	AUX
dpc-1540	145	10	been	be	AUX
dpc-1540	145	11	reported	report	VERB
dpc-1540	145	12	differently	differently	ADV
dpc-1540	145	13	in	in	ADP
dpc-1540	145	14	the	the	DET
dpc-1540	145	15	literature	literature	NOUN
dpc-1540	145	16	[	[	X
dpc-1540	145	17	33	33	NUM
dpc-1540	145	18	]	]	PUNCT
dpc-1540	145	19	,	,	PUNCT
dpc-1540	145	20	ms	ms	PROPN
dpc-1540	145	21	prevalence	prevalence	NOUN
dpc-1540	145	22	usually	usually	ADV
dpc-1540	145	23	increases	increase	VERB
dpc-1540	145	24	with	with	ADP
dpc-1540	145	25	psoriasis	psoriasis	NOUN
dpc-1540	145	26	severity	severity	NOUN
dpc-1540	145	27	,	,	PUNCT
dpc-1540	145	28	when	when	SCONJ
dpc-1540	145	29	ms	ms	PROPN
dpc-1540	145	30	components	component	NOUN
dpc-1540	145	31	are	be	AUX
dpc-1540	145	32	considered	consider	VERB
dpc-1540	145	33	individually	individually	ADV
dpc-1540	145	34	[	[	X
dpc-1540	145	35	21	21	NUM
dpc-1540	145	36	]	]	PUNCT
dpc-1540	145	37	.	.	PUNCT
dpc-1540	146	1	however	however	ADV
dpc-1540	146	2	,	,	PUNCT
dpc-1540	146	3	adisen	adisen	PROPN
dpc-1540	146	4	et	et	NOUN
dpc-1540	146	5	al	al	PROPN
dpc-1540	147	1	[	[	X
dpc-1540	147	2	29]and	29]and	NUM
dpc-1540	147	3	altunay	altunay	NOUN
dpc-1540	147	4	et	et	NOUN
dpc-1540	147	5	al	al	PROPN
dpc-1540	148	1	[	[	X
dpc-1540	148	2	3	3	X
dpc-1540	148	3	]	]	PUNCT
dpc-1540	148	4	found	find	VERB
dpc-1540	148	5	that	that	SCONJ
dpc-1540	148	6	mean	mean	VERB
dpc-1540	148	7	scores	score	NOUN
dpc-1540	148	8	of	of	ADP
dpc-1540	148	9	pasi	pasi	NOUN
dpc-1540	148	10	were	be	AUX
dpc-1540	148	11	not	not	PART
dpc-1540	148	12	different	different	ADJ
dpc-1540	148	13	between	between	ADP
dpc-1540	148	14	patients	patient	NOUN
dpc-1540	148	15	with	with	ADP
dpc-1540	148	16	and	and	CCONJ
dpc-1540	148	17	without	without	ADP
dpc-1540	148	18	ms	ms	PROPN
dpc-1540	148	19	,	,	PUNCT
dpc-1540	148	20	whereas	whereas	SCONJ
dpc-1540	148	21	itani	itani	PROPN
dpc-1540	148	22	et	et	NOUN
dpc-1540	148	23	al	al	PROPN
dpc-1540	149	1	[	[	X
dpc-1540	149	2	33	33	NUM
dpc-1540	149	3	]	]	PUNCT
dpc-1540	149	4	reported	report	VERB
dpc-1540	149	5	that	that	SCONJ
dpc-1540	149	6	the	the	DET
dpc-1540	149	7	mean	mean	ADJ
dpc-1540	149	8	pasi	pasi	NOUN
dpc-1540	149	9	score	score	NOUN
dpc-1540	149	10	was	be	AUX
dpc-1540	149	11	greater	great	ADJ
dpc-1540	149	12	in	in	ADP
dpc-1540	149	13	psoriasis	psoriasis	NOUN
dpc-1540	149	14	patients	patient	NOUN
dpc-1540	149	15	with	with	ADP
dpc-1540	149	16	than	than	ADP
dpc-1540	149	17	without	without	ADP
dpc-1540	149	18	ms	ms	PROPN
dpc-1540	149	19	.	.	PROPN
dpc-1540	150	1	we	we	PRON
dpc-1540	150	2	did	do	AUX
dpc-1540	150	3	not	not	PART
dpc-1540	150	4	find	find	VERB
dpc-1540	150	5	any	any	DET
dpc-1540	150	6	difference	difference	NOUN
dpc-1540	150	7	between	between	ADP
dpc-1540	150	8	groups	group	NOUN
dpc-1540	150	9	according	accord	VERB
dpc-1540	150	10	to	to	ADP
dpc-1540	150	11	pasi	pasi	NOUN
dpc-1540	150	12	.	.	PUNCT
dpc-1540	151	1	however	however	ADV
dpc-1540	151	2	,	,	PUNCT
dpc-1540	151	3	although	although	SCONJ
dpc-1540	151	4	the	the	DET
dpc-1540	151	5	prevalences	prevalence	NOUN
dpc-1540	151	6	of	of	ADP
dpc-1540	151	7	ms	ms	NOUN
dpc-1540	151	8	were	be	AUX
dpc-1540	151	9	not	not	PART
dpc-1540	151	10	different	different	ADJ
dpc-1540	151	11	by	by	ADP
dpc-1540	151	12	gender	gender	NOUN
dpc-1540	151	13	,	,	PUNCT
dpc-1540	151	14	the	the	DET
dpc-1540	151	15	presence	presence	NOUN
dpc-1540	151	16	of	of	ADP
dpc-1540	151	17	ms	ms	PROPN
dpc-1540	151	18	was	be	AUX
dpc-1540	151	19	significantly	significantly	ADV
dpc-1540	151	20	higher	high	ADJ
dpc-1540	151	21	in	in	ADP
dpc-1540	151	22	females	female	NOUN
dpc-1540	151	23	with	with	ADP
dpc-1540	151	24	high	high	ADJ
dpc-1540	151	25	pasi	pasi	NOUN
dpc-1540	151	26	than	than	ADP
dpc-1540	151	27	in	in	ADP
dpc-1540	151	28	males	male	NOUN
dpc-1540	151	29	.	.	PUNCT
dpc-1540	152	1	moreover	moreover	ADV
dpc-1540	152	2	,	,	PUNCT
dpc-1540	152	3	when	when	SCONJ
dpc-1540	152	4	considering	consider	VERB
dpc-1540	152	5	different	different	ADJ
dpc-1540	152	6	pasi	pasi	NOUN
dpc-1540	152	7	groups	group	NOUN
dpc-1540	152	8	,	,	PUNCT
dpc-1540	152	9	only	only	ADV
dpc-1540	152	10	fasting	fast	VERB
dpc-1540	152	11	glucose	glucose	NOUN
dpc-1540	152	12	and	and	CCONJ
dpc-1540	152	13	hdl	hdl	PROPN
dpc-1540	152	14	levels	level	NOUN
dpc-1540	152	15	table	table	VERB
dpc-1540	152	16	2	2	NUM
dpc-1540	152	17	.	.	PUNCT
dpc-1540	152	18	clinical	clinical	ADJ
dpc-1540	152	19	characteristics	characteristic	NOUN
dpc-1540	152	20	of	of	ADP
dpc-1540	152	21	psoriasis	psoriasis	NOUN
dpc-1540	152	22	patients	patient	NOUN
dpc-1540	152	23	without	without	ADP
dpc-1540	152	24	(	(	PUNCT
dpc-1540	152	25	n	n	NOUN
dpc-1540	152	26	=	=	SYM
dpc-1540	152	27	36	36	NUM
dpc-1540	152	28	)	)	PUNCT
dpc-1540	152	29	and	and	CCONJ
dpc-1540	152	30	with	with	ADP
dpc-1540	152	31	(	(	PUNCT
dpc-1540	152	32	n	n	NOUN
dpc-1540	152	33	=	=	SYM
dpc-1540	152	34	76	76	NUM
dpc-1540	152	35	)	)	PUNCT
dpc-1540	152	36	metabolic	metabolic	NOUN
dpc-1540	152	37	syndrome	syndrome	NOUN
dpc-1540	152	38	:	:	PUNCT
dpc-1540	152	39	analysis	analysis	NOUN
dpc-1540	152	40	of	of	ADP
dpc-1540	152	41	frequencies	frequency	NOUN
dpc-1540	152	42	characteristic	characteristic	ADJ
dpc-1540	152	43	  	  	SPACE
dpc-1540	152	44	non	non	PROPN
dpc-1540	152	45	-	-	ADJ
dpc-1540	152	46	ms	ms	ADJ
dpc-1540	152	47	group1	group1	PROPN
dpc-1540	152	48	ms	ms	PROPN
dpc-1540	152	49	group1	group1	PROPN
dpc-1540	152	50	p2	p2	PROPN
dpc-1540	152	51	gender	gender	NOUN
dpc-1540	152	52	m	m	VERB
dpc-1540	152	53	20	20	NUM
dpc-1540	152	54	(	(	PUNCT
dpc-1540	152	55	55.6	55.6	NUM
dpc-1540	152	56	)	)	PUNCT
dpc-1540	152	57	33	33	NUM
dpc-1540	152	58	(	(	PUNCT
dpc-1540	152	59	43.4	43.4	NUM
dpc-1540	152	60	)	)	PUNCT
dpc-1540	152	61	.230	.230	NUM
dpc-1540	153	1	f	f	PROPN
dpc-1540	153	2	16	16	NUM
dpc-1540	153	3	(	(	PUNCT
dpc-1540	153	4	44.4	44.4	NUM
dpc-1540	153	5	)	)	PUNCT
dpc-1540	153	6	43	43	NUM
dpc-1540	153	7	(	(	PUNCT
dpc-1540	153	8	56.6	56.6	NUM
dpc-1540	153	9	)	)	PUNCT
dpc-1540	153	10	waist	waist	NOUN
dpc-1540	153	11	circumference	circumference	NOUN
dpc-1540	153	12	(	(	PUNCT
dpc-1540	153	13	cm	cm	NOUN
dpc-1540	153	14	)	)	PUNCT
dpc-1540	153	15	m<102	m<102	NUM
dpc-1540	153	16	,	,	PUNCT
dpc-1540	153	17	f<88	f<88	PROPN
dpc-1540	153	18	19	19	NUM
dpc-1540	153	19	(	(	PUNCT
dpc-1540	153	20	52.8	52.8	NUM
dpc-1540	153	21	)	)	PUNCT
dpc-1540	153	22	5	5	NUM
dpc-1540	153	23	(	(	PUNCT
dpc-1540	153	24	6.6	6.6	NUM
dpc-1540	153	25	)	)	PUNCT
dpc-1540	153	26	.0001	.0001	PUNCT
dpc-1540	154	1	m>102	m>102	PROPN
dpc-1540	154	2	,	,	PUNCT
dpc-1540	154	3	f>88	f>88	NUM
dpc-1540	154	4	17	17	NUM
dpc-1540	154	5	(	(	PUNCT
dpc-1540	154	6	47.2	47.2	NUM
dpc-1540	154	7	)	)	PUNCT
dpc-1540	154	8	71	71	NUM
dpc-1540	154	9	(	(	PUNCT
dpc-1540	154	10	93.4	93.4	NUM
dpc-1540	154	11	)	)	PUNCT
dpc-1540	154	12	bmi	bmi	NOUN
dpc-1540	154	13	(	(	PUNCT
dpc-1540	154	14	kg	kg	NOUN
dpc-1540	154	15	/	/	SYM
dpc-1540	154	16	m2	m2	PROPN
dpc-1540	154	17	)	)	PUNCT
dpc-1540	155	1	triglyceride	triglyceride	ADV
dpc-1540	155	2	(	(	PUNCT
dpc-1540	155	3	mg	mg	PROPN
dpc-1540	155	4	/	/	SYM
dpc-1540	155	5	dl	dl	NOUN
dpc-1540	155	6	)	)	PUNCT
dpc-1540	155	7	≥30	≥30	PROPN
dpc-1540	155	8	11	11	NUM
dpc-1540	155	9	(	(	PUNCT
dpc-1540	155	10	30.6	30.6	NUM
dpc-1540	155	11	)	)	PUNCT
dpc-1540	155	12	45	45	NUM
dpc-1540	155	13	(	(	PUNCT
dpc-1540	155	14	59.2	59.2	NUM
dpc-1540	155	15	)	)	PUNCT
dpc-1540	155	16	.0001	.0001	NOUN
dpc-1540	156	1	<	<	X
dpc-1540	156	2	150	150	NUM
dpc-1540	156	3	14	14	NUM
dpc-1540	156	4	(	(	PUNCT
dpc-1540	156	5	38.9	38.9	NUM
dpc-1540	156	6	)	)	SYM
dpc-1540	156	7	5	5	NUM
dpc-1540	156	8	(	(	PUNCT
dpc-1540	156	9	6.6	6.6	NUM
dpc-1540	156	10	)	)	PUNCT
dpc-1540	156	11	.0001	.0001	PROPN
dpc-1540	156	12	≥150	≥150	NOUN
dpc-1540	156	13	22	22	NUM
dpc-1540	156	14	(	(	PUNCT
dpc-1540	156	15	61.1	61.1	NUM
dpc-1540	156	16	)	)	PUNCT
dpc-1540	156	17	71	71	NUM
dpc-1540	156	18	(	(	PUNCT
dpc-1540	156	19	93.4	93.4	NUM
dpc-1540	156	20	)	)	PUNCT
dpc-1540	156	21	hdl	hdl	NOUN
dpc-1540	156	22	(	(	PUNCT
dpc-1540	156	23	mg	mg	PROPN
dpc-1540	156	24	/	/	SYM
dpc-1540	156	25	dl	dl	NOUN
dpc-1540	156	26	)	)	PUNCT
dpc-1540	156	27	m<40	m<40	NOUN
dpc-1540	156	28	,	,	PUNCT
dpc-1540	156	29	f<50	f<50	ADJ
dpc-1540	156	30	28	28	NUM
dpc-1540	156	31	(	(	PUNCT
dpc-1540	156	32	22.2	22.2	NUM
dpc-1540	156	33	)	)	PUNCT
dpc-1540	156	34	15	15	NUM
dpc-1540	156	35	(	(	PUNCT
dpc-1540	156	36	80.3	80.3	NUM
dpc-1540	156	37	)	)	PUNCT
dpc-1540	156	38	.0001	.0001	PRON
dpc-1540	156	39	m>40	m>40	NOUN
dpc-1540	156	40	,	,	PUNCT
dpc-1540	156	41	f>50	f>50	PRON
dpc-1540	156	42	8	8	NUM
dpc-1540	156	43	(	(	PUNCT
dpc-1540	156	44	77.8	77.8	NUM
dpc-1540	156	45	)	)	PUNCT
dpc-1540	156	46	61	61	NUM
dpc-1540	156	47	(	(	PUNCT
dpc-1540	156	48	19.7	19.7	NUM
dpc-1540	156	49	)	)	PUNCT
dpc-1540	156	50	fasting	fast	VERB
dpc-1540	156	51	glucose	glucose	NOUN
dpc-1540	156	52	(	(	PUNCT
dpc-1540	156	53	mg	mg	PROPN
dpc-1540	156	54	/	/	SYM
dpc-1540	156	55	dl	dl	NOUN
dpc-1540	156	56	)	)	PUNCT
dpc-1540	157	1	<	<	X
dpc-1540	157	2	110	110	NUM
dpc-1540	157	3	33	33	NUM
dpc-1540	157	4	(	(	PUNCT
dpc-1540	157	5	91.7	91.7	NUM
dpc-1540	157	6	)	)	PUNCT
dpc-1540	157	7	32	32	NUM
dpc-1540	157	8	(	(	PUNCT
dpc-1540	157	9	42.1	42.1	NUM
dpc-1540	157	10	)	)	PUNCT
dpc-1540	157	11	.0001	.0001	X
dpc-1540	157	12	≥110	≥110	ADJ
dpc-1540	157	13	3	3	NUM
dpc-1540	157	14	(	(	PUNCT
dpc-1540	157	15	8.3	8.3	NUM
dpc-1540	157	16	)	)	SYM
dpc-1540	157	17	44	44	NUM
dpc-1540	157	18	(	(	PUNCT
dpc-1540	157	19	57.9	57.9	NUM
dpc-1540	157	20	)	)	PUNCT
dpc-1540	157	21	blood	blood	NOUN
dpc-1540	157	22	pressure	pressure	NOUN
dpc-1540	157	23	(	(	PUNCT
dpc-1540	157	24	mmhg	mmhg	PROPN
dpc-1540	157	25	)	)	PUNCT
dpc-1540	157	26	sbp<130	sbp<130	PROPN
dpc-1540	157	27	,	,	PUNCT
dpc-1540	157	28	dbp<85	dbp<85	PROPN
dpc-1540	157	29	35	35	NUM
dpc-1540	157	30	(	(	PUNCT
dpc-1540	157	31	97.2	97.2	NUM
dpc-1540	157	32	)	)	PUNCT
dpc-1540	157	33	51	51	NUM
dpc-1540	157	34	(	(	PUNCT
dpc-1540	157	35	67.1	67.1	NUM
dpc-1540	157	36	)	)	PUNCT
dpc-1540	157	37	.0001	.0001	PROPN
dpc-1540	157	38	sbp≥130	sbp≥130	NOUN
dpc-1540	157	39	,	,	PUNCT
dpc-1540	157	40	dbp≥85	dbp≥85	PROPN
dpc-1540	157	41	1	1	NUM
dpc-1540	157	42	(	(	PUNCT
dpc-1540	157	43	2.8	2.8	NUM
dpc-1540	157	44	)	)	PUNCT
dpc-1540	157	45	25	25	NUM
dpc-1540	157	46	(	(	PUNCT
dpc-1540	157	47	32.9	32.9	NUM
dpc-1540	157	48	)	)	PUNCT
dpc-1540	157	49	pasi	pasi	NOUN
dpc-1540	157	50	≤10	≤10	PROPN
dpc-1540	157	51	12	12	NUM
dpc-1540	157	52	(	(	PUNCT
dpc-1540	157	53	33.3	33.3	NUM
dpc-1540	157	54	)	)	PUNCT
dpc-1540	157	55	17	17	NUM
dpc-1540	157	56	(	(	PUNCT
dpc-1540	157	57	22.4	22.4	NUM
dpc-1540	157	58	)	)	PUNCT
dpc-1540	157	59	.216	.216	NUM
dpc-1540	157	60	>	>	X
dpc-1540	157	61	10	10	NUM
dpc-1540	157	62	24	24	NUM
dpc-1540	157	63	(	(	PUNCT
dpc-1540	157	64	66.7	66.7	NUM
dpc-1540	157	65	)	)	PUNCT
dpc-1540	157	66	59	59	NUM
dpc-1540	157	67	(	(	PUNCT
dpc-1540	157	68	77.6	77.6	NUM
dpc-1540	157	69	)	)	PUNCT
dpc-1540	157	70	psqi	psqi	NOUN
dpc-1540	157	71	<	<	X
dpc-1540	157	72	5	5	NUM
dpc-1540	157	73	9	9	NUM
dpc-1540	157	74	(	(	PUNCT
dpc-1540	157	75	25.0	25.0	NUM
dpc-1540	157	76	)	)	PUNCT
dpc-1540	157	77	8	8	NUM
dpc-1540	157	78	(	(	PUNCT
dpc-1540	157	79	10.5	10.5	NUM
dpc-1540	157	80	)	)	PUNCT
dpc-1540	157	81	.046	.046	NUM
dpc-1540	158	1	≥5	≥5	NUM
dpc-1540	158	2	27	27	NUM
dpc-1540	158	3	(	(	PUNCT
dpc-1540	158	4	75.0	75.0	NUM
dpc-1540	158	5	)	)	PUNCT
dpc-1540	158	6	68	68	NUM
dpc-1540	158	7	(	(	PUNCT
dpc-1540	158	8	89.5	89.5	NUM
dpc-1540	158	9	)	)	PUNCT
dpc-1540	158	10	homa	homa	NOUN
dpc-1540	158	11	-	-	PUNCT
dpc-1540	158	12	ir	ir	PROPN
dpc-1540	158	13	<	<	PROPN
dpc-1540	158	14	2.5	2.5	NUM
dpc-1540	158	15	19	19	NUM
dpc-1540	158	16	(	(	PUNCT
dpc-1540	158	17	52.8	52.8	NUM
dpc-1540	158	18	)	)	PUNCT
dpc-1540	158	19	22	22	NUM
dpc-1540	158	20	(	(	PUNCT
dpc-1540	158	21	29.0	29.0	NUM
dpc-1540	158	22	)	)	PUNCT
dpc-1540	158	23	.014	.014	NUM
dpc-1540	158	24	≥2.5	≥2.5	X
dpc-1540	158	25	17	17	NUM
dpc-1540	158	26	(	(	PUNCT
dpc-1540	158	27	47.2	47.2	NUM
dpc-1540	158	28	)	)	PUNCT
dpc-1540	158	29	54	54	NUM
dpc-1540	158	30	(	(	PUNCT
dpc-1540	158	31	71.1	71.1	NUM
dpc-1540	158	32	)	)	PUNCT
dpc-1540	158	33	smoking	smoking	NOUN
dpc-1540	158	34	habit	habit	NOUN
dpc-1540	158	35	14	14	NUM
dpc-1540	158	36	(	(	PUNCT
dpc-1540	158	37	38.9	38.9	NUM
dpc-1540	158	38	)	)	PUNCT
dpc-1540	158	39	29	29	NUM
dpc-1540	158	40	(	(	PUNCT
dpc-1540	158	41	38.2	38.2	NUM
dpc-1540	158	42	)	)	PUNCT
dpc-1540	158	43	.941	.941	NUM
dpc-1540	158	44	alcohol	alcohol	NOUN
dpc-1540	158	45	consumption	consumption	NOUN
dpc-1540	158	46	5	5	NUM
dpc-1540	158	47	(	(	PUNCT
dpc-1540	158	48	13.9	13.9	NUM
dpc-1540	158	49	)	)	PUNCT
dpc-1540	158	50	12	12	NUM
dpc-1540	158	51	(	(	PUNCT
dpc-1540	158	52	15.8	15.8	NUM
dpc-1540	158	53	)	)	PUNCT
dpc-1540	158	54	.793	.793	NUM
dpc-1540	158	55	1values	1values	NUM
dpc-1540	158	56	are	be	AUX
dpc-1540	158	57	no	no	PRON
dpc-1540	158	58	.	.	PUNCT
dpc-1540	159	1	(	(	PUNCT
dpc-1540	159	2	%	%	NOUN
dpc-1540	159	3	)	)	PUNCT
dpc-1540	159	4	of	of	ADP
dpc-1540	159	5	patients	patient	NOUN
dpc-1540	159	6	.	.	PUNCT
dpc-1540	160	1	2	2	NUM
dpc-1540	160	2	pearson	pearson	PROPN
dpc-1540	160	3	’s	’s	PART
dpc-1540	160	4	chi	chi	ADJ
dpc-1540	160	5	-	-	PUNCT
dpc-1540	160	6	square	square	ADJ
dpc-1540	160	7	test	test	NOUN
dpc-1540	160	8	.	.	PUNCT
dpc-1540	161	1	bmi	bmi	NOUN
dpc-1540	161	2	=	=	SYM
dpc-1540	161	3	body	body	PROPN
dpc-1540	161	4	mass	mass	PROPN
dpc-1540	161	5	index	index	NOUN
dpc-1540	161	6	;	;	PUNCT
dpc-1540	161	7	dbp	dbp	PROPN
dpc-1540	161	8	=	=	PUNCT
dpc-1540	161	9	diastolic	diastolic	NOUN
dpc-1540	161	10	blood	blood	NOUN
dpc-1540	161	11	pressure;f	pressure;f	NOUN
dpc-1540	161	12	=	=	SYM
dpc-1540	161	13	female	female	NOUN
dpc-1540	161	14	;	;	PUNCT
dpc-1540	161	15	hdl	hdl	PROPN
dpc-1540	161	16	=	=	PUNCT
dpc-1540	161	17	high	high	ADJ
dpc-1540	161	18	-	-	PUNCT
dpc-1540	161	19	density	density	NOUN
dpc-1540	161	20	lipoprotein	lipoprotein	NOUN
dpc-1540	161	21	;	;	PUNCT
dpc-1540	161	22	homa	homa	NOUN
dpc-1540	161	23	-	-	PUNCT
dpc-1540	161	24	ir	ir	NOUN
dpc-1540	161	25	=	=	NOUN
dpc-1540	161	26	homeostatic	homeostatic	ADJ
dpc-1540	161	27	model	model	NOUN
dpc-1540	161	28	assessment	assessment	NOUN
dpc-1540	161	29	insulin	insulin	NOUN
dpc-1540	161	30	resistance;m	resistance;m	NOUN
dpc-1540	161	31	=	=	SYM
dpc-1540	161	32	male	male	NOUN
dpc-1540	161	33	;	;	PUNCT
dpc-1540	161	34	pasi	pasi	NOUN
dpc-1540	161	35	=	=	SYM
dpc-1540	161	36	psoriasis	psoriasis	NOUN
dpc-1540	161	37	area	area	NOUN
dpc-1540	161	38	and	and	CCONJ
dpc-1540	161	39	severity	severity	NOUN
dpc-1540	161	40	index	index	NOUN
dpc-1540	161	41	;	;	PUNCT
dpc-1540	161	42	psqi	psqi	NOUN
dpc-1540	161	43	=	=	SYM
dpc-1540	161	44	pittsburg	pittsburg	PROPN
dpc-1540	161	45	sleep	sleep	VERB
dpc-1540	161	46	quality	quality	NOUN
dpc-1540	161	47	index;sbp	index;sbp	PROPN
dpc-1540	161	48	=	=	PUNCT
dpc-1540	161	49	systolic	systolic	ADJ
dpc-1540	161	50	blood	blood	NOUN
dpc-1540	161	51	pressure	pressure	NOUN
dpc-1540	161	52	.	.	PUNCT
dpc-1540	162	1	6	6	NUM
dpc-1540	162	2	research	research	NOUN
dpc-1540	162	3	|	|	ADV
dpc-1540	162	4	dermatol	dermatol	ADJ
dpc-1540	162	5	pract	pract	NOUN
dpc-1540	162	6	concept	concept	NOUN
dpc-1540	162	7	.	.	PUNCT
dpc-1540	163	1	2021;11(3):e2021049	2021;11(3):e2021049	NUM
dpc-1540	163	2	significantly	significantly	ADV
dpc-1540	163	3	differed	differ	VERB
dpc-1540	163	4	between	between	ADP
dpc-1540	163	5	the	the	DET
dpc-1540	163	6	genders	gender	NOUN
dpc-1540	163	7	.	.	PUNCT
dpc-1540	164	1	thus	thus	ADV
dpc-1540	164	2	,	,	PUNCT
dpc-1540	164	3	higher	high	ADJ
dpc-1540	164	4	rates	rate	NOUN
dpc-1540	164	5	of	of	ADP
dpc-1540	164	6	ms	ms	PROPN
dpc-1540	164	7	in	in	ADP
dpc-1540	164	8	women	woman	NOUN
dpc-1540	164	9	with	with	ADP
dpc-1540	164	10	severe	severe	ADJ
dpc-1540	164	11	psoriasis	psoriasis	NOUN
dpc-1540	164	12	might	might	AUX
dpc-1540	164	13	be	be	AUX
dpc-1540	164	14	related	relate	VERB
dpc-1540	164	15	to	to	ADP
dpc-1540	164	16	their	their	PRON
dpc-1540	164	17	high	high	ADJ
dpc-1540	164	18	fasting	fasting	NOUN
dpc-1540	164	19	glucose	glucose	NOUN
dpc-1540	164	20	and	and	CCONJ
dpc-1540	164	21	low	low	ADJ
dpc-1540	164	22	hdl	hdl	PROPN
dpc-1540	164	23	values	value	NOUN
dpc-1540	164	24	.	.	PUNCT
dpc-1540	165	1	on	on	ADP
dpc-1540	165	2	the	the	DET
dpc-1540	165	3	other	other	ADJ
dpc-1540	165	4	hand	hand	NOUN
dpc-1540	165	5	,	,	PUNCT
dpc-1540	165	6	it	it	PRON
dpc-1540	165	7	has	have	AUX
dpc-1540	165	8	been	be	AUX
dpc-1540	165	9	stated	state	VERB
dpc-1540	165	10	that	that	SCONJ
dpc-1540	165	11	ms	ms	PROPN
dpc-1540	165	12	development	development	NOUN
dpc-1540	165	13	may	may	AUX
dpc-1540	165	14	be	be	AUX
dpc-1540	165	15	affected	affect	VERB
dpc-1540	165	16	by	by	ADP
dpc-1540	165	17	psoriasis	psoriasis	NOUN
dpc-1540	165	18	duration	duration	NOUN
dpc-1540	165	19	.	.	PUNCT
dpc-1540	166	1	altunay	altunay	PROPN
dpc-1540	166	2	et	et	PROPN
dpc-1540	166	3	al	al	PROPN
dpc-1540	166	4	’s	’s	PART
dpc-1540	166	5	study	study	NOUN
dpc-1540	166	6	showed	show	VERB
dpc-1540	166	7	that	that	SCONJ
dpc-1540	166	8	there	there	PRON
dpc-1540	166	9	was	be	VERB
dpc-1540	166	10	no	no	DET
dpc-1540	166	11	relationship	relationship	NOUN
dpc-1540	166	12	between	between	ADP
dpc-1540	166	13	disease	disease	NOUN
dpc-1540	166	14	duration	duration	NOUN
dpc-1540	166	15	and	and	CCONJ
dpc-1540	166	16	the	the	DET
dpc-1540	166	17	presence	presence	NOUN
dpc-1540	166	18	of	of	ADP
dpc-1540	166	19	ms	ms	NOUN
dpc-1540	167	1	[	[	X
dpc-1540	167	2	3	3	NUM
dpc-1540	167	3	]	]	PUNCT
dpc-1540	167	4	,	,	PUNCT
dpc-1540	167	5	whereas	whereas	SCONJ
dpc-1540	167	6	itani	itani	PROPN
dpc-1540	167	7	et	et	NOUN
dpc-1540	167	8	al	al	PROPN
dpc-1540	168	1	[	[	X
dpc-1540	168	2	33]and	33]and	NUM
dpc-1540	168	3	adisen	adisen	NOUN
dpc-1540	168	4	et	et	NOUN
dpc-1540	168	5	al	al	PROPN
dpc-1540	169	1	[	[	X
dpc-1540	169	2	29	29	NUM
dpc-1540	169	3	]	]	PUNCT
dpc-1540	169	4	reported	report	VERB
dpc-1540	169	5	that	that	SCONJ
dpc-1540	169	6	ms	ms	PROPN
dpc-1540	169	7	was	be	AUX
dpc-1540	169	8	significantly	significantly	ADV
dpc-1540	169	9	higher	high	ADJ
dpc-1540	169	10	in	in	ADP
dpc-1540	169	11	psoriasis	psoriasis	NOUN
dpc-1540	169	12	patients	patient	NOUN
dpc-1540	169	13	with	with	ADP
dpc-1540	169	14	longer	long	ADJ
dpc-1540	169	15	than	than	ADP
dpc-1540	169	16	shorter	short	ADJ
dpc-1540	169	17	duration	duration	NOUN
dpc-1540	169	18	,	,	PUNCT
dpc-1540	169	19	as	as	ADP
dpc-1540	169	20	in	in	ADP
dpc-1540	169	21	our	our	PRON
dpc-1540	169	22	study	study	NOUN
dpc-1540	169	23	.	.	PUNCT
dpc-1540	170	1	considering	consider	VERB
dpc-1540	170	2	the	the	DET
dpc-1540	170	3	different	different	ADJ
dpc-1540	170	4	ms	ms	NOUN
dpc-1540	170	5	parameters	parameter	NOUN
dpc-1540	170	6	,	,	PUNCT
dpc-1540	170	7	we	we	PRON
dpc-1540	170	8	found	find	VERB
dpc-1540	170	9	that	that	SCONJ
dpc-1540	170	10	the	the	DET
dpc-1540	170	11	means	mean	NOUN
dpc-1540	170	12	of	of	ADP
dpc-1540	170	13	bmi	bmi	NOUN
dpc-1540	170	14	,	,	PUNCT
dpc-1540	170	15	waist	waist	NOUN
dpc-1540	170	16	circumference	circumference	NOUN
dpc-1540	170	17	,	,	PUNCT
dpc-1540	170	18	fasting	fast	VERB
dpc-1540	170	19	glucose	glucose	NOUN
dpc-1540	170	20	,	,	PUNCT
dpc-1540	170	21	triglyceride	triglyceride	ADJ
dpc-1540	170	22	,	,	PUNCT
dpc-1540	170	23	and	and	CCONJ
dpc-1540	170	24	blood	blood	NOUN
dpc-1540	170	25	pressure	pressure	NOUN
dpc-1540	170	26	were	be	AUX
dpc-1540	170	27	significantly	significantly	ADV
dpc-1540	170	28	higher	high	ADJ
dpc-1540	170	29	in	in	ADP
dpc-1540	170	30	the	the	DET
dpc-1540	170	31	ms	ms	PROPN
dpc-1540	170	32	group	group	NOUN
dpc-1540	170	33	,	,	PUNCT
dpc-1540	170	34	whereas	whereas	SCONJ
dpc-1540	170	35	hdl	hdl	PROPN
dpc-1540	170	36	levels	level	NOUN
dpc-1540	170	37	were	be	AUX
dpc-1540	170	38	significantly	significantly	ADV
dpc-1540	170	39	lower	low	ADJ
dpc-1540	170	40	.	.	PUNCT
dpc-1540	171	1	so	so	ADV
dpc-1540	171	2	,	,	PUNCT
dpc-1540	171	3	our	our	PRON
dpc-1540	171	4	results	result	NOUN
dpc-1540	171	5	support	support	VERB
dpc-1540	171	6	the	the	DET
dpc-1540	171	7	understanding	understanding	NOUN
dpc-1540	171	8	that	that	PRON
dpc-1540	171	9	psoriasis	psoriasis	NOUN
dpc-1540	171	10	patients	patient	NOUN
dpc-1540	171	11	are	be	AUX
dpc-1540	171	12	at	at	ADP
dpc-1540	171	13	risk	risk	NOUN
dpc-1540	171	14	of	of	ADP
dpc-1540	171	15	having	have	VERB
dpc-1540	171	16	all	all	DET
dpc-1540	171	17	ms	ms	ADJ
dpc-1540	171	18	parameters	parameter	NOUN
dpc-1540	171	19	.	.	PUNCT
dpc-1540	172	1	additionally	additionally	ADV
dpc-1540	172	2	,	,	PUNCT
dpc-1540	172	3	we	we	PRON
dpc-1540	172	4	assessed	assess	VERB
dpc-1540	172	5	the	the	DET
dpc-1540	172	6	prevalence	prevalence	NOUN
dpc-1540	172	7	of	of	ADP
dpc-1540	172	8	insulin	insulin	NOUN
dpc-1540	172	9	resistance	resistance	NOUN
dpc-1540	172	10	in	in	ADP
dpc-1540	172	11	our	our	PRON
dpc-1540	172	12	-	-	PUNCT
dpc-1540	172	13	study	study	NOUN
dpc-1540	172	14	subjects	subject	NOUN
dpc-1540	172	15	.	.	PUNCT
dpc-1540	173	1	polic	polic	NOUN
dpc-1540	173	2	et	et	PROPN
dpc-1540	173	3	al	al	PROPN
dpc-1540	174	1	[	[	X
dpc-1540	174	2	34	34	NUM
dpc-1540	174	3	]	]	PUNCT
dpc-1540	174	4	found	find	VERB
dpc-1540	174	5	a	a	DET
dpc-1540	174	6	correlation	correlation	NOUN
dpc-1540	174	7	between	between	ADP
dpc-1540	174	8	high	high	ADJ
dpc-1540	174	9	homa	homa	NOUN
dpc-1540	174	10	-	-	PUNCT
dpc-1540	174	11	ir	ir	PROPN
dpc-1540	174	12	levels	level	NOUN
dpc-1540	174	13	and	and	CCONJ
dpc-1540	174	14	a	a	DET
dpc-1540	174	15	diagnosis	diagnosis	NOUN
dpc-1540	174	16	of	of	ADP
dpc-1540	174	17	ms	ms	NOUN
dpc-1540	174	18	in	in	ADP
dpc-1540	174	19	psoriasis	psoriasis	NOUN
dpc-1540	174	20	patients	patient	NOUN
dpc-1540	174	21	,	,	PUNCT
dpc-1540	174	22	and	and	CCONJ
dpc-1540	174	23	homa	homa	NOUN
dpc-1540	174	24	-	-	PUNCT
dpc-1540	174	25	ir	ir	PROPN
dpc-1540	174	26	was	be	AUX
dpc-1540	174	27	significantly	significantly	ADV
dpc-1540	174	28	higher	high	ADJ
dpc-1540	174	29	in	in	ADP
dpc-1540	174	30	patients	patient	NOUN
dpc-1540	174	31	with	with	ADP
dpc-1540	174	32	severe	severe	ADJ
dpc-1540	174	33	psoriasis	psoriasis	NOUN
dpc-1540	174	34	.	.	PUNCT
dpc-1540	175	1	similarly	similarly	ADV
dpc-1540	175	2	,	,	PUNCT
dpc-1540	175	3	we	we	PRON
dpc-1540	175	4	detected	detect	VERB
dpc-1540	175	5	significantly	significantly	ADV
dpc-1540	175	6	higher	high	ADJ
dpc-1540	175	7	homa	homa	PROPN
dpc-1540	175	8	-	-	PUNCT
dpc-1540	175	9	ir	ir	PROPN
dpc-1540	175	10	levels	level	NOUN
dpc-1540	175	11	in	in	ADP
dpc-1540	175	12	the	the	DET
dpc-1540	175	13	ms	ms	PROPN
dpc-1540	175	14	group	group	NOUN
dpc-1540	175	15	,	,	PUNCT
dpc-1540	175	16	but	but	CCONJ
dpc-1540	175	17	homa	homa	NOUN
dpc-1540	175	18	-	-	PUNCT
dpc-1540	175	19	ir	ir	PROPN
dpc-1540	175	20	was	be	AUX
dpc-1540	175	21	not	not	PART
dpc-1540	175	22	related	relate	VERB
dpc-1540	175	23	to	to	ADP
dpc-1540	175	24	psoriasis	psoriasis	NOUN
dpc-1540	175	25	severity	severity	NOUN
dpc-1540	175	26	.	.	PUNCT
dpc-1540	176	1	moreover	moreover	ADV
dpc-1540	176	2	,	,	PUNCT
dpc-1540	176	3	because	because	SCONJ
dpc-1540	176	4	of	of	ADP
dpc-1540	176	5	the	the	DET
dpc-1540	176	6	stronger	strong	ADJ
dpc-1540	176	7	correlation	correlation	NOUN
dpc-1540	176	8	of	of	ADP
dpc-1540	176	9	ms	ms	NOUN
dpc-1540	176	10	with	with	ADP
dpc-1540	176	11	fasting	fast	VERB
dpc-1540	176	12	glucose	glucose	NOUN
dpc-1540	176	13	than	than	ADP
dpc-1540	176	14	with	with	ADP
dpc-1540	176	15	homa	homa	NOUN
dpc-1540	176	16	-	-	PUNCT
dpc-1540	176	17	ir	ir	PROPN
dpc-1540	176	18	,	,	PUNCT
dpc-1540	176	19	the	the	DET
dpc-1540	176	20	former	former	ADJ
dpc-1540	176	21	may	may	AUX
dpc-1540	176	22	have	have	VERB
dpc-1540	176	23	more	more	ADJ
dpc-1540	176	24	importance	importance	NOUN
dpc-1540	176	25	on	on	ADP
dpc-1540	176	26	the	the	DET
dpc-1540	176	27	development	development	NOUN
dpc-1540	176	28	of	of	ADP
dpc-1540	176	29	ms	ms	PROPN
dpc-1540	176	30	.	.	PROPN
dpc-1540	176	31	alcohol	alcohol	NOUN
dpc-1540	176	32	use	use	NOUN
dpc-1540	176	33	and	and	CCONJ
dpc-1540	176	34	a	a	DET
dpc-1540	176	35	smoking	smoking	NOUN
dpc-1540	176	36	habit	habit	NOUN
dpc-1540	176	37	may	may	AUX
dpc-1540	176	38	trigger	trigger	VERB
dpc-1540	176	39	or	or	CCONJ
dpc-1540	176	40	worsen	worsen	VERB
dpc-1540	176	41	psoriasis	psoriasis	NOUN
dpc-1540	176	42	[	[	X
dpc-1540	176	43	29	29	NUM
dpc-1540	176	44	]	]	PUNCT
dpc-1540	176	45	and	and	CCONJ
dpc-1540	176	46	cardiovascular	cardiovascular	ADJ
dpc-1540	176	47	,	,	PUNCT
dpc-1540	176	48	metabolic	metabolic	NOUN
dpc-1540	176	49	and	and	CCONJ
dpc-1540	176	50	hepatic	hepatic	ADJ
dpc-1540	176	51	complications	complication	NOUN
dpc-1540	176	52	in	in	ADP
dpc-1540	176	53	ms	ms	NOUN
dpc-1540	176	54	[	[	X
dpc-1540	176	55	31	31	NUM
dpc-1540	176	56	]	]	PUNCT
dpc-1540	176	57	.	.	PUNCT
dpc-1540	177	1	smoking	smoking	NOUN
dpc-1540	177	2	may	may	AUX
dpc-1540	177	3	affect	affect	VERB
dpc-1540	177	4	clinical	clinical	ADJ
dpc-1540	177	5	variability	variability	NOUN
dpc-1540	177	6	or	or	CCONJ
dpc-1540	177	7	course	course	NOUN
dpc-1540	177	8	of	of	ADP
dpc-1540	177	9	psoriasis	psoriasis	NOUN
dpc-1540	177	10	because	because	SCONJ
dpc-1540	177	11	of	of	ADP
dpc-1540	177	12	causes	cause	NOUN
dpc-1540	177	13	or	or	CCONJ
dpc-1540	177	14	increases	increase	NOUN
dpc-1540	177	15	in	in	ADP
dpc-1540	177	16	oxidative	oxidative	ADJ
dpc-1540	177	17	stress	stress	NOUN
dpc-1540	177	18	,	,	PUNCT
dpc-1540	177	19	functional	functional	ADJ
dpc-1540	177	20	morphological	morphological	ADJ
dpc-1540	177	21	changes	change	NOUN
dpc-1540	177	22	in	in	ADP
dpc-1540	177	23	polymorphonuclear	polymorphonuclear	NOUN
dpc-1540	177	24	leukocytes	leukocyte	NOUN
dpc-1540	177	25	,	,	PUNCT
dpc-1540	177	26	and	and	CCONJ
dpc-1540	177	27	release	release	NOUN
dpc-1540	177	28	of	of	ADP
dpc-1540	177	29	chemotactic	chemotactic	ADJ
dpc-1540	177	30	factors	factor	NOUN
dpc-1540	177	31	and	and	CCONJ
dpc-1540	177	32	cytokines	cytokine	NOUN
dpc-1540	177	33	like	like	ADP
dpc-1540	177	34	interleukins	interleukin	NOUN
dpc-1540	177	35	,	,	PUNCT
dpc-1540	177	36	tnf	tnf	PROPN
dpc-1540	177	37	-	-	PUNCT
dpc-1540	177	38	alpha	alpha	NOUN
dpc-1540	177	39	,	,	PUNCT
dpc-1540	177	40	and	and	CCONJ
dpc-1540	177	41	transforming	transform	VERB
dpc-1540	177	42	growth	growth	NOUN
dpc-1540	177	43	factor	factor	NOUN
dpc-1540	177	44	beta	beta	NOUN
dpc-1540	177	45	.	.	PUNCT
dpc-1540	178	1	it	it	PRON
dpc-1540	178	2	is	be	AUX
dpc-1540	178	3	also	also	ADV
dpc-1540	178	4	suggested	suggest	VERB
dpc-1540	178	5	that	that	SCONJ
dpc-1540	178	6	alcohol	alcohol	NOUN
dpc-1540	178	7	makes	make	VERB
dpc-1540	178	8	psoriasis	psoriasis	NOUN
dpc-1540	178	9	worse	bad	ADJ
dpc-1540	178	10	by	by	ADP
dpc-1540	178	11	affecting	affect	VERB
dpc-1540	178	12	lymphocyte	lymphocyte	ADJ
dpc-1540	178	13	transformation	transformation	NOUN
dpc-1540	178	14	.	.	PUNCT
dpc-1540	179	1	rates	rate	NOUN
dpc-1540	179	2	of	of	ADP
dpc-1540	179	3	smoking	smoking	NOUN
dpc-1540	179	4	and	and	CCONJ
dpc-1540	179	5	alcohol	alcohol	NOUN
dpc-1540	179	6	use	use	NOUN
dpc-1540	179	7	have	have	AUX
dpc-1540	179	8	been	be	AUX
dpc-1540	179	9	reported	report	VERB
dpc-1540	179	10	as	as	ADP
dpc-1540	179	11	20%-65	20%-65	NUM
dpc-1540	179	12	%	%	NOUN
dpc-1540	179	13	and	and	CCONJ
dpc-1540	179	14	3.3%-24	3.3%-24	NUM
dpc-1540	179	15	%	%	NOUN
dpc-1540	179	16	in	in	ADP
dpc-1540	179	17	psoriasis	psoriasis	NOUN
dpc-1540	179	18	patients	patient	NOUN
dpc-1540	179	19	,	,	PUNCT
dpc-1540	179	20	respectively	respectively	ADV
dpc-1540	179	21	[	[	X
dpc-1540	179	22	29	29	NUM
dpc-1540	179	23	]	]	PUNCT
dpc-1540	179	24	.	.	PUNCT
dpc-1540	180	1	this	this	DET
dpc-1540	180	2	study	study	NOUN
dpc-1540	180	3	found	find	VERB
dpc-1540	180	4	that	that	SCONJ
dpc-1540	180	5	these	these	DET
dpc-1540	180	6	prevalences	prevalence	NOUN
dpc-1540	180	7	were	be	AUX
dpc-1540	180	8	38.39	38.39	NUM
dpc-1540	180	9	%	%	NOUN
dpc-1540	180	10	and	and	CCONJ
dpc-1540	180	11	15.8	15.8	NUM
dpc-1540	180	12	%	%	NOUN
dpc-1540	180	13	,	,	PUNCT
dpc-1540	180	14	which	which	PRON
dpc-1540	180	15	are	be	AUX
dpc-1540	180	16	consistent	consistent	ADJ
dpc-1540	180	17	with	with	ADP
dpc-1540	180	18	the	the	DET
dpc-1540	180	19	literature	literature	NOUN
dpc-1540	180	20	.	.	PUNCT
dpc-1540	181	1	however	however	ADV
dpc-1540	181	2	,	,	PUNCT
dpc-1540	181	3	both	both	DET
dpc-1540	181	4	habits	habit	NOUN
dpc-1540	181	5	did	do	AUX
dpc-1540	181	6	not	not	PART
dpc-1540	181	7	show	show	VERB
dpc-1540	181	8	any	any	DET
dpc-1540	181	9	correlation	correlation	NOUN
dpc-1540	181	10	with	with	ADP
dpc-1540	181	11	the	the	DET
dpc-1540	181	12	presence	presence	NOUN
dpc-1540	181	13	of	of	ADP
dpc-1540	181	14	ms	ms	PROPN
dpc-1540	181	15	.	.	PROPN
dpc-1540	181	16	on	on	ADP
dpc-1540	181	17	the	the	DET
dpc-1540	181	18	other	other	ADJ
dpc-1540	181	19	hand	hand	NOUN
dpc-1540	181	20	,	,	PUNCT
dpc-1540	181	21	sleep	sleep	NOUN
dpc-1540	181	22	disturbances	disturbance	NOUN
dpc-1540	181	23	have	have	AUX
dpc-1540	181	24	been	be	AUX
dpc-1540	181	25	reported	report	VERB
dpc-1540	181	26	in	in	ADP
dpc-1540	181	27	approximately	approximately	ADV
dpc-1540	181	28	50%-60	50%-60	NUM
dpc-1540	181	29	%	%	NOUN
dpc-1540	181	30	of	of	ADP
dpc-1540	181	31	psoriasis	psoriasis	NOUN
dpc-1540	181	32	patients	patient	NOUN
dpc-1540	181	33	[	[	X
dpc-1540	181	34	35	35	NUM
dpc-1540	181	35	]	]	PUNCT
dpc-1540	181	36	.	.	PUNCT
dpc-1540	182	1	hawro	hawro	PROPN
dpc-1540	182	2	et	et	PROPN
dpc-1540	182	3	al	al	PROPN
dpc-1540	182	4	reported	report	VERB
dpc-1540	182	5	that	that	SCONJ
dpc-1540	182	6	39	39	NUM
dpc-1540	182	7	%	%	NOUN
dpc-1540	182	8	of	of	ADP
dpc-1540	182	9	psoriasis	psoriasis	NOUN
dpc-1540	182	10	patients	patient	NOUN
dpc-1540	182	11	had	have	VERB
dpc-1540	182	12	overall	overall	ADJ
dpc-1540	182	13	poor	poor	ADJ
dpc-1540	182	14	sleep	sleep	NOUN
dpc-1540	182	15	quality	quality	NOUN
dpc-1540	182	16	,	,	PUNCT
dpc-1540	182	17	especially	especially	ADV
dpc-1540	182	18	daytime	daytime	ADJ
dpc-1540	182	19	sleepiness	sleepiness	NOUN
dpc-1540	182	20	and	and	CCONJ
dpc-1540	182	21	awakenings	awakening	NOUN
dpc-1540	182	22	during	during	ADP
dpc-1540	182	23	sleep	sleep	NOUN
dpc-1540	182	24	[	[	X
dpc-1540	182	25	36	36	NUM
dpc-1540	182	26	]	]	PUNCT
dpc-1540	182	27	.	.	PUNCT
dpc-1540	183	1	disturbances	disturbance	NOUN
dpc-1540	183	2	in	in	ADP
dpc-1540	183	3	sleep	sleep	NOUN
dpc-1540	183	4	quality	quality	NOUN
dpc-1540	183	5	have	have	AUX
dpc-1540	183	6	usually	usually	ADV
dpc-1540	183	7	been	be	AUX
dpc-1540	183	8	associated	associate	VERB
dpc-1540	183	9	with	with	ADP
dpc-1540	183	10	itchiness	itchiness	NOUN
dpc-1540	183	11	and	and	CCONJ
dpc-1540	183	12	low	low	ADJ
dpc-1540	183	13	quality	quality	NOUN
dpc-1540	183	14	of	of	ADP
dpc-1540	183	15	life	life	NOUN
dpc-1540	183	16	in	in	ADP
dpc-1540	183	17	psoriasis	psoriasis	NOUN
dpc-1540	183	18	patients	patient	NOUN
dpc-1540	184	1	[	[	X
dpc-1540	184	2	37	37	NUM
dpc-1540	184	3	,	,	PUNCT
dpc-1540	184	4	38	38	NUM
dpc-1540	184	5	]	]	PUNCT
dpc-1540	184	6	.	.	PUNCT
dpc-1540	185	1	melikoğlu	melikoğlu	PROPN
dpc-1540	186	1	[	[	X
dpc-1540	186	2	39]and	39]and	NUM
dpc-1540	186	3	jensen	jensen	PROPN
dpc-1540	186	4	et	et	PROPN
dpc-1540	186	5	al	al	PROPN
dpc-1540	187	1	[	[	X
dpc-1540	187	2	40	40	NUM
dpc-1540	187	3	]	]	PUNCT
dpc-1540	187	4	reported	report	VERB
dpc-1540	187	5	that	that	SCONJ
dpc-1540	187	6	psoriasis	psoriasis	NOUN
dpc-1540	187	7	patients	patient	NOUN
dpc-1540	187	8	had	have	VERB
dpc-1540	187	9	significantly	significantly	ADV
dpc-1540	187	10	poorer	poor	ADJ
dpc-1540	187	11	overall	overall	ADJ
dpc-1540	187	12	sleep	sleep	NOUN
dpc-1540	187	13	quality	quality	NOUN
dpc-1540	187	14	than	than	ADP
dpc-1540	187	15	controls	control	NOUN
dpc-1540	187	16	,	,	PUNCT
dpc-1540	187	17	at	at	ADP
dpc-1540	187	18	the	the	DET
dpc-1540	187	19	rates	rate	NOUN
dpc-1540	187	20	of	of	ADP
dpc-1540	187	21	60	60	NUM
dpc-1540	187	22	%	%	NOUN
dpc-1540	187	23	and	and	CCONJ
dpc-1540	187	24	53.9	53.9	NUM
dpc-1540	187	25	%	%	NOUN
dpc-1540	187	26	,	,	PUNCT
dpc-1540	187	27	respectively	respectively	ADV
dpc-1540	187	28	,	,	PUNCT
dpc-1540	187	29	whereas	whereas	SCONJ
dpc-1540	187	30	shutty	shutty	PROPN
dpc-1540	187	31	et	et	PROPN
dpc-1540	187	32	al	al	PROPN
dpc-1540	188	1	[	[	X
dpc-1540	188	2	41	41	NUM
dpc-1540	188	3	]	]	PUNCT
dpc-1540	188	4	reported	report	VERB
dpc-1540	188	5	table	table	NOUN
dpc-1540	188	6	3	3	NUM
dpc-1540	188	7	.	.	PUNCT
dpc-1540	189	1	clinical	clinical	ADJ
dpc-1540	189	2	characteristics	characteristic	NOUN
dpc-1540	189	3	of	of	ADP
dpc-1540	189	4	psoriasis	psoriasis	NOUN
dpc-1540	189	5	patients	patient	NOUN
dpc-1540	189	6	without	without	ADP
dpc-1540	189	7	(	(	PUNCT
dpc-1540	189	8	n	n	NOUN
dpc-1540	189	9	=	=	SYM
dpc-1540	189	10	36	36	NUM
dpc-1540	189	11	)	)	PUNCT
dpc-1540	189	12	and	and	CCONJ
dpc-1540	189	13	with	with	ADP
dpc-1540	189	14	(	(	PUNCT
dpc-1540	189	15	n	n	NOUN
dpc-1540	189	16	=	=	SYM
dpc-1540	189	17	76	76	NUM
dpc-1540	189	18	)	)	PUNCT
dpc-1540	189	19	metabolic	metabolic	NOUN
dpc-1540	189	20	syndrome	syndrome	NOUN
dpc-1540	189	21	:	:	PUNCT
dpc-1540	189	22	analysis	analysis	NOUN
dpc-1540	189	23	of	of	ADP
dpc-1540	189	24	means	mean	NOUN
dpc-1540	189	25	characteristic	characteristic	ADJ
dpc-1540	189	26	no	no	PRON
dpc-1540	189	27	-	-	PUNCT
dpc-1540	189	28	ms	ms	PROPN
dpc-1540	189	29	group1	group1	PROPN
dpc-1540	189	30	ms	ms	PROPN
dpc-1540	189	31	group1	group1	PROPN
dpc-1540	189	32	p	p	PROPN
dpc-1540	189	33	age	age	NOUN
dpc-1540	189	34	(	(	PUNCT
dpc-1540	189	35	years	year	NOUN
dpc-1540	189	36	)	)	PUNCT
dpc-1540	189	37	44.17±13.24	44.17±13.24	NUM
dpc-1540	190	1	47.58±13.1	47.58±13.1	NUM
dpc-1540	190	2	.202	.202	NUM
dpc-1540	190	3	*	*	SYM
dpc-1540	190	4	bmi	bmi	X
dpc-1540	190	5	(	(	PUNCT
dpc-1540	190	6	kg	kg	NOUN
dpc-1540	190	7	/	/	SYM
dpc-1540	190	8	m2	m2	PROPN
dpc-1540	190	9	)	)	PUNCT
dpc-1540	190	10	28.33±4.08	28.33±4.08	PROPN
dpc-1540	191	1	31.15±4.88	31.15±4.88	NUM
dpc-1540	191	2	.003	.003	NUM
dpc-1540	191	3	*	*	PROPN
dpc-1540	191	4	waist	waist	NOUN
dpc-1540	191	5	circumference(cm	circumference(cm	NOUN
dpc-1540	191	6	)	)	PUNCT
dpc-1540	191	7	97.47±13.3	97.47±13.3	NUM
dpc-1540	191	8	112.54±12.14	112.54±12.14	NUM
dpc-1540	191	9	.0001	.0001	NOUN
dpc-1540	191	10	*	*	PUNCT
dpc-1540	191	11	triglyceride	triglyceride	ADJ
dpc-1540	191	12	(	(	PUNCT
dpc-1540	191	13	mg	mg	PROPN
dpc-1540	191	14	/	/	SYM
dpc-1540	191	15	dl	dl	NOUN
dpc-1540	191	16	)	)	PUNCT
dpc-1540	191	17	163.81±62.47	163.81±62.47	NUM
dpc-1540	191	18	203.68±80.24	203.68±80.24	NUM
dpc-1540	191	19	.01	.01	NUM
dpc-1540	191	20	*	*	PUNCT
dpc-1540	191	21	hdl	hdl	X
dpc-1540	191	22	(	(	PUNCT
dpc-1540	191	23	mg	mg	PROPN
dpc-1540	191	24	/	/	SYM
dpc-1540	191	25	dl	dl	PROPN
dpc-1540	191	26	)	)	PUNCT
dpc-1540	191	27	48.13±10.07	48.13±10.07	NOUN
dpc-1540	191	28	39.75±5.21	39.75±5.21	NUM
dpc-1540	191	29	.0001	.0001	NOUN
dpc-1540	191	30	*	*	VERB
dpc-1540	191	31	fasting	fast	VERB
dpc-1540	191	32	glucose	glucose	NOUN
dpc-1540	191	33	(	(	PUNCT
dpc-1540	191	34	mg	mg	PROPN
dpc-1540	191	35	/	/	SYM
dpc-1540	191	36	dl	dl	PROPN
dpc-1540	191	37	)	)	PUNCT
dpc-1540	191	38	97.82±12.41	97.82±12.41	PROPN
dpc-1540	192	1	115.92±21.98	115.92±21.98	NUM
dpc-1540	192	2	.0001	.0001	NOUN
dpc-1540	192	3	*	*	PUNCT
dpc-1540	192	4	homa	homa	NOUN
dpc-1540	192	5	-	-	PUNCT
dpc-1540	192	6	ir	ir	PROPN
dpc-1540	192	7	2.39±1.06	2.39±1.06	NUM
dpc-1540	192	8	3.48±3.19	3.48±3.19	NUM
dpc-1540	192	9	.048ǂ	.048ǂ	NOUN
dpc-1540	192	10	pasi	pasi	PROPN
dpc-1540	192	11	22.59±18.69	22.59±18.69	NUM
dpc-1540	192	12	23.97±15.83	23.97±15.83	NUM
dpc-1540	192	13	.684	.684	NUM
dpc-1540	192	14	*	*	PUNCT
dpc-1540	192	15	disease	disease	NOUN
dpc-1540	192	16	duration	duration	NOUN
dpc-1540	192	17	(	(	PUNCT
dpc-1540	192	18	years	year	NOUN
dpc-1540	192	19	)	)	PUNCT
dpc-1540	192	20	8.76±5.78	8.76±5.78	PROPN
dpc-1540	192	21	13.09±8.99	13.09±8.99	NUM
dpc-1540	192	22	.01ǂ	.01ǂ	PROPN
dpc-1540	192	23	psqi	psqi	NOUN
dpc-1540	192	24	(	(	PUNCT
dpc-1540	192	25	total	total	ADJ
dpc-1540	192	26	)	)	PUNCT
dpc-1540	192	27	7.94±4.72	7.94±4.72	NOUN
dpc-1540	192	28	10.01±4.78	10.01±4.78	NUM
dpc-1540	192	29	.034	.034	NUM
dpc-1540	192	30	*	*	PUNCT
dpc-1540	192	31	pssq	pssq	PROPN
dpc-1540	192	32	1.75±0.87	1.75±0.87	NUM
dpc-1540	192	33	1.79±0.79	1.79±0.79	NUM
dpc-1540	192	34	.812ǂ	.812ǂ	PROPN
dpc-1540	192	35	psl	psl	PROPN
dpc-1540	192	36	1.25±1.00	1.25±1.00	NUM
dpc-1540	193	1	1.74±1.00	1.74±1.00	PROPN
dpc-1540	193	2	.018ǂ	.018ǂ	PROPN
dpc-1540	193	3	psdu	psdu	PROPN
dpc-1540	193	4	1.17±1.13	1.17±1.13	PROPN
dpc-1540	193	5	1.43±1.20	1.43±1.20	NUM
dpc-1540	193	6	.266ǂ	.266ǂ	PROPN
dpc-1540	193	7	phse	phse	PROPN
dpc-1540	193	8	0.61±0.99	0.61±0.99	PROPN
dpc-1540	193	9	0.92±1.12	0.92±1.12	PROPN
dpc-1540	193	10	.159ǂ	.159ǂ	PROPN
dpc-1540	193	11	psdi	psdi	NOUN
dpc-1540	193	12	1.36±0.64	1.36±0.64	NUM
dpc-1540	194	1	1.62±0.65	1.62±0.65	NUM
dpc-1540	194	2	.052ǂ	.052ǂ	PUNCT
dpc-1540	194	3	pusm	pusm	PROPN
dpc-1540	194	4	0.58±0.81	0.58±0.81	PROPN
dpc-1540	195	1	0.71±0.92	0.71±0.92	NOUN
dpc-1540	195	2	.480ǂ	.480ǂ	INTJ
dpc-1540	196	1	pdsd	pdsd	ADV
dpc-1540	197	1	1.22±0.96	1.22±0.96	NUM
dpc-1540	197	2	1.79±0.88	1.79±0.88	NUM
dpc-1540	197	3	.003ǂ	.003ǂ	PUNCT
dpc-1540	197	4	1values	1value	NOUN
dpc-1540	197	5	are	be	AUX
dpc-1540	197	6	mean	mean	ADJ
dpc-1540	197	7	(	(	PUNCT
dpc-1540	197	8	sd	sd	NOUN
dpc-1540	197	9	)	)	PUNCT
dpc-1540	197	10	.	.	PUNCT
dpc-1540	198	1	*	*	PUNCT
dpc-1540	198	2	independent	independent	ADJ
dpc-1540	198	3	-	-	PUNCT
dpc-1540	198	4	samples	sample	NOUN
dpc-1540	198	5	t	t	NOUN
dpc-1540	198	6	test.ǂmann	test.ǂmann	PROPN
dpc-1540	198	7	-	-	PUNCT
dpc-1540	198	8	whitney	whitney	NOUN
dpc-1540	198	9	u	u	PROPN
dpc-1540	198	10	non	non	ADJ
dpc-1540	198	11	-	-	ADJ
dpc-1540	198	12	parametric	parametric	ADJ
dpc-1540	198	13	test	test	NOUN
dpc-1540	198	14	bmi	bmi	NOUN
dpc-1540	198	15	=	=	PUNCT
dpc-1540	198	16	body	body	PROPN
dpc-1540	198	17	mass	mass	PROPN
dpc-1540	198	18	index	index	NOUN
dpc-1540	198	19	;	;	PUNCT
dpc-1540	198	20	homa	homa	NOUN
dpc-1540	198	21	-	-	PUNCT
dpc-1540	198	22	ir	ir	NOUN
dpc-1540	198	23	=	=	NOUN
dpc-1540	198	24	homeostatic	homeostatic	ADJ
dpc-1540	198	25	model	model	NOUN
dpc-1540	198	26	assessment	assessment	NOUN
dpc-1540	198	27	insulin	insulin	NOUN
dpc-1540	198	28	resistance	resistance	NOUN
dpc-1540	198	29	;	;	PUNCT
dpc-1540	198	30	pasi	pasi	NOUN
dpc-1540	198	31	=	=	SYM
dpc-1540	198	32	psoriasis	psoriasis	NOUN
dpc-1540	198	33	severity	severity	NOUN
dpc-1540	198	34	index	index	NOUN
dpc-1540	198	35	;	;	PUNCT
dpc-1540	198	36	pdsd	pdsd	ADJ
dpc-1540	198	37	=	=	SYM
dpc-1540	198	38	pittsburg	pittsburg	PROPN
dpc-1540	198	39	daytime	daytime	ADJ
dpc-1540	198	40	sleep	sleep	NOUN
dpc-1540	198	41	dysfunction	dysfunction	NOUN
dpc-1540	198	42	;	;	PUNCT
dpc-1540	198	43	phsenm	phsenm	NOUN
dpc-1540	198	44	=	=	SYM
dpc-1540	198	45	pittsburg	pittsburg	PROPN
dpc-1540	198	46	habitual	habitual	ADJ
dpc-1540	198	47	sleep	sleep	NOUN
dpc-1540	198	48	efficiency	efficiency	NOUN
dpc-1540	198	49	;	;	PUNCT
dpc-1540	198	50	psdi	psdi	NOUN
dpc-1540	198	51	=	=	SYM
dpc-1540	198	52	pittsburg	pittsburg	PROPN
dpc-1540	198	53	sleep	sleep	NOUN
dpc-1540	198	54	disturbance	disturbance	NOUN
dpc-1540	198	55	;	;	PUNCT
dpc-1540	198	56	psdu	psdu	NOUN
dpc-1540	198	57	=	=	SYM
dpc-1540	198	58	pittsburg	pittsburg	PROPN
dpc-1540	198	59	sleep	sleep	NOUN
dpc-1540	198	60	duration	duration	NOUN
dpc-1540	198	61	;	;	PUNCT
dpc-1540	198	62	psl	psl	PROPN
dpc-1540	198	63	=	=	PROPN
dpc-1540	198	64	pittsburg	pittsburg	PROPN
dpc-1540	198	65	sleep	sleep	NOUN
dpc-1540	198	66	latency	latency	NOUN
dpc-1540	198	67	;	;	PUNCT
dpc-1540	198	68	psqi	psqi	PROPN
dpc-1540	198	69	=	=	SYM
dpc-1540	198	70	pittsburg	pittsburg	PROPN
dpc-1540	198	71	sleep	sleep	VERB
dpc-1540	198	72	quality	quality	NOUN
dpc-1540	198	73	index;pssq	index;pssq	PROPN
dpc-1540	198	74	=	=	SYM
dpc-1540	198	75	pittsburg	pittsburg	ADJ
dpc-1540	198	76	subjective	subjective	ADJ
dpc-1540	198	77	sleep	sleep	NOUN
dpc-1540	198	78	quality	quality	NOUN
dpc-1540	198	79	;	;	PUNCT
dpc-1540	198	80	pusm	pusm	NOUN
dpc-1540	198	81	=	=	PUNCT
dpc-1540	198	82	pittsburg	pittsburg	PROPN
dpc-1540	198	83	use	use	NOUN
dpc-1540	198	84	of	of	ADP
dpc-1540	198	85	sleeping	sleep	VERB
dpc-1540	198	86	medication	medication	NOUN
dpc-1540	198	87	.	.	PUNCT
dpc-1540	199	1	research	research	NOUN
dpc-1540	199	2	|	|	ADV
dpc-1540	199	3	dermatol	dermatol	ADJ
dpc-1540	199	4	pract	pract	NOUN
dpc-1540	199	5	concept	concept	NOUN
dpc-1540	199	6	.	.	PUNCT
dpc-1540	200	1	2021;11(3):e2021049	2021;11(3):e2021049	NUM
dpc-1540	200	2	7	7	NUM
dpc-1540	200	3	table	table	NOUN
dpc-1540	200	4	4	4	NUM
dpc-1540	200	5	.	.	PUNCT
dpc-1540	200	6	comparison	comparison	NOUN
dpc-1540	200	7	of	of	ADP
dpc-1540	200	8	metabolic	metabolic	NOUN
dpc-1540	200	9	syndromeparameters	syndromeparameter	NOUN
dpc-1540	200	10	,	,	PUNCT
dpc-1540	200	11	by	by	ADP
dpc-1540	200	12	pasi	pasi	NOUN
dpc-1540	200	13	and	and	CCONJ
dpc-1540	200	14	gender1	gender1	NOUN
dpc-1540	200	15	parameter	parameter	NOUN
dpc-1540	200	16	gender	gender	NOUN
dpc-1540	200	17	  	  	SPACE
dpc-1540	200	18	pasi	pasi	NOUN
dpc-1540	200	19	p2	p2	VERB
dpc-1540	200	20	≤10	≤10	PROPN
dpc-1540	200	21	(	(	PUNCT
dpc-1540	200	22	n	n	NOUN
dpc-1540	200	23	=	=	SYM
dpc-1540	200	24	29	29	NUM
dpc-1540	200	25	)	)	PUNCT
dpc-1540	200	26	>	>	X
dpc-1540	201	1	10	10	NUM
dpc-1540	202	1	(	(	PUNCT
dpc-1540	203	1	n	n	NOUN
dpc-1540	203	2	=	=	NUM
dpc-1540	203	3	83	83	NUM
dpc-1540	203	4	)	)	PUNCT
dpc-1540	203	5	waist	waist	NOUN
dpc-1540	203	6	circumference(cm	circumference(cm	NOUN
dpc-1540	203	7	)	)	PUNCT
dpc-1540	203	8	m	m	VERB
dpc-1540	203	9	<	<	X
dpc-1540	203	10	102	102	NUM
dpc-1540	203	11	3	3	NUM
dpc-1540	203	12	20.00	20.00	NUM
dpc-1540	203	13	%	%	NOUN
dpc-1540	203	14	13	13	NUM
dpc-1540	203	15	34.21	34.21	NUM
dpc-1540	203	16	%	%	NOUN
dpc-1540	203	17	.310	.310	NUM
dpc-1540	203	18	>	>	X
dpc-1540	203	19	102	102	NUM
dpc-1540	203	20	12	12	NUM
dpc-1540	203	21	80.00	80.00	NUM
dpc-1540	203	22	%	%	NOUN
dpc-1540	203	23	25	25	NUM
dpc-1540	203	24	65.79	65.79	NUM
dpc-1540	203	25	%	%	NOUN
dpc-1540	203	26	f	f	X
dpc-1540	203	27	<	<	X
dpc-1540	203	28	88	88	NUM
dpc-1540	203	29	3	3	NUM
dpc-1540	203	30	21.43	21.43	NUM
dpc-1540	203	31	%	%	NOUN
dpc-1540	203	32	5	5	NUM
dpc-1540	203	33	11.11	11.11	NUM
dpc-1540	203	34	%	%	NOUN
dpc-1540	203	35	.325	.325	NUM
dpc-1540	203	36	>	>	X
dpc-1540	203	37	88	88	NUM
dpc-1540	203	38	11	11	NUM
dpc-1540	203	39	78.57	78.57	NUM
dpc-1540	203	40	%	%	NOUN
dpc-1540	203	41	40	40	NUM
dpc-1540	203	42	88.89	88.89	NUM
dpc-1540	203	43	%	%	NOUN
dpc-1540	203	44	bmi	bmi	NOUN
dpc-1540	203	45	(	(	PUNCT
dpc-1540	203	46	kg	kg	NOUN
dpc-1540	203	47	/	/	SYM
dpc-1540	203	48	m2	m2	PROPN
dpc-1540	203	49	)	)	PUNCT
dpc-1540	203	50	m	m	PROPN
dpc-1540	203	51	≥30	≥30	PROPN
dpc-1540	203	52	14	14	NUM
dpc-1540	203	53	26.41	26.41	NUM
dpc-1540	203	54	%	%	NOUN
dpc-1540	203	55	39	39	NUM
dpc-1540	203	56	73.58	73.58	NUM
dpc-1540	203	57	%	%	NOUN
dpc-1540	203	58	f	f	NOUN
dpc-1540	203	59	≥30	≥30	PROPN
dpc-1540	203	60	15	15	NUM
dpc-1540	203	61	25.42	25.42	NUM
dpc-1540	203	62	%	%	NOUN
dpc-1540	203	63	44	44	NUM
dpc-1540	203	64	74.57	74.57	NUM
dpc-1540	203	65	%	%	NOUN
dpc-1540	203	66	.052	.052	NUM
dpc-1540	203	67	blood	blood	NOUN
dpc-1540	203	68	pressure(mmhg	pressure(mmhg	PROPN
dpc-1540	203	69	)	)	PUNCT
dpc-1540	203	70	m	m	PROPN
dpc-1540	203	71	sbp<130	sbp<130	PROPN
dpc-1540	203	72	,	,	PUNCT
dpc-1540	203	73	dbp<85	dbp<85	PROPN
dpc-1540	203	74	12	12	NUM
dpc-1540	203	75	80.00	80.00	NUM
dpc-1540	203	76	%	%	NOUN
dpc-1540	203	77	29	29	NUM
dpc-1540	203	78	76.32	76.32	NUM
dpc-1540	203	79	%	%	NOUN
dpc-1540	203	80	.773	.773	NUM
dpc-1540	203	81	sbp>130	sbp>130	PROPN
dpc-1540	203	82	,	,	PUNCT
dpc-1540	203	83	dbp>85	dbp>85	PROPN
dpc-1540	203	84	3	3	NUM
dpc-1540	203	85	20.00	20.00	NUM
dpc-1540	203	86	%	%	NOUN
dpc-1540	203	87	9	9	NUM
dpc-1540	203	88	23.68	23.68	NUM
dpc-1540	203	89	%	%	NOUN
dpc-1540	203	90	f	f	PROPN
dpc-1540	203	91	sbp<130	sbp<130	PROPN
dpc-1540	203	92	,	,	PUNCT
dpc-1540	203	93	dbp<85	dbp<85	PROPN
dpc-1540	203	94	12	12	NUM
dpc-1540	203	95	85.71	85.71	NUM
dpc-1540	203	96	%	%	NOUN
dpc-1540	203	97	33	33	NUM
dpc-1540	203	98	73.33	73.33	NUM
dpc-1540	203	99	%	%	NOUN
dpc-1540	203	100	.342	.342	NUM
dpc-1540	203	101	sbp>130	sbp>130	NOUN
dpc-1540	203	102	,	,	PUNCT
dpc-1540	203	103	dbp>85	dbp>85	PROPN
dpc-1540	203	104	2	2	NUM
dpc-1540	203	105	14.29	14.29	NUM
dpc-1540	203	106	%	%	NOUN
dpc-1540	203	107	12	12	NUM
dpc-1540	203	108	26.67	26.67	NUM
dpc-1540	203	109	%	%	NOUN
dpc-1540	203	110	fasting	fast	VERB
dpc-1540	203	111	glucose(mg	glucose(mg	PROPN
dpc-1540	203	112	/	/	SYM
dpc-1540	203	113	dl	dl	PROPN
dpc-1540	203	114	)	)	PUNCT
dpc-1540	203	115	m	m	PROPN
dpc-1540	203	116	<	<	X
dpc-1540	203	117	110	110	NUM
dpc-1540	203	118	11	11	NUM
dpc-1540	203	119	73.33	73.33	NUM
dpc-1540	203	120	%	%	NOUN
dpc-1540	203	121	19	19	NUM
dpc-1540	203	122	50.00	50.00	NUM
dpc-1540	203	123	%	%	NOUN
dpc-1540	203	124	.123	.123	NUM
dpc-1540	203	125	≥110	≥110	ADJ
dpc-1540	203	126	4	4	NUM
dpc-1540	203	127	26.67	26.67	NUM
dpc-1540	203	128	%	%	NOUN
dpc-1540	203	129	19	19	NUM
dpc-1540	203	130	50.00	50.00	NUM
dpc-1540	203	131	%	%	NOUN
dpc-1540	203	132	f	f	NOUN
dpc-1540	204	1	<	<	X
dpc-1540	204	2	110	110	NUM
dpc-1540	204	3	13	13	NUM
dpc-1540	204	4	92.86	92.86	NUM
dpc-1540	204	5	%	%	NOUN
dpc-1540	204	6	22	22	NUM
dpc-1540	204	7	48.89	48.89	NUM
dpc-1540	204	8	%	%	NOUN
dpc-1540	204	9	.003	.003	NUM
dpc-1540	204	10	≥110	≥110	PROPN
dpc-1540	204	11	1	1	NUM
dpc-1540	204	12	7.14	7.14	NUM
dpc-1540	204	13	%	%	NOUN
dpc-1540	204	14	23	23	NUM
dpc-1540	204	15	51.11	51.11	NUM
dpc-1540	204	16	%	%	NOUN
dpc-1540	204	17	homa	homa	NOUN
dpc-1540	204	18	-	-	PUNCT
dpc-1540	204	19	ir	ir	NOUN
dpc-1540	204	20	m	m	PROPN
dpc-1540	204	21	<	<	X
dpc-1540	204	22	2.5	2.5	NUM
dpc-1540	204	23	7	7	NUM
dpc-1540	204	24	46.67	46.67	NUM
dpc-1540	204	25	%	%	NOUN
dpc-1540	204	26	13	13	NUM
dpc-1540	204	27	34.21	34.21	NUM
dpc-1540	204	28	%	%	NOUN
dpc-1540	204	29	.399	.399	NUM
dpc-1540	204	30	≥2.5	≥2.5	NOUN
dpc-1540	204	31	8	8	NUM
dpc-1540	204	32	53.33	53.33	NUM
dpc-1540	204	33	%	%	NOUN
dpc-1540	204	34	25	25	NUM
dpc-1540	204	35	65.79	65.79	NUM
dpc-1540	204	36	%	%	NOUN
dpc-1540	205	1	f	f	X
dpc-1540	205	2	<	<	X
dpc-1540	205	3	2.5	2.5	NUM
dpc-1540	205	4	7	7	NUM
dpc-1540	205	5	50.00	50.00	NUM
dpc-1540	205	6	%	%	NOUN
dpc-1540	205	7	14	14	NUM
dpc-1540	205	8	31.11	31.11	NUM
dpc-1540	205	9	%	%	NOUN
dpc-1540	205	10	.197	.197	NUM
dpc-1540	205	11	≥2.5	≥2.5	NOUN
dpc-1540	205	12	7	7	NUM
dpc-1540	205	13	50.00	50.00	NUM
dpc-1540	205	14	%	%	NOUN
dpc-1540	205	15	31	31	NUM
dpc-1540	205	16	68.89	68.89	NUM
dpc-1540	205	17	%	%	NOUN
dpc-1540	205	18	triglyceride	triglyceride	INTJ
dpc-1540	205	19	(	(	PUNCT
dpc-1540	205	20	mg	mg	PROPN
dpc-1540	205	21	/	/	SYM
dpc-1540	205	22	dl	dl	NOUN
dpc-1540	205	23	)	)	PUNCT
dpc-1540	205	24	m	m	PROPN
dpc-1540	205	25	<	<	X
dpc-1540	205	26	150	150	NUM
dpc-1540	205	27	1	1	NUM
dpc-1540	205	28	6.67	6.67	NUM
dpc-1540	205	29	%	%	NOUN
dpc-1540	205	30	3	3	NUM
dpc-1540	205	31	7.89	7.89	NUM
dpc-1540	205	32	%	%	NOUN
dpc-1540	205	33	.879	.879	NUM
dpc-1540	205	34	>	>	X
dpc-1540	205	35	150	150	NUM
dpc-1540	205	36	14	14	NUM
dpc-1540	205	37	93.33	93.33	NUM
dpc-1540	205	38	%	%	NOUN
dpc-1540	205	39	35	35	NUM
dpc-1540	205	40	92.11	92.11	NUM
dpc-1540	205	41	%	%	NOUN
dpc-1540	205	42	f	f	NOUN
dpc-1540	205	43	<	<	X
dpc-1540	205	44	150	150	NUM
dpc-1540	205	45	6	6	NUM
dpc-1540	205	46	42.86	42.86	NUM
dpc-1540	205	47	%	%	NOUN
dpc-1540	205	48	9	9	NUM
dpc-1540	205	49	20.00	20.00	NUM
dpc-1540	205	50	%	%	NOUN
dpc-1540	205	51	.086	.086	NUM
dpc-1540	205	52	>	>	PUNCT
dpc-1540	205	53	150	150	NUM
dpc-1540	205	54	8	8	NUM
dpc-1540	205	55	57.14	57.14	NUM
dpc-1540	205	56	%	%	NOUN
dpc-1540	205	57	36	36	NUM
dpc-1540	205	58	80.00	80.00	NUM
dpc-1540	205	59	%	%	NOUN
dpc-1540	205	60	hdl	hdl	NOUN
dpc-1540	205	61	(	(	PUNCT
dpc-1540	205	62	mg	mg	PROPN
dpc-1540	205	63	/	/	SYM
dpc-1540	205	64	dl	dl	NOUN
dpc-1540	205	65	)	)	PUNCT
dpc-1540	205	66	m	m	PROPN
dpc-1540	205	67	<	<	X
dpc-1540	205	68	40	40	NUM
dpc-1540	205	69	7	7	NUM
dpc-1540	205	70	46.67	46.67	NUM
dpc-1540	205	71	%	%	NOUN
dpc-1540	205	72	23	23	NUM
dpc-1540	205	73	60.53	60.53	NUM
dpc-1540	205	74	%	%	NOUN
dpc-1540	205	75	.359	.359	NUM
dpc-1540	205	76	>	>	X
dpc-1540	205	77	40	40	NUM
dpc-1540	205	78	8	8	NUM
dpc-1540	205	79	53.33	53.33	NUM
dpc-1540	205	80	%	%	NOUN
dpc-1540	205	81	15	15	NUM
dpc-1540	205	82	39.47	39.47	NUM
dpc-1540	205	83	%	%	NOUN
dpc-1540	205	84	f	f	NOUN
dpc-1540	205	85	<	<	X
dpc-1540	205	86	50	50	NUM
dpc-1540	205	87	8	8	NUM
dpc-1540	205	88	57.14	57.14	NUM
dpc-1540	205	89	%	%	NOUN
dpc-1540	205	90	38	38	NUM
dpc-1540	205	91	84.44	84.44	NUM
dpc-1540	205	92	%	%	NOUN
dpc-1540	205	93	.031	.031	NUM
dpc-1540	205	94	>	>	X
dpc-1540	205	95	50	50	NUM
dpc-1540	205	96	6	6	NUM
dpc-1540	205	97	42.86	42.86	NUM
dpc-1540	205	98	%	%	NOUN
dpc-1540	205	99	7	7	NUM
dpc-1540	205	100	15.56	15.56	NUM
dpc-1540	205	101	%	%	NOUN
dpc-1540	205	102	metabolic	metabolic	NOUN
dpc-1540	205	103	syndrome	syndrome	NOUN
dpc-1540	205	104	diagnosis	diagnosis	NOUN
dpc-1540	205	105	m	m	VERB
dpc-1540	205	106	ms	ms	NOUN
dpc-1540	205	107	(	(	PUNCT
dpc-1540	205	108	-	-	PUNCT
dpc-1540	205	109	)	)	PUNCT
dpc-1540	205	110	5	5	NUM
dpc-1540	205	111	33.33	33.33	NUM
dpc-1540	205	112	%	%	NOUN
dpc-1540	205	113	15	15	NUM
dpc-1540	205	114	39.47	39.47	NUM
dpc-1540	205	115	%	%	NOUN
dpc-1540	205	116	.678	.678	NUM
dpc-1540	205	117	ms	ms	PROPN
dpc-1540	205	118	(	(	PUNCT
dpc-1540	205	119	+	+	NOUN
dpc-1540	205	120	)	)	PUNCT
dpc-1540	205	121	10	10	NUM
dpc-1540	205	122	66.67	66.67	NUM
dpc-1540	205	123	%	%	NOUN
dpc-1540	205	124	23	23	NUM
dpc-1540	205	125	60.53	60.53	NUM
dpc-1540	205	126	%	%	NOUN
dpc-1540	205	127	f	f	PROPN
dpc-1540	205	128	ms	ms	PROPN
dpc-1540	205	129	(	(	PUNCT
dpc-1540	205	130	-	-	PUNCT
dpc-1540	205	131	)	)	PUNCT
dpc-1540	205	132	7	7	NUM
dpc-1540	205	133	50.00	50.00	NUM
dpc-1540	205	134	%	%	NOUN
dpc-1540	205	135	9	9	NUM
dpc-1540	205	136	20.00	20.00	NUM
dpc-1540	205	137	%	%	NOUN
dpc-1540	205	138	.027	.027	NUM
dpc-1540	205	139	ms	ms	PROPN
dpc-1540	205	140	(	(	PUNCT
dpc-1540	205	141	+	+	NOUN
dpc-1540	205	142	)	)	PUNCT
dpc-1540	205	143	7	7	NUM
dpc-1540	205	144	50.00	50.00	NUM
dpc-1540	205	145	%	%	NOUN
dpc-1540	205	146	36	36	NUM
dpc-1540	205	147	80.00	80.00	NUM
dpc-1540	205	148	%	%	NOUN
dpc-1540	205	149	total	total	NOUN
dpc-1540	205	150	ms	ms	PROPN
dpc-1540	205	151	(	(	PUNCT
dpc-1540	205	152	-	-	PUNCT
dpc-1540	205	153	)	)	PUNCT
dpc-1540	205	154	12	12	NUM
dpc-1540	205	155	41.38	41.38	NUM
dpc-1540	205	156	%	%	NOUN
dpc-1540	205	157	24	24	NUM
dpc-1540	205	158	28.92	28.92	NUM
dpc-1540	205	159	%	%	NOUN
dpc-1540	205	160	.216	.216	NUM
dpc-1540	205	161	ms	ms	PROPN
dpc-1540	205	162	(	(	PUNCT
dpc-1540	205	163	+	+	PROPN
dpc-1540	205	164	)	)	PUNCT
dpc-1540	205	165	17	17	NUM
dpc-1540	205	166	58.62	58.62	NUM
dpc-1540	205	167	%	%	NOUN
dpc-1540	205	168	59	59	NUM
dpc-1540	205	169	71.08	71.08	NUM
dpc-1540	205	170	%	%	NOUN
dpc-1540	205	171	1values	1values	NUM
dpc-1540	205	172	are	be	AUX
dpc-1540	205	173	no	no	PRON
dpc-1540	205	174	.	.	PUNCT
dpc-1540	206	1	(	(	PUNCT
dpc-1540	206	2	%	%	NOUN
dpc-1540	206	3	)	)	PUNCT
dpc-1540	206	4	of	of	ADP
dpc-1540	206	5	patients	patient	NOUN
dpc-1540	206	6	.	.	PUNCT
dpc-1540	207	1	2	2	NUM
dpc-1540	207	2	pearson	pearson	PROPN
dpc-1540	207	3	’s	’s	PART
dpc-1540	207	4	chi	chi	ADJ
dpc-1540	207	5	-	-	PUNCT
dpc-1540	207	6	square	square	ADJ
dpc-1540	207	7	test	test	NOUN
dpc-1540	207	8	bmi	bmi	NOUN
dpc-1540	207	9	=	=	PUNCT
dpc-1540	207	10	body	body	PROPN
dpc-1540	207	11	mass	mass	PROPN
dpc-1540	207	12	index	index	NOUN
dpc-1540	207	13	;	;	PUNCT
dpc-1540	207	14	homa	homa	NOUN
dpc-1540	207	15	-	-	PUNCT
dpc-1540	207	16	ir	ir	NOUN
dpc-1540	207	17	=	=	NOUN
dpc-1540	207	18	homeostatic	homeostatic	ADJ
dpc-1540	207	19	model	model	NOUN
dpc-1540	207	20	assessment	assessment	NOUN
dpc-1540	207	21	insulin	insulin	NOUN
dpc-1540	207	22	resistance	resistance	NOUN
dpc-1540	207	23	;	;	PUNCT
dpc-1540	207	24	ms	ms	PROPN
dpc-1540	207	25	=	=	PROPN
dpc-1540	207	26	metabolic	metabolic	NOUN
dpc-1540	207	27	syndrome	syndrome	NOUN
dpc-1540	207	28	;	;	PUNCT
dpc-1540	207	29	pasi	pasi	NOUN
dpc-1540	207	30	=	=	SYM
dpc-1540	207	31	psoriasis	psoriasis	NOUN
dpc-1540	207	32	area	area	NOUN
dpc-1540	207	33	and	and	CCONJ
dpc-1540	207	34	severity	severity	NOUN
dpc-1540	207	35	index	index	NOUN
dpc-1540	207	36	.	.	PUNCT
dpc-1540	208	1	that	that	DET
dpc-1540	208	2	poor	poor	ADJ
dpc-1540	208	3	sleep	sleep	VERB
dpc-1540	208	4	quality	quality	NOUN
dpc-1540	208	5	in	in	ADP
dpc-1540	208	6	psoriasis	psoriasis	NOUN
dpc-1540	208	7	patients	patient	NOUN
dpc-1540	208	8	was	be	AUX
dpc-1540	208	9	4.3	4.3	NUM
dpc-1540	208	10	-	-	PUNCT
dpc-1540	208	11	times	time	NOUN
dpc-1540	208	12	higher	high	ADJ
dpc-1540	208	13	than	than	ADP
dpc-1540	208	14	in	in	ADP
dpc-1540	208	15	healthy	healthy	ADJ
dpc-1540	208	16	controls	control	NOUN
dpc-1540	208	17	.	.	PUNCT
dpc-1540	209	1	however	however	ADV
dpc-1540	209	2	,	,	PUNCT
dpc-1540	209	3	stinco	stinco	PROPN
dpc-1540	209	4	et	et	NOUN
dpc-1540	209	5	al	al	PROPN
dpc-1540	209	6	[	[	X
dpc-1540	209	7	42	42	NUM
dpc-1540	209	8	]	]	PUNCT
dpc-1540	209	9	did	do	AUX
dpc-1540	209	10	not	not	PART
dpc-1540	209	11	find	find	VERB
dpc-1540	209	12	any	any	DET
dpc-1540	209	13	difference	difference	NOUN
dpc-1540	209	14	in	in	ADP
dpc-1540	209	15	sleep	sleep	NOUN
dpc-1540	209	16	quality	quality	NOUN
dpc-1540	209	17	between	between	ADP
dpc-1540	209	18	psoriasis	psoriasis	NOUN
dpc-1540	209	19	patients	patient	NOUN
dpc-1540	209	20	and	and	CCONJ
dpc-1540	209	21	healthy	healthy	ADJ
dpc-1540	209	22	controls	control	NOUN
dpc-1540	209	23	.	.	PUNCT
dpc-1540	210	1	in	in	ADP
dpc-1540	210	2	our	our	PRON
dpc-1540	210	3	study	study	NOUN
dpc-1540	210	4	,	,	PUNCT
dpc-1540	210	5	84.8	84.8	NUM
dpc-1540	210	6	%	%	NOUN
dpc-1540	210	7	of	of	ADP
dpc-1540	210	8	patients	patient	NOUN
dpc-1540	210	9	had	have	VERB
dpc-1540	210	10	psqi	psqi	NOUN
dpc-1540	210	11	values	value	NOUN
dpc-1540	210	12	≥5	≥5	PROPN
dpc-1540	210	13	,	,	PUNCT
dpc-1540	210	14	indicating	indicate	VERB
dpc-1540	210	15	poor	poor	ADJ
dpc-1540	210	16	sleep	sleep	NOUN
dpc-1540	210	17	quality	quality	NOUN
dpc-1540	210	18	.	.	PUNCT
dpc-1540	211	1	this	this	DET
dpc-1540	211	2	result	result	NOUN
dpc-1540	211	3	agrees	agree	VERB
dpc-1540	211	4	with	with	ADP
dpc-1540	211	5	the	the	DET
dpc-1540	211	6	literature	literature	NOUN
dpc-1540	211	7	,	,	PUNCT
dpc-1540	211	8	but	but	CCONJ
dpc-1540	211	9	the	the	DET
dpc-1540	211	10	rate	rate	NOUN
dpc-1540	211	11	is	be	AUX
dpc-1540	211	12	higher	high	ADJ
dpc-1540	211	13	.	.	PUNCT
dpc-1540	212	1	additionally	additionally	ADV
dpc-1540	212	2	,	,	PUNCT
dpc-1540	212	3	the	the	DET
dpc-1540	212	4	psqi	psqi	NOUN
dpc-1540	212	5	mean	mean	VERB
dpc-1540	212	6	was	be	AUX
dpc-1540	212	7	significantly	significantly	ADV
dpc-1540	212	8	higher	high	ADJ
dpc-1540	212	9	in	in	ADP
dpc-1540	212	10	the	the	DET
dpc-1540	212	11	ms	ms	PROPN
dpc-1540	212	12	group	group	NOUN
dpc-1540	212	13	than	than	ADP
dpc-1540	212	14	non	non	ADJ
dpc-1540	212	15	-	-	ADJ
dpc-1540	212	16	ms	ms	ADJ
dpc-1540	212	17	group	group	NOUN
dpc-1540	212	18	.	.	PUNCT
dpc-1540	213	1	sleep	sleep	NOUN
dpc-1540	213	2	latency	latency	NOUN
dpc-1540	213	3	and	and	CCONJ
dpc-1540	213	4	daytime	daytime	PROPN
dpc-1540	213	5	sleep	sleep	NOUN
dpc-1540	213	6	dysfunction	dysfunction	NOUN
dpc-1540	213	7	were	be	AUX
dpc-1540	213	8	significantly	significantly	ADV
dpc-1540	213	9	higher	high	ADJ
dpc-1540	213	10	in	in	ADP
dpc-1540	213	11	the	the	DET
dpc-1540	213	12	ms	ms	PROPN
dpc-1540	213	13	group	group	NOUN
dpc-1540	213	14	;	;	PUNCT
dpc-1540	213	15	these	these	DET
dpc-1540	213	16	results	result	NOUN
dpc-1540	213	17	are	be	AUX
dpc-1540	213	18	similar	similar	ADJ
dpc-1540	213	19	to	to	ADP
dpc-1540	213	20	those	those	PRON
dpc-1540	213	21	of	of	ADP
dpc-1540	213	22	hawro	hawro	NOUN
dpc-1540	213	23	et	et	PROPN
dpc-1540	213	24	al	al	PROPN
dpc-1540	214	1	[	[	X
dpc-1540	214	2	36	36	NUM
dpc-1540	214	3	]	]	PUNCT
dpc-1540	214	4	.	.	PUNCT
dpc-1540	215	1	moreover	moreover	ADV
dpc-1540	215	2	,	,	PUNCT
dpc-1540	215	3	it	it	PRON
dpc-1540	215	4	is	be	AUX
dpc-1540	215	5	a	a	DET
dpc-1540	215	6	wellknown	wellknown	ADJ
dpc-1540	215	7	fact	fact	NOUN
dpc-1540	215	8	that	that	SCONJ
dpc-1540	215	9	the	the	DET
dpc-1540	215	10	prevalence	prevalence	NOUN
dpc-1540	215	11	of	of	ADP
dpc-1540	215	12	respiratory	respiratory	ADJ
dpc-1540	215	13	difficulties	difficulty	NOUN
dpc-1540	215	14	such	such	ADJ
dpc-1540	215	15	as	as	ADP
dpc-1540	215	16	obstructive	obstructive	ADJ
dpc-1540	215	17	sleep	sleep	NOUN
dpc-1540	215	18	apnea	apnea	NOUN
dpc-1540	215	19	is	be	AUX
dpc-1540	215	20	higher	high	ADJ
dpc-1540	215	21	in	in	ADP
dpc-1540	215	22	obese	obese	ADJ
dpc-1540	215	23	patients	patient	NOUN
dpc-1540	215	24	,	,	PUNCT
dpc-1540	215	25	which	which	PRON
dpc-1540	215	26	lead	lead	VERB
dpc-1540	215	27	to	to	ADP
dpc-1540	215	28	sleep	sleep	NOUN
dpc-1540	215	29	disorders	disorder	NOUN
dpc-1540	215	30	,	,	PUNCT
dpc-1540	215	31	and	and	CCONJ
dpc-1540	215	32	there	there	PRON
dpc-1540	215	33	is	be	VERB
dpc-1540	215	34	high	high	ADJ
dpc-1540	215	35	prevalence	prevalence	NOUN
dpc-1540	215	36	of	of	ADP
dpc-1540	215	37	obesity	obesity	NOUN
dpc-1540	215	38	in	in	ADP
dpc-1540	215	39	patients	patient	NOUN
dpc-1540	215	40	with	with	ADP
dpc-1540	215	41	psoriasis	psoriasis	NOUN
dpc-1540	215	42	[	[	X
dpc-1540	215	43	11	11	NUM
dpc-1540	215	44	]	]	PUNCT
dpc-1540	215	45	.	.	PUNCT
dpc-1540	216	1	because	because	SCONJ
dpc-1540	216	2	most	most	ADJ
dpc-1540	216	3	of	of	ADP
dpc-1540	216	4	our	our	PRON
dpc-1540	216	5	ms	ms	NOUN
dpc-1540	216	6	subjects	subject	NOUN
dpc-1540	216	7	were	be	AUX
dpc-1540	216	8	obese	obese	ADJ
dpc-1540	216	9	,	,	PUNCT
dpc-1540	216	10	and	and	CCONJ
dpc-1540	216	11	there	there	PRON
dpc-1540	216	12	was	be	VERB
dpc-1540	216	13	no	no	DET
dpc-1540	216	14	relation	relation	NOUN
dpc-1540	216	15	between	between	ADP
dpc-1540	216	16	the	the	DET
dpc-1540	216	17	presence	presence	NOUN
dpc-1540	216	18	of	of	ADP
dpc-1540	216	19	ms	ms	NOUN
dpc-1540	216	20	and	and	CCONJ
dpc-1540	216	21	psoriasis	psoriasis	NOUN
dpc-1540	216	22	severity	severity	NOUN
dpc-1540	216	23	in	in	ADP
dpc-1540	216	24	the	the	DET
dpc-1540	216	25	whole	whole	ADJ
dpc-1540	216	26	group	group	NOUN
dpc-1540	216	27	,	,	PUNCT
dpc-1540	216	28	their	their	PRON
dpc-1540	216	29	poor	poor	ADJ
dpc-1540	216	30	sleep	sleep	NOUN
dpc-1540	216	31	quality	quality	NOUN
dpc-1540	216	32	might	might	AUX
dpc-1540	216	33	be	be	AUX
dpc-1540	216	34	more	more	ADV
dpc-1540	216	35	related	related	ADJ
dpc-1540	216	36	to	to	ADP
dpc-1540	216	37	their	their	PRON
dpc-1540	216	38	obesity	obesity	NOUN
dpc-1540	216	39	than	than	ADP
dpc-1540	216	40	their	their	PRON
dpc-1540	216	41	psoriasis	psoriasis	NOUN
dpc-1540	216	42	severity	severity	NOUN
dpc-1540	216	43	.	.	PUNCT
dpc-1540	217	1	however	however	ADV
dpc-1540	217	2	,	,	PUNCT
dpc-1540	217	3	ms	ms	PROPN
dpc-1540	217	4	prevalence	prevalence	NOUN
dpc-1540	217	5	was	be	AUX
dpc-1540	217	6	significantly	significantly	ADV
dpc-1540	217	7	higher	high	ADJ
dpc-1540	217	8	in	in	ADP
dpc-1540	217	9	females	female	NOUN
dpc-1540	217	10	with	with	ADP
dpc-1540	217	11	severe	severe	ADJ
dpc-1540	217	12	psoriasis	psoriasis	NOUN
dpc-1540	217	13	,	,	PUNCT
dpc-1540	217	14	compared	compare	VERB
dpc-1540	217	15	to	to	ADP
dpc-1540	217	16	males	male	NOUN
dpc-1540	217	17	.	.	PUNCT
dpc-1540	218	1	because	because	SCONJ
dpc-1540	218	2	the	the	DET
dpc-1540	218	3	significantly	significantly	ADV
dpc-1540	218	4	higher	high	ADJ
dpc-1540	218	5	fasting	fasting	NOUN
dpc-1540	218	6	glucose	glucose	NOUN
dpc-1540	218	7	and	and	CCONJ
dpc-1540	218	8	lower	low	ADJ
dpc-1540	218	9	hdl	hdl	PROPN
dpc-1540	218	10	were	be	AUX
dpc-1540	218	11	also	also	ADV
dpc-1540	218	12	detected	detect	VERB
dpc-1540	218	13	only	only	ADV
dpc-1540	218	14	in	in	ADP
dpc-1540	218	15	females	female	NOUN
dpc-1540	218	16	with	with	ADP
dpc-1540	218	17	severe	severe	ADJ
dpc-1540	218	18	psoriasis	psoriasis	NOUN
dpc-1540	218	19	,	,	PUNCT
dpc-1540	218	20	these	these	DET
dpc-1540	218	21	abnormalities	abnormality	NOUN
dpc-1540	218	22	might	might	AUX
dpc-1540	218	23	be	be	AUX
dpc-1540	218	24	more	more	ADV
dpc-1540	218	25	related	related	ADJ
dpc-1540	218	26	to	to	ADP
dpc-1540	218	27	the	the	DET
dpc-1540	218	28	8	8	NUM
dpc-1540	218	29	research	research	NOUN
dpc-1540	218	30	|	|	ADV
dpc-1540	218	31	dermatol	dermatol	NOUN
dpc-1540	218	32	pract	pract	NOUN
dpc-1540	218	33	concept	concept	NOUN
dpc-1540	218	34	.	.	PUNCT
dpc-1540	219	1	2021;11(3):e2021049	2021;11(3):e2021049	NUM
dpc-1540	219	2	ta	ta	X
dpc-1540	219	3	b	b	PROPN
dpc-1540	219	4	le	le	X
dpc-1540	219	5	5	5	NUM
dpc-1540	219	6	.	.	PUNCT
dpc-1540	220	1	p	p	NOUN
dpc-1540	220	2	ea	ea	INTJ
dpc-1540	220	3	rs	rs	X
dpc-1540	220	4	on	on	ADP
dpc-1540	220	5	’s	’s	NOUN
dpc-1540	220	6	r	r	NOUN
dpc-1540	220	7	ho	ho	PROPN
dpc-1540	220	8	(	(	PUNCT
dpc-1540	220	9	an	an	PRON
dpc-1540	220	10	d	d	X
dpc-1540	220	11	p	p	PROPN
dpc-1540	220	12	va	va	PROPN
dpc-1540	220	13	lu	lu	PROPN
dpc-1540	220	14	e	e	PROPN
dpc-1540	220	15	)	)	PUNCT
dpc-1540	220	16	b	b	PROPN
dpc-1540	220	17	et	et	PROPN
dpc-1540	220	18	w	w	PROPN
dpc-1540	220	19	ee	ee	PROPN
dpc-1540	220	20	n	n	PROPN
dpc-1540	220	21	a	a	PROPN
dpc-1540	220	22	d	d	X
dpc-1540	220	23	ia	ia	PROPN
dpc-1540	220	24	gn	gn	PROPN
dpc-1540	221	1	os	os	NOUN
dpc-1540	221	2	is	be	AUX
dpc-1540	221	3	o	o	PROPN
dpc-1540	221	4	f	f	X
dpc-1540	221	5	m	m	VERB
dpc-1540	221	6	et	et	PROPN
dpc-1540	221	7	ab	ab	PROPN
dpc-1540	221	8	ol	ol	PROPN
dpc-1540	221	9	ic	ic	PROPN
dpc-1540	221	10	s	s	PROPN
dpc-1540	221	11	yn	yn	PROPN
dpc-1540	221	12	dr	dr	PROPN
dpc-1540	221	13	om	om	PROPN
dpc-1540	221	14	e	e	PROPN
dpc-1540	221	15	(	(	PUNCT
dpc-1540	221	16	m	m	PROPN
dpc-1540	221	17	s	s	PART
dpc-1540	221	18	)	)	PUNCT
dpc-1540	221	19	a	a	DET
dpc-1540	221	20	nd	nd	NOUN
dpc-1540	221	21	c	c	PROPN
dpc-1540	221	22	lin	lin	PROPN
dpc-1540	222	1	ic	ic	PROPN
dpc-1540	222	2	al	al	PROPN
dpc-1540	222	3	c	c	PROPN
dpc-1540	223	1	ha	ha	INTJ
dpc-1540	223	2	ra	ra	INTJ
dpc-1540	224	1	ct	ct	INTJ
dpc-1540	224	2	er	er	INTJ
dpc-1540	224	3	is	be	AUX
dpc-1540	224	4	ti	ti	X
dpc-1540	224	5	cs	cs	PROPN
dpc-1540	224	6	f	f	PROPN
dpc-1540	224	7	or	or	CCONJ
dpc-1540	224	8	1	1	NUM
dpc-1540	224	9	12	12	NUM
dpc-1540	224	10	p	p	NOUN
dpc-1540	224	11	so	so	ADV
dpc-1540	224	12	ri	ri	PROPN
dpc-1540	224	13	as	as	SCONJ
dpc-1540	224	14	is	be	AUX
dpc-1540	224	15	p	p	NOUN
dpc-1540	224	16	at	at	ADP
dpc-1540	224	17	ie	ie	X
dpc-1540	224	18	nt	not	PART
dpc-1540	224	19	s	s	VERB
dpc-1540	224	20	m	m	NOUN
dpc-1540	224	21	s	s	NOUN
dpc-1540	224	22	d	d	NOUN
dpc-1540	224	23	is	be	AUX
dpc-1540	224	24	ea	ea	X
dpc-1540	224	25	se	se	PROPN
dpc-1540	225	1	d	d	X
dpc-1540	225	2	u	u	X
dpc-1540	225	3	ra	ra	INTJ
dpc-1540	225	4	ti	ti	NOUN
dpc-1540	225	5	o	o	PROPN
dpc-1540	225	6	n	n	PROPN
dpc-1540	225	7	b	b	NOUN
dpc-1540	225	8	m	m	VERB
dpc-1540	226	1	i	i	PRON
dpc-1540	226	2	w	w	NOUN
dpc-1540	226	3	ai	ai	PROPN
dpc-1540	226	4	st	st	PROPN
dpc-1540	226	5	ci	ci	PROPN
dpc-1540	226	6	rc	rc	PROPN
dpc-1540	226	7	u	u	PROPN
dpc-1540	226	8	m	m	PROPN
dpc-1540	226	9	fe	fe	X
dpc-1540	226	10	re	re	X
dpc-1540	226	11	n	n	X
dpc-1540	226	12	ce	ce	PROPN
dpc-1540	226	13	tr	tr	VERB
dpc-1540	226	14	ig	ig	PROPN
dpc-1540	226	15	ly	ly	NUM
dpc-1540	226	16	ce	ce	PROPN
dpc-1540	226	17	ri	ri	PROPN
dpc-1540	227	1	d	d	PROPN
dpc-1540	227	2	e	e	PROPN
dpc-1540	227	3	h	h	NOUN
dpc-1540	227	4	d	d	NOUN
dpc-1540	227	5	l	l	NOUN
dpc-1540	227	6	b	b	X
dpc-1540	228	1	lo	lo	NOUN
dpc-1540	229	1	o	o	NOUN
dpc-1540	230	1	d	d	X
dpc-1540	230	2	pr	pr	NOUN
dpc-1540	230	3	es	es	X
dpc-1540	230	4	su	su	PROPN
dpc-1540	230	5	re	re	PROPN
dpc-1540	230	6	fa	fa	PROPN
dpc-1540	230	7	st	st	PROPN
dpc-1540	230	8	in	in	ADP
dpc-1540	230	9	g	g	PROPN
dpc-1540	230	10	g	g	PROPN
dpc-1540	230	11	lu	lu	PROPN
dpc-1540	230	12	co	co	PROPN
dpc-1540	230	13	se	se	PROPN
dpc-1540	231	1	h	h	PROPN
dpc-1540	232	1	o	o	X
dpc-1540	232	2	m	m	VERB
dpc-1540	232	3	a	a	DET
dpc-1540	232	4	-ir	-ir	NOUN
dpc-1540	232	5	pa	pa	NOUN
dpc-1540	232	6	si	si	PROPN
dpc-1540	232	7	ps	ps	PROPN
dpc-1540	232	8	q	q	PROPN
dpc-1540	233	1	i	i	PRON
dpc-1540	233	2	sm	sm	INTJ
dpc-1540	234	1	o	o	INTJ
dpc-1540	234	2	ki	ki	PROPN
dpc-1540	235	1	n	n	CCONJ
dpc-1540	236	1	g	g	PROPN
dpc-1540	236	2	h	h	PROPN
dpc-1540	236	3	ab	ab	PROPN
dpc-1540	236	4	it	it	PRON
dpc-1540	236	5	a	a	DET
dpc-1540	236	6	lc	lc	NOUN
dpc-1540	237	1	o	o	NOUN
dpc-1540	237	2	h	h	NOUN
dpc-1540	237	3	o	o	X
dpc-1540	237	4	l	l	X
dpc-1540	237	5	co	co	X
dpc-1540	237	6	n	n	PROPN
dpc-1540	237	7	su	su	PROPN
dpc-1540	237	8	m	m	PROPN
dpc-1540	237	9	p	p	NOUN
dpc-1540	237	10	ti	ti	X
dpc-1540	237	11	o	o	NOUN
dpc-1540	237	12	n	n	PROPN
dpc-1540	237	13	1	1	NUM
dpc-1540	237	14	0	0	NUM
dpc-1540	237	15	.	.	NOUN
dpc-1540	237	16	24	24	NUM
dpc-1540	237	17	4	4	NUM
dpc-1540	237	18	0	0	NUM
dpc-1540	237	19	.	.	PUNCT
dpc-1540	237	20	27	27	NUM
dpc-1540	237	21	5	5	NUM
dpc-1540	237	22	0	0	NUM
dpc-1540	237	23	.	.	NOUN
dpc-1540	238	1	52	52	NUM
dpc-1540	238	2	6	6	NUM
dpc-1540	238	3	0	0	NUM
dpc-1540	238	4	.	.	NUM
dpc-1540	238	5	24	24	NUM
dpc-1540	238	6	3	3	NUM
dpc-1540	238	7	-0	-0	NOUN
dpc-1540	238	8	.2	.2	NUM
dpc-1540	238	9	79	79	NUM
dpc-1540	238	10	0	0	NUM
dpc-1540	238	11	.	.	PUNCT
dpc-1540	239	1	33	33	NUM
dpc-1540	239	2	3	3	NUM
dpc-1540	239	3	0	0	NUM
dpc-1540	239	4	.	.	PUNCT
dpc-1540	240	1	46	46	NUM
dpc-1540	240	2	9	9	NUM
dpc-1540	240	3	0	0	NUM
dpc-1540	240	4	.	.	PUNCT
dpc-1540	240	5	18	18	NUM
dpc-1540	240	6	7	7	NUM
dpc-1540	240	7	0	0	NUM
dpc-1540	240	8	.	.	PUNCT
dpc-1540	241	1	03	03	NUM
dpc-1540	242	1	9	9	NUM
dpc-1540	242	2	0	0	NUM
dpc-1540	242	3	.	.	NOUN
dpc-1540	242	4	2	2	NUM
dpc-1540	242	5	-0	-0	SYM
dpc-1540	242	6	.0	.0	NUM
dpc-1540	242	7	07	07	NUM
dpc-1540	242	8	0	0	NUM
dpc-1540	242	9	.	.	PUNCT
dpc-1540	243	1	02	02	NUM
dpc-1540	243	2	5	5	NUM
dpc-1540	243	3	m	m	NOUN
dpc-1540	243	4	s	s	PART
dpc-1540	243	5	(	(	PUNCT
dpc-1540	243	6	0	0	NUM
dpc-1540	243	7	.0	.0	NUM
dpc-1540	243	8	1	1	NUM
dpc-1540	243	9	)	)	PUNCT
dpc-1540	243	10	(	(	PUNCT
dpc-1540	243	11	0	0	NUM
dpc-1540	243	12	.0	.0	NUM
dpc-1540	243	13	03	03	NUM
dpc-1540	243	14	)	)	PUNCT
dpc-1540	243	15	(	(	PUNCT
dpc-1540	243	16	0	0	NUM
dpc-1540	243	17	.0	.0	NUM
dpc-1540	243	18	00	00	NUM
dpc-1540	243	19	1	1	NUM
dpc-1540	243	20	)	)	PUNCT
dpc-1540	243	21	(	(	PUNCT
dpc-1540	243	22	0	0	NUM
dpc-1540	243	23	.0	.0	NUM
dpc-1540	243	24	1	1	NUM
dpc-1540	243	25	)	)	PUNCT
dpc-1540	243	26	(	(	PUNCT
dpc-1540	243	27	0	0	NUM
dpc-1540	243	28	.0	.0	NUM
dpc-1540	243	29	03	03	NUM
dpc-1540	243	30	)	)	PUNCT
dpc-1540	244	1	(	(	PUNCT
dpc-1540	244	2	0	0	NUM
dpc-1540	244	3	.0	.0	NUM
dpc-1540	244	4	00	00	NUM
dpc-1540	244	5	1	1	NUM
dpc-1540	244	6	)	)	PUNCT
dpc-1540	244	7	(	(	PUNCT
dpc-1540	244	8	0	0	NUM
dpc-1540	244	9	.0	.0	NUM
dpc-1540	244	10	00	00	NUM
dpc-1540	244	11	1	1	NUM
dpc-1540	244	12	)	)	PUNCT
dpc-1540	244	13	(	(	PUNCT
dpc-1540	244	14	0	0	NUM
dpc-1540	244	15	.0	.0	NUM
dpc-1540	244	16	48	48	NUM
dpc-1540	244	17	)	)	PUNCT
dpc-1540	244	18	(	(	PUNCT
dpc-1540	244	19	0	0	NUM
dpc-1540	244	20	.6	.6	NUM
dpc-1540	244	21	84	84	NUM
dpc-1540	244	22	)	)	PUNCT
dpc-1540	244	23	0	0	NUM
dpc-1540	244	24	.	.	X
dpc-1540	245	1	03	03	NUM
dpc-1540	245	2	4	4	NUM
dpc-1540	245	3	)	)	PUNCT
dpc-1540	245	4	(	(	PUNCT
dpc-1540	245	5	0	0	NUM
dpc-1540	245	6	.9	.9	NUM
dpc-1540	245	7	41	41	NUM
dpc-1540	245	8	)	)	PUNCT
dpc-1540	245	9	(	(	PUNCT
dpc-1540	245	10	0	0	NUM
dpc-1540	245	11	.7	.7	NUM
dpc-1540	245	12	96	96	NUM
dpc-1540	245	13	)	)	PUNCT
dpc-1540	245	14	1	1	NUM
dpc-1540	245	15	0	0	NUM
dpc-1540	245	16	.	.	NOUN
dpc-1540	245	17	21	21	NUM
dpc-1540	245	18	3	3	NUM
dpc-1540	245	19	0	0	NUM
dpc-1540	245	20	.	.	PUNCT
dpc-1540	246	1	08	08	NUM
dpc-1540	246	2	5	5	NUM
dpc-1540	246	3	0	0	NUM
dpc-1540	246	4	.	.	NUM
dpc-1540	246	5	06	06	NUM
dpc-1540	247	1	-0	-0	PUNCT
dpc-1540	247	2	.1	.1	NUM
dpc-1540	247	3	39	39	NUM
dpc-1540	247	4	0	0	NUM
dpc-1540	247	5	.	.	PUNCT
dpc-1540	248	1	12	12	NUM
dpc-1540	248	2	7	7	NUM
dpc-1540	248	3	0	0	NUM
dpc-1540	248	4	.	.	PUNCT
dpc-1540	248	5	21	21	NUM
dpc-1540	248	6	2	2	NUM
dpc-1540	248	7	-0	-0	SYM
dpc-1540	248	8	.0	.0	NUM
dpc-1540	248	9	81	81	NUM
dpc-1540	248	10	0	0	NUM
dpc-1540	248	11	.	.	PUNCT
dpc-1540	248	12	04	04	NUM
dpc-1540	248	13	2	2	NUM
dpc-1540	248	14	0	0	NUM
dpc-1540	248	15	.	.	PUNCT
dpc-1540	248	16	18	18	NUM
dpc-1540	248	17	0	0	NUM
dpc-1540	248	18	.	.	PUNCT
dpc-1540	248	19	00	00	NUM
dpc-1540	249	1	2	2	NUM
dpc-1540	249	2	0	0	NUM
dpc-1540	249	3	.	.	PUNCT
dpc-1540	250	1	10	10	NUM
dpc-1540	250	2	5	5	NUM
dpc-1540	250	3	d	d	NOUN
dpc-1540	250	4	is	be	AUX
dpc-1540	250	5	ea	ea	X
dpc-1540	250	6	se	se	X
dpc-1540	250	7	(	(	PUNCT
dpc-1540	250	8	0	0	NUM
dpc-1540	250	9	.0	.0	NUM
dpc-1540	250	10	24	24	NUM
dpc-1540	250	11	)	)	PUNCT
dpc-1540	250	12	(	(	PUNCT
dpc-1540	250	13	0	0	NUM
dpc-1540	250	14	.3	.3	NUM
dpc-1540	250	15	73	73	NUM
dpc-1540	250	16	)	)	PUNCT
dpc-1540	250	17	(	(	PUNCT
dpc-1540	250	18	0	0	NUM
dpc-1540	250	19	.5	.5	NUM
dpc-1540	250	20	3	3	NUM
dpc-1540	250	21	)	)	PUNCT
dpc-1540	250	22	(	(	PUNCT
dpc-1540	250	23	0	0	NUM
dpc-1540	250	24	.1	.1	NUM
dpc-1540	250	25	44	44	NUM
dpc-1540	250	26	)	)	PUNCT
dpc-1540	250	27	(	(	PUNCT
dpc-1540	250	28	0	0	NUM
dpc-1540	250	29	.1	.1	NUM
dpc-1540	250	30	82	82	NUM
dpc-1540	250	31	)	)	PUNCT
dpc-1540	250	32	(	(	PUNCT
dpc-1540	250	33	0	0	NUM
dpc-1540	250	34	.0	.0	NUM
dpc-1540	250	35	25	25	NUM
dpc-1540	250	36	)	)	PUNCT
dpc-1540	250	37	(	(	PUNCT
dpc-1540	250	38	0	0	NUM
dpc-1540	250	39	.3	.3	NUM
dpc-1540	250	40	95	95	NUM
dpc-1540	250	41	)	)	PUNCT
dpc-1540	250	42	(	(	PUNCT
dpc-1540	250	43	0	0	NUM
dpc-1540	250	44	.6	.6	NUM
dpc-1540	250	45	6	6	NUM
dpc-1540	250	46	)	)	PUNCT
dpc-1540	250	47	(	(	PUNCT
dpc-1540	250	48	0	0	NUM
dpc-1540	250	49	.0	.0	NUM
dpc-1540	250	50	57	57	NUM
dpc-1540	250	51	)	)	PUNCT
dpc-1540	250	52	(	(	PUNCT
dpc-1540	250	53	0	0	NUM
dpc-1540	250	54	.9	.9	NUM
dpc-1540	250	55	84	84	NUM
dpc-1540	250	56	)	)	PUNCT
dpc-1540	250	57	(	(	PUNCT
dpc-1540	250	58	0	0	NUM
dpc-1540	250	59	.2	.2	NUM
dpc-1540	250	60	69	69	NUM
dpc-1540	250	61	)	)	PUNCT
dpc-1540	250	62	du	du	PROPN
dpc-1540	250	63	ra	ra	PROPN
dpc-1540	250	64	ti	ti	NOUN
dpc-1540	250	65	on	on	ADP
dpc-1540	250	66	1	1	NUM
dpc-1540	250	67	0	0	NUM
dpc-1540	250	68	.	.	PUNCT
dpc-1540	251	1	44	44	NUM
dpc-1540	251	2	7	7	NUM
dpc-1540	251	3	0	0	NUM
dpc-1540	251	4	.	.	NOUN
dpc-1540	251	5	09	09	NUM
dpc-1540	251	6	6	6	NUM
dpc-1540	251	7	0	0	NUM
dpc-1540	251	8	.	.	PUNCT
dpc-1540	252	1	03	03	NUM
dpc-1540	252	2	1	1	NUM
dpc-1540	252	3	0	0	NUM
dpc-1540	252	4	.	.	PUNCT
dpc-1540	252	5	21	21	NUM
dpc-1540	252	6	9	9	NUM
dpc-1540	252	7	0	0	NUM
dpc-1540	252	8	.	.	NOUN
dpc-1540	253	1	04	04	NUM
dpc-1540	253	2	0	0	NUM
dpc-1540	253	3	.	.	PUNCT
dpc-1540	254	1	10	10	NUM
dpc-1540	254	2	3	3	NUM
dpc-1540	254	3	0	0	NUM
dpc-1540	254	4	.	.	PUNCT
dpc-1540	255	1	01	01	NUM
dpc-1540	255	2	2	2	NUM
dpc-1540	255	3	0	0	NUM
dpc-1540	255	4	.	.	PUNCT
dpc-1540	256	1	05	05	NUM
dpc-1540	257	1	3	3	NUM
dpc-1540	257	2	0	0	NUM
dpc-1540	257	3	.	.	NOUN
dpc-1540	257	4	04	04	NUM
dpc-1540	258	1	2	2	NUM
dpc-1540	258	2	-0	-0	SYM
dpc-1540	258	3	.0	.0	NUM
dpc-1540	258	4	57	57	NUM
dpc-1540	259	1	b	b	NOUN
dpc-1540	259	2	m	m	VERB
dpc-1540	259	3	i	i	NOUN
dpc-1540	259	4	(	(	PUNCT
dpc-1540	259	5	0	0	NUM
dpc-1540	259	6	.0	.0	NUM
dpc-1540	259	7	00	00	NUM
dpc-1540	259	8	1	1	NUM
dpc-1540	259	9	)	)	PUNCT
dpc-1540	259	10	(	(	PUNCT
dpc-1540	259	11	0	0	NUM
dpc-1540	259	12	.3	.3	NUM
dpc-1540	259	13	14	14	NUM
dpc-1540	259	14	)	)	PUNCT
dpc-1540	259	15	(	(	PUNCT
dpc-1540	259	16	0	0	NUM
dpc-1540	259	17	.7	.7	NUM
dpc-1540	259	18	43	43	NUM
dpc-1540	259	19	)	)	PUNCT
dpc-1540	259	20	(	(	PUNCT
dpc-1540	259	21	0	0	NUM
dpc-1540	259	22	.0	.0	NUM
dpc-1540	259	23	21	21	NUM
dpc-1540	259	24	)	)	PUNCT
dpc-1540	259	25	(	(	PUNCT
dpc-1540	259	26	0	0	NUM
dpc-1540	259	27	.6	.6	NUM
dpc-1540	259	28	75	75	NUM
dpc-1540	259	29	)	)	PUNCT
dpc-1540	259	30	(	(	PUNCT
dpc-1540	259	31	0	0	NUM
dpc-1540	259	32	.2	.2	NUM
dpc-1540	259	33	81	81	NUM
dpc-1540	259	34	)	)	PUNCT
dpc-1540	259	35	(	(	PUNCT
dpc-1540	259	36	0	0	NUM
dpc-1540	259	37	.9	.9	NUM
dpc-1540	259	38	02	02	NUM
dpc-1540	259	39	)	)	PUNCT
dpc-1540	259	40	(	(	PUNCT
dpc-1540	259	41	0	0	NUM
dpc-1540	259	42	.5	.5	NUM
dpc-1540	259	43	76	76	NUM
dpc-1540	259	44	)	)	PUNCT
dpc-1540	259	45	(	(	PUNCT
dpc-1540	259	46	0	0	NUM
dpc-1540	259	47	.6	.6	NUM
dpc-1540	259	48	59	59	NUM
dpc-1540	259	49	)	)	PUNCT
dpc-1540	259	50	(	(	PUNCT
dpc-1540	259	51	0	0	NUM
dpc-1540	259	52	.5	.5	NUM
dpc-1540	259	53	54	54	NUM
dpc-1540	259	54	)	)	PUNCT
dpc-1540	259	55	1	1	NUM
dpc-1540	259	56	0	0	NUM
dpc-1540	259	57	.	.	X
dpc-1540	259	58	08	08	NUM
dpc-1540	259	59	5	5	NUM
dpc-1540	259	60	-0	-0	SYM
dpc-1540	259	61	.0	.0	NUM
dpc-1540	259	62	22	22	NUM
dpc-1540	259	63	0	0	NUM
dpc-1540	259	64	.	.	PUNCT
dpc-1540	259	65	18	18	NUM
dpc-1540	259	66	4	4	NUM
dpc-1540	259	67	0	0	NUM
dpc-1540	259	68	.	.	NOUN
dpc-1540	259	69	13	13	NUM
dpc-1540	259	70	5	5	NUM
dpc-1540	259	71	0	0	NUM
dpc-1540	259	72	.	.	PUNCT
dpc-1540	260	1	05	05	NUM
dpc-1540	260	2	2	2	NUM
dpc-1540	260	3	-0	-0	SYM
dpc-1540	260	4	.0	.0	NUM
dpc-1540	260	5	17	17	NUM
dpc-1540	260	6	0	0	NUM
dpc-1540	260	7	.	.	PROPN
dpc-1540	260	8	2	2	NUM
dpc-1540	260	9	-0	-0	SYM
dpc-1540	260	10	.0	.0	NUM
dpc-1540	260	11	35	35	NUM
dpc-1540	260	12	-0	-0	SYM
dpc-1540	260	13	.0	.0	NUM
dpc-1540	260	14	82	82	NUM
dpc-1540	260	15	w	w	NOUN
dpc-1540	260	16	ai	ai	PROPN
dpc-1540	260	17	st	st	PROPN
dpc-1540	260	18	(	(	PUNCT
dpc-1540	260	19	0	0	NUM
dpc-1540	260	20	.3	.3	NUM
dpc-1540	260	21	73	73	NUM
dpc-1540	260	22	)	)	PUNCT
dpc-1540	260	23	(	(	PUNCT
dpc-1540	260	24	0	0	NUM
dpc-1540	260	25	.8	.8	NUM
dpc-1540	260	26	14	14	NUM
dpc-1540	260	27	)	)	PUNCT
dpc-1540	260	28	(	(	PUNCT
dpc-1540	260	29	0	0	NUM
dpc-1540	260	30	.0	.0	NUM
dpc-1540	260	31	52	52	NUM
dpc-1540	260	32	)	)	PUNCT
dpc-1540	260	33	(	(	PUNCT
dpc-1540	260	34	0	0	NUM
dpc-1540	260	35	.1	.1	NUM
dpc-1540	260	36	55	55	NUM
dpc-1540	260	37	)	)	PUNCT
dpc-1540	260	38	(	(	PUNCT
dpc-1540	260	39	0	0	NUM
dpc-1540	260	40	.5	.5	NUM
dpc-1540	260	41	89	89	NUM
dpc-1540	260	42	)	)	PUNCT
dpc-1540	260	43	(	(	PUNCT
dpc-1540	260	44	0	0	NUM
dpc-1540	260	45	.8	.8	NUM
dpc-1540	260	46	6	6	NUM
dpc-1540	260	47	)	)	PUNCT
dpc-1540	260	48	(	(	PUNCT
dpc-1540	260	49	0	0	NUM
dpc-1540	260	50	.0	.0	NUM
dpc-1540	260	51	34	34	NUM
dpc-1540	260	52	)	)	PUNCT
dpc-1540	260	53	(	(	PUNCT
dpc-1540	260	54	0	0	NUM
dpc-1540	260	55	.7	.7	PROPN
dpc-1540	260	56	13	13	NUM
dpc-1540	260	57	)	)	PUNCT
dpc-1540	260	58	(	(	PUNCT
dpc-1540	260	59	0	0	NUM
dpc-1540	260	60	.3	.3	NUM
dpc-1540	260	61	88	88	NUM
dpc-1540	260	62	)	)	PUNCT
dpc-1540	260	63	ci	ci	PROPN
dpc-1540	260	64	rc	rc	PROPN
dpc-1540	260	65	um	um	INTJ
dpc-1540	260	66	fe	fe	X
dpc-1540	260	67	re	re	X
dpc-1540	260	68	nc	nc	PROPN
dpc-1540	260	69	e	e	PROPN
dpc-1540	260	70	1	1	NUM
dpc-1540	260	71	-0	-0	SYM
dpc-1540	260	72	.0	.0	NUM
dpc-1540	260	73	63	63	NUM
dpc-1540	260	74	0	0	NUM
dpc-1540	260	75	.	.	NOUN
dpc-1540	260	76	15	15	NUM
dpc-1540	260	77	2	2	NUM
dpc-1540	260	78	0	0	NUM
dpc-1540	260	79	.	.	PUNCT
dpc-1540	260	80	18	18	NUM
dpc-1540	260	81	0	0	NUM
dpc-1540	260	82	.	.	PUNCT
dpc-1540	260	83	23	23	NUM
dpc-1540	260	84	5	5	NUM
dpc-1540	260	85	0	0	NUM
dpc-1540	260	86	.	.	NOUN
dpc-1540	260	87	15	15	NUM
dpc-1540	260	88	8	8	NUM
dpc-1540	260	89	0	0	NUM
dpc-1540	260	90	.	.	NOUN
dpc-1540	260	91	15	15	NUM
dpc-1540	260	92	2	2	NUM
dpc-1540	260	93	0	0	NUM
dpc-1540	260	94	.	.	NOUN
dpc-1540	260	95	04	04	NUM
dpc-1540	260	96	3	3	NUM
dpc-1540	260	97	0	0	NUM
dpc-1540	260	98	.	.	NOUN
dpc-1540	260	99	04	04	NUM
dpc-1540	260	100	6	6	NUM
dpc-1540	260	101	t	t	NOUN
dpc-1540	260	102	ri	ri	NOUN
dpc-1540	260	103	gl	gl	INTJ
dpc-1540	261	1	yc	yc	INTJ
dpc-1540	261	2	er	er	INTJ
dpc-1540	261	3	i	i	PROPN
dpc-1540	261	4	d	d	PROPN
dpc-1540	261	5	e	e	X
dpc-1540	261	6	(	(	PUNCT
dpc-1540	261	7	0	0	NUM
dpc-1540	261	8	.5	.5	NUM
dpc-1540	261	9	12	12	NUM
dpc-1540	261	10	)	)	PUNCT
dpc-1540	261	11	(	(	PUNCT
dpc-1540	261	12	0	0	NUM
dpc-1540	261	13	.1	.1	NUM
dpc-1540	261	14	09	09	NUM
dpc-1540	261	15	)	)	PUNCT
dpc-1540	261	16	(	(	PUNCT
dpc-1540	261	17	0	0	NUM
dpc-1540	261	18	.0	.0	NUM
dpc-1540	261	19	58	58	NUM
dpc-1540	261	20	)	)	PUNCT
dpc-1540	261	21	(	(	PUNCT
dpc-1540	261	22	0	0	NUM
dpc-1540	261	23	.0	.0	NUM
dpc-1540	261	24	13	13	NUM
dpc-1540	261	25	)	)	PUNCT
dpc-1540	261	26	(	(	PUNCT
dpc-1540	261	27	0	0	NUM
dpc-1540	261	28	.0	.0	NUM
dpc-1540	261	29	96	96	NUM
dpc-1540	261	30	)	)	PUNCT
dpc-1540	261	31	(	(	PUNCT
dpc-1540	261	32	0	0	NUM
dpc-1540	261	33	.1	.1	NUM
dpc-1540	261	34	1	1	NUM
dpc-1540	261	35	)	)	PUNCT
dpc-1540	261	36	(	(	PUNCT
dpc-1540	261	37	0	0	NUM
dpc-1540	261	38	.6	.6	NUM
dpc-1540	261	39	51	51	NUM
dpc-1540	261	40	)	)	PUNCT
dpc-1540	261	41	(	(	PUNCT
dpc-1540	261	42	0	0	NUM
dpc-1540	261	43	.6	.6	NUM
dpc-1540	261	44	28	28	NUM
dpc-1540	261	45	)	)	PUNCT
dpc-1540	261	46	1	1	NUM
dpc-1540	261	47	-0	-0	SYM
dpc-1540	261	48	.1	.1	NUM
dpc-1540	261	49	18	18	NUM
dpc-1540	261	50	-0	-0	SYM
dpc-1540	261	51	.1	.1	NUM
dpc-1540	261	52	54	54	NUM
dpc-1540	261	53	0	0	NUM
dpc-1540	261	54	.	.	PUNCT
dpc-1540	262	1	03	03	NUM
dpc-1540	262	2	1	1	NUM
dpc-1540	262	3	0	0	NUM
dpc-1540	262	4	.	.	NOUN
dpc-1540	262	5	20	20	NUM
dpc-1540	262	6	4	4	NUM
dpc-1540	262	7	0	0	NUM
dpc-1540	262	8	.	.	PUNCT
dpc-1540	262	9	12	12	NUM
dpc-1540	262	10	2	2	NUM
dpc-1540	262	11	0	0	NUM
dpc-1540	262	12	.	.	NOUN
dpc-1540	262	13	08	08	NUM
dpc-1540	262	14	6	6	NUM
dpc-1540	262	15	-0	-0	SYM
dpc-1540	262	16	.0	.0	NUM
dpc-1540	262	17	69	69	NUM
dpc-1540	262	18	h	h	NOUN
dpc-1540	263	1	d	d	NOUN
dpc-1540	263	2	l	l	NOUN
dpc-1540	263	3	(	(	PUNCT
dpc-1540	263	4	0	0	NUM
dpc-1540	263	5	.2	.2	NUM
dpc-1540	263	6	16	16	NUM
dpc-1540	263	7	)	)	PUNCT
dpc-1540	263	8	(	(	PUNCT
dpc-1540	263	9	0	0	NUM
dpc-1540	263	10	.1	.1	NUM
dpc-1540	263	11	06	06	NUM
dpc-1540	263	12	)	)	PUNCT
dpc-1540	263	13	(	(	PUNCT
dpc-1540	263	14	0	0	NUM
dpc-1540	263	15	.7	.7	NUM
dpc-1540	263	16	46	46	NUM
dpc-1540	263	17	)	)	PUNCT
dpc-1540	263	18	(	(	PUNCT
dpc-1540	263	19	0	0	NUM
dpc-1540	263	20	.0	.0	NUM
dpc-1540	263	21	31	31	NUM
dpc-1540	263	22	)	)	PUNCT
dpc-1540	263	23	(	(	PUNCT
dpc-1540	263	24	0	0	NUM
dpc-1540	263	25	.2	.2	NUM
dpc-1540	263	26	02	02	NUM
dpc-1540	263	27	)	)	PUNCT
dpc-1540	263	28	(	(	PUNCT
dpc-1540	263	29	0	0	NUM
dpc-1540	263	30	.3	.3	NUM
dpc-1540	263	31	69	69	NUM
dpc-1540	263	32	)	)	PUNCT
dpc-1540	263	33	(	(	PUNCT
dpc-1540	263	34	0	0	NUM
dpc-1540	263	35	.4	.4	NUM
dpc-1540	263	36	68	68	NUM
dpc-1540	263	37	)	)	PUNCT
dpc-1540	263	38	1	1	NUM
dpc-1540	263	39	0	0	NUM
dpc-1540	263	40	.	.	PUNCT
dpc-1540	263	41	00	00	NUM
dpc-1540	263	42	4	4	NUM
dpc-1540	263	43	0	0	NUM
dpc-1540	263	44	.	.	NOUN
dpc-1540	263	45	20	20	NUM
dpc-1540	263	46	6	6	NUM
dpc-1540	263	47	0	0	NUM
dpc-1540	263	48	.	.	NOUN
dpc-1540	263	49	15	15	NUM
dpc-1540	263	50	-0	-0	SYM
dpc-1540	263	51	.0	.0	NUM
dpc-1540	263	52	31	31	NUM
dpc-1540	263	53	0	0	NUM
dpc-1540	263	54	.	.	PUNCT
dpc-1540	263	55	04	04	NUM
dpc-1540	263	56	4	4	NUM
dpc-1540	263	57	0	0	NUM
dpc-1540	263	58	.	.	NOUN
dpc-1540	263	59	06	06	NUM
dpc-1540	263	60	2	2	NUM
dpc-1540	263	61	b	b	X
dpc-1540	263	62	lo	lo	PROPN
dpc-1540	263	63	od	od	PROPN
dpc-1540	263	64	(	(	PUNCT
dpc-1540	263	65	0	0	NUM
dpc-1540	263	66	.9	.9	NUM
dpc-1540	263	67	68	68	NUM
dpc-1540	263	68	)	)	PUNCT
dpc-1540	263	69	(	(	PUNCT
dpc-1540	263	70	0	0	NUM
dpc-1540	263	71	.0	.0	NUM
dpc-1540	263	72	3	3	NUM
dpc-1540	263	73	)	)	PUNCT
dpc-1540	263	74	(	(	PUNCT
dpc-1540	263	75	0	0	NUM
dpc-1540	263	76	.1	.1	NUM
dpc-1540	263	77	15	15	NUM
dpc-1540	263	78	)	)	PUNCT
dpc-1540	263	79	(	(	PUNCT
dpc-1540	263	80	0	0	NUM
dpc-1540	263	81	.7	.7	NUM
dpc-1540	263	82	46	46	NUM
dpc-1540	263	83	)	)	PUNCT
dpc-1540	263	84	(	(	PUNCT
dpc-1540	263	85	0	0	NUM
dpc-1540	263	86	.6	.6	NUM
dpc-1540	263	87	43	43	NUM
dpc-1540	263	88	)	)	PUNCT
dpc-1540	263	89	(	(	PUNCT
dpc-1540	263	90	0	0	NUM
dpc-1540	263	91	.5	.5	NUM
dpc-1540	263	92	15	15	NUM
dpc-1540	263	93	)	)	PUNCT
dpc-1540	263	94	pr	pr	NOUN
dpc-1540	263	95	es	es	X
dpc-1540	263	96	su	su	PROPN
dpc-1540	263	97	re	re	PROPN
dpc-1540	263	98	1	1	NUM
dpc-1540	263	99	0	0	NUM
dpc-1540	263	100	.	.	PUNCT
dpc-1540	263	101	19	19	NUM
dpc-1540	263	102	9	9	NUM
dpc-1540	263	103	0	0	NUM
dpc-1540	263	104	.	.	PUNCT
dpc-1540	263	105	18	18	NUM
dpc-1540	263	106	7	7	NUM
dpc-1540	263	107	0	0	NUM
dpc-1540	263	108	.	.	PUNCT
dpc-1540	263	109	26	26	NUM
dpc-1540	263	110	5	5	NUM
dpc-1540	263	111	-0	-0	SYM
dpc-1540	263	112	.0	.0	NUM
dpc-1540	263	113	02	02	NUM
dpc-1540	263	114	-0	-0	SYM
dpc-1540	263	115	.0	.0	NUM
dpc-1540	263	116	57	57	NUM
dpc-1540	263	117	fa	fa	PROPN
dpc-1540	263	118	st	st	PROPN
dpc-1540	263	119	in	in	ADP
dpc-1540	263	120	g	g	PROPN
dpc-1540	263	121	(	(	PUNCT
dpc-1540	263	122	0	0	NUM
dpc-1540	263	123	.0	.0	NUM
dpc-1540	263	124	35	35	NUM
dpc-1540	263	125	)	)	PUNCT
dpc-1540	263	126	0	0	NUM
dpc-1540	263	127	.	.	X
dpc-1540	263	128	04	04	NUM
dpc-1540	263	129	8)	8)	NUM
dpc-1540	263	130	(	(	PUNCT
dpc-1540	263	131	0	0	NUM
dpc-1540	263	132	.0	.0	NUM
dpc-1540	263	133	05	05	NUM
dpc-1540	263	134	)	)	PUNCT
dpc-1540	264	1	(	(	PUNCT
dpc-1540	264	2	0	0	NUM
dpc-1540	264	3	.9	.9	NUM
dpc-1540	264	4	86	86	NUM
dpc-1540	264	5	)	)	PUNCT
dpc-1540	264	6	(	(	PUNCT
dpc-1540	264	7	0	0	NUM
dpc-1540	264	8	.5	.5	NUM
dpc-1540	264	9	49	49	NUM
dpc-1540	264	10	)	)	PUNCT
dpc-1540	264	11	gl	gl	INTJ
dpc-1540	265	1	uc	uc	INTJ
dpc-1540	265	2	os	os	PROPN
dpc-1540	265	3	e	e	PROPN
dpc-1540	265	4	1	1	NUM
dpc-1540	265	5	-0	-0	SYM
dpc-1540	265	6	.0	.0	NUM
dpc-1540	265	7	09	09	NUM
dpc-1540	265	8	0	0	NUM
dpc-1540	265	9	.	.	PUNCT
dpc-1540	266	1	01	01	NUM
dpc-1540	266	2	3	3	NUM
dpc-1540	266	3	0	0	NUM
dpc-1540	266	4	.	.	PUNCT
dpc-1540	267	1	18	18	NUM
dpc-1540	267	2	0	0	NUM
dpc-1540	267	3	.	.	NOUN
dpc-1540	267	4	04	04	NUM
dpc-1540	268	1	1	1	NUM
dpc-1540	268	2	h	h	NOUN
dpc-1540	269	1	o	o	NOUN
dpc-1540	269	2	m	m	VERB
dpc-1540	269	3	a	a	DET
dpc-1540	269	4	-i	-i	PUNCT
dpc-1540	269	5	r	r	NOUN
dpc-1540	269	6	(	(	PUNCT
dpc-1540	269	7	0	0	NUM
dpc-1540	269	8	.9	.9	NUM
dpc-1540	269	9	26	26	NUM
dpc-1540	269	10	)	)	PUNCT
dpc-1540	269	11	(	(	PUNCT
dpc-1540	269	12	0	0	NUM
dpc-1540	269	13	.8	.8	PROPN
dpc-1540	269	14	93	93	NUM
dpc-1540	269	15	)	)	PUNCT
dpc-1540	269	16	(	(	PUNCT
dpc-1540	269	17	0	0	NUM
dpc-1540	269	18	.0	.0	NUM
dpc-1540	269	19	57	57	NUM
dpc-1540	269	20	)	)	PUNCT
dpc-1540	269	21	(	(	PUNCT
dpc-1540	269	22	0	0	NUM
dpc-1540	269	23	.6	.6	NUM
dpc-1540	269	24	71	71	NUM
dpc-1540	269	25	)	)	PUNCT
dpc-1540	269	26	1	1	NUM
dpc-1540	269	27	0	0	NUM
dpc-1540	269	28	.	.	NOUN
dpc-1540	269	29	29	29	NUM
dpc-1540	269	30	8	8	NUM
dpc-1540	269	31	-0	-0	SYM
dpc-1540	269	32	.0	.0	NUM
dpc-1540	269	33	46	46	NUM
dpc-1540	269	34	0	0	NUM
dpc-1540	269	35	.	.	PUNCT
dpc-1540	270	1	07	07	NUM
dpc-1540	270	2	3	3	NUM
dpc-1540	270	3	pa	pa	PROPN
dpc-1540	270	4	si	si	X
dpc-1540	270	5	(	(	PUNCT
dpc-1540	270	6	0	0	NUM
dpc-1540	270	7	.0	.0	NUM
dpc-1540	270	8	01	01	NUM
dpc-1540	270	9	)	)	PUNCT
dpc-1540	270	10	(	(	PUNCT
dpc-1540	270	11	0	0	NUM
dpc-1540	270	12	.6	.6	NUM
dpc-1540	270	13	32	32	NUM
dpc-1540	270	14	)	)	PUNCT
dpc-1540	270	15	(	(	PUNCT
dpc-1540	270	16	0	0	NUM
dpc-1540	270	17	.4	.4	NUM
dpc-1540	270	18	43	43	NUM
dpc-1540	270	19	)	)	PUNCT
dpc-1540	270	20	1	1	NUM
dpc-1540	270	21	0	0	NUM
dpc-1540	270	22	.	.	PUNCT
dpc-1540	270	23	00	00	NUM
dpc-1540	270	24	4	4	NUM
dpc-1540	270	25	0	0	NUM
dpc-1540	270	26	.	.	NOUN
dpc-1540	270	27	04	04	NUM
dpc-1540	270	28	2	2	NUM
dpc-1540	270	29	ps	ps	INTJ
dpc-1540	270	30	q	q	PROPN
dpc-1540	270	31	i	i	NOUN
dpc-1540	270	32	(	(	PUNCT
dpc-1540	270	33	0	0	NUM
dpc-1540	270	34	.9	.9	NUM
dpc-1540	270	35	67	67	NUM
dpc-1540	270	36	)	)	PUNCT
dpc-1540	270	37	(	(	PUNCT
dpc-1540	270	38	0	0	NUM
dpc-1540	270	39	.6	.6	NUM
dpc-1540	270	40	62	62	NUM
dpc-1540	270	41	)	)	PUNCT
dpc-1540	270	42	1	1	NUM
dpc-1540	270	43	0	0	NUM
dpc-1540	270	44	.	.	X
dpc-1540	271	1	43	43	NUM
dpc-1540	271	2	4	4	NUM
dpc-1540	271	3	sm	sm	INTJ
dpc-1540	271	4	ok	ok	INTJ
dpc-1540	271	5	in	in	ADP
dpc-1540	271	6	g	g	PROPN
dpc-1540	271	7	(	(	PUNCT
dpc-1540	271	8	0	0	NUM
dpc-1540	271	9	.0	.0	NUM
dpc-1540	271	10	00	00	NUM
dpc-1540	271	11	1	1	X
dpc-1540	271	12	)	)	PUNCT
dpc-1540	272	1	ha	ha	INTJ
dpc-1540	273	1	bi	bi	PROPN
dpc-1540	273	2	t	t	PROPN
dpc-1540	273	3	1	1	NUM
dpc-1540	273	4	a	a	DET
dpc-1540	273	5	lc	lc	NOUN
dpc-1540	273	6	oh	oh	INTJ
dpc-1540	273	7	ol	ol	INTJ
dpc-1540	273	8	co	co	X
dpc-1540	273	9	ns	ns	PROPN
dpc-1540	273	10	um	um	INTJ
dpc-1540	273	11	pt	pt	X
dpc-1540	273	12	io	io	PROPN
dpc-1540	273	13	n	n	PROPN
dpc-1540	273	14	b	b	PROPN
dpc-1540	273	15	m	m	VERB
dpc-1540	274	1	i	i	NOUN
dpc-1540	274	2	=	=	PUNCT
dpc-1540	274	3	bo	bo	PROPN
dpc-1540	274	4	dy	dy	X
dpc-1540	274	5	m	m	NOUN
dpc-1540	274	6	as	as	ADP
dpc-1540	274	7	s	s	PRON
dpc-1540	274	8	in	in	ADP
dpc-1540	274	9	de	de	X
dpc-1540	274	10	x	x	PROPN
dpc-1540	274	11	;	;	PUNCT
dpc-1540	275	1	h	h	NOUN
dpc-1540	275	2	o	o	NOUN
dpc-1540	275	3	m	m	VERB
dpc-1540	275	4	a	a	DET
dpc-1540	275	5	-i	-i	PUNCT
dpc-1540	275	6	r	r	NOUN
dpc-1540	275	7	=	=	NOUN
dpc-1540	275	8	h	h	NOUN
dpc-1540	275	9	om	om	PROPN
dpc-1540	275	10	eo	eo	PROPN
dpc-1540	275	11	st	st	PROPN
dpc-1540	275	12	at	at	ADP
dpc-1540	275	13	ic	ic	PROPN
dpc-1540	275	14	m	m	PROPN
dpc-1540	275	15	od	od	PROPN
dpc-1540	275	16	el	el	PROPN
dpc-1540	276	1	a	a	PROPN
dpc-1540	276	2	ss	ss	NOUN
dpc-1540	276	3	es	es	X
dpc-1540	276	4	sm	sm	PROPN
dpc-1540	276	5	en	en	PROPN
dpc-1540	276	6	t	t	PROPN
dpc-1540	276	7	in	in	ADP
dpc-1540	276	8	su	su	PROPN
dpc-1540	276	9	lin	lin	PROPN
dpc-1540	276	10	r	r	PROPN
dpc-1540	276	11	es	es	NOUN
dpc-1540	276	12	is	be	AUX
dpc-1540	276	13	ta	ta	PROPN
dpc-1540	276	14	nc	nc	PROPN
dpc-1540	276	15	e	e	PROPN
dpc-1540	276	16	;	;	PUNCT
dpc-1540	276	17	m	m	PROPN
dpc-1540	276	18	s	s	PART
dpc-1540	276	19	=	=	X
dpc-1540	276	20	m	m	VERB
dpc-1540	276	21	et	et	NOUN
dpc-1540	276	22	ab	ab	PROPN
dpc-1540	276	23	ol	ol	PROPN
dpc-1540	276	24	ic	ic	PROPN
dpc-1540	276	25	s	s	PROPN
dpc-1540	276	26	yn	yn	PROPN
dpc-1540	276	27	dr	dr	PROPN
dpc-1540	276	28	om	om	PROPN
dpc-1540	276	29	e	e	PROPN
dpc-1540	276	30	;	;	PUNCT
dpc-1540	276	31	p	p	X
dpc-1540	276	32	a	a	DET
dpc-1540	276	33	si	si	X
dpc-1540	276	34	=	=	SYM
dpc-1540	276	35	p	p	NOUN
dpc-1540	276	36	so	so	ADV
dpc-1540	276	37	ri	ri	PROPN
dpc-1540	276	38	as	as	SCONJ
dpc-1540	276	39	is	be	AUX
dpc-1540	276	40	a	a	PRON
dpc-1540	276	41	re	re	NOUN
dpc-1540	276	42	a	a	DET
dpc-1540	276	43	an	an	PROPN
dpc-1540	276	44	d	d	X
dpc-1540	276	45	se	se	X
dpc-1540	276	46	ve	ve	VERB
dpc-1540	276	47	ri	ri	INTJ
dpc-1540	277	1	ty	ty	INTJ
dpc-1540	277	2	i	i	PRON
dpc-1540	277	3	nd	nd	ADV
dpc-1540	277	4	ex	ex	NOUN
dpc-1540	277	5	;	;	PUNCT
dpc-1540	278	1	p	p	NOUN
dpc-1540	278	2	sq	sq	ADJ
dpc-1540	278	3	i	i	NOUN
dpc-1540	278	4	=	=	PROPN
dpc-1540	279	1	pi	pi	PROPN
dpc-1540	279	2	tt	tt	PROPN
dpc-1540	279	3	sb	sb	PROPN
dpc-1540	280	1	ur	ur	INTJ
dpc-1540	280	2	gh	gh	PROPN
dpc-1540	280	3	s	s	PROPN
dpc-1540	280	4	le	le	X
dpc-1540	280	5	ep	ep	PROPN
dpc-1540	280	6	q	q	PROPN
dpc-1540	280	7	ua	ua	PROPN
dpc-1540	280	8	lit	light	VERB
dpc-1540	280	9	y	y	PROPN
dpc-1540	280	10	in	in	ADP
dpc-1540	280	11	de	de	PROPN
dpc-1540	280	12	x.	x.	PROPN
dpc-1540	280	13	research	research	NOUN
dpc-1540	280	14	|	|	ADV
dpc-1540	280	15	dermatol	dermatol	ADJ
dpc-1540	280	16	pract	pract	NOUN
dpc-1540	280	17	concept	concept	NOUN
dpc-1540	280	18	.	.	PUNCT
dpc-1540	281	1	2021;11(3):e2021049	2021;11(3):e2021049	NUM
dpc-1540	281	2	9	9	NUM
dpc-1540	281	3	development	development	NOUN
dpc-1540	281	4	of	of	ADP
dpc-1540	281	5	ms	ms	PROPN
dpc-1540	281	6	in	in	ADP
dpc-1540	281	7	females	female	NOUN
dpc-1540	281	8	than	than	ADP
dpc-1540	281	9	in	in	ADP
dpc-1540	281	10	males	male	NOUN
dpc-1540	281	11	.	.	PUNCT
dpc-1540	282	1	considering	consider	VERB
dpc-1540	282	2	the	the	DET
dpc-1540	282	3	correlations	correlation	NOUN
dpc-1540	282	4	between	between	ADP
dpc-1540	282	5	the	the	DET
dpc-1540	282	6	presence	presence	NOUN
dpc-1540	282	7	of	of	ADP
dpc-1540	282	8	ms	ms	NOUN
dpc-1540	282	9	and	and	CCONJ
dpc-1540	282	10	study	study	NOUN
dpc-1540	282	11	parameters	parameter	NOUN
dpc-1540	282	12	,	,	PUNCT
dpc-1540	282	13	significant	significant	ADJ
dpc-1540	282	14	positives	positive	NOUN
dpc-1540	282	15	were	be	AUX
dpc-1540	282	16	detected	detect	VERB
dpc-1540	282	17	between	between	ADP
dpc-1540	282	18	the	the	DET
dpc-1540	282	19	presence	presence	NOUN
dpc-1540	282	20	of	of	ADP
dpc-1540	282	21	ms	ms	NOUN
dpc-1540	282	22	and	and	CCONJ
dpc-1540	282	23	waist	waist	NOUN
dpc-1540	282	24	circumference	circumference	NOUN
dpc-1540	282	25	,	,	PUNCT
dpc-1540	282	26	fasting	fast	VERB
dpc-1540	282	27	glucose	glucose	NOUN
dpc-1540	282	28	,	,	PUNCT
dpc-1540	282	29	high	high	ADJ
dpc-1540	282	30	blood	blood	NOUN
dpc-1540	282	31	pressure	pressure	NOUN
dpc-1540	282	32	,	,	PUNCT
dpc-1540	282	33	bmi	bmi	NOUN
dpc-1540	282	34	,	,	PUNCT
dpc-1540	282	35	psoriasis	psoriasis	NOUN
dpc-1540	282	36	duration	duration	NOUN
dpc-1540	282	37	,	,	PUNCT
dpc-1540	282	38	high	high	ADJ
dpc-1540	282	39	triglyceride	triglyceride	ADJ
dpc-1540	282	40	,	,	PUNCT
dpc-1540	282	41	poor	poor	ADJ
dpc-1540	282	42	sleep	sleep	NOUN
dpc-1540	282	43	quality	quality	NOUN
dpc-1540	282	44	,	,	PUNCT
dpc-1540	282	45	and	and	CCONJ
dpc-1540	282	46	high	high	ADJ
dpc-1540	282	47	homa	homa	NOUN
dpc-1540	282	48	-	-	PUNCT
dpc-1540	282	49	ir	ir	NOUN
dpc-1540	282	50	,	,	PUNCT
dpc-1540	282	51	whereas	whereas	SCONJ
dpc-1540	282	52	high	high	ADJ
dpc-1540	282	53	hdl	hdl	PROPN
dpc-1540	282	54	levels	level	NOUN
dpc-1540	282	55	were	be	AUX
dpc-1540	282	56	negatively	negatively	ADV
dpc-1540	282	57	correlated	correlate	VERB
dpc-1540	282	58	.	.	PUNCT
dpc-1540	283	1	when	when	SCONJ
dpc-1540	283	2	the	the	DET
dpc-1540	283	3	effects	effect	NOUN
dpc-1540	283	4	of	of	ADP
dpc-1540	283	5	correlative	correlative	ADJ
dpc-1540	283	6	factors	factor	NOUN
dpc-1540	283	7	were	be	AUX
dpc-1540	283	8	evaluated	evaluate	VERB
dpc-1540	283	9	with	with	ADP
dpc-1540	283	10	a	a	DET
dpc-1540	283	11	logistic	logistic	ADJ
dpc-1540	283	12	regression	regression	NOUN
dpc-1540	283	13	analysis	analysis	NOUN
dpc-1540	283	14	,	,	PUNCT
dpc-1540	283	15	only	only	ADV
dpc-1540	283	16	high	high	ADJ
dpc-1540	283	17	fasting	fasting	NOUN
dpc-1540	283	18	glucose	glucose	NOUN
dpc-1540	283	19	,	,	PUNCT
dpc-1540	283	20	low	low	ADJ
dpc-1540	283	21	hdl	hdl	PROPN
dpc-1540	283	22	,	,	PUNCT
dpc-1540	283	23	hypertension	hypertension	NOUN
dpc-1540	283	24	,	,	PUNCT
dpc-1540	283	25	and	and	CCONJ
dpc-1540	283	26	waist	waist	NOUN
dpc-1540	283	27	circumference	circumference	NOUN
dpc-1540	283	28	had	have	VERB
dpc-1540	283	29	predictive	predictive	ADJ
dpc-1540	283	30	effects	effect	NOUN
dpc-1540	283	31	on	on	ADP
dpc-1540	283	32	the	the	DET
dpc-1540	283	33	development	development	NOUN
dpc-1540	283	34	of	of	ADP
dpc-1540	283	35	ms	ms	PROPN
dpc-1540	283	36	.	.	PROPN
dpc-1540	284	1	the	the	DET
dpc-1540	284	2	present	present	ADJ
dpc-1540	284	3	study	study	NOUN
dpc-1540	284	4	is	be	AUX
dpc-1540	284	5	not	not	PART
dpc-1540	284	6	without	without	ADP
dpc-1540	284	7	limitations	limitation	NOUN
dpc-1540	284	8	.	.	PUNCT
dpc-1540	285	1	the	the	DET
dpc-1540	285	2	study	study	NOUN
dpc-1540	285	3	population	population	NOUN
dpc-1540	285	4	is	be	AUX
dpc-1540	285	5	relatively	relatively	ADV
dpc-1540	285	6	small	small	ADJ
dpc-1540	285	7	,	,	PUNCT
dpc-1540	285	8	and	and	CCONJ
dpc-1540	285	9	the	the	DET
dpc-1540	285	10	study	study	NOUN
dpc-1540	285	11	was	be	AUX
dpc-1540	285	12	done	do	VERB
dpc-1540	285	13	at	at	ADP
dpc-1540	285	14	only	only	ADV
dpc-1540	285	15	a	a	DET
dpc-1540	285	16	single	single	ADJ
dpc-1540	285	17	research	research	NOUN
dpc-1540	285	18	center	center	NOUN
dpc-1540	285	19	.	.	PUNCT
dpc-1540	286	1	moreover	moreover	ADV
dpc-1540	286	2	,	,	PUNCT
dpc-1540	286	3	a	a	DET
dpc-1540	286	4	relationship	relationship	NOUN
dpc-1540	286	5	between	between	ADP
dpc-1540	286	6	the	the	DET
dpc-1540	286	7	presence	presence	NOUN
dpc-1540	286	8	of	of	ADP
dpc-1540	286	9	ms	ms	NOUN
dpc-1540	286	10	and	and	CCONJ
dpc-1540	286	11	psoriasis	psoriasis	NOUN
dpc-1540	286	12	severity	severity	NOUN
dpc-1540	286	13	was	be	AUX
dpc-1540	286	14	not	not	PART
dpc-1540	286	15	established	establish	VERB
dpc-1540	286	16	,	,	PUNCT
dpc-1540	286	17	which	which	PRON
dpc-1540	286	18	may	may	AUX
dpc-1540	286	19	seem	seem	VERB
dpc-1540	286	20	contradictory	contradictory	ADJ
dpc-1540	286	21	to	to	ADP
dpc-1540	286	22	some	some	DET
dpc-1540	286	23	literature	literature	NOUN
dpc-1540	287	1	[	[	X
dpc-1540	287	2	11,21,29	11,21,29	NUM
dpc-1540	287	3	]	]	PUNCT
dpc-1540	287	4	.	.	PUNCT
dpc-1540	288	1	lastly	lastly	ADV
dpc-1540	288	2	,	,	PUNCT
dpc-1540	288	3	a	a	DET
dpc-1540	288	4	relative	relative	ADJ
dpc-1540	288	5	inequality	inequality	NOUN
dpc-1540	288	6	in	in	ADP
dpc-1540	288	7	the	the	DET
dpc-1540	288	8	gender	gender	NOUN
dpc-1540	288	9	of	of	ADP
dpc-1540	288	10	study	study	NOUN
dpc-1540	288	11	subjects	subject	NOUN
dpc-1540	288	12	can	can	AUX
dpc-1540	288	13	raise	raise	VERB
dpc-1540	288	14	concerns	concern	NOUN
dpc-1540	288	15	regarding	regard	VERB
dpc-1540	288	16	the	the	DET
dpc-1540	288	17	validity	validity	NOUN
dpc-1540	288	18	of	of	ADP
dpc-1540	288	19	our	our	PRON
dpc-1540	288	20	findings	finding	NOUN
dpc-1540	288	21	.	.	PUNCT
dpc-1540	289	1	however	however	ADV
dpc-1540	289	2	,	,	PUNCT
dpc-1540	289	3	we	we	PRON
dpc-1540	289	4	believe	believe	VERB
dpc-1540	289	5	that	that	SCONJ
dpc-1540	289	6	this	this	DET
dpc-1540	289	7	inequality	inequality	NOUN
dpc-1540	289	8	may	may	AUX
dpc-1540	289	9	in	in	ADP
dpc-1540	289	10	some	some	DET
dpc-1540	289	11	sense	sense	NOUN
dpc-1540	289	12	be	be	AUX
dpc-1540	289	13	valuable	valuable	ADJ
dpc-1540	289	14	in	in	ADP
dpc-1540	289	15	indicating	indicate	VERB
dpc-1540	289	16	real	real	ADJ
dpc-1540	289	17	predominance	predominance	NOUN
dpc-1540	289	18	of	of	ADP
dpc-1540	289	19	ms	ms	NOUN
dpc-1540	289	20	in	in	ADP
dpc-1540	289	21	females	female	NOUN
dpc-1540	289	22	with	with	ADP
dpc-1540	289	23	severe	severe	ADJ
dpc-1540	289	24	psoriasis	psoriasis	NOUN
dpc-1540	289	25	,	,	PUNCT
dpc-1540	289	26	although	although	SCONJ
dpc-1540	289	27	there	there	PRON
dpc-1540	289	28	was	be	VERB
dpc-1540	289	29	no	no	DET
dpc-1540	289	30	significant	significant	ADJ
dpc-1540	289	31	difference	difference	NOUN
dpc-1540	289	32	in	in	ADP
dpc-1540	289	33	the	the	DET
dpc-1540	289	34	presence	presence	NOUN
dpc-1540	289	35	of	of	ADP
dpc-1540	289	36	ms	ms	NOUN
dpc-1540	289	37	according	accord	VERB
dpc-1540	289	38	to	to	ADP
dpc-1540	289	39	gender	gender	NOUN
dpc-1540	289	40	.	.	PUNCT
dpc-1540	290	1	our	our	PRON
dpc-1540	290	2	results	result	NOUN
dpc-1540	290	3	are	be	AUX
dpc-1540	290	4	still	still	ADV
dpc-1540	290	5	striking	strike	VERB
dpc-1540	290	6	enough	enough	ADV
dpc-1540	290	7	to	to	PART
dpc-1540	290	8	reach	reach	VERB
dpc-1540	290	9	significant	significant	ADJ
dpc-1540	290	10	conclusions	conclusion	NOUN
dpc-1540	290	11	as	as	SCONJ
dpc-1540	290	12	follows	follow	VERB
dpc-1540	290	13	:	:	PUNCT
dpc-1540	290	14	detection	detection	NOUN
dpc-1540	290	15	of	of	ADP
dpc-1540	290	16	higher	high	ADJ
dpc-1540	290	17	ms	ms	NOUN
dpc-1540	290	18	prevalence	prevalence	NOUN
dpc-1540	290	19	than	than	SCONJ
dpc-1540	290	20	previously	previously	ADV
dpc-1540	290	21	reported	report	VERB
dpc-1540	290	22	in	in	ADP
dpc-1540	290	23	turkey	turkey	NOUN
dpc-1540	290	24	[	[	X
dpc-1540	290	25	23	23	NUM
dpc-1540	290	26	,	,	PUNCT
dpc-1540	290	27	24	24	NUM
dpc-1540	290	28	,	,	PUNCT
dpc-1540	290	29	31	31	NUM
dpc-1540	290	30	]	]	PUNCT
dpc-1540	290	31	,	,	PUNCT
dpc-1540	290	32	confirmation	confirmation	NOUN
dpc-1540	290	33	of	of	ADP
dpc-1540	290	34	previous	previous	ADJ
dpc-1540	290	35	predictions	prediction	NOUN
dpc-1540	290	36	that	that	SCONJ
dpc-1540	290	37	the	the	DET
dpc-1540	290	38	prevalence	prevalence	NOUN
dpc-1540	290	39	of	of	ADP
dpc-1540	290	40	ms	ms	PROPN
dpc-1540	290	41	will	will	AUX
dpc-1540	290	42	gradually	gradually	ADV
dpc-1540	290	43	increase	increase	VERB
dpc-1540	290	44	over	over	ADP
dpc-1540	290	45	time	time	NOUN
dpc-1540	290	46	,	,	PUNCT
dpc-1540	290	47	agreement	agreement	NOUN
dpc-1540	290	48	with	with	ADP
dpc-1540	290	49	the	the	DET
dpc-1540	290	50	literature	literature	NOUN
dpc-1540	290	51	that	that	PRON
dpc-1540	290	52	ms	ms	PROPN
dpc-1540	290	53	development	development	NOUN
dpc-1540	290	54	increases	increase	VERB
dpc-1540	290	55	with	with	ADP
dpc-1540	290	56	psoriasis	psoriasis	NOUN
dpc-1540	290	57	duration	duration	NOUN
dpc-1540	290	58	,	,	PUNCT
dpc-1540	290	59	and	and	CCONJ
dpc-1540	290	60	significantly	significantly	ADV
dpc-1540	290	61	higher	high	ADJ
dpc-1540	290	62	values	value	NOUN
dpc-1540	290	63	of	of	ADP
dpc-1540	290	64	psqi	psqi	NOUN
dpc-1540	290	65	and	and	CCONJ
dpc-1540	290	66	homa	homa	NOUN
dpc-1540	290	67	-	-	PUNCT
dpc-1540	290	68	ir	ir	PROPN
dpc-1540	290	69	only	only	ADV
dpc-1540	290	70	in	in	ADP
dpc-1540	290	71	the	the	DET
dpc-1540	290	72	ms	ms	PROPN
dpc-1540	290	73	group	group	NOUN
dpc-1540	290	74	(	(	PUNCT
dpc-1540	290	75	apart	apart	ADV
dpc-1540	290	76	from	from	ADP
dpc-1540	290	77	diagnostic	diagnostic	ADJ
dpc-1540	290	78	parameters	parameter	NOUN
dpc-1540	290	79	of	of	ADP
dpc-1540	290	80	ms	ms	NOUN
dpc-1540	290	81	)	)	PUNCT
dpc-1540	290	82	despite	despite	SCONJ
dpc-1540	290	83	the	the	DET
dpc-1540	290	84	absence	absence	NOUN
dpc-1540	290	85	of	of	ADP
dpc-1540	290	86	significant	significant	ADJ
dpc-1540	290	87	differences	difference	NOUN
dpc-1540	290	88	between	between	ADP
dpc-1540	290	89	the	the	DET
dpc-1540	290	90	groups	group	NOUN
dpc-1540	290	91	by	by	ADP
dpc-1540	290	92	age	age	NOUN
dpc-1540	290	93	,	,	PUNCT
dpc-1540	290	94	gender	gender	NOUN
dpc-1540	290	95	or	or	CCONJ
dpc-1540	290	96	psoriasis	psoriasis	NOUN
dpc-1540	290	97	severity	severity	NOUN
dpc-1540	290	98	.	.	PUNCT
dpc-1540	291	1	finally	finally	ADV
dpc-1540	291	2	,	,	PUNCT
dpc-1540	291	3	and	and	CCONJ
dpc-1540	291	4	perhaps	perhaps	ADV
dpc-1540	291	5	most	most	ADV
dpc-1540	291	6	importantly	importantly	ADV
dpc-1540	291	7	,	,	PUNCT
dpc-1540	291	8	an	an	DET
dpc-1540	291	9	inference	inference	NOUN
dpc-1540	291	10	of	of	ADP
dpc-1540	291	11	the	the	DET
dpc-1540	291	12	present	present	ADJ
dpc-1540	291	13	study	study	NOUN
dpc-1540	291	14	is	be	AUX
dpc-1540	291	15	detection	detection	NOUN
dpc-1540	291	16	of	of	ADP
dpc-1540	291	17	significantly	significantly	ADV
dpc-1540	291	18	high	high	ADJ
dpc-1540	291	19	fasting	fasting	NOUN
dpc-1540	291	20	glucose	glucose	NOUN
dpc-1540	291	21	and	and	CCONJ
dpc-1540	291	22	low	low	ADJ
dpc-1540	291	23	hdl	hdl	PROPN
dpc-1540	291	24	values	value	NOUN
dpc-1540	291	25	only	only	ADV
dpc-1540	291	26	in	in	ADP
dpc-1540	291	27	females	female	NOUN
dpc-1540	291	28	with	with	ADP
dpc-1540	291	29	severe	severe	ADJ
dpc-1540	291	30	psoriasis	psoriasis	NOUN
dpc-1540	291	31	,	,	PUNCT
dpc-1540	291	32	compared	compare	VERB
dpc-1540	291	33	to	to	ADP
dpc-1540	291	34	males	male	NOUN
dpc-1540	291	35	,	,	PUNCT
dpc-1540	291	36	which	which	PRON
dpc-1540	291	37	may	may	AUX
dpc-1540	291	38	be	be	AUX
dpc-1540	291	39	the	the	DET
dpc-1540	291	40	reason	reason	NOUN
dpc-1540	291	41	why	why	SCONJ
dpc-1540	291	42	ms	ms	PROPN
dpc-1540	291	43	was	be	AUX
dpc-1540	291	44	detected	detect	VERB
dpc-1540	291	45	at	at	ADP
dpc-1540	291	46	a	a	DET
dpc-1540	291	47	higher	high	ADJ
dpc-1540	291	48	rate	rate	NOUN
dpc-1540	291	49	in	in	ADP
dpc-1540	291	50	females	female	NOUN
dpc-1540	291	51	with	with	ADP
dpc-1540	291	52	psoriasis	psoriasis	NOUN
dpc-1540	291	53	.	.	PUNCT
dpc-1540	292	1	to	to	ADP
dpc-1540	292	2	the	the	DET
dpc-1540	292	3	best	good	ADJ
dpc-1540	292	4	of	of	ADP
dpc-1540	292	5	our	our	PRON
dpc-1540	292	6	knowledge	knowledge	NOUN
dpc-1540	292	7	,	,	PUNCT
dpc-1540	292	8	this	this	DET
dpc-1540	292	9	association	association	NOUN
dpc-1540	292	10	has	have	AUX
dpc-1540	292	11	not	not	PART
dpc-1540	292	12	been	be	AUX
dpc-1540	292	13	reported	report	VERB
dpc-1540	292	14	previously	previously	ADV
dpc-1540	292	15	.	.	PUNCT
dpc-1540	293	1	however	however	ADV
dpc-1540	293	2	,	,	PUNCT
dpc-1540	293	3	controlled	control	VERB
dpc-1540	293	4	,	,	PUNCT
dpc-1540	293	5	broad	broad	ADV
dpc-1540	293	6	-	-	PUNCT
dpc-1540	293	7	based	base	VERB
dpc-1540	293	8	and	and	CCONJ
dpc-1540	293	9	prospective	prospective	ADJ
dpc-1540	293	10	studies	study	NOUN
dpc-1540	293	11	are	be	AUX
dpc-1540	293	12	needed	need	VERB
dpc-1540	293	13	to	to	PART
dpc-1540	293	14	confirm	confirm	VERB
dpc-1540	293	15	our	our	PRON
dpc-1540	293	16	results	result	NOUN
dpc-1540	293	17	.	.	PUNCT
dpc-1540	294	1	acknowledgement	acknowledgement	NOUN
dpc-1540	294	2	we	we	PRON
dpc-1540	294	3	thank	thank	VERB
dpc-1540	294	4	jessica	jessica	PROPN
dpc-1540	294	5	eri	eri	PROPN
dpc-1540	294	6	motai	motai	PROPN
dpc-1540	294	7	from	from	ADP
dpc-1540	294	8	bogazici	bogazici	PROPN
dpc-1540	294	9	university	university	PROPN
dpc-1540	294	10	department	department	NOUN
dpc-1540	294	11	of	of	ADP
dpc-1540	294	12	foreign	foreign	ADJ
dpc-1540	294	13	languages	language	NOUN
dpc-1540	294	14	for	for	ADP
dpc-1540	294	15	editing	edit	VERB
dpc-1540	294	16	the	the	DET
dpc-1540	294	17	english	english	PROPN
dpc-1540	294	18	of	of	ADP
dpc-1540	294	19	the	the	DET
dpc-1540	294	20	paper	paper	NOUN
dpc-1540	294	21	.	.	PUNCT
dpc-1540	295	1	references	reference	NOUN
dpc-1540	295	2	1	1	NUM
dpc-1540	295	3	.	.	PUNCT
dpc-1540	295	4	kim	kim	PROPN
dpc-1540	295	5	n	n	CCONJ
dpc-1540	295	6	,	,	PUNCT
dpc-1540	295	7	thrash	thrash	VERB
dpc-1540	295	8	b	b	NOUN
dpc-1540	295	9	,	,	PUNCT
dpc-1540	295	10	menter	menter	ADJ
dpc-1540	295	11	a.	a.	NOUN
dpc-1540	295	12	comorbidities	comorbiditie	NOUN
dpc-1540	295	13	in	in	ADP
dpc-1540	295	14	psoriasis	psoriasis	NOUN
dpc-1540	295	15	patients	patient	NOUN
dpc-1540	295	16	.	.	PUNCT
dpc-1540	296	1	semin	semin	PROPN
dpc-1540	296	2	cutan	cutan	PROPN
dpc-1540	296	3	med	med	PROPN
dpc-1540	296	4	surg	surg	NOUN
dpc-1540	296	5	.	.	PUNCT
dpc-1540	297	1	2010;29(1):10	2010;29(1):10	NUM
dpc-1540	297	2	-	-	SYM
dpc-1540	297	3	15	15	NUM
dpc-1540	298	1	.	.	PUNCT
dpc-1540	298	2	doi	doi	NOUN
dpc-1540	298	3	:	:	PUNCT
dpc-1540	298	4	10.1016	10.1016	NUM
dpc-1540	298	5	/	/	SYM
dpc-1540	298	6	j.	j.	PROPN
dpc-1540	298	7	sder.2010.01.002	sder.2010.01.002	PROPN
dpc-1540	298	8	.	.	PUNCT
dpc-1540	299	1	pmid	pmid	NOUN
dpc-1540	299	2	:	:	PUNCT
dpc-1540	299	3	20430302	20430302	NUM
dpc-1540	299	4	.	.	PUNCT
dpc-1540	300	1	2	2	X
dpc-1540	300	2	.	.	X
dpc-1540	300	3	lotti	lotti	PROPN
dpc-1540	300	4	t	t	PROPN
dpc-1540	300	5	,	,	PUNCT
dpc-1540	300	6	hercogova	hercogova	PROPN
dpc-1540	300	7	j	j	PROPN
dpc-1540	300	8	,	,	PUNCT
dpc-1540	300	9	prignano	prignano	PROPN
dpc-1540	300	10	f.	f.	PROPN
dpc-1540	300	11	the	the	DET
dpc-1540	300	12	concept	concept	NOUN
dpc-1540	300	13	of	of	ADP
dpc-1540	300	14	psoriatic	psoriatic	ADJ
dpc-1540	300	15	disease	disease	NOUN
dpc-1540	300	16	:	:	PUNCT
dpc-1540	300	17	can	can	AUX
dpc-1540	300	18	cutaneous	cutaneous	VERB
dpc-1540	300	19	psoriasis	psoriasis	NOUN
dpc-1540	300	20	any	any	ADV
dpc-1540	300	21	longer	long	ADV
dpc-1540	300	22	be	be	AUX
dpc-1540	300	23	separated	separate	VERB
dpc-1540	300	24	by	by	ADP
dpc-1540	300	25	the	the	DET
dpc-1540	300	26	systemic	systemic	ADJ
dpc-1540	300	27	comorbidities	comorbiditie	NOUN
dpc-1540	300	28	?	?	PUNCT
dpc-1540	301	1	dermatol	dermatol	NOUN
dpc-1540	301	2	ther	ther	ADV
dpc-1540	301	3	.	.	PUNCT
dpc-1540	302	1	2010;23(2):119	2010;23(2):119	NUM
dpc-1540	302	2	-	-	SYM
dpc-1540	302	3	122	122	NUM
dpc-1540	302	4	.	.	PUNCT
dpc-1540	303	1	doi	doi	NOUN
dpc-1540	303	2	:	:	PUNCT
dpc-1540	303	3	10.1111	10.1111	NUM
dpc-1540	303	4	/	/	SYM
dpc-1540	303	5	j.1529	j.1529	NOUN
dpc-1540	303	6	-	-	PUNCT
dpc-1540	303	7	8019.2010.01305.x	8019.2010.01305.x	NUM
dpc-1540	303	8	.	.	PUNCT
dpc-1540	304	1	pmid	pmid	NOUN
dpc-1540	304	2	:	:	PUNCT
dpc-1540	304	3	20415818	20415818	NUM
dpc-1540	304	4	.	.	PUNCT
dpc-1540	305	1	3	3	X
dpc-1540	305	2	.	.	X
dpc-1540	305	3	altunay	altunay	PROPN
dpc-1540	305	4	i	i	PRON
dpc-1540	305	5	,	,	PUNCT
dpc-1540	305	6	tukenmezdemirci	tukenmezdemirci	ADJ
dpc-1540	305	7	g	g	PROPN
dpc-1540	305	8	,	,	PUNCT
dpc-1540	305	9	ates	ates	PROPN
dpc-1540	305	10	b	b	PROPN
dpc-1540	305	11	,	,	PUNCT
dpc-1540	305	12	et	et	PROPN
dpc-1540	305	13	al	al	PROPN
dpc-1540	305	14	.	.	PROPN
dpc-1540	306	1	do	do	AUX
dpc-1540	306	2	eating	eat	VERB
dpc-1540	306	3	disorders	disorder	NOUN
dpc-1540	306	4	accompany	accompany	VERB
dpc-1540	306	5	metabolic	metabolic	NOUN
dpc-1540	306	6	syndrome	syndrome	NOUN
dpc-1540	306	7	in	in	ADP
dpc-1540	306	8	psoriasis	psoriasis	NOUN
dpc-1540	306	9	patients	patient	NOUN
dpc-1540	306	10	?	?	PUNCT
dpc-1540	307	1	results	result	NOUN
dpc-1540	307	2	of	of	ADP
dpc-1540	307	3	a	a	DET
dpc-1540	307	4	preliminary	preliminary	ADJ
dpc-1540	307	5	study	study	NOUN
dpc-1540	307	6	.	.	PUNCT
dpc-1540	308	1	clin	clin	PROPN
dpc-1540	308	2	cosmetinvestig	cosmetinvestig	PROPN
dpc-1540	308	3	dermatol.2011;4:139	dermatol.2011;4:139	PROPN
dpc-1540	308	4	-	-	PUNCT
dpc-1540	308	5	143	143	NUM
dpc-1540	308	6	.	.	PUNCT
dpc-1540	308	7	doi	doi	NOUN
dpc-1540	308	8	:	:	PUNCT
dpc-1540	308	9	10.2147	10.2147	NUM
dpc-1540	308	10	/	/	SYM
dpc-1540	308	11	ccid.s24165	ccid.s24165	NOUN
dpc-1540	308	12	.	.	PUNCT
dpc-1540	309	1	pmid	pmid	NOUN
dpc-1540	309	2	:	:	PUNCT
dpc-1540	309	3	21931499	21931499	NUM
dpc-1540	309	4	.	.	PUNCT
dpc-1540	310	1	4	4	X
dpc-1540	310	2	.	.	X
dpc-1540	310	3	herron	herron	PROPN
dpc-1540	310	4	md	md	PROPN
dpc-1540	310	5	,	,	PUNCT
dpc-1540	310	6	hincley	hincley	PROPN
dpc-1540	310	7	m	m	PROPN
dpc-1540	310	8	,	,	PUNCT
dpc-1540	310	9	hoffman	hoffman	PROPN
dpc-1540	310	10	ms	ms	PROPN
dpc-1540	310	11	,	,	PUNCT
dpc-1540	310	12	et	et	PROPN
dpc-1540	310	13	al	al	PROPN
dpc-1540	310	14	.	.	PROPN
dpc-1540	310	15	impact	impact	NOUN
dpc-1540	310	16	of	of	ADP
dpc-1540	310	17	obesity	obesity	NOUN
dpc-1540	310	18	and	and	CCONJ
dpc-1540	310	19	smoking	smoking	NOUN
dpc-1540	310	20	on	on	ADP
dpc-1540	310	21	psoriasis	psoriasis	NOUN
dpc-1540	310	22	presentation	presentation	NOUN
dpc-1540	310	23	and	and	CCONJ
dpc-1540	310	24	management	management	NOUN
dpc-1540	310	25	.	.	PUNCT
dpc-1540	311	1	arch	arch	ADJ
dpc-1540	311	2	dermatol	dermatol	NOUN
dpc-1540	311	3	.	.	PUNCT
dpc-1540	312	1	2005;141(12):1527	2005;141(12):1527	NUM
dpc-1540	312	2	-	-	SYM
dpc-1540	312	3	1533	1533	NUM
dpc-1540	312	4	.	.	PUNCT
dpc-1540	313	1	doi:10.1001	doi:10.1001	PROPN
dpc-1540	313	2	/	/	SYM
dpc-1540	313	3	archderm.141.12.1527	archderm.141.12.1527	NOUN
dpc-1540	313	4	.	.	PUNCT
dpc-1540	314	1	pmid	pmid	NOUN
dpc-1540	314	2	:	:	PUNCT
dpc-1540	314	3	16365253	16365253	NUM
dpc-1540	314	4	.	.	PUNCT
dpc-1540	315	1	5	5	X
dpc-1540	315	2	.	.	X
dpc-1540	315	3	sterry	sterry	PROPN
dpc-1540	315	4	w	w	PROPN
dpc-1540	315	5	,	,	PUNCT
dpc-1540	315	6	strober	strober	ADV
dpc-1540	315	7	be	be	AUX
dpc-1540	315	8	,	,	PUNCT
dpc-1540	315	9	menter	menter	X
dpc-1540	315	10	a	a	X
dpc-1540	315	11	;	;	PUNCT
dpc-1540	315	12	international	international	ADJ
dpc-1540	315	13	psoriasis	psoriasis	NOUN
dpc-1540	315	14	council	council	NOUN
dpc-1540	315	15	.	.	PUNCT
dpc-1540	316	1	obesity	obesity	NOUN
dpc-1540	316	2	in	in	ADP
dpc-1540	316	3	psoriasis	psoriasis	NOUN
dpc-1540	316	4	:	:	PUNCT
dpc-1540	316	5	the	the	DET
dpc-1540	316	6	metabolic	metabolic	NOUN
dpc-1540	316	7	,	,	PUNCT
dpc-1540	316	8	clinical	clinical	ADJ
dpc-1540	316	9	and	and	CCONJ
dpc-1540	316	10	therapeutic	therapeutic	ADJ
dpc-1540	316	11	implications	implication	NOUN
dpc-1540	316	12	.	.	PUNCT
dpc-1540	317	1	report	report	NOUN
dpc-1540	317	2	of	of	ADP
dpc-1540	317	3	an	an	DET
dpc-1540	317	4	interdisciplinary	interdisciplinary	ADJ
dpc-1540	317	5	conference	conference	NOUN
dpc-1540	317	6	and	and	CCONJ
dpc-1540	317	7	review	review	NOUN
dpc-1540	317	8	.	.	PUNCT
dpc-1540	318	1	br	br	PROPN
dpc-1540	318	2	j	j	PROPN
dpc-1540	318	3	dermatol.2007;157(4):649	dermatol.2007;157(4):649	X
dpc-1540	318	4	-	-	NOUN
dpc-1540	318	5	655	655	NUM
dpc-1540	318	6	.	.	PUNCT
dpc-1540	319	1	doi	doi	NOUN
dpc-1540	319	2	:	:	PUNCT
dpc-1540	319	3	10.1111	10.1111	NUM
dpc-1540	319	4	/	/	SYM
dpc-1540	319	5	j.13652133.2007.08068.x	j.13652133.2007.08068.x	PROPN
dpc-1540	319	6	.	.	PUNCT
dpc-1540	320	1	pmid	pmid	NOUN
dpc-1540	320	2	:	:	PUNCT
dpc-1540	320	3	17627791	17627791	NUM
dpc-1540	320	4	.	.	PUNCT
dpc-1540	321	1	6	6	X
dpc-1540	321	2	.	.	X
dpc-1540	321	3	hamminga	hamminga	PROPN
dpc-1540	321	4	ea	ea	NUM
dpc-1540	321	5	,	,	PUNCT
dpc-1540	321	6	van	van	PROPN
dpc-1540	321	7	der	der	PROPN
dpc-1540	321	8	lely	lely	PROPN
dpc-1540	321	9	aj	aj	PROPN
dpc-1540	321	10	,	,	PUNCT
dpc-1540	321	11	neumann	neumann	PROPN
dpc-1540	321	12	ha	ha	INTJ
dpc-1540	321	13	,	,	PUNCT
dpc-1540	321	14	thio	thio	ADJ
dpc-1540	321	15	hb	hb	PROPN
dpc-1540	321	16	.	.	PUNCT
dpc-1540	322	1	chronic	chronic	ADJ
dpc-1540	322	2	inflammation	inflammation	NOUN
dpc-1540	322	3	in	in	ADP
dpc-1540	322	4	psoriasis	psoriasis	NOUN
dpc-1540	322	5	and	and	CCONJ
dpc-1540	322	6	obesity	obesity	NOUN
dpc-1540	322	7	:	:	PUNCT
dpc-1540	322	8	implications	implication	NOUN
dpc-1540	322	9	for	for	ADP
dpc-1540	322	10	therapy	therapy	NOUN
dpc-1540	322	11	.	.	PUNCT
dpc-1540	323	1	med	med	ADJ
dpc-1540	323	2	hypotheses	hypothesis	NOUN
dpc-1540	323	3	.	.	PUNCT
dpc-1540	324	1	2006;67(4):768	2006;67(4):768	NUM
dpc-1540	324	2	-	-	SYM
dpc-1540	324	3	773	773	NUM
dpc-1540	324	4	.	.	PUNCT
dpc-1540	325	1	doi	doi	NOUN
dpc-1540	325	2	:	:	PUNCT
dpc-1540	325	3	10.1016	10.1016	NUM
dpc-1540	325	4	/	/	SYM
dpc-1540	325	5	j.	j.	PROPN
dpc-1540	325	6	mehy.2005.11.050	mehy.2005.11.050	PROPN
dpc-1540	325	7	.	.	PUNCT
dpc-1540	326	1	pmid	pmid	NOUN
dpc-1540	326	2	:	:	PUNCT
dpc-1540	326	3	16781085	16781085	NUM
dpc-1540	326	4	.	.	PUNCT
dpc-1540	327	1	table	table	NOUN
dpc-1540	327	2	6	6	NUM
dpc-1540	327	3	.	.	PUNCT
dpc-1540	328	1	predictivity	predictivity	NOUN
dpc-1540	328	2	of	of	ADP
dpc-1540	328	3	correlative	correlative	ADJ
dpc-1540	328	4	parameters	parameter	NOUN
dpc-1540	328	5	on	on	ADP
dpc-1540	328	6	the	the	DET
dpc-1540	328	7	development	development	NOUN
dpc-1540	328	8	of	of	ADP
dpc-1540	328	9	metabolic	metabolic	NOUN
dpc-1540	328	10	syndrome	syndrome	NOUN
dpc-1540	328	11	,	,	PUNCT
dpc-1540	328	12	by	by	ADP
dpc-1540	328	13	logistic	logistic	ADJ
dpc-1540	328	14	regression	regression	NOUN
dpc-1540	328	15	parameter	parameter	NOUN
dpc-1540	328	16	p	p	NOUN
dpc-1540	328	17	or	or	CCONJ
dpc-1540	328	18	(	(	PUNCT
dpc-1540	328	19	95	95	NUM
dpc-1540	328	20	%	%	NOUN
dpc-1540	328	21	ci	ci	NOUN
dpc-1540	328	22	)	)	PUNCT
dpc-1540	328	23	disease	disease	NOUN
dpc-1540	328	24	duration	duration	NOUN
dpc-1540	328	25	(	(	PUNCT
dpc-1540	328	26	years	year	NOUN
dpc-1540	328	27	)	)	PUNCT
dpc-1540	328	28	.485	.485	NUM
dpc-1540	328	29	1.04	1.04	NUM
dpc-1540	328	30	(	(	PUNCT
dpc-1540	328	31	0.93	0.93	NUM
dpc-1540	328	32	to	to	ADP
dpc-1540	328	33	1.16	1.16	NUM
dpc-1540	328	34	)	)	PUNCT
dpc-1540	328	35	bmi	bmi	NOUN
dpc-1540	328	36	(	(	PUNCT
dpc-1540	328	37	kg	kg	NOUN
dpc-1540	328	38	/	/	SYM
dpc-1540	328	39	m2	m2	PROPN
dpc-1540	328	40	)	)	PUNCT
dpc-1540	328	41	.471	.471	NUM
dpc-1540	328	42	1.06	1.06	NUM
dpc-1540	328	43	(	(	PUNCT
dpc-1540	328	44	0.90	0.90	NUM
dpc-1540	328	45	to	to	ADP
dpc-1540	328	46	1.26	1.26	NUM
dpc-1540	328	47	)	)	PUNCT
dpc-1540	328	48	waist	waist	NOUN
dpc-1540	328	49	circumference	circumference	NOUN
dpc-1540	328	50	(	(	PUNCT
dpc-1540	328	51	cm	cm	NOUN
dpc-1540	328	52	)	)	PUNCT
dpc-1540	328	53	.037	.037	NUM
dpc-1540	328	54	1.07	1.07	NUM
dpc-1540	328	55	(	(	PUNCT
dpc-1540	328	56	1.00	1.00	NUM
dpc-1540	328	57	to	to	PART
dpc-1540	328	58	1.14	1.14	NUM
dpc-1540	328	59	)	)	PUNCT
dpc-1540	328	60	fasting	fast	VERB
dpc-1540	328	61	glucose	glucose	NOUN
dpc-1540	328	62	.004	.004	NUM
dpc-1540	328	63	1.09	1.09	NUM
dpc-1540	328	64	(	(	PUNCT
dpc-1540	328	65	1.03	1.03	NUM
dpc-1540	328	66	to	to	ADP
dpc-1540	328	67	1.15	1.15	NUM
dpc-1540	328	68	)	)	PUNCT
dpc-1540	328	69	homa	homa	NOUN
dpc-1540	328	70	-	-	PUNCT
dpc-1540	328	71	ir	ir	PROPN
dpc-1540	328	72	.65	.65	NUM
dpc-1540	328	73	0.89	0.89	NUM
dpc-1540	328	74	(	(	PUNCT
dpc-1540	328	75	0.54	0.54	NUM
dpc-1540	328	76	to	to	PART
dpc-1540	328	77	1.47	1.47	NUM
dpc-1540	328	78	)	)	PUNCT
dpc-1540	328	79	low	low	PROPN
dpc-1540	328	80	hdl	hdl	PROPN
dpc-1540	328	81	.005	.005	NUM
dpc-1540	328	82	0.84	0.84	NUM
dpc-1540	328	83	(	(	PUNCT
dpc-1540	328	84	0.75	0.75	NUM
dpc-1540	328	85	to	to	PART
dpc-1540	328	86	0.95	0.95	NUM
dpc-1540	328	87	)	)	PUNCT
dpc-1540	328	88	triglyceride	triglyceride	ADP
dpc-1540	328	89	.282	.282	NUM
dpc-1540	328	90	1.01	1.01	NUM
dpc-1540	328	91	(	(	PUNCT
dpc-1540	328	92	0.99	0.99	NUM
dpc-1540	328	93	to	to	PART
dpc-1540	328	94	1.03	1.03	NUM
dpc-1540	328	95	)	)	PUNCT
dpc-1540	328	96	hypertension	hypertension	NOUN
dpc-1540	328	97	.02	.02	NUM
dpc-1540	328	98	0.04	0.04	NUM
dpc-1540	328	99	(	(	PUNCT
dpc-1540	328	100	0to	0to	NOUN
dpc-1540	328	101	0.60	0.60	NUM
dpc-1540	328	102	)	)	PUNCT
dpc-1540	328	103	pasi	pasi	NOUN
dpc-1540	328	104	.223	.223	NUM
dpc-1540	329	1	2.76	2.76	NUM
dpc-1540	329	2	(	(	PUNCT
dpc-1540	329	3	0.54	0.54	NUM
dpc-1540	329	4	to	to	ADP
dpc-1540	329	5	14.08	14.08	NUM
dpc-1540	329	6	)	)	PUNCT
dpc-1540	329	7	psqi	psqi	NOUN
dpc-1540	329	8	.918	.918	NUM
dpc-1540	329	9	0.91	0.91	NUM
dpc-1540	329	10	(	(	PUNCT
dpc-1540	329	11	0.14	0.14	NUM
dpc-1540	329	12	to	to	ADP
dpc-1540	329	13	5.91	5.91	NUM
dpc-1540	329	14	)	)	PUNCT
dpc-1540	329	15	bmi	bmi	NOUN
dpc-1540	329	16	=	=	SYM
dpc-1540	329	17	body	body	PROPN
dpc-1540	329	18	mass	mass	PROPN
dpc-1540	329	19	index	index	NOUN
dpc-1540	329	20	;	;	PUNCT
dpc-1540	329	21	ci	ci	NOUN
dpc-1540	329	22	=	=	NOUN
dpc-1540	329	23	confidence	confidence	NOUN
dpc-1540	329	24	interval	interval	NOUN
dpc-1540	329	25	;	;	PUNCT
dpc-1540	329	26	homa	homa	NOUN
dpc-1540	329	27	-	-	PUNCT
dpc-1540	329	28	ir	ir	NOUN
dpc-1540	329	29	=	=	NOUN
dpc-1540	329	30	homeostatic	homeostatic	ADJ
dpc-1540	329	31	model	model	NOUN
dpc-1540	329	32	assessment	assessment	NOUN
dpc-1540	329	33	insulin	insulin	NOUN
dpc-1540	329	34	resistance	resistance	NOUN
dpc-1540	329	35	;	;	PUNCT
dpc-1540	329	36	or	or	CCONJ
dpc-1540	329	37	=	=	NOUN
dpc-1540	329	38	odds	odd	NOUN
dpc-1540	329	39	ratio	ratio	NOUN
dpc-1540	329	40	;	;	PUNCT
dpc-1540	329	41	pasi	pasi	NOUN
dpc-1540	329	42	=	=	SYM
dpc-1540	329	43	psoriasis	psoriasis	NOUN
dpc-1540	329	44	area	area	NOUN
dpc-1540	329	45	and	and	CCONJ
dpc-1540	329	46	severity	severity	NOUN
dpc-1540	329	47	index;psqi	index;psqi	PROPN
dpc-1540	329	48	=	=	PUNCT
dpc-1540	329	49	pittsburg	pittsburg	PROPN
dpc-1540	329	50	sleep	sleep	NOUN
dpc-1540	329	51	quality	quality	PROPN
dpc-1540	329	52	index	index	NOUN
dpc-1540	329	53	.	.	PUNCT
dpc-1540	330	1	10	10	NUM
dpc-1540	330	2	research	research	NOUN
dpc-1540	330	3	|	|	ADV
dpc-1540	330	4	dermatol	dermatol	ADJ
dpc-1540	330	5	pract	pract	NOUN
dpc-1540	330	6	concept	concept	NOUN
dpc-1540	330	7	.	.	PUNCT
dpc-1540	331	1	2021;11(3):e2021049	2021;11(3):e2021049	NUM
dpc-1540	331	2	7	7	NUM
dpc-1540	331	3	.	.	PUNCT
dpc-1540	332	1	bonifati	bonifati	PROPN
dpc-1540	332	2	c	c	PROPN
dpc-1540	332	3	,	,	PUNCT
dpc-1540	332	4	carducci	carducci	PROPN
dpc-1540	332	5	m	m	PROPN
dpc-1540	332	6	,	,	PUNCT
dpc-1540	332	7	cordialifei	cordialifei	PROPN
dpc-1540	332	8	p	p	NOUN
dpc-1540	332	9	,	,	PUNCT
dpc-1540	332	10	et	et	PROPN
dpc-1540	332	11	al	al	PROPN
dpc-1540	332	12	.	.	PROPN
dpc-1540	332	13	correlated	correlate	VERB
dpc-1540	332	14	increases	increase	NOUN
dpc-1540	332	15	of	of	ADP
dpc-1540	332	16	tumour	tumour	NOUN
dpc-1540	332	17	necrosis	necrosis	NOUN
dpc-1540	332	18	factor	factor	NOUN
dpc-1540	332	19	-	-	PUNCT
dpc-1540	332	20	alpha	alpha	NOUN
dpc-1540	332	21	,	,	PUNCT
dpc-1540	332	22	interleukin-6	interleukin-6	NUM
dpc-1540	332	23	and	and	CCONJ
dpc-1540	332	24	granulocyte	granulocyte	ADJ
dpc-1540	332	25	monocytecolony	monocytecolony	NOUN
dpc-1540	332	26	stimulating	stimulate	VERB
dpc-1540	332	27	factor	factor	NOUN
dpc-1540	332	28	levels	level	NOUN
dpc-1540	332	29	in	in	ADP
dpc-1540	332	30	suction	suction	NOUN
dpc-1540	332	31	blister	blister	NOUN
dpc-1540	332	32	fluids	fluid	NOUN
dpc-1540	332	33	and	and	CCONJ
dpc-1540	332	34	sera	sera	NOUN
dpc-1540	332	35	of	of	ADP
dpc-1540	332	36	psoriatic	psoriatic	ADJ
dpc-1540	332	37	patients	patient	NOUN
dpc-1540	332	38	—	—	PUNCT
dpc-1540	332	39	relationships	relationship	NOUN
dpc-1540	332	40	with	with	ADP
dpc-1540	332	41	disease	disease	NOUN
dpc-1540	332	42	severity	severity	NOUN
dpc-1540	332	43	.	.	PUNCT
dpc-1540	333	1	clin	clin	PROPN
dpc-1540	333	2	exp	exp	NOUN
dpc-1540	333	3	dermatol	dermatol	NOUN
dpc-1540	333	4	.	.	PUNCT
dpc-1540	334	1	1994;19(5):383	1994;19(5):383	NUM
dpc-1540	334	2	-	-	SYM
dpc-1540	334	3	387	387	NUM
dpc-1540	334	4	.	.	PUNCT
dpc-1540	334	5	doi	doi	NOUN
dpc-1540	334	6	:	:	PUNCT
dpc-1540	334	7	10.1111	10.1111	NUM
dpc-1540	334	8	/	/	SYM
dpc-1540	334	9	j.13652230.1994.tb02687.x	j.13652230.1994.tb02687.x	PROPN
dpc-1540	334	10	.	.	PROPN
dpc-1540	334	11	8	8	NUM
dpc-1540	334	12	.	.	X
dpc-1540	335	1	shirai	shirai	PROPN
dpc-1540	335	2	k.	k.	PROPN
dpc-1540	335	3	obesity	obesity	NOUN
dpc-1540	335	4	as	as	ADP
dpc-1540	335	5	the	the	DET
dpc-1540	335	6	core	core	NOUN
dpc-1540	335	7	of	of	ADP
dpc-1540	335	8	the	the	DET
dpc-1540	335	9	metabolic	metabolic	NOUN
dpc-1540	335	10	syndrome	syndrome	NOUN
dpc-1540	335	11	and	and	CCONJ
dpc-1540	335	12	the	the	DET
dpc-1540	335	13	management	management	NOUN
dpc-1540	335	14	of	of	ADP
dpc-1540	335	15	coronary	coronary	ADJ
dpc-1540	335	16	heart	heart	NOUN
dpc-1540	335	17	disease	disease	NOUN
dpc-1540	335	18	.	.	PUNCT
dpc-1540	336	1	curr	curr	PROPN
dpc-1540	336	2	med	med	PROPN
dpc-1540	336	3	res	re	NOUN
dpc-1540	336	4	opin	opin	NOUN
dpc-1540	336	5	.	.	PUNCT
dpc-1540	337	1	2004;20(3):295	2004;20(3):295	NUM
dpc-1540	337	2	-	-	SYM
dpc-1540	337	3	304	304	NUM
dpc-1540	337	4	.	.	PUNCT
dpc-1540	337	5	doi	doi	NOUN
dpc-1540	337	6	:	:	PUNCT
dpc-1540	337	7	10.1185/030079903125003008	10.1185/030079903125003008	NUM
dpc-1540	337	8	.	.	PUNCT
dpc-1540	338	1	pmid	pmid	NOUN
dpc-1540	338	2	:	:	PUNCT
dpc-1540	338	3	15025838	15025838	NUM
dpc-1540	338	4	.	.	PUNCT
dpc-1540	339	1	9	9	X
dpc-1540	339	2	.	.	X
dpc-1540	339	3	davidovici	davidovici	PROPN
dpc-1540	339	4	bb	bb	PROPN
dpc-1540	339	5	,	,	PUNCT
dpc-1540	339	6	sattar	sattar	PROPN
dpc-1540	339	7	n	n	CCONJ
dpc-1540	339	8	,	,	PUNCT
dpc-1540	339	9	prinz	prinz	PROPN
dpc-1540	339	10	jc	jc	PROPN
dpc-1540	339	11	,	,	PUNCT
dpc-1540	339	12	et	et	PROPN
dpc-1540	339	13	al	al	PROPN
dpc-1540	339	14	.	.	PUNCT
dpc-1540	339	15	psoriasis	psoriasis	NOUN
dpc-1540	339	16	and	and	CCONJ
dpc-1540	339	17	systemic	systemic	ADJ
dpc-1540	339	18	inflammatory	inflammatory	ADJ
dpc-1540	339	19	diseases	disease	NOUN
dpc-1540	339	20	:	:	PUNCT
dpc-1540	339	21	potential	potential	ADJ
dpc-1540	339	22	mechanistic	mechanistic	ADJ
dpc-1540	339	23	links	link	NOUN
dpc-1540	339	24	between	between	ADP
dpc-1540	339	25	skin	skin	NOUN
dpc-1540	339	26	disease	disease	NOUN
dpc-1540	339	27	and	and	CCONJ
dpc-1540	339	28	co	co	ADJ
dpc-1540	339	29	-	-	ADJ
dpc-1540	339	30	morbid	morbid	ADJ
dpc-1540	339	31	conditions	condition	NOUN
dpc-1540	339	32	.	.	PUNCT
dpc-1540	340	1	j	j	PROPN
dpc-1540	340	2	invest	invest	VERB
dpc-1540	340	3	dermatol	dermatol	NOUN
dpc-1540	340	4	.	.	PUNCT
dpc-1540	341	1	2010;130(7):1785	2010;130(7):1785	NUM
dpc-1540	341	2	-	-	SYM
dpc-1540	341	3	1796	1796	NUM
dpc-1540	341	4	.	.	PUNCT
dpc-1540	342	1	doi	doi	NOUN
dpc-1540	342	2	:	:	PUNCT
dpc-1540	342	3	10.1038	10.1038	NUM
dpc-1540	342	4	/	/	SYM
dpc-1540	342	5	jid.2010.103	jid.2010.103	PROPN
dpc-1540	342	6	.	.	PUNCT
dpc-1540	343	1	pmid	pmid	NOUN
dpc-1540	343	2	:	:	PUNCT
dpc-1540	343	3	20445552	20445552	NUM
dpc-1540	343	4	.	.	PUNCT
dpc-1540	344	1	10	10	NUM
dpc-1540	344	2	.	.	PUNCT
dpc-1540	345	1	lam	lam	PROPN
dpc-1540	345	2	jcm	jcm	PROPN
dpc-1540	345	3	,	,	PUNCT
dpc-1540	345	4	mak	mak	PROPN
dpc-1540	345	5	jcw	jcw	PROPN
dpc-1540	345	6	,	,	PUNCT
dpc-1540	345	7	ip	ip	NOUN
dpc-1540	345	8	msm	msm	NOUN
dpc-1540	345	9	.	.	PUNCT
dpc-1540	346	1	obesity	obesity	NOUN
dpc-1540	346	2	,	,	PUNCT
dpc-1540	346	3	obstructive	obstructive	ADJ
dpc-1540	346	4	sleep	sleep	NOUN
dpc-1540	346	5	apnoea	apnoea	NOUN
dpc-1540	346	6	and	and	CCONJ
dpc-1540	346	7	metabolic	metabolic	NOUN
dpc-1540	346	8	syndrome	syndrome	NOUN
dpc-1540	346	9	.	.	PUNCT
dpc-1540	347	1	respirology	respirology	NOUN
dpc-1540	347	2	.	.	PUNCT
dpc-1540	348	1	2010;17(2):223	2010;17(2):223	NUM
dpc-1540	348	2	-	-	PUNCT
dpc-1540	348	3	236	236	NUM
dpc-1540	348	4	.	.	PUNCT
dpc-1540	349	1	doi	doi	NOUN
dpc-1540	349	2	:	:	PUNCT
dpc-1540	349	3	10.1111	10.1111	NUM
dpc-1540	349	4	/	/	SYM
dpc-1540	349	5	j.1440	j.1440	PROPN
dpc-1540	349	6	-	-	PUNCT
dpc-1540	349	7	1843.2011.02081.x	1843.2011.02081.x	NOUN
dpc-1540	349	8	.	.	PUNCT
dpc-1540	350	1	pmid	pmid	NOUN
dpc-1540	350	2	:	:	PUNCT
dpc-1540	350	3	21992649	21992649	NUM
dpc-1540	350	4	.	.	PUNCT
dpc-1540	351	1	11	11	NUM
dpc-1540	351	2	.	.	PUNCT
dpc-1540	352	1	hawro	hawro	PROPN
dpc-1540	352	2	t	t	PROPN
dpc-1540	352	3	,	,	PUNCT
dpc-1540	352	4	hawro	hawro	PROPN
dpc-1540	352	5	m	m	PROPN
dpc-1540	352	6	,	,	PUNCT
dpc-1540	352	7	zalewska	zalewska	PROPN
dpc-1540	352	8	-	-	PUNCT
dpc-1540	352	9	janowska	janowska	PROPN
dpc-1540	352	10	a	a	PRON
dpc-1540	352	11	,	,	PUNCT
dpc-1540	352	12	weller	weller	PROPN
dpc-1540	352	13	k	k	PROPN
dpc-1540	352	14	,	,	PUNCT
dpc-1540	352	15	metz	metz	PROPN
dpc-1540	352	16	m	m	PROPN
dpc-1540	352	17	,	,	PUNCT
dpc-1540	352	18	maurer	maurer	PROPN
dpc-1540	352	19	m.	m.	PROPN
dpc-1540	352	20	pruritus	pruritus	PROPN
dpc-1540	352	21	and	and	CCONJ
dpc-1540	352	22	sleep	sleep	VERB
dpc-1540	352	23	disturbances	disturbance	NOUN
dpc-1540	352	24	in	in	ADP
dpc-1540	352	25	patients	patient	NOUN
dpc-1540	352	26	with	with	ADP
dpc-1540	352	27	psoriasis	psoriasis	NOUN
dpc-1540	352	28	.	.	PUNCT
dpc-1540	353	1	arch	arch	ADJ
dpc-1540	353	2	dermatol	dermatol	NOUN
dpc-1540	353	3	res	re	NOUN
dpc-1540	353	4	.	.	PUNCT
dpc-1540	354	1	2020;312(2):103	2020;312(2):103	NUM
dpc-1540	354	2	-	-	SYM
dpc-1540	354	3	111	111	NUM
dpc-1540	354	4	.	.	PUNCT
dpc-1540	355	1	doi:10.1007/	doi:10.1007/	NUM
dpc-1540	355	2	s00403	s00403	PROPN
dpc-1540	355	3	-	-	PUNCT
dpc-1540	355	4	019	019	NUM
dpc-1540	355	5	-	-	PUNCT
dpc-1540	355	6	01998	01998	NUM
dpc-1540	355	7	-	-	SYM
dpc-1540	355	8	7	7	NUM
dpc-1540	355	9	.	.	PUNCT
dpc-1540	356	1	pmid	pmid	NOUN
dpc-1540	356	2	:	:	PUNCT
dpc-1540	356	3	31616971	31616971	NUM
dpc-1540	356	4	.	.	PUNCT
dpc-1540	357	1	12	12	NUM
dpc-1540	357	2	.	.	PUNCT
dpc-1540	358	1	feldman	feldman	PROPN
dpc-1540	358	2	sr	sr	PROPN
dpc-1540	358	3	,	,	PUNCT
dpc-1540	358	4	krueger	krueger	PROPN
dpc-1540	358	5	gg	gg	PROPN
dpc-1540	358	6	.	.	PUNCT
dpc-1540	358	7	psoriasis	psoriasis	NOUN
dpc-1540	358	8	assessment	assessment	NOUN
dpc-1540	358	9	tools	tool	NOUN
dpc-1540	358	10	in	in	ADP
dpc-1540	358	11	clinical	clinical	ADJ
dpc-1540	358	12	trials	trial	NOUN
dpc-1540	358	13	.	.	PUNCT
dpc-1540	359	1	ann	ann	PROPN
dpc-1540	359	2	rheum	rheum	PROPN
dpc-1540	359	3	dis	dis	PROPN
dpc-1540	359	4	.	.	PUNCT
dpc-1540	360	1	2005;64(suppl2):65	2005;64(suppl2):65	PROPN
dpc-1540	360	2	-	-	PUNCT
dpc-1540	360	3	68	68	NUM
dpc-1540	360	4	.	.	PUNCT
dpc-1540	361	1	doi	doi	NOUN
dpc-1540	361	2	:	:	PUNCT
dpc-1540	361	3	10.1136/	10.1136/	NUM
dpc-1540	361	4	ard.2004.031237	ard.2004.031237	NUM
dpc-1540	361	5	.	.	PUNCT
dpc-1540	362	1	pmid	pmid	NOUN
dpc-1540	362	2	:	:	PUNCT
dpc-1540	362	3	15708941	15708941	NUM
dpc-1540	362	4	.	.	PUNCT
dpc-1540	363	1	13	13	NUM
dpc-1540	363	2	.	.	X
dpc-1540	363	3	buysse	buysse	NOUN
dpc-1540	363	4	dj	dj	PROPN
dpc-1540	363	5	,	,	PUNCT
dpc-1540	363	6	reynolds	reynolds	PROPN
dpc-1540	363	7	cf	cf	PROPN
dpc-1540	363	8	,	,	PUNCT
dpc-1540	363	9	monk	monk	PROPN
dpc-1540	363	10	th	th	PROPN
dpc-1540	363	11	,	,	PUNCT
dpc-1540	363	12	berman	berman	PROPN
dpc-1540	363	13	sr	sr	PROPN
dpc-1540	363	14	,	,	PUNCT
dpc-1540	363	15	kupfer	kupfer	PROPN
dpc-1540	363	16	dj	dj	PROPN
dpc-1540	363	17	.	.	PUNCT
dpc-1540	364	1	the	the	DET
dpc-1540	364	2	pittsburgh	pittsburgh	PROPN
dpc-1540	364	3	sleep	sleep	PROPN
dpc-1540	364	4	quality	quality	PROPN
dpc-1540	364	5	index	index	NOUN
dpc-1540	364	6	:	:	PUNCT
dpc-1540	364	7	a	a	DET
dpc-1540	364	8	new	new	ADJ
dpc-1540	364	9	instrument	instrument	NOUN
dpc-1540	364	10	for	for	ADP
dpc-1540	364	11	psychiatric	psychiatric	ADJ
dpc-1540	364	12	practice	practice	NOUN
dpc-1540	364	13	and	and	CCONJ
dpc-1540	364	14	research	research	NOUN
dpc-1540	364	15	.	.	PUNCT
dpc-1540	365	1	psychiatry	psychiatry	NOUN
dpc-1540	365	2	res.1989;28(2):193	res.1989;28(2):193	PROPN
dpc-1540	365	3	-	-	PUNCT
dpc-1540	365	4	213	213	NUM
dpc-1540	365	5	.	.	PUNCT
dpc-1540	366	1	doi	doi	NOUN
dpc-1540	366	2	:	:	PUNCT
dpc-1540	366	3	10.1016/0165	10.1016/0165	NUM
dpc-1540	366	4	-	-	SYM
dpc-1540	366	5	1781(89)90047	1781(89)90047	NUM
dpc-1540	366	6	-	-	PUNCT
dpc-1540	366	7	4	4	NUM
dpc-1540	366	8	.	.	PUNCT
dpc-1540	367	1	pmid	pmid	NOUN
dpc-1540	367	2	:	:	PUNCT
dpc-1540	367	3	2748771	2748771	NUM
dpc-1540	367	4	.	.	PUNCT
dpc-1540	368	1	14	14	NUM
dpc-1540	368	2	.	.	PUNCT
dpc-1540	368	3	agargun	agargun	VERB
dpc-1540	368	4	my	my	PRON
dpc-1540	368	5	,	,	PUNCT
dpc-1540	368	6	kara	kara	PROPN
dpc-1540	368	7	h	h	PROPN
dpc-1540	368	8	,	,	PUNCT
dpc-1540	368	9	anlar	anlar	ADJ
dpc-1540	368	10	o.	o.	NOUN
dpc-1540	369	1	[	[	X
dpc-1540	369	2	the	the	DET
dpc-1540	369	3	validity	validity	NOUN
dpc-1540	369	4	and	and	CCONJ
dpc-1540	369	5	reliability	reliability	NOUN
dpc-1540	369	6	of	of	ADP
dpc-1540	369	7	the	the	DET
dpc-1540	369	8	pittsburgh	pittsburgh	PROPN
dpc-1540	369	9	sleep	sleep	PROPN
dpc-1540	369	10	quality	quality	PROPN
dpc-1540	369	11	index	index	NOUN
dpc-1540	369	12	.	.	PUNCT
dpc-1540	369	13	]	]	PUNCT
dpc-1540	370	1	abstract	abstract	ADV
dpc-1540	370	2	in	in	ADP
dpc-1540	370	3	english.turkpsikiyatriderg	english.turkpsikiyatriderg	PROPN
dpc-1540	370	4	.	.	PUNCT
dpc-1540	371	1	1996;7(2):107	1996;7(2):107	NUM
dpc-1540	371	2	-	-	SYM
dpc-1540	371	3	115	115	NUM
dpc-1540	371	4	.	.	PUNCT
dpc-1540	372	1	15	15	NUM
dpc-1540	372	2	.	.	PUNCT
dpc-1540	373	1	expert	expert	ADJ
dpc-1540	373	2	panel	panel	NOUN
dpc-1540	373	3	on	on	ADP
dpc-1540	373	4	detection	detection	NOUN
dpc-1540	373	5	,	,	PUNCT
dpc-1540	373	6	evaluation	evaluation	NOUN
dpc-1540	373	7	,	,	PUNCT
dpc-1540	373	8	and	and	CCONJ
dpc-1540	373	9	treatment	treatment	NOUN
dpc-1540	373	10	of	of	ADP
dpc-1540	373	11	high	high	ADJ
dpc-1540	373	12	blood	blood	NOUN
dpc-1540	373	13	cholesterol	cholesterol	NOUN
dpc-1540	373	14	in	in	ADP
dpc-1540	373	15	adults	adult	NOUN
dpc-1540	373	16	.	.	PUNCT
dpc-1540	374	1	executive	executive	ADJ
dpc-1540	374	2	summary	summary	NOUN
dpc-1540	374	3	of	of	ADP
dpc-1540	374	4	the	the	DET
dpc-1540	374	5	third	third	ADJ
dpc-1540	374	6	report	report	NOUN
dpc-1540	374	7	of	of	ADP
dpc-1540	374	8	the	the	DET
dpc-1540	374	9	national	national	ADJ
dpc-1540	374	10	cholesterol	cholesterol	PROPN
dpc-1540	374	11	education	education	NOUN
dpc-1540	374	12	program	program	NOUN
dpc-1540	374	13	(	(	PUNCT
dpc-1540	374	14	ncep	ncep	NOUN
dpc-1540	374	15	)	)	PUNCT
dpc-1540	374	16	expert	expert	NOUN
dpc-1540	374	17	panel	panel	NOUN
dpc-1540	374	18	on	on	ADP
dpc-1540	374	19	detection	detection	NOUN
dpc-1540	374	20	,	,	PUNCT
dpc-1540	374	21	evaluation	evaluation	NOUN
dpc-1540	374	22	,	,	PUNCT
dpc-1540	374	23	and	and	CCONJ
dpc-1540	374	24	treatment	treatment	NOUN
dpc-1540	374	25	of	of	ADP
dpc-1540	374	26	high	high	ADJ
dpc-1540	374	27	blood	blood	NOUN
dpc-1540	374	28	cholesterol	cholesterol	NOUN
dpc-1540	374	29	in	in	ADP
dpc-1540	374	30	adults	adult	NOUN
dpc-1540	374	31	(	(	PUNCT
dpc-1540	374	32	adult	adult	NOUN
dpc-1540	374	33	treatment	treatment	NOUN
dpc-1540	374	34	panel	panel	NOUN
dpc-1540	374	35	iii	iii	PROPN
dpc-1540	374	36	)	)	PUNCT
dpc-1540	374	37	.	.	PUNCT
dpc-1540	375	1	jama	jama	PROPN
dpc-1540	375	2	.	.	PUNCT
dpc-1540	376	1	2001;285(19):2486	2001;285(19):2486	NUM
dpc-1540	376	2	-	-	SYM
dpc-1540	376	3	2497	2497	NUM
dpc-1540	376	4	.	.	PUNCT
dpc-1540	377	1	doi	doi	NOUN
dpc-1540	377	2	:	:	PUNCT
dpc-1540	377	3	10.1001	10.1001	NUM
dpc-1540	377	4	/	/	SYM
dpc-1540	377	5	jama.285.19.2486	jama.285.19.2486	NOUN
dpc-1540	377	6	.	.	PUNCT
dpc-1540	378	1	pmid	pmid	NOUN
dpc-1540	378	2	:	:	PUNCT
dpc-1540	378	3	11368702	11368702	NUM
dpc-1540	378	4	.	.	PUNCT
dpc-1540	379	1	16	16	NUM
dpc-1540	379	2	.	.	PUNCT
dpc-1540	380	1	who	who	PRON
dpc-1540	380	2	expert	expert	VERB
dpc-1540	380	3	consultation.appropriate	consultation.appropriate	PROPN
dpc-1540	380	4	body	body	NOUN
dpc-1540	380	5	-	-	PUNCT
dpc-1540	380	6	mass	mass	NOUN
dpc-1540	380	7	index	index	NOUN
dpc-1540	380	8	for	for	ADP
dpc-1540	380	9	asian	asian	ADJ
dpc-1540	380	10	populations	population	NOUN
dpc-1540	380	11	and	and	CCONJ
dpc-1540	380	12	its	its	PRON
dpc-1540	380	13	implications	implication	NOUN
dpc-1540	380	14	for	for	ADP
dpc-1540	380	15	policy	policy	NOUN
dpc-1540	380	16	and	and	CCONJ
dpc-1540	380	17	intervention	intervention	NOUN
dpc-1540	380	18	strategies.lancet.2004;363(9403):157	strategies.lancet.2004;363(9403):157	PROPN
dpc-1540	380	19	-	-	SYM
dpc-1540	380	20	163	163	NUM
dpc-1540	380	21	.	.	PUNCT
dpc-1540	381	1	doi	doi	NOUN
dpc-1540	381	2	:	:	PUNCT
dpc-1540	381	3	10.1016/	10.1016/	NUM
dpc-1540	381	4	s0140	s0140	PROPN
dpc-1540	381	5	-	-	PUNCT
dpc-1540	381	6	6736(03)15268	6736(03)15268	NUM
dpc-1540	381	7	-	-	PUNCT
dpc-1540	381	8	3	3	NUM
dpc-1540	381	9	.	.	PUNCT
dpc-1540	382	1	pmid	pmid	NOUN
dpc-1540	382	2	:	:	PUNCT
dpc-1540	382	3	14726171	14726171	NUM
dpc-1540	382	4	.	.	PUNCT
dpc-1540	383	1	17	17	NUM
dpc-1540	383	2	.	.	PUNCT
dpc-1540	384	1	obesity	obesity	NOUN
dpc-1540	384	2	:	:	PUNCT
dpc-1540	384	3	preventing	prevent	VERB
dpc-1540	384	4	and	and	CCONJ
dpc-1540	384	5	managing	manage	VERB
dpc-1540	384	6	the	the	DET
dpc-1540	384	7	global	global	ADJ
dpc-1540	384	8	epidemic	epidemic	NOUN
dpc-1540	384	9	.	.	PUNCT
dpc-1540	385	1	report	report	NOUN
dpc-1540	385	2	of	of	ADP
dpc-1540	385	3	a	a	DET
dpc-1540	385	4	who	who	PRON
dpc-1540	385	5	consultation	consultation	NOUN
dpc-1540	385	6	.	.	PUNCT
dpc-1540	386	1	world	world	PROPN
dpc-1540	386	2	health	health	PROPN
dpc-1540	386	3	organ	organ	NOUN
dpc-1540	386	4	tech	tech	NOUN
dpc-1540	386	5	rep	rep	NOUN
dpc-1540	386	6	ser	ser	PROPN
dpc-1540	386	7	.	.	PROPN
dpc-1540	386	8	2000	2000	NUM
dpc-1540	386	9	;	;	PUNCT
dpc-1540	386	10	894	894	NUM
dpc-1540	386	11	:	:	PUNCT
dpc-1540	386	12	i	i	PROPN
dpc-1540	386	13	-	-	PUNCT
dpc-1540	386	14	xii	xii	PROPN
dpc-1540	386	15	,	,	PUNCT
dpc-1540	386	16	1	1	NUM
dpc-1540	386	17	-	-	SYM
dpc-1540	386	18	253	253	NUM
dpc-1540	386	19	.	.	PUNCT
dpc-1540	387	1	pmid	pmid	NOUN
dpc-1540	387	2	:	:	PUNCT
dpc-1540	387	3	11234459	11234459	NUM
dpc-1540	387	4	.	.	PUNCT
dpc-1540	388	1	18	18	NUM
dpc-1540	388	2	.	.	PUNCT
dpc-1540	389	1	alderman	alderman	PROPN
dpc-1540	389	2	mh	mh	PROPN
dpc-1540	389	3	.	.	PUNCT
dpc-1540	390	1	jnc	jnc	PROPN
dpc-1540	390	2	7	7	NUM
dpc-1540	390	3	:	:	PUNCT
dpc-1540	390	4	brief	brief	ADJ
dpc-1540	390	5	summary	summary	NOUN
dpc-1540	390	6	and	and	CCONJ
dpc-1540	390	7	critique	critique	NOUN
dpc-1540	390	8	.	.	PUNCT
dpc-1540	391	1	clin	clin	PROPN
dpc-1540	391	2	exp	exp	NOUN
dpc-1540	391	3	hypertens.2004;26(7	hypertens.2004;26(7	PROPN
dpc-1540	391	4	-	-	PUNCT
dpc-1540	391	5	8):753	8):753	NOUN
dpc-1540	391	6	-	-	PUNCT
dpc-1540	391	7	761	761	NUM
dpc-1540	391	8	.	.	PUNCT
dpc-1540	392	1	doi	doi	NOUN
dpc-1540	392	2	:	:	PUNCT
dpc-1540	392	3	10.1081	10.1081	NUM
dpc-1540	392	4	/	/	SYM
dpc-1540	392	5	ceh-200032158	ceh-200032158	NOUN
dpc-1540	392	6	.	.	PUNCT
dpc-1540	393	1	pmid	pmid	NOUN
dpc-1540	393	2	:	:	PUNCT
dpc-1540	393	3	15702631	15702631	NUM
dpc-1540	393	4	.	.	PUNCT
dpc-1540	394	1	19	19	NUM
dpc-1540	394	2	.	.	PUNCT
dpc-1540	394	3	matthews	matthews	PROPN
dpc-1540	394	4	dr	dr	PROPN
dpc-1540	394	5	,	,	PUNCT
dpc-1540	394	6	hosker	hosker	PROPN
dpc-1540	394	7	jk	jk	PROPN
dpc-1540	394	8	,	,	PUNCT
dpc-1540	394	9	rudenski	rudenski	VERB
dpc-1540	394	10	as	as	ADP
dpc-1540	394	11	,	,	PUNCT
dpc-1540	394	12	naylor	naylor	PROPN
dpc-1540	394	13	ba	ba	PROPN
dpc-1540	394	14	,	,	PUNCT
dpc-1540	394	15	treacher	treacher	PROPN
dpc-1540	394	16	df	df	PROPN
dpc-1540	394	17	,	,	PUNCT
dpc-1540	394	18	turner	turner	PROPN
dpc-1540	394	19	rc	rc	PROPN
dpc-1540	394	20	.	.	PUNCT
dpc-1540	394	21	homeostasis	homeostasis	NOUN
dpc-1540	394	22	model	model	NOUN
dpc-1540	394	23	assessment	assessment	NOUN
dpc-1540	394	24	:	:	PUNCT
dpc-1540	394	25	insulin	insulin	NOUN
dpc-1540	394	26	resistance	resistance	NOUN
dpc-1540	394	27	and	and	CCONJ
dpc-1540	394	28	β	β	NOUN
dpc-1540	394	29	-	-	NOUN
dpc-1540	394	30	cell	cell	NOUN
dpc-1540	394	31	function	function	NOUN
dpc-1540	394	32	from	from	ADP
dpc-1540	394	33	fasting	fast	VERB
dpc-1540	394	34	plasma	plasma	NOUN
dpc-1540	394	35	glucose	glucose	NOUN
dpc-1540	394	36	and	and	CCONJ
dpc-1540	394	37	insulin	insulin	NOUN
dpc-1540	394	38	concentrations	concentration	NOUN
dpc-1540	394	39	in	in	ADP
dpc-1540	394	40	man	man	NOUN
dpc-1540	394	41	.	.	PUNCT
dpc-1540	395	1	diabetologia	diabetologia	NOUN
dpc-1540	395	2	.	.	PUNCT
dpc-1540	396	1	1985;28(7):412	1985;28(7):412	NUM
dpc-1540	396	2	-	-	SYM
dpc-1540	396	3	419	419	NUM
dpc-1540	396	4	.	.	PUNCT
dpc-1540	397	1	doi	doi	NOUN
dpc-1540	397	2	:	:	PUNCT
dpc-1540	397	3	10.1007/	10.1007/	NUM
dpc-1540	397	4	bf00280883	bf00280883	NOUN
dpc-1540	397	5	.	.	PUNCT
dpc-1540	398	1	pmid	pmid	NOUN
dpc-1540	398	2	:	:	PUNCT
dpc-1540	398	3	3899825	3899825	NUM
dpc-1540	398	4	.	.	PUNCT
dpc-1540	399	1	20	20	NUM
dpc-1540	399	2	.	.	PUNCT
dpc-1540	400	1	singh	singh	PROPN
dpc-1540	400	2	y	y	PROPN
dpc-1540	400	3	,	,	PUNCT
dpc-1540	400	4	garg	garg	PROPN
dpc-1540	400	5	mk	mk	PROPN
dpc-1540	400	6	,	,	PUNCT
dpc-1540	400	7	tandon	tandon	PROPN
dpc-1540	400	8	n	n	CCONJ
dpc-1540	400	9	,	,	PUNCT
dpc-1540	400	10	marwaha	marwaha	VERB
dpc-1540	400	11	rk	rk	NOUN
dpc-1540	400	12	.	.	PUNCT
dpc-1540	401	1	a	a	DET
dpc-1540	401	2	study	study	NOUN
dpc-1540	401	3	of	of	ADP
dpc-1540	401	4	insulin	insulin	NOUN
dpc-1540	401	5	resistance	resistance	NOUN
dpc-1540	401	6	by	by	ADP
dpc-1540	401	7	homa	homa	PROPN
dpc-1540	401	8	-	-	PUNCT
dpc-1540	401	9	ir	ir	PROPN
dpc-1540	401	10	and	and	CCONJ
dpc-1540	401	11	its	its	PRON
dpc-1540	401	12	cut	cut	VERB
dpc-1540	401	13	-	-	PUNCT
dpc-1540	401	14	off	off	ADP
dpc-1540	401	15	value	value	NOUN
dpc-1540	401	16	to	to	PART
dpc-1540	401	17	identify	identify	VERB
dpc-1540	401	18	metabolic	metabolic	NOUN
dpc-1540	401	19	syndrome	syndrome	NOUN
dpc-1540	401	20	in	in	ADP
dpc-1540	401	21	urban	urban	ADJ
dpc-1540	401	22	indian	indian	ADJ
dpc-1540	401	23	adolescents	adolescent	NOUN
dpc-1540	401	24	.	.	PUNCT
dpc-1540	402	1	j	j	PROPN
dpc-1540	402	2	clin	clin	PROPN
dpc-1540	402	3	res	re	NOUN
dpc-1540	402	4	pediatr	pediatr	ADJ
dpc-1540	402	5	endocrinol	endocrinol	NOUN
dpc-1540	402	6	.	.	PUNCT
dpc-1540	403	1	2013;5(4):245	2013;5(4):245	NUM
dpc-1540	403	2	-	-	SYM
dpc-1540	403	3	251	251	NUM
dpc-1540	403	4	.	.	PUNCT
dpc-1540	404	1	doi	doi	NOUN
dpc-1540	404	2	:	:	PUNCT
dpc-1540	404	3	10.4274	10.4274	NUM
dpc-1540	404	4	/	/	SYM
dpc-1540	404	5	jcrpe.1127	jcrpe.1127	PROPN
dpc-1540	404	6	.	.	PUNCT
dpc-1540	405	1	pmid	pmid	PROPN
dpc-1540	405	2	:	:	PUNCT
dpc-1540	405	3	24379034	24379034	NUM
dpc-1540	405	4	.	.	PUNCT
dpc-1540	406	1	21	21	NUM
dpc-1540	406	2	.	.	PUNCT
dpc-1540	407	1	singh	singh	PROPN
dpc-1540	407	2	s	s	PROPN
dpc-1540	407	3	,	,	PUNCT
dpc-1540	407	4	young	young	ADJ
dpc-1540	407	5	p	p	X
dpc-1540	407	6	,	,	PUNCT
dpc-1540	407	7	armstrong	armstrong	PROPN
dpc-1540	407	8	aw	aw	INTJ
dpc-1540	407	9	.	.	PUNCT
dpc-1540	408	1	an	an	DET
dpc-1540	408	2	update	update	NOUN
dpc-1540	408	3	on	on	ADP
dpc-1540	408	4	psoriasis	psoriasis	NOUN
dpc-1540	408	5	and	and	CCONJ
dpc-1540	408	6	metabolic	metabolic	NOUN
dpc-1540	408	7	syndrome	syndrome	NOUN
dpc-1540	408	8	:	:	PUNCT
dpc-1540	408	9	a	a	DET
dpc-1540	408	10	meta	meta	ADJ
dpc-1540	408	11	-	-	PUNCT
dpc-1540	408	12	analysis	analysis	NOUN
dpc-1540	408	13	of	of	ADP
dpc-1540	408	14	observational	observational	ADJ
dpc-1540	408	15	studies	study	NOUN
dpc-1540	408	16	.	.	PUNCT
dpc-1540	409	1	plos	plos	PROPN
dpc-1540	409	2	one	one	NUM
dpc-1540	409	3	.	.	PUNCT
dpc-1540	410	1	2017;12(7):e0181039	2017;12(7):e0181039	NUM
dpc-1540	410	2	.	.	PUNCT
dpc-1540	411	1	doi	doi	NOUN
dpc-1540	411	2	:	:	PUNCT
dpc-1540	411	3	10.1371	10.1371	NUM
dpc-1540	411	4	/	/	SYM
dpc-1540	411	5	journal	journal	NOUN
dpc-1540	411	6	.	.	PUNCT
dpc-1540	412	1	pone.0181039	pone.0181039	PROPN
dpc-1540	412	2	.	.	PUNCT
dpc-1540	413	1	pmid	pmid	NOUN
dpc-1540	413	2	:	:	PUNCT
dpc-1540	413	3	28719618	28719618	NUM
dpc-1540	413	4	.	.	PUNCT
dpc-1540	414	1	22	22	NUM
dpc-1540	414	2	.	.	PUNCT
dpc-1540	415	1	yayli	yayli	PROPN
dpc-1540	415	2	s	s	PROPN
dpc-1540	415	3	,	,	PUNCT
dpc-1540	415	4	topbas	topbas	PROPN
dpc-1540	415	5	m	m	NOUN
dpc-1540	415	6	,	,	PUNCT
dpc-1540	415	7	aksu	aksu	PROPN
dpc-1540	415	8	arica	arica	PROPN
dpc-1540	416	1	d	d	PROPN
dpc-1540	416	2	,	,	PUNCT
dpc-1540	416	3	et	et	PROPN
dpc-1540	416	4	al	al	PROPN
dpc-1540	416	5	.	.	PUNCT
dpc-1540	417	1	the	the	DET
dpc-1540	417	2	prevalence	prevalence	NOUN
dpc-1540	417	3	of	of	ADP
dpc-1540	417	4	psoriasis	psoriasis	NOUN
dpc-1540	417	5	in	in	ADP
dpc-1540	417	6	trabzon	trabzon	PROPN
dpc-1540	417	7	.	.	PUNCT
dpc-1540	418	1	turkderm	turkderm	ADJ
dpc-1540	418	2	.	.	PUNCT
dpc-1540	419	1	2016;50(4):141	2016;50(4):141	NUM
dpc-1540	419	2	-	-	SYM
dpc-1540	419	3	144	144	NUM
dpc-1540	419	4	.	.	PUNCT
dpc-1540	420	1	doi	doi	NOUN
dpc-1540	420	2	:	:	PUNCT
dpc-1540	420	3	10.4274/	10.4274/	NUM
dpc-1540	420	4	turkderm.75735	turkderm.75735	NOUN
dpc-1540	420	5	.	.	PROPN
dpc-1540	420	6	23	23	NUM
dpc-1540	420	7	.	.	PUNCT
dpc-1540	420	8	gundogan	gundogan	VERB
dpc-1540	421	1	k	k	PROPN
dpc-1540	421	2	,	,	PUNCT
dpc-1540	421	3	bayram	bayram	PROPN
dpc-1540	421	4	f	f	PROPN
dpc-1540	421	5	,	,	PUNCT
dpc-1540	421	6	capak	capak	PROPN
dpc-1540	421	7	m	m	PROPN
dpc-1540	421	8	,	,	PUNCT
dpc-1540	421	9	et	et	PROPN
dpc-1540	421	10	al	al	PROPN
dpc-1540	421	11	.	.	PUNCT
dpc-1540	422	1	prevalence	prevalence	NOUN
dpc-1540	422	2	of	of	ADP
dpc-1540	422	3	metabolic	metabolic	NOUN
dpc-1540	422	4	syndrome	syndrome	NOUN
dpc-1540	422	5	in	in	ADP
dpc-1540	422	6	the	the	DET
dpc-1540	422	7	world	world	NOUN
dpc-1540	422	8	and	and	CCONJ
dpc-1540	422	9	turkey.turkiyeklinikleri	turkey.turkiyeklinikleri	PROPN
dpc-1540	422	10	j	j	PROPN
dpc-1540	422	11	int	int	PROPN
dpc-1540	422	12	med	med	PROPN
dpc-1540	422	13	sci.2006;2:18	sci.2006;2:18	PROPN
dpc-1540	422	14	-	-	PUNCT
dpc-1540	422	15	24	24	NUM
dpc-1540	422	16	.	.	PUNCT
dpc-1540	422	17	24	24	NUM
dpc-1540	422	18	.	.	PUNCT
dpc-1540	423	1	gemalmaz	gemalmaz	NOUN
dpc-1540	423	2	a	a	PRON
dpc-1540	423	3	,	,	PUNCT
dpc-1540	423	4	aydin	aydin	NOUN
dpc-1540	423	5	s	s	PROPN
dpc-1540	423	6	,	,	PUNCT
dpc-1540	423	7	basak	basak	PROPN
dpc-1540	423	8	o	o	PROPN
dpc-1540	423	9	,	,	PUNCT
dpc-1540	423	10	discigil	discigil	PROPN
dpc-1540	423	11	g	g	NOUN
dpc-1540	423	12	,	,	PUNCT
dpc-1540	423	13	kurul	kurul	NOUN
dpc-1540	423	14	a.	a.	NOUN
dpc-1540	423	15	prevalence	prevalence	NOUN
dpc-1540	423	16	of	of	ADP
dpc-1540	423	17	metabolic	metabolic	NOUN
dpc-1540	423	18	syndrome	syndrome	NOUN
dpc-1540	423	19	in	in	ADP
dpc-1540	423	20	a	a	DET
dpc-1540	423	21	rural	rural	ADJ
dpc-1540	423	22	turkish	turkish	ADJ
dpc-1540	423	23	population	population	NOUN
dpc-1540	423	24	:	:	PUNCT
dpc-1540	423	25	comparison	comparison	NOUN
dpc-1540	423	26	and	and	CCONJ
dpc-1540	423	27	concordance	concordance	NOUN
dpc-1540	423	28	of	of	ADP
dpc-1540	423	29	two	two	NUM
dpc-1540	423	30	diagnostic	diagnostic	ADJ
dpc-1540	423	31	criteria	criterion	NOUN
dpc-1540	423	32	.	.	PUNCT
dpc-1540	424	1	turk	turk	PROPN
dpc-1540	424	2	j	j	PROPN
dpc-1540	424	3	med	med	PROPN
dpc-1540	424	4	sci.2008;38(2):159	sci.2008;38(2):159	PROPN
dpc-1540	424	5	-	-	PUNCT
dpc-1540	424	6	165.https://app.trdizin.gov.tr	165.https://app.trdizin.gov.tr	NUM
dpc-1540	424	7	/	/	SYM
dpc-1540	424	8	publication/	publication/	NUM
dpc-1540	424	9	paper	paper	NOUN
dpc-1540	424	10	/	/	SYM
dpc-1540	424	11	detail	detail	NOUN
dpc-1540	424	12	/	/	SYM
dpc-1540	424	13	tnpnne5uvte=	tnpnne5uvte=	PROPN
dpc-1540	424	14	25	25	NUM
dpc-1540	424	15	.	.	PUNCT
dpc-1540	425	1	ferdinando	ferdinando	PROPN
dpc-1540	425	2	lb	lb	PROPN
dpc-1540	425	3	,	,	PUNCT
dpc-1540	425	4	fukumoto	fukumoto	DET
dpc-1540	425	5	pk	pk	NOUN
dpc-1540	425	6	,	,	PUNCT
dpc-1540	425	7	sanches	sanches	PROPN
dpc-1540	425	8	s	s	PROPN
dpc-1540	425	9	,	,	PUNCT
dpc-1540	425	10	fabricio	fabricio	PROPN
dpc-1540	425	11	lhz	lhz	PROPN
dpc-1540	425	12	,	,	PUNCT
dpc-1540	425	13	skare	skare	VERB
dpc-1540	425	14	tl	tl	PROPN
dpc-1540	425	15	.	.	PUNCT
dpc-1540	425	16	metabolic	metabolic	PROPN
dpc-1540	425	17	syndrome	syndrome	NOUN
dpc-1540	425	18	and	and	CCONJ
dpc-1540	425	19	psoriasis	psoriasis	NOUN
dpc-1540	425	20	:	:	PUNCT
dpc-1540	425	21	a	a	DET
dpc-1540	425	22	study	study	NOUN
dpc-1540	425	23	in	in	ADP
dpc-1540	425	24	97	97	NUM
dpc-1540	425	25	patients	patient	NOUN
dpc-1540	425	26	.	.	PUNCT
dpc-1540	426	1	rev	rev	PROPN
dpc-1540	426	2	assoc	assoc	PROPN
dpc-1540	426	3	med	med	PROPN
dpc-1540	426	4	bras	bras	NOUN
dpc-1540	426	5	.	.	PUNCT
dpc-1540	427	1	2018;64(4):368	2018;64(4):368	NUM
dpc-1540	427	2	-	-	PUNCT
dpc-1540	427	3	373	373	NUM
dpc-1540	427	4	.	.	PUNCT
dpc-1540	428	1	doi	doi	NOUN
dpc-1540	428	2	:	:	PUNCT
dpc-1540	428	3	10.1590/18069282.64.04.368	10.1590/18069282.64.04.368	NUM
dpc-1540	428	4	.	.	PUNCT
dpc-1540	429	1	pmid	pmid	NOUN
dpc-1540	429	2	:	:	PUNCT
dpc-1540	429	3	30133617	30133617	NUM
dpc-1540	429	4	.	.	PUNCT
dpc-1540	430	1	26	26	NUM
dpc-1540	430	2	.	.	PUNCT
dpc-1540	431	1	gisondi	gisondi	PROPN
dpc-1540	431	2	p	p	NOUN
dpc-1540	431	3	,	,	PUNCT
dpc-1540	431	4	fostini	fostini	ADJ
dpc-1540	431	5	ac	ac	PROPN
dpc-1540	431	6	,	,	PUNCT
dpc-1540	431	7	fossà	fossà	VERB
dpc-1540	431	8	i	i	PRON
dpc-1540	431	9	,	,	PUNCT
dpc-1540	431	10	girolomoni	girolomoni	VERB
dpc-1540	431	11	g	g	NOUN
dpc-1540	431	12	,	,	PUNCT
dpc-1540	431	13	targher	targher	ADJ
dpc-1540	431	14	g.	g.	PROPN
dpc-1540	431	15	psoriasisandthemetabolicsyndrome	psoriasisandthemetabolicsyndrome	PROPN
dpc-1540	431	16	.	.	PUNCT
dpc-1540	432	1	clindermatol	clindermatol	NOUN
dpc-1540	432	2	.	.	PUNCT
dpc-1540	433	1	2018;36(1):21	2018;36(1):21	NUM
dpc-1540	433	2	-	-	SYM
dpc-1540	433	3	28	28	NUM
dpc-1540	433	4	.	.	PUNCT
dpc-1540	434	1	doi:10.1016	doi:10.1016	PROPN
dpc-1540	434	2	/	/	SYM
dpc-1540	434	3	j.clindermatol.2017.09.005	j.clindermatol.2017.09.005	PROPN
dpc-1540	434	4	.	.	PUNCT
dpc-1540	435	1	pmid	pmid	NOUN
dpc-1540	435	2	:	:	PUNCT
dpc-1540	435	3	29241748	29241748	NUM
dpc-1540	435	4	.	.	PUNCT
dpc-1540	436	1	27	27	NUM
dpc-1540	436	2	.	.	PUNCT
dpc-1540	437	1	zindanci	zindanci	PROPN
dpc-1540	438	1	i	i	PROPN
dpc-1540	438	2	,	,	PUNCT
dpc-1540	438	3	albayrak	albayrak	PROPN
dpc-1540	438	4	o	o	NOUN
dpc-1540	438	5	,	,	PUNCT
dpc-1540	438	6	kavala	kavala	PROPN
dpc-1540	438	7	m	m	PROPN
dpc-1540	438	8	,	,	PUNCT
dpc-1540	438	9	et	et	PROPN
dpc-1540	438	10	al	al	PROPN
dpc-1540	438	11	.	.	PUNCT
dpc-1540	439	1	prevalence	prevalence	NOUN
dpc-1540	439	2	of	of	ADP
dpc-1540	439	3	metabolic	metabolic	NOUN
dpc-1540	439	4	syndrome	syndrome	NOUN
dpc-1540	439	5	in	in	ADP
dpc-1540	439	6	patients	patient	NOUN
dpc-1540	439	7	with	with	ADP
dpc-1540	439	8	psoriasis	psoriasis	NOUN
dpc-1540	439	9	.	.	PUNCT
dpc-1540	440	1	the	the	DET
dpc-1540	440	2	scientific	scientific	ADJ
dpc-1540	440	3	world	world	NOUN
dpc-1540	440	4	journal	journal	NOUN
dpc-1540	440	5	.	.	PUNCT
dpc-1540	441	1	2012;2012:312463	2012;2012:312463	NUM
dpc-1540	441	2	.	.	PUNCT
dpc-1540	442	1	doi:10.1100/2012/312463	doi:10.1100/2012/312463	PROPN
dpc-1540	442	2	.	.	PUNCT
dpc-1540	443	1	pmid:22654590	pmid:22654590	NOUN
dpc-1540	443	2	.	.	PROPN
dpc-1540	443	3	28	28	NUM
dpc-1540	443	4	.	.	PUNCT
dpc-1540	444	1	tasliyurt	tasliyurt	PROPN
dpc-1540	444	2	t	t	PROPN
dpc-1540	444	3	,	,	PUNCT
dpc-1540	444	4	bilir	bilir	NOUN
dpc-1540	444	5	y	y	PROPN
dpc-1540	444	6	,	,	PUNCT
dpc-1540	444	7	sahin	sahin	PROPN
dpc-1540	444	8	s	s	PROPN
dpc-1540	444	9	,	,	PUNCT
dpc-1540	444	10	et	et	PROPN
dpc-1540	444	11	al	al	PROPN
dpc-1540	444	12	.	.	PROPN
dpc-1540	445	1	erectile	erectile	ADJ
dpc-1540	445	2	dysfunction	dysfunction	NOUN
dpc-1540	445	3	in	in	ADP
dpc-1540	445	4	patients	patient	NOUN
dpc-1540	445	5	with	with	ADP
dpc-1540	445	6	psoriasis	psoriasis	NOUN
dpc-1540	445	7	:	:	PUNCT
dpc-1540	445	8	potential	potential	ADJ
dpc-1540	445	9	impact	impact	NOUN
dpc-1540	445	10	of	of	ADP
dpc-1540	445	11	the	the	DET
dpc-1540	445	12	metabolic	metabolic	NOUN
dpc-1540	445	13	syndrome	syndrome	NOUN
dpc-1540	445	14	.	.	PUNCT
dpc-1540	446	1	eur	eur	PROPN
dpc-1540	446	2	rev	rev	PROPN
dpc-1540	446	3	med	med	PROPN
dpc-1540	446	4	pharmacol	pharmacol	PROPN
dpc-1540	446	5	sci	sci	PROPN
dpc-1540	446	6	.	.	PUNCT
dpc-1540	447	1	2014;18(4):581–586	2014;18(4):581–586	NUM
dpc-1540	447	2	.	.	PUNCT
dpc-1540	448	1	pmid	pmid	NOUN
dpc-1540	448	2	:	:	PUNCT
dpc-1540	448	3	24610625	24610625	NUM
dpc-1540	448	4	29	29	NUM
dpc-1540	448	5	.	.	PUNCT
dpc-1540	449	1	adişen	adişen	PROPN
dpc-1540	449	2	e	e	PROPN
dpc-1540	449	3	,	,	PUNCT
dpc-1540	449	4	uzun	uzun	PROPN
dpc-1540	449	5	s	s	PART
dpc-1540	449	6	,	,	PUNCT
dpc-1540	449	7	erduran	erduran	ADJ
dpc-1540	449	8	f	f	NOUN
dpc-1540	449	9	,	,	PUNCT
dpc-1540	449	10	gürer	gürer	PROPN
dpc-1540	449	11	ma	ma	PROPN
dpc-1540	449	12	.	.	PROPN
dpc-1540	449	13	prevalence	prevalence	NOUN
dpc-1540	449	14	of	of	ADP
dpc-1540	449	15	smoking	smoking	NOUN
dpc-1540	449	16	,	,	PUNCT
dpc-1540	449	17	alcohol	alcohol	NOUN
dpc-1540	449	18	consumption	consumption	NOUN
dpc-1540	449	19	and	and	CCONJ
dpc-1540	449	20	metabolic	metabolic	NOUN
dpc-1540	449	21	syndrome	syndrome	NOUN
dpc-1540	449	22	in	in	ADP
dpc-1540	449	23	patients	patient	NOUN
dpc-1540	449	24	with	with	ADP
dpc-1540	449	25	psoriasis	psoriasis	NOUN
dpc-1540	449	26	.	.	PUNCT
dpc-1540	450	1	an	an	DET
dpc-1540	450	2	bras	bras	NOUN
dpc-1540	450	3	dermatol	dermatol	NOUN
dpc-1540	450	4	.	.	PUNCT
dpc-1540	451	1	2018;93(2):205	2018;93(2):205	NOUN
dpc-1540	451	2	-	-	PUNCT
dpc-1540	451	3	211	211	NUM
dpc-1540	451	4	.	.	PUNCT
dpc-1540	452	1	doi	doi	NOUN
dpc-1540	452	2	:	:	PUNCT
dpc-1540	452	3	10.1590/	10.1590/	NUM
dpc-1540	452	4	abd1806	abd1806	NOUN
dpc-1540	452	5	-	-	PUNCT
dpc-1540	452	6	4841.20186168	4841.20186168	NOUN
dpc-1540	452	7	.	.	PUNCT
dpc-1540	453	1	pmid	pmid	NOUN
dpc-1540	453	2	:	:	PUNCT
dpc-1540	453	3	29723384	29723384	NUM
dpc-1540	453	4	.	.	PUNCT
dpc-1540	454	1	30	30	NUM
dpc-1540	454	2	.	.	PUNCT
dpc-1540	454	3	baeta	baeta	PROPN
dpc-1540	454	4	ig	ig	PROPN
dpc-1540	454	5	,	,	PUNCT
dpc-1540	454	6	bittencourt	bittencourt	NOUN
dpc-1540	454	7	fv	fv	PROPN
dpc-1540	454	8	,	,	PUNCT
dpc-1540	454	9	gontijo	gontijo	PROPN
dpc-1540	454	10	b	b	PROPN
dpc-1540	454	11	,	,	PUNCT
dpc-1540	454	12	marcos	marcos	PROPN
dpc-1540	454	13	e	e	PROPN
dpc-1540	454	14	,	,	PUNCT
dpc-1540	454	15	goulart	goulart	PROPN
dpc-1540	454	16	a.	a.	NOUN
dpc-1540	454	17	comorbidities	comorbiditie	NOUN
dpc-1540	454	18	and	and	CCONJ
dpc-1540	454	19	cardiovascular	cardiovascular	ADJ
dpc-1540	454	20	risk	risk	NOUN
dpc-1540	454	21	factors	factor	NOUN
dpc-1540	454	22	in	in	ADP
dpc-1540	454	23	patients	patient	NOUN
dpc-1540	454	24	with	with	ADP
dpc-1540	454	25	psoriasis	psoriasis	NOUN
dpc-1540	454	26	.	.	PUNCT
dpc-1540	455	1	an	an	DET
dpc-1540	455	2	bras	bras	NOUN
dpc-1540	455	3	dermatol	dermatol	NOUN
dpc-1540	455	4	.	.	PUNCT
dpc-1540	456	1	2014;89(5):735	2014;89(5):735	NUM
dpc-1540	456	2	-	-	PUNCT
dpc-1540	456	3	744	744	NUM
dpc-1540	456	4	.	.	PUNCT
dpc-1540	457	1	doi:10.1590	doi:10.1590	ADJ
dpc-1540	457	2	/	/	SYM
dpc-1540	457	3	abd18064841.20142874	abd18064841.20142874	PROPN
dpc-1540	457	4	.	.	PUNCT
dpc-1540	458	1	pmid	pmid	NOUN
dpc-1540	458	2	:	:	PUNCT
dpc-1540	458	3	25184912	25184912	NUM
dpc-1540	458	4	.	.	PUNCT
dpc-1540	459	1	31	31	NUM
dpc-1540	459	2	.	.	PUNCT
dpc-1540	460	1	balkan	balkan	PROPN
dpc-1540	460	2	f.	f.	PROPN
dpc-1540	460	3	metabolic	metabolic	PROPN
dpc-1540	460	4	syndrome.article	syndrome.article	PROPN
dpc-1540	460	5	in	in	ADP
dpc-1540	460	6	turkish	turkish	PROPN
dpc-1540	460	7	.	.	PUNCT
dpc-1540	461	1	ankara	ankara	PROPN
dpc-1540	461	2	med	med	PROPN
dpc-1540	461	3	j.2013;13:85	j.2013;13:85	PROPN
dpc-1540	461	4	-	-	PUNCT
dpc-1540	461	5	90	90	NUM
dpc-1540	461	6	.	.	PUNCT
dpc-1540	462	1	https://dergipark.org.tr/tr/pub/amj/issue/1739/21396	https://dergipark.org.tr/tr/pub/amj/issue/1739/21396	PROPN
dpc-1540	462	2	32	32	NUM
dpc-1540	462	3	.	.	PUNCT
dpc-1540	463	1	kim	kim	PROPN
dpc-1540	463	2	gw	gw	PROPN
dpc-1540	463	3	,	,	PUNCT
dpc-1540	463	4	park	park	PROPN
dpc-1540	463	5	hj	hj	PROPN
dpc-1540	463	6	,	,	PUNCT
dpc-1540	463	7	kim	kim	PROPN
dpc-1540	463	8	hs	hs	PROPN
dpc-1540	463	9	,	,	PUNCT
dpc-1540	463	10	et	et	PROPN
dpc-1540	463	11	al	al	PROPN
dpc-1540	463	12	.	.	PUNCT
dpc-1540	464	1	analysis	analysis	NOUN
dpc-1540	464	2	of	of	ADP
dpc-1540	464	3	cardiovascular	cardiovascular	ADJ
dpc-1540	464	4	risk	risk	NOUN
dpc-1540	464	5	factors	factor	NOUN
dpc-1540	464	6	and	and	CCONJ
dpc-1540	464	7	metabolic	metabolic	NOUN
dpc-1540	464	8	syndrome	syndrome	NOUN
dpc-1540	464	9	in	in	ADP
dpc-1540	464	10	korean	korean	ADJ
dpc-1540	464	11	patients	patient	NOUN
dpc-1540	464	12	with	with	ADP
dpc-1540	464	13	psoriasis	psoriasis	NOUN
dpc-1540	464	14	.	.	PUNCT
dpc-1540	465	1	ann	ann	PROPN
dpc-1540	465	2	dermatol.2012;24(1):11	dermatol.2012;24(1):11	PROPN
dpc-1540	465	3	-	-	PUNCT
dpc-1540	465	4	15	15	NUM
dpc-1540	465	5	.	.	PUNCT
dpc-1540	466	1	doi	doi	NOUN
dpc-1540	466	2	:	:	PUNCT
dpc-1540	466	3	10.5021/	10.5021/	NUM
dpc-1540	466	4	ad.2012.24.1.11	ad.2012.24.1.11	NOUN
dpc-1540	466	5	.	.	PUNCT
dpc-1540	467	1	pmid	pmid	NOUN
dpc-1540	467	2	:	:	PUNCT
dpc-1540	467	3	22363149	22363149	NUM
dpc-1540	467	4	.	.	PUNCT
dpc-1540	468	1	33	33	NUM
dpc-1540	468	2	.	.	PUNCT
dpc-1540	469	1	itani	itani	PROPN
dpc-1540	469	2	s	s	PROPN
dpc-1540	469	3	,	,	PUNCT
dpc-1540	469	4	arabi	arabi	PROPN
dpc-1540	469	5	a	a	X
dpc-1540	469	6	,	,	PUNCT
dpc-1540	469	7	harb	harb	PROPN
dpc-1540	470	1	d	d	X
dpc-1540	470	2	,	,	PUNCT
dpc-1540	470	3	hamzeh	hamzeh	PROPN
dpc-1540	470	4	d	d	PROPN
dpc-1540	470	5	,	,	PUNCT
dpc-1540	470	6	kıbbi	kıbbi	PROPN
dpc-1540	470	7	ag	ag	PROPN
dpc-1540	470	8	.	.	PROPN
dpc-1540	470	9	high	high	ADJ
dpc-1540	470	10	prevalence	prevalence	NOUN
dpc-1540	470	11	of	of	ADP
dpc-1540	470	12	metabolic	metabolic	NOUN
dpc-1540	470	13	syndrome	syndrome	NOUN
dpc-1540	470	14	in	in	ADP
dpc-1540	470	15	patients	patient	NOUN
dpc-1540	470	16	with	with	ADP
dpc-1540	470	17	psoriasis	psoriasis	NOUN
dpc-1540	470	18	in	in	ADP
dpc-1540	470	19	lebanon	lebanon	PROPN
dpc-1540	470	20	:	:	PUNCT
dpc-1540	470	21	a	a	DET
dpc-1540	470	22	prospective	prospective	ADJ
dpc-1540	470	23	study	study	NOUN
dpc-1540	470	24	.	.	PUNCT
dpc-1540	471	1	int	int	PROPN
dpc-1540	471	2	j	j	PROPN
dpc-1540	471	3	dermatol.2016;55(4):390	dermatol.2016;55(4):390	PROPN
dpc-1540	471	4	-	-	PUNCT
dpc-1540	471	5	395	395	NUM
dpc-1540	471	6	.	.	PUNCT
dpc-1540	471	7	doi	doi	NOUN
dpc-1540	471	8	:	:	PUNCT
dpc-1540	471	9	10.1111	10.1111	NUM
dpc-1540	471	10	/	/	SYM
dpc-1540	471	11	ijd.12811	ijd.12811	NOUN
dpc-1540	471	12	.	.	PUNCT
dpc-1540	472	1	pmid	pmid	NOUN
dpc-1540	472	2	:	:	PUNCT
dpc-1540	472	3	26748974	26748974	NUM
dpc-1540	472	4	.	.	PUNCT
dpc-1540	473	1	34	34	NUM
dpc-1540	473	2	.	.	PUNCT
dpc-1540	474	1	polic	polic	PROPN
dpc-1540	474	2	mv	mv	PROPN
dpc-1540	474	3	,	,	PUNCT
dpc-1540	474	4	miskulin	miskulin	PROPN
dpc-1540	474	5	m	m	PROPN
dpc-1540	474	6	,	,	PUNCT
dpc-1540	474	7	smolic	smolic	PROPN
dpc-1540	474	8	m	m	PROPN
dpc-1540	474	9	,	,	PUNCT
dpc-1540	474	10	et	et	PROPN
dpc-1540	474	11	al	al	PROPN
dpc-1540	474	12	.	.	PUNCT
dpc-1540	474	13	psoriasis	psoriasis	NOUN
dpc-1540	474	14	severity	severity	NOUN
dpc-1540	474	15	-	-	PUNCT
dpc-1540	474	16	a	a	DET
dpc-1540	474	17	risk	risk	NOUN
dpc-1540	474	18	factor	factor	NOUN
dpc-1540	474	19	of	of	ADP
dpc-1540	474	20	insulin	insulin	NOUN
dpc-1540	474	21	resistance	resistance	NOUN
dpc-1540	474	22	independent	independent	ADJ
dpc-1540	474	23	of	of	ADP
dpc-1540	474	24	metabolic	metabolic	NOUN
dpc-1540	474	25	syndrome	syndrome	NOUN
dpc-1540	474	26	.	.	PUNCT
dpc-1540	475	1	int	int	PROPN
dpc-1540	476	1	j	j	PROPN
dpc-1540	476	2	environ	environ	PROPN
dpc-1540	476	3	res	re	VERB
dpc-1540	476	4	public	public	ADJ
dpc-1540	476	5	health	health	NOUN
dpc-1540	476	6	.	.	PUNCT
dpc-1540	477	1	2018	2018	NUM
dpc-1540	477	2	13;15(7):1486	13;15(7):1486	NUM
dpc-1540	477	3	.	.	PUNCT
dpc-1540	478	1	doi	doi	NOUN
dpc-1540	478	2	:	:	PUNCT
dpc-1540	478	3	10.3390	10.3390	NUM
dpc-1540	478	4	/	/	SYM
dpc-1540	478	5	ijerph15071486	ijerph15071486	PROPN
dpc-1540	478	6	.	.	PUNCT
dpc-1540	479	1	pmid	pmid	NOUN
dpc-1540	479	2	:	:	PUNCT
dpc-1540	479	3	3001841	3001841	NUM
dpc-1540	479	4	.	.	PUNCT
dpc-1540	480	1	35	35	NUM
dpc-1540	480	2	.	.	PUNCT
dpc-1540	481	1	henry	henry	PROPN
dpc-1540	481	2	al	al	PROPN
dpc-1540	481	3	,	,	PUNCT
dpc-1540	481	4	kyle	kyle	PROPN
dpc-1540	481	5	sd	sd	PROPN
dpc-1540	481	6	,	,	PUNCT
dpc-1540	481	7	bhandari	bhandari	PROPN
dpc-1540	481	8	s	s	PROPN
dpc-1540	481	9	,	,	PUNCT
dpc-1540	481	10	chisholm	chisholm	PROPN
dpc-1540	481	11	a	a	PROPN
dpc-1540	481	12	,	,	PUNCT
dpc-1540	481	13	griffiths	griffiths	PROPN
dpc-1540	481	14	cem	cem	PROPN
dpc-1540	481	15	,	,	PUNCT
dpc-1540	481	16	bundy	bundy	PROPN
dpc-1540	481	17	c.	c.	PROPN
dpc-1540	481	18	measurement	measurement	PROPN
dpc-1540	481	19	,	,	PUNCT
dpc-1540	481	20	classification	classification	NOUN
dpc-1540	481	21	and	and	CCONJ
dpc-1540	481	22	evaluation	evaluation	NOUN
dpc-1540	481	23	of	of	ADP
dpc-1540	481	24	sleep	sleep	NOUN
dpc-1540	481	25	disturbance	disturbance	NOUN
dpc-1540	481	26	in	in	ADP
dpc-1540	481	27	psoriasis	psoriasis	NOUN
dpc-1540	481	28	:	:	PUNCT
dpc-1540	481	29	a	a	DET
dpc-1540	481	30	systematic	systematic	ADJ
dpc-1540	481	31	review	review	NOUN
dpc-1540	481	32	.	.	PUNCT
dpc-1540	482	1	plos	plos	PROPN
dpc-1540	482	2	one	one	NUM
dpc-1540	482	3	.	.	PUNCT
dpc-1540	483	1	2016;21;11(6):e0157843	2016;21;11(6):e0157843	X
dpc-1540	483	2	.	.	PUNCT
dpc-1540	484	1	doi	doi	NOUN
dpc-1540	484	2	:	:	PUNCT
dpc-1540	484	3	10.1371	10.1371	NUM
dpc-1540	484	4	/	/	SYM
dpc-1540	484	5	journal.pone.0157843	journal.pone.0157843	PROPN
dpc-1540	484	6	.	.	PUNCT
dpc-1540	485	1	pmid	pmid	PROPN
dpc-1540	485	2	:	:	PUNCT
dpc-1540	485	3	27327082	27327082	NUM
dpc-1540	485	4	.	.	PUNCT
dpc-1540	486	1	36	36	NUM
dpc-1540	486	2	.	.	PUNCT
dpc-1540	487	1	hawro	hawro	PROPN
dpc-1540	487	2	t	t	PROPN
dpc-1540	487	3	,	,	PUNCT
dpc-1540	487	4	hawro	hawro	PROPN
dpc-1540	487	5	m	m	PROPN
dpc-1540	487	6	,	,	PUNCT
dpc-1540	487	7	zalewska	zalewska	PROPN
dpc-1540	487	8	-	-	PUNCT
dpc-1540	487	9	janowska	janowska	PROPN
dpc-1540	487	10	a	a	PRON
dpc-1540	487	11	,	,	PUNCT
dpc-1540	487	12	weller	weller	PROPN
dpc-1540	487	13	k	k	PROPN
dpc-1540	487	14	,	,	PUNCT
dpc-1540	487	15	metz	metz	PROPN
dpc-1540	487	16	m	m	PROPN
dpc-1540	487	17	,	,	PUNCT
dpc-1540	487	18	maurer	maurer	PROPN
dpc-1540	487	19	m.	m.	PROPN
dpc-1540	487	20	pruritus	pruritus	PROPN
dpc-1540	487	21	and	and	CCONJ
dpc-1540	487	22	sleep	sleep	VERB
dpc-1540	487	23	disturbances	disturbance	NOUN
dpc-1540	487	24	in	in	ADP
dpc-1540	487	25	patients	patient	NOUN
dpc-1540	487	26	with	with	ADP
dpc-1540	487	27	psoresearch	psoresearch	NOUN
dpc-1540	487	28	|	|	ADV
dpc-1540	487	29	dermatol	dermatol	ADJ
dpc-1540	487	30	pract	pract	NOUN
dpc-1540	487	31	concept	concept	NOUN
dpc-1540	487	32	.	.	PUNCT
dpc-1540	488	1	2021;11(3):e2021049	2021;11(3):e2021049	NUM
dpc-1540	488	2	11	11	NUM
dpc-1540	488	3	riasis	riasis	NOUN
dpc-1540	488	4	.	.	PUNCT
dpc-1540	489	1	arch	arch	ADJ
dpc-1540	489	2	dermatol	dermatol	NOUN
dpc-1540	489	3	res.2019;312(2):103	res.2019;312(2):103	NOUN
dpc-1540	489	4	-	-	SYM
dpc-1540	489	5	111	111	NUM
dpc-1540	489	6	.	.	PUNCT
dpc-1540	490	1	doi	doi	NOUN
dpc-1540	490	2	:	:	PUNCT
dpc-1540	490	3	10.1007/	10.1007/	NUM
dpc-1540	490	4	s00403-019-01998-7.pmid	s00403-019-01998-7.pmid	NOUN
dpc-1540	490	5	:	:	PUNCT
dpc-1540	490	6	3131671	3131671	NUM
dpc-1540	490	7	.	.	PUNCT
dpc-1540	491	1	37	37	NUM
dpc-1540	491	2	.	.	PUNCT
dpc-1540	492	1	biçici	biçici	PROPN
dpc-1540	492	2	f	f	PROPN
dpc-1540	492	3	,	,	PUNCT
dpc-1540	492	4	hayta	hayta	PROPN
dpc-1540	492	5	sb	sb	PROPN
dpc-1540	492	6	,	,	PUNCT
dpc-1540	492	7	akyol	akyol	PROPN
dpc-1540	492	8	m	m	PROPN
dpc-1540	492	9	,	,	PUNCT
dpc-1540	492	10	özçelik	özçelik	PROPN
dpc-1540	492	11	s	s	PART
dpc-1540	492	12	,	,	PUNCT
dpc-1540	492	13	çınar	çınar	PROPN
dpc-1540	492	14	z.	z.	PROPN
dpc-1540	492	15	evaluation	evaluation	NOUN
dpc-1540	492	16	of	of	ADP
dpc-1540	492	17	sleep	sleep	NOUN
dpc-1540	492	18	quality	quality	NOUN
dpc-1540	492	19	in	in	ADP
dpc-1540	492	20	patients	patient	NOUN
dpc-1540	492	21	with	with	ADP
dpc-1540	492	22	psoriasis	psoriasis	NOUN
dpc-1540	492	23	.	.	PUNCT
dpc-1540	493	1	turkderm	turkderm	ADJ
dpc-1540	493	2	.	.	PUNCT
dpc-1540	494	1	2015;49(3):208	2015;49(3):208	NUM
dpc-1540	494	2	-	-	SYM
dpc-1540	494	3	212	212	NUM
dpc-1540	494	4	.	.	PUNCT
dpc-1540	495	1	doi	doi	NOUN
dpc-1540	495	2	:	:	PUNCT
dpc-1540	495	3	10.4274	10.4274	NUM
dpc-1540	495	4	/	/	SYM
dpc-1540	495	5	turkderm.70707	turkderm.70707	PROPN
dpc-1540	495	6	38	38	NUM
dpc-1540	495	7	.	.	PUNCT
dpc-1540	496	1	gowda	gowda	PROPN
dpc-1540	496	2	s	s	PROPN
dpc-1540	496	3	,	,	PUNCT
dpc-1540	496	4	goldblum	goldblum	PROPN
dpc-1540	496	5	om	om	PROPN
dpc-1540	496	6	,	,	PUNCT
dpc-1540	496	7	mccall	mccall	PROPN
dpc-1540	496	8	wv	wv	PROPN
dpc-1540	496	9	,	,	PUNCT
dpc-1540	496	10	feldman	feldman	PROPN
dpc-1540	496	11	sr	sr	PROPN
dpc-1540	496	12	.	.	PUNCT
dpc-1540	497	1	factors	factor	NOUN
dpc-1540	497	2	affecting	affect	VERB
dpc-1540	497	3	sleep	sleep	NOUN
dpc-1540	497	4	quality	quality	NOUN
dpc-1540	497	5	in	in	ADP
dpc-1540	497	6	patients	patient	NOUN
dpc-1540	497	7	with	with	ADP
dpc-1540	497	8	psoriasis	psoriasis	NOUN
dpc-1540	497	9	.	.	PUNCT
dpc-1540	498	1	j	j	PROPN
dpc-1540	498	2	am	be	AUX
dpc-1540	498	3	acad	acad	ADJ
dpc-1540	498	4	dermatol	dermatol	NOUN
dpc-1540	498	5	.	.	PUNCT
dpc-1540	499	1	2010;63(1):114	2010;63(1):114	NUM
dpc-1540	499	2	-	-	SYM
dpc-1540	499	3	123	123	NUM
dpc-1540	499	4	.	.	PUNCT
dpc-1540	500	1	doi	doi	NOUN
dpc-1540	500	2	:	:	PUNCT
dpc-1540	500	3	10.1016	10.1016	NUM
dpc-1540	500	4	/	/	SYM
dpc-1540	500	5	j.jaad.2009.07.003	j.jaad.2009.07.003	PROPN
dpc-1540	500	6	.	.	PUNCT
dpc-1540	501	1	pmid	pmid	NOUN
dpc-1540	501	2	:	:	PUNCT
dpc-1540	501	3	19944485	19944485	NUM
dpc-1540	501	4	.	.	PUNCT
dpc-1540	502	1	39	39	NUM
dpc-1540	502	2	.	.	PUNCT
dpc-1540	503	1	melikoglu	melikoglu	NOUN
dpc-1540	503	2	m.	m.	NOUN
dpc-1540	503	3	sleep	sleep	VERB
dpc-1540	503	4	quality	quality	NOUN
dpc-1540	503	5	and	and	CCONJ
dpc-1540	503	6	its	its	PRON
dpc-1540	503	7	association	association	NOUN
dpc-1540	503	8	with	with	ADP
dpc-1540	503	9	disease	disease	NOUN
dpc-1540	503	10	severity	severity	NOUN
dpc-1540	503	11	in	in	ADP
dpc-1540	503	12	psoriasis	psoriasis	NOUN
dpc-1540	503	13	.	.	PUNCT
dpc-1540	504	1	eurasian	eurasian	PROPN
dpc-1540	504	2	j	j	PROPN
dpc-1540	504	3	med.2017;49:124	med.2017;49:124	PROPN
dpc-1540	504	4	-	-	PUNCT
dpc-1540	504	5	127	127	NUM
dpc-1540	504	6	.	.	PUNCT
dpc-1540	505	1	doi	doi	NOUN
dpc-1540	505	2	:	:	PUNCT
dpc-1540	505	3	10.5152/	10.5152/	NUM
dpc-1540	505	4	eurasianjmed.2017.17132	eurasianjmed.2017.17132	NOUN
dpc-1540	505	5	.	.	PUNCT
dpc-1540	506	1	pmid	pmid	NOUN
dpc-1540	506	2	:	:	PUNCT
dpc-1540	506	3	28638255	28638255	NUM
dpc-1540	506	4	.	.	PUNCT
dpc-1540	507	1	40	40	NUM
dpc-1540	507	2	.	.	PUNCT
dpc-1540	508	1	jensen	jensen	PROPN
dpc-1540	508	2	p	p	PROPN
dpc-1540	508	3	,	,	PUNCT
dpc-1540	508	4	zachariae	zachariae	PROPN
dpc-1540	508	5	c	c	NOUN
dpc-1540	508	6	,	,	PUNCT
dpc-1540	508	7	skov	skov	PROPN
dpc-1540	508	8	l	l	NOUN
dpc-1540	508	9	,	,	PUNCT
dpc-1540	508	10	zachariae	zachariae	PROPN
dpc-1540	508	11	r.	r.	PROPN
dpc-1540	508	12	sleep	sleep	PROPN
dpc-1540	508	13	disturbance	disturbance	NOUN
dpc-1540	508	14	in	in	ADP
dpc-1540	508	15	psoriasis	psoriasis	NOUN
dpc-1540	508	16	—	—	PUNCT
dpc-1540	508	17	a	a	DET
dpc-1540	508	18	case	case	NOUN
dpc-1540	508	19	-	-	PUNCT
dpc-1540	508	20	controlled	control	VERB
dpc-1540	508	21	study	study	NOUN
dpc-1540	508	22	.	.	PUNCT
dpc-1540	509	1	br	br	PROPN
dpc-1540	509	2	j	j	PROPN
dpc-1540	509	3	dermatol	dermatol	NOUN
dpc-1540	509	4	.	.	PUNCT
dpc-1540	510	1	2018;179(6):1376	2018;179(6):1376	PROPN
dpc-1540	510	2	-	-	SYM
dpc-1540	510	3	1384	1384	NUM
dpc-1540	510	4	.	.	PUNCT
dpc-1540	511	1	doi	doi	NOUN
dpc-1540	511	2	:	:	PUNCT
dpc-1540	511	3	10.1111	10.1111	NUM
dpc-1540	511	4	/	/	SYM
dpc-1540	511	5	bjd.16702	bjd.16702	NOUN
dpc-1540	511	6	.	.	PUNCT
dpc-1540	512	1	pmid	pmid	NOUN
dpc-1540	512	2	:	:	PUNCT
dpc-1540	512	3	29704428	29704428	NUM
dpc-1540	512	4	.	.	PUNCT
dpc-1540	513	1	41	41	NUM
dpc-1540	513	2	.	.	PUNCT
dpc-1540	514	1	shutty	shutty	PROPN
dpc-1540	514	2	bg	bg	PROPN
dpc-1540	514	3	,	,	PUNCT
dpc-1540	514	4	west	west	PROPN
dpc-1540	514	5	c	c	PROPN
dpc-1540	514	6	,	,	PUNCT
dpc-1540	514	7	huang	huang	PROPN
dpc-1540	514	8	ke	ke	PROPN
dpc-1540	514	9	,	,	PUNCT
dpc-1540	514	10	et	et	PROPN
dpc-1540	514	11	al	al	PROPN
dpc-1540	514	12	.	.	PUNCT
dpc-1540	515	1	sleep	sleep	NOUN
dpc-1540	515	2	disturbances	disturbance	NOUN
dpc-1540	515	3	in	in	ADP
dpc-1540	515	4	psoriasis	psoriasis	NOUN
dpc-1540	515	5	.	.	PUNCT
dpc-1540	516	1	dermatol	dermatol	NOUN
dpc-1540	516	2	online	online	ADV
dpc-1540	516	3	j.	j.	PROPN
dpc-1540	516	4	2013;19(1)1	2013;19(1)1	NUM
dpc-1540	516	5	.	.	PUNCT
dpc-1540	517	1	pmid	pmid	NOUN
dpc-1540	517	2	:	:	PUNCT
dpc-1540	517	3	23374943	23374943	NUM
dpc-1540	517	4	.	.	PUNCT
dpc-1540	518	1	42	42	NUM
dpc-1540	518	2	.	.	PUNCT
dpc-1540	519	1	stinco	stinco	PROPN
dpc-1540	519	2	g	g	PROPN
dpc-1540	519	3	,	,	PUNCT
dpc-1540	519	4	trevisan	trevisan	PROPN
dpc-1540	519	5	g	g	NOUN
dpc-1540	519	6	,	,	PUNCT
dpc-1540	519	7	piccirillo	piccirillo	PROPN
dpc-1540	520	1	f	f	X
dpc-1540	520	2	,	,	PUNCT
dpc-1540	520	3	et	et	PROPN
dpc-1540	520	4	al	al	PROPN
dpc-1540	520	5	.	.	PUNCT
dpc-1540	520	6	psoriasis	psoriasis	NOUN
dpc-1540	520	7	vulgaris	vulgaris	NOUN
dpc-1540	520	8	does	do	AUX
dpc-1540	520	9	not	not	PART
dpc-1540	520	10	adversely	adversely	ADV
dpc-1540	520	11	influence	influence	VERB
dpc-1540	520	12	the	the	DET
dpc-1540	520	13	quality	quality	NOUN
dpc-1540	520	14	of	of	ADP
dpc-1540	520	15	sleep	sleep	NOUN
dpc-1540	520	16	.	.	PUNCT
dpc-1540	521	1	g	g	ADP
dpc-1540	521	2	ital	ital	ADJ
dpc-1540	521	3	dermatol	dermatol	NOUN
dpc-1540	521	4	venerol	venerol	NOUN
dpc-1540	521	5	.	.	PUNCT
dpc-1540	522	1	2013;148(6):655	2013;148(6):655	NUM
dpc-1540	522	2	-	-	SYM
dpc-1540	522	3	659	659	NUM
dpc-1540	522	4	.	.	PUNCT
dpc-1540	523	1	pmid	pmid	NOUN
dpc-1540	523	2	:	:	PUNCT
dpc-1540	523	3	24442047	24442047	NUM
dpc-1540	523	4	.	.	PUNCT